

# **Contents**

| Sonic Healthcare core values           | 1   | <i>In-vivo</i> Tests                 | 135 |
|--|-----|--------------------------------------|-----|
| Complaints policy                      | 2   | Therapeutic Drug Assays              | 136 |
| Helpful information                    | 3   | Allergy                              | 139 |
| Quality assurance                      | 14  | Vitamins, Nutrition and Lifestyle    | 149 |
| Special instructions for samples       | 25  | Self-collection samples              | 153 |
| TDL Screening Profiles DL1-DL12        | 26  | Screening for Drugs of Abuse/Alcohol | 161 |
| Biochemistry                           | 29  | Occupational Health                  | 163 |
| Haematology                            | 40  | Cervical Screening                   | 165 |
| Microbiology                           | 45  | Self-collection HPV samples          | 171 |
| Endocrinology                          | 55  | Non-Gynae Cytology                   | 172 |
| TDL Andrology                          | 63  | Histopathology                       | 173 |
| Sexual Health                          | 69  | Alphabetical test index              | 181 |
| Immunology                             | 79  | TDL Referral laboratories            | 217 |
| Tropical and Travel-Related Immunology | 89  | TDL Terms and Conditions of Business |     |
| Virology                               | 91  | from 1st Jan 2024                    | 220 |
| Tumour Markers/Sites                   | 102 | Request forms                        | 228 |
| TDL Genetics                           | 105 |                                      |     |

The TDL Laboratory Guide Is designed to give you an easy-to-use reference for the most regularly requested services, pathology profiles and tests. If you are not able to find details of the tests and services you need, please contact the laboratory on **020 7307 7373** for advice and information.

For details about all services, please contact the laboratory on **020 7307 7373**, or visit **www.tdlpathology.com** 

### TDL services include:

- Comprehensive, multidisciplinary pathology services
- Specialist diagnostic analysis for other laboratories
- Pathology partnerships with NHS Trusts
- Support for CRO and pharmaceutical companies

# **Sonic Healthcare core values**

Sonic Healthcare's core values were created by our staff more than 20 years ago, and act as guiding principles for how we conduct ourselves as an organisation.

Our core values set the standard for the collegiate and supportive way in which we behave towards one another, as well as the professionalism with which we conduct ourselves in our day-to-day duties. Individually, our core values articulate our commitment to medical excellence. Collectively, they empower our people to deliver exceptional medical services to doctors and patients.

Since their inception, Sonic Healthcare's core values have been embraced by Sonic Healthcare staff around the world as a unifying code of conduct.

### Commit to service excellence

 To willingly serve all those with whom we deal, with unsurpassed excellence.

# Treat each other with respect and honesty

To grow a workplace where trust, team spirit and equity are an integral part of everything we do.

# Demonstrate responsibility and accountability

To set an example, to take ownership of each situation to the best of our ability and to seek help when needed.

# Be enthusiastic about continuous improvement

To never be complacent, to recognise limitations and opportunities for ourselves and processes and to learn through these.

# **Maintain confidentiality**

 To keep all information pertaining to patients, as well as professional and commercial issues, in strict confidence.



# **Complaints policy**

It is the aim of the company to maintain its core values. Two of these core values are:

- Commit to service excellence.
- Be enthusiastic about continuous improvement.

Where a doctor or patient needs to raise a complaint about service levels they should contact Cyril Taylor, Director of Laboratory Compliance, or Annette Wilkinson, Director of Service at tdlservice@tdlpathology.com giving details of the complaint.

The information forwarded will be treated as confidential and investigated by the above persons. This process will link into Quality Management procedure for incident investigation. Corrective and preventative actions will be introduced where indicated.

The Doctors Laboratory
The Halo Building, 1 Mabledon Place
London, WC1H 9AX, UK

Tel: +44 (0)20 7307 7373 – 24 hour telephone (Main switchboard/All services)

Email: tdl@tdlpathology.com

Laboratory times: 24 hours

Samples can be delivered at any time to this location.

Patients' samples cannot be taken at The Halo Building. This service is undertaken at 76 Wimpole Street, London W1G 9RT



SCAN MF

To download a location map or to get directions visit:

www.tdlpathology.com/ about-us/locations/ TDL Manchester Regents Place, 4 Windsor Street Salford, M5 4HB, UK

Tel: +44 (0)161 332 7181

Email: tdlmanchester@tdlpathology.com

Laboratory times: 24 hours

Samples can be delivered at any time to this location.

Patients' samples cannot be taken at TDL Manchester.

### **TDL Manchester Couriers**

Direct Tel: +44 (0)161 332 7187 Email: couriersman@tdlpathology.com

### **TDL Manchester Supplies**

Email: supplies@tdlpathology.com



# Patient Reception/ Phlebotomy Services

Patient Reception provides a sample collection service for patients attending at the request of their doctor/clinic.

Patients, of all ages, are welcome to attend Patient Reception, 76 Wimpole Street, London W1G 9RT for their samples to be taken. Patients need to be referred by their clinic or doctor and are required to bring a request form or letter of referral.

Appointments are only necessary if a patient needs specialised investigations or care. Instructions can be telephoned or emailed ahead of the patient's attendance, if this is more convenient.

Sample-taking is undertaken by qualified phlebotomy staff for which a standard sample-taking fee of  $\mathfrak{L}60.00$  is charged to patients. Doctors and clinics are charged  $\mathfrak{L}35.00$  for each patient. Sample-taking services for Extended Tests and Drugs of Abuse with Chain of Custody, and semen analysis are routinely available.

Cervical cytology, HVS and cervical swabs are not taken at Patient Reception.

Patient Reception sample-taking services are not available in Manchester.

# TDL Patient Reception 76 Wimpole Street, London, W1G 9RT, UK

Tel: +44 (0)20 7307 7383

Email: patientreception@tdlpathology.com

Out of hours samples can be dropped off at this location. **Phlebotomy Services are only available at this location**. Patients' samples cannot be taken at the main laboratory.

### Opening times

Monday to Friday 7.00am - 7.00pm

Saturday 7.00am-1.00pm


Closed Sunday and bank holidays.



SCAN MF

To download a location map or to get directions visit:

www.tdlpathology.com/ patients/patient-reception/



# TDL Collect: specimen collection services by courier

TDL Collect provides a dedicated medical sample collection service (vans by arrangement) on a scheduled or ad hoc basis.

No charge is made for collections from practices within the M25. Courier collections from private addresses are not undertaken.

The courier collection service for Inner London postcodes operates on a 24/7 basis, as shown. Postcodes extending beyond to the M25 operate from 9.00am to 8.00pm. Outside the M25, and throughout the UK, sample collections are by arrangement and may incur courier charges.

TDL Collect Online Courier Booking is a time-saving option for arranging couriers for sample collection: www.tdlpathology.com/services/tdl-collect/

Please contact **couriers@tdlpathology.com** for your practice's secure login and password.

High-risk samples should be clearly labelled and packed separately from other samples.


TDL's couriers cannot transport samples containing Hazard Group 4 Pathogens such as Ebola Fever or Haemorrhagic Fever.



SCAN ME

Use the TDL Collect Online Courier Booking service to arrange a courier for sample collection:

www.tdlpathology.com/ services/tdl-collect/



Courier collection from Inner London postcodes (see below) operates 24/7: E1, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11,

E12, E13, E14, E15, E16, E17, E18, E20 EC1, EC2, EC3, EC4

N1, N2, N3, N4, N5, N6, N7, N8, N9, N10, N11, N12, N13, N14, N15, N16, N17, N18, N19, N20, N21, N22

NW1, NW2, NW3, NW4, NW5, NW6, NW7, NW8, NW9, NW10, NW11

SE1, SE2, SE3, SE4, SE5, SE6, SE7, SE8, SE9, SE10, SE11, SE12, SE13, SE14, SE15, SE16, SE17, SE18, SE19, SE20, SE21, SE22, SE23, SE24, SE25, SE26, SE27, SE28

SW1, SW2, SW3, SW4, SW5, SW6, SW7, SW8, SW9, SW10, SW11, SW12, SW13, SW14, SW15, SW16, SW17, SW18, SW19, SW20

W1, W2, W3, W4, W5, W6, W7, W8, W9, W10, W11, W12, W13, W14

WC1, WC2

# **Semen Analysis**

Semen samples need specialist and Immediate handling within the laboratory. For this reason, all requests for Semen Analysis must be made by appointment. Practices or patients can make an online appointment at **www.tdlpathology.com/andrologybooking** or call **020 7025 7940** to make appointments and confirm instructions for sample collection. There is an attendance fee of £50.00.

- Patients must abstain from ejaculation for at least 2 days but not longer than 5 days before the test. Instructions will be given to patients at the time of arranging their appointment.
- Semen samples should be produced at The Doctors Laboratory, 76 Wimpole Street, unless there are exceptional circumstances. If there are exceptional circumstances please contact **TDL Andrology** on **020 7025 7940** for special arrangements and instructions. Refer to Andrology, see page 63.

Semen Analysis services are not provided in Manchester.



SCAN ME

To make an appointment for Semen Analysis online please visit:

www.tdlpathology.com/ andrologybooking

# **Patient request form**

To comply with good clinical practice it is important that there is one request form for each patient's request, and specimens and form are correctly matched, fully labelled, and include three unique patient identifiers and other relevant Information.

- First name, Surname, Date of birth, Hospital/Clinic Number, Medical Record Number (MRN) are examples of patient identifiers
- Time and Date of collection of samples
- Type of sample and Anatomical site, where appropriate (e.g. swabs)
- Relevant clinical information.
- Relevant details of medication
- High-Risk Samples should be clearly identified on the form and individually packed separately from other samples
- Known cases of Hazard Group 4 pathogens such as Ebola or Viral Haemorrhagic Fever must NOT be sent to the laboratory. If there Is doubt about a patient's symptoms and presentation please contact the Imported Fever Service on 0844 778 8990 for advice before sending samples to TDL or any laboratory.

If additional tests are required for a sample already received please contact the laboratory on **020 7307 7373** with your request for specific further analysis. Samples are stored within timeframes according to their discipline. Laboratory staff will advise on the ability to undertake further testing from samples already received in the laboratory.



SCAN ME

Download TDL Request Forms from:

www.tdlpathology.com/ tests/request-forms/

# **Emailed requests for add ons**

The majority of samples received in the laboratory are kept for one week. If sample type and volume allow, further testing can be requested by telephone on **020 7307 7373** or by email to **addons@tdlpathology.com**. Please specify the details of the test(s) to be added.

If requests for **Add ons** are made by email, the **patient's details** and **Laboratory Number** need to be referenced.

## **Home visits**

This service is available for patients who, for whatever reason, prefer samples to be taken at home or at locations other than a doctor's practice or TDL's Patient Reception at 76 Wimpole Street, London. This is a service that is used regularly to save time for both doctors and patients, and ensures that results can be made available before consultation is undertaken.

There is a visit fee from £150.00 to patients within the M25, and from £200.00 for children when two nurses need to attend. Home visits outside the M25, for weekends, bank holidays and night fees are by special arrangement. To arrange a home visit please telephone Patient Reception on **020 7307 7383** or email **homevisits@tdlpathology.com**.

# Sample packing

Samples need to be packed and transported appropriately for subsequent processing and testing. Transport systems will be various and cover both long and short distances.

Samples need to be collected and packed into appropriate sample containers provided by the laboratory in order to maintain integrity. Attention needs to be given to temperature, special transport containers and time limitations. Each testing has a different sample requirement, which should be referenced prior to sample taking.

Clinics, practices and laboratories who are posting or transporting samples by air, sea, rail and road between local, regional and reference laboratories, or between laboratories in other countries, must adhere to a number of regulations. These regulations are designed to deal with transportation accidents and spills, reduce biohazards and keep samples intact for testing.

Regulations are given by several sources including:

- National transport regulations
- International air transport regulations
- Rail and road traffic agencies
- Postal services

Compliance is mandatory in order to reduce risk to couriers, carrier, laboratory staff and passengers.

Sample transport requirements are based on the category of samples being transported. Infectious substances are classified as Category A (for example a substance that causes viral haemorrhagic fevers or Category B.

TDL does not arrange for transport of Category A samples (infectious substances capable of causing permanent disability or life-threatening or fatal disease to humans or animals).

Instruction and packaging for Category B is provided, covering Biological Substances, UN3373.

# **Packaging requirements**

There are specific labelling and triple packaging requirements for Category B samples such that it meets packaging instruction P650:

- Primary receptacle tube or vial containing the sample which is placed in the secondary packaging.
- Secondary packaging for example, a protective packaging case or ziplock bag with absorbent material.
- The outer packaging intended to protect the entire contents.

There may also be additional postal envelopes to place the entire package in for postal return. The external surface of the package must be labelled with UN3373 and clearly state BIOLOGICAL SUBSTANCE CATEGORY B.

There are additional packaging requirements for frozen samples requiring shipment using BioFreeze bottles or Dry Ice.

For information please contact the Referrals Dept (**ReferralsOffice@tdlpathology.com**).

# Postal pathology

Postal pathology services should be considered by all practices in the UK who need a rapid delivery service to the laboratory as it is a quick and efficient method of sample return, which causes little to no disruption to the patient. Royal Mail require that ALL pathology postal packs are sent using Tracked 24 returns. This provides a particularly suitable method of transport for any healthcare organisation. Royal Mail postal pathology with Tracked 24 returns provides:

- Simple and convenient sample handling throughout the UK for most tests. It is not suitable for samples that need to be received within 24 hours of sample taking (e.g. coagulation, Quantiferon TBQ).
- Scope for large and small numbers of samples.
- Next morning delivery.
- Allows patients and practices to track samples to the Distribution Office through the Royal Mail system.
- Samples can be posted from any Royal Mail post box.
- There is a charge of £3.36 for each Royal Mail Tracked 24 pack. This charge will be itemised in monthly invoices to the practice or patient, as requested.

# **TDL** website

The TDL website gives updated details of our tests — sample types, turnaround times and special instructions. The Specialities section provides a new way to find tests you need, and a Services section has additional information for TDL Collect, Postal Pathology and TestGuide app. Reference Ranges can be requested by emailing **refranges@tdlpathology.com**. Full details of our tests and profiles are also available in the TDL TestGuide app.



Visit the TDL website at:

www.tdlpathology.com

SCAN ME



# **DX System**

DX is a well known next-day courier of Category B specimens – transporting biological samples in compliance with the industry's highest regulations. DX is compliant to IATA regulations, is audited independently by Dangerous Goods Safety Advisors. They work with a combination of large health organisations and smaller, independent laboratories to ensure the safe delivery of specimens every year.

TDL's DX Address is **DX 340201, St Pancras 90 WC**.

# Pathology consumables / Request Forms / Postal packs

TDL Supplies Department provides all appropriate sample collection consumables required for sample collection. Orders will be dispatched on the same or next day and can be made by email to **supplies@tdlpathology.com**. A Supplies Order Form is available from the TDL website.



Download TDL Request Forms from:

www.tdlpathology.com/ tests/request-forms/

# Requesting and reporting options

We continually review and update our IT Services for receiving requests and reporting results electronically between practices and the laboratory. A number of innovative report formats are now available.

# **Encrypted Email**

Results will be sent in encrypted format to any number of predetermined email addresses. Copy reports will be emailed automatically to email addresses on the system.

# **Link to Practice Management System**

Bidirectional requests and results can be received and delivered electronically using a number of integrated practice systems. Practice software that accepts data in an HL7 format can be linked to securely receive results from the laboratory.

Security of information in TDL systems and processes is managed by our Information Security Management System, which is certified to the latest International Standard for Information Security ISO/IEC 27001:2013.

## **TDL eViewPlus**

Provides the most accurate requesting option for clinics who don't have a practice management system. As well as producing QR coded forms to accompany samples to the laboratory, registered users of this secure Login/Password protected system can request self-collection kits to be sent directly to their patients.

eViewPlus users can also view their results online, with cumulative reporting, anytime, anywhere.

For information about eViewPlus please contact **eviewplus@tdlpathology.com**.

# **Printed Copy**

Printed results will only be sent, as standard, if requested.

# **Emailed results incorporating your logo**

If a practice or company receives results by email, and would like these to be personalised with the practice's logo, please email your company details and logo in GIF format to logo@tdlpathology.com.

# **Fees for pathology**

Fees can be paid directly by patients or by the practice, clinic or requesting organisation. A payment instruction clearly identifying to whom invoices need to be sent must be given with each patient's request.

Patients are normally invoiced within 7 days to the address provided by the patient or practice. Their pathology fees include a standard credit/administration charge.

Receipts for insurance purposes are sent, if requested. Patients visiting Wimpole Street for sample-taking have the opportunity to settle their pathology fees at the time of their visit. A credit/administration fee is raised if invoices are sent to patients. All normal credit, debit or charge cards are accepted and payment can be made by following the telephone payment instructions given with each invoice.

The Terms and Conditions of Business appearing on pages 220-227 of this Laboratory Guide shall apply to the services we provide to you, unless otherwise agreed.

# Protection of personally identifiable information

The General Data Protection (GDPR) and UK Data Protection Act 2018 came in to force in 2018 and have had significant impact upon the way that personal data is managed; placing legal requirements upon data processors and controllers to manage that information securely, maintain records of the processing that is carried out, and report when breaches of the regulation do occur.

This has impacted the way many businesses operate, and is not restricted to the healthcare sector.

# **TDL TestGuide app**


Available for iOS and Android, the TDL TestGuide app offers:

- Full details of TDL's tests and profiles
- The TDL Pathology Handbook, which provides information on more than 1000 pathology topics, reflecting our deep collective knowledge across all areas of pathology

The app can be downloaded from the Apple App Store or Google Play Store. To register for the app, you will just need your TDL Source Code and an email address.

Please contact **testguide@tdlpathology.com** if you need help with finding your Source Code.

Feedback for the TestGuide app is always welcome; please send suggestions and comments to **tdl@tdlpathology.com**.




At TDL, these requirements have been implemented within the context of a mature ISO 27001 Information Security Management System – the globally accepted standard by which information is secured.

This ensures that senior management have regular visibility of the threats to the confidentiality, availability and integrity of the information that we process, and are able to steer the efforts of their teams to provide an efficient service that places the confidentiality of our customers and their patients at the heart of everything we do.

In order to support our customers compliance with the regulation and as a part of a wider GDPR compliance project TDL has updated its standard terms and conditions to include revised data processing clauses, which are mandatory when providing personal data to another organisation.

Customers can find out more about how TDL protects their data by reading the TDL Privacy Notice at www.tdlpathology.com/about-us/corporate-information/tdl-group-privacy-notice.



# **Key contacts**

# 24 HOUR TELEPHONE (MAIN SWITCHBOARD/ALL SERVICES): 020 7307 7373

### **CEO**

### **David Byrne**

david.byrne@tdlpathology.com

# **Group Commercial Director**

### **Brian Madden**

brian.madden@tdlpathology.com

### **Chief Medical Officer**

### **Dr Rachael Liebmann OBE**

rachael.liebmann@tdlpathology.com

### **Group Laboratory Director**

#### **Tim Herriman**

tim.herriman@tdlpathologv.com

#### Director of Sales / Service

#### **Annette Wilkinson**

annette.wilkinson@tdlpathology.com

# Director of Genetics &

# **Molecular Pathology**

### Dr Lisa Levett

lisa.levett@tdlpathologv.com

### **Chief Information Officer (IT)**

#### John Matthews

john.matthews@tdlpathology.com

# **Director of Group Laboratory Operations**

#### Lisa Manze

lisa.manze@tdlpathology.com

# **Heads of Support Departments**

# **Director of Laboratory Compliance**

### **Cyril Taylor**

Cyril.taylor@tdlpathology.com

### **Director of Governance**

#### **Emer Nestor**

emer.nestor@tdlpathology.com

### **Credit Control Manager**

### **William Howard**

william.howard@tdlpathology.com

### Logistics / Couriers

#### Steve Kettle

steve.kettle@tdlpathology.com

### **Patient Reception**

### Becca Gallagher

Becca.Gallagher@tdlpathology.com patient.reception@tdlpathology.com

#### **Call and Service Centre**

### Chris Tanalega

chris.tanalega@tdlpathology.com

### **IT Operations / Customer Service**

### Rochelle Fakhri

rochelle.fakhri@tdlpathology.com

### Sample Reception

#### **Chanaide Butler**

chanaide.butler@tdlpathologv.com

### **Referrals Department**

#### Maulik Trivedi

maulik.trivedi@tdlpathology.com

# Heads of Laboratory Departments (London)

# Haem/Bio/Automated Pathology

### Naina Chavda

naina.chavda@hslpathology.com

# Microbiology/Infection Sciences

### **Alan Spratt**

alan.spratt@tdlpathology.com

## **Andrology**

### **Andrew Dawkins**

andrew.dawkins@tdlpathology.com

### **Cervical Screening**

### **Julie Smith**

Julie.smith@tdlpathology.com

### Immunology / Virology

### **Kushen Ramessur**

kushen.ramessur@tdlpathology.com

### Cytogenetics

### **Rebecca Watts**

rebecca.watts@hslpathology.com

### **Molecular Genetics**

### **Dr Stuart Liddle**

stuart.liddle@tdlpathology.com

### **TDL Trials**

### **Abraham Roodt**

abraham.roodt@tdlpathology.com

# **TDL Manchester**

## **Operational Site Lead**

### **Diane Benson**

diane.benson@tdlpathology.com

# Deputy Site Lead

### **Andy Leeson**

andy.leeson@tdlpathology.com

# **SRA and Kit Distribution Manager**

# **Georgina Taylor**

georgina.taylor@tdlpathology.com

### **Quality Manager**

### **Carol Tonge**

carol.tonge@tdlpathology.com

# **Courier Control**

#### **Marc Rennard**

marc.rennard@tdlpathology.com

# The Doctors Laboratory is committed to providing doctors with pathology of the highest quality.

The quality of results is of fundamental importance, and the laboratory operates to stringent technical and administrative standards.

Internal quality assurance is achieved by strict adherence to standard operating procedures for all analytical processes. TDL participates in recognised National External Quality Assessment Schemes; these schemes are subscribed to by NHS and private laboratories. The United Kingdom Accreditation Service (UKAS) provides accreditation to the internationally recognised ISO 15189 Medical Laboratories: Requirements for Quality and Competence standard. Results are subjected to strict internal and external quality control.

Details of the laboratories to whom TDL refers specialist testing are available from TDL Referrals. These laboratories are UKAS accredited or of equal accreditation status.

Quality Assurance is administered by TDL's Quality Management Group (QMG), who also adhere to regulatory and accreditation requirements.

### **BIOCHEMISTRY**

### UKNEQAS, WEQAS, RIQAS, BIORAD

ACF

AFP/CEA & HCG

Antibiotics (Gentamicin, Vancomycin and Amikacin)

Anti-Hbs Detection

Ammonia

Autoimmune (RF and TPO)

B2 Microalobulin

Cardiac Markers

Clinical Chemistry

CMV IgG/IgM

CRP & Ultra-Sensitive CRP

**CSF** 

Cyclosporin and Tacrolimus

DEQAS

Diagnostic Serology Exanthem

Diagnostic Serology Hepatitis

Drugs of Abuse

Ethanol

Faecal Markers for Inflammation (Calprotectin)

Free Beta HCG and PAPP-A

GFR

Glucose / Glucometer

Glycated Haemoglobins

**Guildford Peptides** 

Haematinics

Healthcontrol Therapeutic Drugs Screen (TDM)

Hepatitis A (with B and C)

Hepatitis B Serology

Hepatitis C Serology

**HIV Serology** 

Homocysteine

HTLV

IGF-1

Infectious Immunology

Lipase

Lipid Investigations

NT-Pro BNP

Paediatric Bilirubins

Parasitology

Peptide Hormones

PSA. Free PSA

PTH. ACTH and hCT

QFIT

Rubella IgG Serology

Salicylate and Paracetamol

Specific Proteins

Steroid Hormones

Syphilis Serology

Thyroglobulin Surveys

Thyroid Hormones

Total IgE

**Tumour Markers** 

Toxoplasma IgM Serology

Toxoplasma IgG Serology

Trace Elements

Urine Chemistry

Vitamin D (25 OH)

#### **HAEMATOLOGY**

### **UKNEQAS**

Automated Differential Leucocyte Count

Blood Film Morphology

Coagulation (Including PoCT Coagulation)

**EBV Mononucleosis** 

ESR and NRBC (nucleated Rbc)

Flow Cytometry

Leukaemia immunophenotyping

Myeloperoxidase

Iron stain

Full Blood Count

Haematology

Haematology Analysis

Malaria

Parasite Films

Reticulocyte

Sickle Screening

Thrombophilia Screening

Blood Transfusion Laboratory Practice Scheme (BTLP)

### Special Coagulation

Von Willebrand (vWD) screen

Anti-Xa assays

Plasma viscosities

ADAMTS-13 activity

ADAMTS-13 antibody

Heparin/Platelet Factor 4

Induced Antibodies

Platelet function analysis (RCPA)

Lupus anticoagulant:

Taipan Venom Time

DRVVT assay

### **GENETICS AND MOLECULAR VIROLOGY**

### Molecular genetics and Cytogenetics

Acquired array (CLL/MDS)

Acute Lymphoblastic Leukaemia (ALL)

- G banding and FISH

BCR ABL1 and AML Translocation Identification

BCR ABL1 Kinase Domain Variant

BCR ABL1 Major Quantification

BCR ABL1 Minor Quantification

BoBs Rapid Aneuploidy detection

BRAF p.Val600Glu (V600E) Mutation

Status for Hairy Cell Leukaemia

Chlamydia & Gonorrhoea detection by PCR

Chronic Lymphocytic Leukaemia (CLL)

Constitutional Clinical Cytogenetics (Rounds for

Amniocentesis, CVS, Solid Tissue, Blood, Array CGH)

Cystic Fibrosis

Duchenne/Becker Muscular Dystrophy

FLT3 Mutation Status

Haematological Technical FISH

Hereditary Haemochromotosis

(C282Y+H63D) genotyping + reporting

HLA Class I (HLA-A, HLA-B, HLA-C)

Tissue Typing (low resolution)

HLA Class II (HLA-DRB1, HLA-DQB1)

Tissue Typing (low resolution)

HLA-B27 Genotyping

HLA-B57\*01 Genotyping

HLA+ Disease Typing Cytochrome

P450 2C19 genotyping

Human Papillomavirus DNA

IG/TCR Clonality Status

IGHV for CLL

Inborn Errors of Metabolism

JAK2 p.Val617Phe (V617F) Mutation Status

KIT p.Asp816Val (D816V) Mutation

Status for Mast Cell Disease

Lymphoid Gene Panels

Lymphoma

Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinaemia

Measurable Residual Disease for AML by Molecular Methods

Myeloid (AML/MDS/CML) - G-banding and FISH

Myeloid Gene Panels

Myeloma – sample FISH set up

and analysis plus online

Myeloproliferative Neoplasms Diagnostic Testing

NGS AML gene panel

NGS Myeloid Target Panel

NIPT for aneuploidies and sexing

NMP1 Mutation Status

Paediatric Acute Leukaemia Translocations

Paternity Testing

Prader-Willi and Angelman Syndromes

QF-PCR Aneuploidy Detection

Sexually Transmitted Diseases

(CT/NG/MGEN/TV/UU/UP)

Spinal Muscular Atrophy

Thrombophilia (Factor II, V, MTHFR)

TP53 for CLL

Y Microdeletion PCR Assay

# Molecular virology

Adenovirus DNA Viral load and Qualitative PCR

Bacterial 16S

B19 virus DNA Viral load

BK virus DNA Viral load

CMV DBS (dried blood spots)

CMV DNA Plasma Viral load

CMV DNA Whole Blood Viral load

CMV Resistance

EBV DNA Plasma Viral load

EBV DNA Whole Blood Viral load

Enterovirus RNA

Gastroenteritis Virus Panel

Hepatitis B Genotyping

Hepatitis B Drug Resistance Typing

Hepatitis B Viral Load

Hepatitis C Genotyping

Hepatitis C Resistance genome detection (NS5a & b)

Hepatitis C Resistance Typing (NS3 & NS5a)

Hepatitis C Viral Load

Hepatitis D Virus Viral load and Qualitative PCR

Hepatitis E Virus Viral load and Qualitative PCR

HIV-1 Drug Resistance (Pol)

HIV-1 Drug Resistance (Integrase)

HIV-1 RNA Viral load and Qualitative PCR

HIV-1 DNA Genome Detection

HIV-1 Tropism Genome Detection

HSV 1&2 DNA

HSV 1&2 DNA HSV Drug Resistance

HIV-2 Viral Load

Human Herpes virus 6 DNA

Human Herpes Virus 8 Viral load and Qualitative PCR

Influenza Haemagglutinin typing

JC Virus DNA

Measles and Mumps PCR

MFRS Coronavirus

Parechovirus RNA

Respiratory panel I

Respiratory panel II

SARS-CoV-2 (COVID-19) PCR/NAAT

SARS-CoV-2 Variants of Concern (VOC) sequencing

Syphilis PCR

Transplantation Virus Panel

**VZV DNA** 

### **MICROBIOLOGY**

### **Laboratory Quality Scheme**

Helicobacter pylori antigen from faeces

Polarising crystal microscopy from synovial fluid

Streptococcus pyogenes (Group A)

detection in pharyngeal samples

Surveillance for multi drug resistant bacteria

Blood culture and gram stain

Candida PCR

Mycoplasma PCR

Aspergillus PCR

#### UKNEQAS

Clostridium difficile detection and toxin testing

Faecal parasites

General bacteriology

Genital pathogens

MRSA screening

Microbial susceptibilities

Mycobacterial microscopy

Mycobacterial culture and molecular detection

Antifungal assays

Antifungal susceptibilities

Cryptococcal antigen

Fungal culture

Fungal biomarkers

Urinary antigen

#### **WEGAS POCT**

Urinalysis

### **QCMD**

Dermatophyte PCR

PCP PCR

Atypical pneumoniae PCR

### **IMMUNOLOGY**

## UKNEQAS - General Immunology

Allergen Component Testing

Autoimmune Serology ANCA/GBM Antibodies

**Bullous Dermatosis Antibodies** 

Allergen Specific IgE Antibodies

General Autoimmune Serology

Anti-Phospholipid Antibodies (B2GP)

Nuclear and Related Antigens

IGRA (Interferon gamma release assay)

Intrinsic Factor Antibodies

Diabetic Marker (Islet Cell Antibodies)

Myositis Associated Antibodies

Specific Microbial Antibodies

Syphilis (THPA and RPR)

Lyme (IgG + IgM)

Hepatitis E (IgG and IgM)

Coeliac Disease

(Endomysium, Tissue transglutaminase)

Triptase

Covid 19 Antibodies

Faecal Markers (Calprotectin)

# **UKNEQAS - Infectious Immunology**

Anti-Hbs Detection

CMV IgG/IgM

Diagnostic Serology Hepatitis

Helicobacter pylori antigen from faeces

Hepatitis B Serology

Hepatitis C Serology

HIV Serology/POCT

HTLV

Measles and Mumps Serology

Parasite Serology

Parvovirus and Rubella Serology

Syphilis Serology

Toxoplasma IgM Serology

Toxoplasma IgG Serology

### **RCPAQAP Scheme**

Legionella (IgG) Serology Striated Muscle Antibodies Chlamydia Serology

### **INSTAND Scheme**

Adrenal Antibodies
HDV Serology and Functional Complement
Hepatitis E Serology

#### CSCQ Scheme

Lyme Borrelia Serology

### **Laboratory Quality Scheme**

Herpes Simplex 1 & 2 Antibodies Cytomegalovirus Antibodies

Antistreptolysin O Titre

Helicobacter Pylori IgG Antibodies

RNA Polymerase III

Euroimmun ifQ-Lubeck (Liver) Autoimmune Disease Scheme

Measles Serology

Mumps Serology

Mycoplasma Serology

**VZV** Serology

**EBV Serology** 

### **ENDOCRINOLOGY**

### **UKNEQAS**

Steroid Hormones

Peptide Schemes 1 to 4

Thyroid Scheme

Allergens Scheme

SHBG

Prostate Specific Antigen

**Tumour Markers** 

PTH

Specific IgE/Total IgE

AFP/CFA

### **CERVICAL SCREENING**

### PHE

Gynaecological Cytopathology EQA Scheme (GEQA)
National EQA Scheme for the Preparation and Staining
of Cervical Liquid Based Cytology Samples (TEQA)

### HOLOGIC

ThinPrep Stain EQA

## **UKNEQAS** for Microbiology

Molecular Detection of HPV

### DIAGNOSTIC CYTOLOGY

### UKNEQAS for CPT

Stained Non-Gynaecological Cytology Module.

All non-gynaecological (diagnostic cytology), including Urine Cytology, are referred to a UKAS accredited laboratory for reporting.

### **ANDROLOGY**

#### UKNEQAS

Semen Analysis Scheme

### INFORMATION SECURITY

Accredited by British Standards Institute ISO/IEC 27001:2013

### Links to the UKAS Schedules of Accreditation

**HSL Blood Sciences (8169)** 

https://www.ukas.com/wp-content/uploads/schedule\_uploads/00007/8169-Medical-Single.pdf

**HSL Infection Sciences (8860)** 

https://www.ukas.com/wp-content/uploads/schedule\_uploads/00007/8860-Medical-Single.pdf

HSL Molecular Pathology and Genetics (8059)

https://www.ukas.com/wp-content/uploads/schedule\_uploads/00007/8059-Medical-Single.pdf

TDL Manchester (8812)

https://www.ukas.com/wp-content/uploads/schedule\_uploads/00007/8812-Medical-Multiple.pdf

TDL Andrology (10199)

https://www.ukas.com/wp-content/uploads/schedule\_uploads/00007/10199-Medical-Single.pdf

**HSL Cervical Screening (8511)** 

https://www.ukas.com/wp-content/uploads/schedule\_uploads/00007/8511-Medical-Single.pdf

# **Measurement Uncertainty**

Medical laboratories are responsible for ensuring that test results are fit for clinical application by defining analytical performance goals and selecting appropriate measurement procedures. All types of measurement have some inaccuracy due to bias and imprecision; therefore measurement results can only be estimates of the values of the quantities being measured. To properly use such results, medical laboratories and their clinical users need some knowledge of the accuracy of such estimates.

The complete result of a measurement is a value, a unit and an estimate of uncertainty. This estimate of uncertainty is conventionally referred to as Measurement Uncertainty (MU) and incorporates the cumulative range of factors involved in the testing procedure itself in addition to consideration of the inter-individual and intra-individual biological variation which will potentially influence the overall test result. Evaluating measurement uncertainty is an ISO 15189:2012 accreditation requirement.

In terms of MU determined by the TDL/HSL group of laboratories, it should be noted all assays are performed in strict accordance with the manufacturers' instructions. MU, which has been estimated for each assay during the verification procedure, is reviewed at regular intervals to ensure that MU values do not exceed the pre-defined maximum allowable uncertainty for each assay.

Overall assay performance is also regularly monitored through internal quality control (IQC) and external quality assessment (EQA) schemes and incorporated in test result interpretation.

MU for individual assays is available upon request.

# Sample rejection criteria

Sometimes tests cannot be performed in the laboratory if samples fall short of the quality, volume or other eligibility criteria such as clear sample labelling. In these cases, the potential risk to the patient management is that the laboratory may need to reject the samples, and not carry out processing. Sometimes the laboratory can rectify a situation where a sample falls short of the sample acceptance criteria though in this case the risk to the patient management may be a breach of stated turnaround time and a delay to provision of the result. In order to reduce the risk of sample rejection or delay to provision of results, please ensure all sample taking criteria are met.

# **Summary list for sample rejection**

- Incorrect sample types received:
  - Basic incorrect blood tube/other sample.
  - Samples without the appropriate preservative (e.g. acidified urine samples).
  - Samples that are received ambient, when a frozen sample is required.
  - Samples that are received unprotected from light, when they are required to be covered at the point of venepuncture.
- Samples in incorrect containers
   (e.g. cervical cytology must be a ThinPrep vial;
   urine cytology must be in a uricyte container).
- Insufficient sample received.
- No sample received.
- Labelling or form issues (mislabelled/ unlabelled/no forms/no clinical information).
- Clotted/haemolysed/lipaemic/icteric samples.
- Sample is broken or has leaked in transit.
- Stability time has been exceeded. Stability time is test dependant, and also refers to tests that can only be carried out on certain days of the week.
- Sample contamination (e.g. being in the same bag as a leaking sample).
- Samples are high risk or infectious.

- Samples that are received in expired tubes.
- Discontinued tests.

# **Department specific**

- Sample Reception will not accept samples packaged with needles of any kind.
- Haematology cannot accept frozen whole blood for testing.
- Coagulation cannot accept over or under filled samples for testing.
- Coagulation cannot accept previously frozen samples that have thawed in transit.
- Biochemistry cannot accept previously frozen samples that have thawed in transit.
- Biochemistry cannot accept samples that display antibody interference.
- Biochemistry cannot accept samples that have had separation delays/un-centrifuged samples that have been stored in the fridge.
- Biochemistry cannot accept paraprotein resulting in viscous samples.
- Biochemistry cannot accept CSF protein that is blood stained.
- Immunology cannot accept TBQ kits that:
  - Do not contain all of the appropriate tubes.
  - Are incubated for more than the specified 16 hours.
  - Have passed the incubation time period.
  - Are over or under filled.
- Microbiology cannot accept samples in non-sterile containers or in formalin.
- Referrals cannot accept samples without three points of identification for DRP testing.
- Referrals cannot accept samples that are not labelled by hand for blood group testing.
- Molecular Pathology cannot accept samples for Haemophilia testing without informed consent.
- Cervical Cytology cannot accept over or under filled samples for testing.

- Cervical Cytology cannot accept samples received within three months of the previous test in order to allow epithelial cells to regenerate.
- Cervical Cytology cannot accept samples containing a sample broom.
- Cervical Cytology can only accept samples received in a Hologic ThinPrep Vial.
- Urine cytology cannot accept delayed samples unless they have been refrigerated.

Samples deemed to be PRECIOUS (e.g. CSF, fluid, tissue, bone marrow and paediatric samples) will not be discarded by the laboratory. Results will include a comment relating to the condition of the sample (e.g. sample unlabelled).

# **Consultant advice and opinion**

Each department in the laboratory is consultant led. The TDL Consultants listed below have defined advice or professional support, TDL consultants can be contacted via the laboratory.

# **TDL Lead Consultants**

### **Chief Medical Officer**

# Dr Rachael Liebmann OBE

BSc Hons, MB, BCh, BAO, FRCPath, FAcadMed, SFFMI M

# **Allergy and Immunology**

### **Dr Scott Pereira**

MA, MB, B Chir, PhD, FRCPath

### **Professor Suranjith Seneviratne**

DPhil (Oxon), FRCP, FRCPath

### **Andrology**

### **Dr Shervl Homa**

PhD, ARCS, FIBMS

# **Biochemistry**

# **Dr Frank Geoghegan**

**FRCPath** 

### **Blood Transfusion**

### **Dr Vivienne Andrews**

**FRCPath** 

# **Cervical Cytology**

### **Dr Geraldine Soosay**

MB, BS, FRCPath

### **Dr Mary Falzon**

MRCS, LRCP, FRCPath

# **Diagnostic (Non-Cervical) Cytology**

### **Dr Tanya Levine**

**FRCPath** 

### **Dr Miguel Perez Machado**

**FRCPath** 

### Genetics

#### **Professor Michael Patton**

FRCP. FRCPCH

### **Haematology**

### Professor Adrian Bloor

MA, PhD, FRCP, FRCPath

### Histopathology

#### Dr Rachael Liebmann OBE

BSc Hons, MB, BCh, BAO, FRCPath, FAcadMed. SFFMLM

## **Medical Microbiology**

#### **Dr Robin Smith**

**FRCPath** 

# **Parasitology**

### Dr Laura Nabarro

**FRCPath** 

# **Point of Care Testing**

### **Dr Gilbert Wieringa**

MSc. FRCPath. EuSpLM

# **Special Coagulation**

### **Professor Marie Scully**

MRCP. FRCPath

# Virology

#### **Dr Mark Atkins**

BSc (Hons), MSc, MBBS, FRCPath

# **TDI Consultants**

# Allergy and Immunology

### Dr Scott Pereira

MA, MB, B Chir, PhD, FRCPath

### **Professor Suranjith Seneviratne**

DPhil (Oxon), FRCP, FRCPath

# **Andrology**

### **Dr Sheryl Homa**

PhD, ARCS, FIBMS

# **Biochemistry and Point of Care Testing**

### Dr Frank Geoghegan

FRCPath

### **Dr Gilbert Wieringa**

MSc, FRCPath, EuSpLM

# Professor Carel le Roux

**FRCPath** 

#### Dr Bernie Croal

MB, ChB, BSc Hons, MSc, MD, FRCP, FRCPath, CSci, EuSpLM

# Dr Colleen Ross

**FRCPath** 

# **Dr Denise Darby**

MRCP. FRCPath

# Mr Craig Webster

**FRCPath** 

## Mr Ed Kearnev

MSc, MCB, FRCPath

## **Dr Mavur Patel**

MB. BS. FRCPath

### Dr Michael Thomas

BSc, PhD, MSc, FRCPath, EuSpLM, SRCS, CSci

## Prof Pankaj Vadgama

MB. BS. FRCPath

### Dr Paul Holloway

**FRCPath** 

# **Dr Paul Masters**

MRCP. FRCPath

### **Dr Peter Galloway**

BSc. MB, ChB, MRCP, DCH, FRCPath

### Dr Rachel Webster

PhD, FRCPath

### **Dr Raieev Srivastava**

MBBS, MS, FRCS, FRCPath, EuSpLm

# **Blood Transfusion** and Haematology

### **Dr Vivienne Andrews**

**FRCPath** 

### Professor Adrian Bloor

MA, PhD, FRCP, FRCPath

#### Dr Abdel-Razek Abu-Sitta

**FRCPath** 

### Dr Alex Sternberg

MB, ChB, FRCPath

Dr Ali Rismani

FRCPath

**Dr Anastasia Chew** 

**FRCPath** 

**Prof Atul Mehta** 

B Chir. FRCPath

**Dr Chris McNamara** 

MB, BS, FRCPath

**Dr Clare Barnes** 

MRCP, FRCPath

**Dr Faris Al-Refaie** 

MB, ChB, FRCPath

**Dr Gerard Dolan** 

MBChB, FRCP, FRCPath

**Dr Glenn Rainey** 

**FRCPath** 

**Dr James Uprichard** 

**FRCPath** 

Dr Jindriska Lindsav

**FRCPath** 

**Dr John Paul Westwood** 

MD. FRCPath

**Dr Keith Gomez** 

**FRCPath** 

**Dr Kenneth Douglas** 

MB. ChB. FRCPath

Dr Kim Eliott

MB. ChB. FRCPath

Dr Maadh Aldouri

MB, BCh, FRCPath

Dr Mallika Sekhar

**FRCPath** 

**Dr Mamta Sohail** 

BM, BS, FRCPath

**Dr Mansour Ceesav** 

**FRCPath** 

**Professor Marie Scully** 

MRCP, FRCPath

**Dr Mark Vickers** 

MBChB, MCRP, DM, FRCPath

**Dr Philip Robson** 

**FRCPath** 

Dr Sajitha Sachchithanantham

**FRCPath** 

**Dr Salim Shafeek** 

MB. BS. FRCPath

**Dr Sreetharan Munisamy** 

MB, BChir, BA (Hons), MA,

MRCP FRCPath, PGCert, MedEd

Dr Taku Sugai

MB. BS. FRCPath

Dr Will Lester

BSc Hons, FRCP, FRCPath, PhD

**Cervical Cytology** 

**Dr Geraldine Soosay** 

MB. BS. FRCPath

**Dr Mary Falzon** 

MRCS, LRCP, FRCPath

Diagnostic

(Non-Cervical) Cytology

**Dr Tanya Levine** 

**FRCPath** 

**Dr Miguel Perez Machado** 

FRCPath

**Genetics: Molecular/Cytogenetics** 

**Professor Michael Patton** 

FRCP, FRCPCH

Dr Dragana Josif Josifova

MD. FRCPath

# Histopathology

### **Dr Rachael Liebmann OBE**

BSc Hons, MB, BCh, BAO, FRCPath, FAcadMed, SFFMLM

**Dr Adriana Martinez** 

**FRCPath** 

**Dr Anna Silvanto** 

**FRCPath** 

**Dr Carmel Ryan** 

**FRCPath** 

Dr Ezra Nigar

**FRCPath** 

**Dr Gillian Williams** 

**FRCPath** 

Dr Lajja Panchal

**FRCPath** 

Dr Nidhi Prasad

**FRCPath** 

Dr Rashmi Haria

MB BS FRCPath

**Dr Tanya Levine** 

**FRCPath** 

Dr Shymala Fernandez

**FRCPath** 

## **Medical Microbiology**

### **Dr Robin Smith**

**FRCPath** 

**Dr Alistair Leanord** 

**FRCPath** 

Dr Antonia Scobie

MBBS, BSc MSc, DTM&H,

MRCP(ID), FRCPath

**Professor Brian Jones** 

MB. ChB. FRCPath

Dr Damien Mack

MB, BS, MRCP, MSc, FRCPath

**Dr Emmanuel Wey** 

MB, BS, FRCPath

Dr Indran Balakrishnan

BSc, MSc, MRCP, FRCPath

**Dr Jonathon Lambourne** 

MB, BS, FRCPath

Dr Rajeev Rajendran

MB, BS, FRCPath

Dr Rajesh Rajendran

**FRCPath** 

**Dr Simon Warren** 

**FRCPath** 

**Dr Sophie Collier** 

**FRCPath** 

Dr Stephen Mepham

MB. ChB. FRCPath

**Dr Vanya Gant** 

**FRCPath** 

**Parasitology** 

Dr Laura Nabarro

**FRCPath** 

Dr Gauri Godbole

**FRCPath** 

**Special Coagulation** 

**Professor Marie Scully** 

MRCP, FRCPath

**Virology** 

**Dr Mark Atkins** 

BSc (Hons), MSc, MBBS, FRCPath

**Dr Colin Graham Fink** 

MB, ChB, FRCPath

# **Special instructions for samples**

- Contact the laboratory for special sample tubes/containers/instructions.
- 2 Confirmation of not negative drug screens by LCMS/MS may take up to 5 days.
- 3 Clinical history essential and protect from light.
- 4 Send to the laboratory same day.
- 5 Do not send sample to the laboratory between Friday noon and Monday morning.
- 6 Contact the Referrals Department before taking and sending sample to the laboratory.
- 7 Sample should be separated and frozen if sending overnight.
- 8 DRP Form required. DRP Form can be found at the back of the guide.
- 9 Clinical history must be provided.
- 10 Contact the laboratory for special stability tubes for lymphocyte subsets – or take an EDTA sample and ensure same day delivery to the laboratory, Monday to Friday noon (do not send sample between Friday noon and Monday morning).
- 11 Patient consent required. Consent Form can be found at the back of this guide.
- 12 Please provide one sample for each person being tested.
- 13 Protect from light.
- 14 Provide details of travel history.
- 15 Ammonia

Sample: EDTA plasma only. Full tubes and tightly stoppered. On ice, centrifuged and analysed 20-30 mins post venepuncture (or plasma can be frozen). If haemolysed gives falsely high results.

Patient: Fasting. Avoid smoking.

# **Profile panel information**

| Profile name ———    | Coagulation Profile 1                        |
|---------------------|--|
| Profile content —   | Prothrombin Time<br>APTT<br>Fibrinogen       |
| Turnaround time ——  | TAT: 4 hours                                 |
| Code —              | - CLPF                                       |
| Sample requirements | Special instructions for samples (see above) |

16 Lactate

Sample: Fluoride oxalate plasma only. On ice and separate from cells 15-30 mins, analyse promptly. Handle with care as sweat contains large amounts of lactate. No tourniquet.

Patient: Rest 30 mins prior to test.

17 Homocysteine

Should be spun and separated within 1 hour of venepuncture.

18 Citrate Samples

Samples should be double spun and separated and frozen within 4-8 hours of sample taking, if a delay is expected with transportation to the laboratory, samples must be transported as frozen.

- 19 Must include patient's age, height and weight.
- 21 Urine cytology container, ideally first catch, mid-morning specimen.
- 22 Must be fresh.
- 30 Collect sample at end of exposure.
- 33 Sample must be labelled by hand with first name, family name, gender and date of birth detailed on sample and form. Do not use labels other than the tube label.
- 34 Samples must arrive in the laboratory on the same day of sample taking or contact the laboratory.
- 35 Patient should be fasting and resting for 30 mins before sample taking. Samples need handling urgently.
- 36 Renin: Sample collected either upright/active or resting/supine (3 hours lying). EDTA Plasma must be frozen within 2 hours.
- 37 Provide sample time and date of collection.
- 38 EDTA sample should not be separated: send whole blood.
- 40 Informed Consent is required for these tests.
- 41 Recommendation for patient to attend Patient Reception for sample taking.
- 42 LGV can be added to a positive chlamydia sample using the same swab if requested within 4 days of receipt of result.
- 43 Please contact lisa.levett@tdlpathology.com for details for referring samples to the laboratory for sequencing testing.

# **TDL Screening Profiles DL1-DL12**

### **DL1 Biochemistry Profile**

Urea and Electrolytes: Sodium, Potassium, Chloride, Bicarbonate, Urea. Creatinine. eGFR

### **Liver Function Tests:**

Bilirubin, Alk Phosphate, AST, ALT, Gamma GT, Total Protein, Albumin, Globulin

Cardiac/Muscle Enzymes: LDH, CK

Bone Markers: Calcium. Phosphate, Uric Acid

Glucose Trialvcerides Cholesterol Iron (TIBC included)

#### TAT: 4 hours

DL<sub>1</sub>

### DL1L

plus HDL Cholesterol, LDL Cholesterol, Non-HDL Cholesterol



# **DL5 Biochemistry** & Haematology **Postal Profile**

### AS DL4

DL5/DL5L do not include ESR and Phosphate as these results may be more affected by overnight transit times.

### TAT: 4 hours

DL<sub>5</sub>

#### DL5L

plus HDL Cholesterol, LDL Cholesterol, Non-HDL Cholesterol



# **DL2 Biochemistry** (24 Parameters) & **Haematology Profile**

#### **HAEMATOLOGY**

FBC, FSR

#### **BIOCHEMISTRY**

Urea and Electrolytes: Sodium, Potassium, Chloride, Bicarbonate, Urea. Creatinine. eGFR

### **Liver Function Tests:**

Bilirubin. Alk Phosphate. AST, ALT, Gamma GT, Total Protein, Albumin, Globulin

Cardiac/Muscle Enzymes: LDH, CK

Bone Markers: Calcium. Phosphate, Uric Acid

Trialvcerides Cholesterol Iron (TIBC included)

### TAT: 4 hours

DL<sub>2</sub>

Glucose

#### DI 21

plus HDL Cholesterol, LDL Cholesterol, Non-HDL Cholesterol





# **DL6 General Well Person Profile**

DL<sub>2</sub> FT4/TSH Ferritin

### TAT: 4 hours

DL<sub>6</sub>

### DL6L

plus HDL Cholesterol, LDL Cholesterol, Non-HDL Cholesterol



# **DL3 Haematology Profile**

FBC **FSR** 

#### TAT: 4 hours

DL3



# **DL4 Biochemistry** (16 Parameters) & **Haematology Profile**

#### **HAEMATOLOGY**

FBC, ESR

### RIOCHEMISTRY

Renal Function: Urea. Creatinine, eGFR

#### **Liver Function Tests:**

Bilirubin. Alk Phosphate. AST, ALT, Gamma GT, Total Protein, Albumin, Globulin

Bone Markers: Calcium. Phosphate, Uric Acid

Glucose Trialvcerides Cholesterol

### TAT: 4 hours

DL4

#### DL4L

plus HDL Cholesterol, LDL Cholesterol, Non-HDL Cholesterol





### **TDL Screening Profiles DL1-DL12**

### **DL7 Well Man Profile**

DL<sub>2</sub> FT4/TSH Ferritin Prostate Profile

#### TAT: 4 hours

DI 7

### DL7L

plus HDL Cholesterol, LDL Cholesterol, Non-HDL Cholesterol



# **DL9M Senior Male** Profile 60+

DL<sub>2</sub> HDI /I DI Cholesterol HbA1C FT4/TSH Prostate Profile CRP Ferritin MSU Vitamin D (25 OH)

Lp-PLA2 (PLAC) Test

### TAT: 2 days

DL9M







# **DL8 Well Person Profile**

DL<sub>2</sub> FT4/TSH Ferritin Vitamin D

#### TAT: 4 hours

DI 8

#### DL8L

plus HDL Cholesterol, LDL Cholesterol, Non-HDL Cholesterol



# DL10 Cardiovascular Risk Profile 1

Cholesterol Triglycerides **HDL Cholesterol** LDL Cholesterol Non-HDL Cholesterol Apolipoprotein A1 Apolipoprotein B Lipoprotein (a) hsCRP Lp-PLA2 (PLAC) Test

### TAT: 3 days

**DL10** 



# DL12 7 STI Profile by PCR (7 PCR Tests from 1 Sample)

Chlamvdia trachomatis Neisseria gonorrhoea Mycoplasma genitalium Ureaplasma species Trichomonas vaginalis Gardnerella vaginali Herpes Simplex I/II

## All tests can be requested individually

TAT: 2 days

DL12

### FCRU / PCR Swab / TPV or Aptima urine or multisite swab

# **DL9F Senior Female** Profile 60+

HDL/LDL Cholesterol HbA1C FT4/TSH CRP Ferritin MSU Vitamin D (25 OH) HF4

#### TAT: 2 days

Lp-PLA2 (PLAC) Test

DL9F

DL<sub>2</sub>



# **DL11 Cardiovascular** Risk Profile 2

Cholesterol Trialvcerides **HDL Cholesterol** LDL Cholesterol Non-HDL Cholesterol Apolipoprotein A1 Apolipoprotein B Lipoprotein (a) Fibrinogen hsCRP Lp-PLA2 (PLAC) Test Homocysteine

### TAT: 3 days

DL11



| TEST   | CODE | SAMPLE REQS                       | TAT             |
|--|------|-----------------------------------|-----------------|
| 5 HIAA   | RU5H | PU (collect on acid) <sup>1</sup> | 5 days          |
| 5' Nucleotidase  | 5NT  | B                                 | 5 days          |
| 6-Thioguanine Nucleotides  | TGN  | AA                                | 2 weeks         |
| 21 Hydroxylase Ab's  | 21HA | (Frozen)                          | 10 days         |
| Acetylcholine Receptor Autoantibodies                              | ACRA | <b>B</b> 4                        | 5 days          |
| Acid Phosphatase – Total   | APT  | В                                 | 5 days          |
| Adenosine Deaminase  | AD   | (A) (B) / Fluid                   | 3 weeks         |
| Adiponectin  | ADIP | B                                 | 2 weeks         |
| Albumin  | ALB  | B                                 | 4 hours         |
| Alcohol (Medical) [Do not use alcohol swab prior to sample taking] | ALC0 | <b>G</b> 1                        | 4 hours         |
| Alcohol (Urine)  | UALC | RU                                | 4 hours         |
| Aldolase   | ALD0 | B                                 | 5 days          |
| Alkaline Phosphatase   | ALP  | B                                 | 4 hours         |
| Alkaline Phosphatase Isoenzymes                                    | APIE | B                                 | 5 days          |
| Alpha-1-Antitrypsin (Serum)  | A1AT | B                                 | 1 day           |
| Alpha-1-Antitrypsin (Stool)  | A1AF | RF                                | 10 days         |
| Alpha-1-Antitrypsin Genotype<br>- PI*M, PI*S, PI*Z                 | GENE | <b>A</b> 9                        | 5 weeks         |
| Requires patient informed consent.                                 |      |                                   |                 |
| Alpha-1-Glycoprotein   | OROS | (Frozen)                          | 5 days          |
| Alpha-1-Microglobulin  | A1MG | RU 1,22                           | 10 days         |
| Alpha-2-Macroglobulins   | A2MG | B                                 | 5 days          |
| Alpha-Fetoprotein  | AFP  | B                                 | 4 hours         |
| ALT (Alanine Aminotransferase) (SGPT)                              | ALT  | B                                 | 4 hours         |
| Aluminium (Blood)  | ALUM | <b>(</b>                          | 7 days          |
| Amino Acid (EDTA Plasma)   | AMIN | (Frozen EDTA Plasma)              | 7 days          |
| Amino Acid Quantitative (Urine)                                    | UAAQ | RU (Frozen)                       | 7 days          |
| Aminolevulinic Acid (Urine)  | RUAL | 100mls <b>PU</b>                  | 5 days          |
| Ammonia  | AMMO | (Frozen) 15                       | 4 hours         |
| Amylase (Urine)  | UAMY | CU                                | 4 hours         |
| Amylase (Venous/Self-collect)                                      | AMY  | B / B (TDL Tiny)                  | 4 hours / 1 day |
| Amylase Isoenzymes   | AMYI | B                                 | 5 days          |
| Amyloidosis (Amyloid A Protein)                                    | SAA  | В                                 | 5 days          |
| Androstanediol Glucuronide   | ANDG | В                                 | 3 weeks         |
|  |      |                                   |                 |

| TEST   | CODE | SAMPLE REQS                        | TAT             |
|--|------|------------------------------------|-----------------|
| Angiotensin II   | ANG2 | (Frozen plasma)                    | 2 weeks         |
| Angiotensin Converting Enzyme                                  | ACE  | B                                  | 4 hours         |
| Angiotensin Converting Enzyme – CSF                            | ACEF | CSF (Frozen)                       | 2 weeks         |
| Antimony (Urine)   | ANTI | <b>RU</b> 30                       | 10 days         |
| Antimullerian Hormone (AMH)<br>(Venous/Self-collect)           | АМН  | B / B (TDL Tiny)                   | 4 hours / 1 day |
| AP50 Alternative Hemolytic Complement                          | AP50 | (Frozen)                           | 2 weeks         |
| Apolipoprotein A1  | APOA | B                                  | 3 days          |
| Apolipoprotein B   | APOB | B                                  | 3 days          |
| Apolipoprotein C   | APOC | B                                  | 3 months        |
| Apolipoprotein E (12 hours fasting)                            | AP0E | (fasting)                          | 5 days          |
| Arsenic (Blood)  | ARS  | A or H                             | 5 days          |
| Arsenic (Urine)  | ARSE | RU <sup>30</sup>                   | 5 days          |
| Arylsulphatase A   | ARYL | <b>(1)</b> 5,6                     | 8 weeks         |
| Aspartate Transaminase (AST) (SGOT)                            | AST  | B                                  | 4 hours         |
| Bence-Jones Protein  | RBJP | RU or CU                           | 5 days          |
| Beta 2 Microglobulin (Serum)                                   | B2MG | B                                  | 2 days          |
| Beta 2 Microglobulin (Urine)                                   | UB2M | RU                                 | 3 days          |
| Beta-Glucuronidase (Sly Disease)                               | BGLU | <b>(1) (1)</b> 9,4                 | 8 weeks         |
| Bicarbonate  | HC03 | B                                  | 4 hours         |
| Bile Acids – Serum   | BILE | В                                  | 4 hours         |
| Bilirubin (Direct)   | DBIL | В                                  | 4 hours         |
| Bilirubin (Total)  | BILI | В                                  | 4 hours         |
| Bilirubin (Urine)  | UBIL | RU                                 | 1 day           |
| Biotinidase  | BIOT | (Frozen plasma) <sup>4</sup>       | 3 weeks         |
| Bismuth  | BISM | В                                  | 5 days          |
| BNP (NT-pro BNP)   | BNP  | B                                  | 4 hours         |
| Bone Alkaline Phosphatase                                      | BALP | (Frozen)                           | 2 weeks         |
| Bone Screen  | BONE | <b>₿</b> CU                        | 4 hours         |
| Bone Screen (Bloods only)                                      | BON2 | В                                  | 4 hours         |
| BUN (Blood Urea Nitrogen)                                      | BUN  | B                                  | 4 hours         |
| C Reactive Protein (Venous/Self-collect)                       | CRP  | B / B (TDL Tiny)                   | 4 hours / 1 day |
| C Reactive Protein (High Sensitivity)<br>(Venous/Self-collect) | HCRP | B / B (TDL Tiny)                   | 4 hours / 1 day |
| C1 Esterase: Function & Total                                  | FC1E | (Plasma<br>Frozen) <sup>4,18</sup> | 10 days         |

| TEST   | CODE | SAMPLE REQS                   | TAT             |
|--|------|-------------------------------|-----------------|
| C1q Binding Immune Complex   | IMCP | B                             | 5 days          |
| Cadmium (Blood)  | CADM | A or (1)                      | 5 days          |
| Cadmium (Urine)  | URCD | <b>RU</b> 30                  | 5 days          |
| Calcium (24 hour Urine)  | UCA  | PU or acid urine              | 4 hours         |
| Calcium (Venous/Self-collect) Sample integrity of self-collected samples may be compromised on received samples older than 2 days.             | CA   | B / B (TDL Tiny)              | 4 hours / 1 day |
| Calcium + Vitamin D (Venous/Self-collect) Sample integrity of self-collected samples may be compromised on received samples older than 2 days. | CALD | B / B (TDL Tiny)              | 1 day           |
| Calcium/Creatinine Ratio   | CACR | RU 🕒                          | 4 hours         |
| Carbohydrate Deficient Glycoprotein  | CDG  | B                             | 2 weeks         |
| Carbohydrate Deficient Transferrin<br>(CDT) (Venous/Self-collect)  | CDT  | B / B (TDL Tiny) <sup>4</sup> | 3 days          |
| Cardiovascular Risk Profile 1  | PP10 | BB                            | 3 days          |
| Cardiovascular Risk Profile 2  | PP11 | <b>B B B C</b> 34             | 3 days          |
| Caeruloplasmin   | CERU | B                             | 1 day           |
| Chest Pain Profile   | CPP  | B                             | STAT            |
| Chloride   | CL   | B                             | 4 hours         |
| Cholesterol  | СНО  | B                             | 4 hours         |
| Cholesterol (Familial<br>Hypercholesterolaemia)<br>Requires patient informed consent.  | GENE | <b>A A</b> <sup>9</sup>       | 7 weeks         |
| Cholinesterase (Serum/Pseudo)  | CHPS | B                             | 4 hours         |
| Chromium (Blood)   | CHRO | A                             | 5 days          |
| Chromium (Urine)   | URCR | <b>RU</b> 30                  | 4 weeks         |
| Chromogranin A   | CGA  | B                             | 5 days          |
| Chromogranin A & B   | MTAB | (Frozen Plasma)               | 3 weeks         |
| Citrate (Blood)  | CITR | B                             | 5 days          |
| Citrate (Urine)  | UCIT | CU (Frozen)                   | 5 days          |
| CK (MB Fraction)   | CKMB | В                             | 4 hours         |
| CK Isoenzymes  | CKIE | В                             | 5 days          |
| Cobalt (Blood)   | СОВ  | A                             | 5 days          |
| Cobalt (Urine)   | COBA | <b>RU</b> 30                  | 5 days          |
| Coenzyme Q10   | CQ10 | B                             | 2 weeks         |
| Cold Agglutinin  | CAGG | <b>J</b> <sup>1</sup>         | 5 days          |
| Collagen (Type I, II, IV) Antibodies   | COAB | <b>3</b>                      | 10 days         |

| Collagen Type 1 Cross-Linked NTX  N-Telopeptide – NTX  Complement C1q  C1Q  C1Q  C1Q  C1Q  C1Q  C2  C2  C3  C3  Complement C5  C5A  C5A  C6  C6  C6  C6  C7  C7  C7  C7  C7  C7  | TEST                                    | CODE | SAMPLE REQS      | TAT             |
|--|---|------|------------------|-----------------|
| Complement C2  C5A  C5A  C5A  C5A  C5A  C6A  C6A  C6A  | 0 71                                    | NTX  | 2nd EMU          | 2 weeks         |
| Complement C5 Complement C6 Separate and freeze within 2 hours after collection.  Complement C7 Separate and freeze within 2 hours after collection.  Complement C8 Separate and freeze within 2 hours after collection.  Complement C8 Separate and freeze within 2 hours after collection.  Complement C9 C9 Separate and freeze within 2 hours after collection.  Complement C9 Separate and freeze within 2 hours after collection.  Complement C9 Separate and freeze within 2 hours after collection.  Complement Factor H FACH Separate Separate and freeze within 2 hours after collection.  Complement Factor H FACH Separate  | Complement C1q                          | C1Q  | B                | 5 days          |
| Complement C6  * Separate and freeze within 2 hours after collection.  Complement C7  * Separate and freeze within 2 hours after collection.  Complement C8  * Separate and freeze within 2 hours after collection.  Complement C9  * Separate and freeze within 2 hours after collection.  Complement C9  * Separate and freeze within 2 hours after collection.  Complement C9  * Separate and freeze within 2 hours after collection.  Complement Factor H  FACH  3 weeks  Copper (Serum)  5 weeks  5 weeks  5 weeks  5 weeks   | Complement C2                           | C2   | B                | 10 days         |
| * Separate and freeze within 2 hours after collection.  Complement C7  * Separate and freeze within 2 hours after collection.  Complement C8  * Separate and freeze within 2 hours after collection.  Complement C9  * Separate and freeze within 2 hours after collection.  Complement C9  * Separate and freeze within 2 hours after collection.  Complement Factor H  FACH  3 weeks  Copper (Serum)  COPP  5 days   | Complement C5                           | C5A  | B                | 2 weeks         |
| * Separate and freeze within 2 hours after collection.  Complement C8 * Separate and freeze within 2 hours after collection.  Complement C9 * Separate and freeze within 2 hours after collection.  Complement Factor H  FACH  Gopper (Serum)  COPP  To weeks  S weeks  S weeks  Topper (Serum)  FACH  To weeks  S weeks  Topper (Serum)  To weeks  S weeks  Topper (Serum)  To weeks  S weeks   | •                                       | C6   | B (Frozen)*      | 5 weeks         |
| * Separate and freeze within 2 hours after collection.  Complement C9  * Separate and freeze within 2 hours after collection.  Complement Factor H  Copper (Serum)  COPP  GOPP  FACH  GOPP  FACH  GOPP  GOPP  GOPP  FACH  FACH | • • •                                   | C7   | B (Frozen)*      | 5 weeks         |
| * Separate and freeze within 2 hours after collection.  Complement Factor H FACH 3 weeks  Copper (Serum) COPP 3 or \$\mathbb{K}\$ 5 days   | •                                       | C8   | B (Frozen)*      | 5 weeks         |
| Copper (Serum) COPP 3 or 6 5 days  | • | C9   | B (Frozen)*      | 5 weeks         |
|  | Complement Factor H                     | FACH | B                | 3 weeks         |
|  | Copper (Serum)                          | COPP | B or 🚯           | 5 days          |
| Copper (Urine) URCU CU 5 days  | Copper (Urine)                          | URCU | CU               | 5 days          |
| Cortisol Binding Globulin CBG (Frozen) 1 month   | Cortisol Binding Globulin               | CBG  | (Frozen)         | 1 month         |
| Cotinine (Urine) COTT RU 2 days  | Cotinine (Urine)                        | COTT | RU               | 2 days          |
| Creatine Kinase (CK, CPK) CKNA (3) 4 hours   | Creatine Kinase (CK, CPK)               | CKNA | В                | 4 hours         |
| Creatinine (including eGFR) CREA (3) / (5) (TDL Tiny) 4 hours / 1 day (Venous/Self-collect)  |   | CREA | B / B (TDL Tiny) | 4 hours / 1 day |
| Creatinine (Urine) UCR CU 4 hours  | Creatinine (Urine)                      | UCR  | CU               | 4 hours         |
| Creatinine Clearance CRCL 3 CU 4 hours   | Creatinine Clearance                    | CRCL | <b>₿</b> CU      | 4 hours         |
| Crosslaps (Serum DPD) SDPD Greeze within 4 days 24 hours)  | Crosslaps (Serum DPD)                   | SDPD | • (              | 4 days          |
| Cryoglobulins CRYO J <sup>6</sup> 10 days  | Cryoglobulins                           | CRY0 | <b>J</b> 6       | 10 days         |
| Cyclosporin CYCL (A) 1 day   | Cyclosporin                             | CYCL | A                | 1 day           |
| Cystatin C CYCC (3 5 days  | Cystatin C                              | CYCC | B                | 5 days          |
| Cystine – Quantitative (Beta-CTX) QCYS PU 5 days   | Cystine – Quantitative (Beta-CTX)       | QCYS | PU               | 5 days          |
| Deoxypyridinoline (DPD) – Serum SDPD (Freeze within 4 days 24 hours)   | Deoxypyridinoline (DPD) – Serum         | SDPD | • (              | 4 days          |
| Deoxypyridinoline (DPD) – Urine DPD EMU 4 days   | Deoxypyridinoline (DPD) – Urine         | DPD  | EMU              | 4 days          |
| Diabetic Profile 1 DIAB (A) (G) 8 hours  | Diabetic Profile 1                      | DIAB | AG               | 8 hours         |
| Diabetic Profile 2 DIA2 (A) G RU 2 days  | Diabetic Profile 2                      | DIA2 | (A) (G) RU       | 2 days          |
| Diamine Oxidase Activity DIAM 3 2 weeks  | Diamine Oxidase Activity                | DIAM | В                | 2 weeks         |
| Elastase (RF/Self-collect) ELAS RF* / Stool/faecal 5 days *5 day stability time ambient. container*  | ,                                       | ELAS |                  | 5 days          |
| Electrolytes ELEC 3 4 hours  | Electrolytes                            | ELEC | В                | 4 hours         |

| TEST  | CODE  | SAMPLE REQS  | TAT   |
|---|---|--|---|
| Electrolytes (Urine)  | UELE  | CU   | 4 hours   |
| ELF/Enhanced Liver Fibrosis   | ELF   | B  | 5 days  |
| Eosinophil Cationic Protein   | ECP   | В  | 7 days  |
| Faecal Fat (1 day collection)   | TFFA  | LF 6   | 5 days  |
| Faecal Fat (3 day)  | FFAT  | LF 6   | 5 days  |
| Faecal Lactoferrin  | FLAC  | RF   | 5 days  |
| Faecal Sugar Chromatography   | FCR0  | RF (Frozen)  | 3 weeks   |
| Ferritin (Venous/Self-collect)  | FERR  | B / B (TDL Tiny)   | 4 hours / 1 day   |
| Fibrotest (Liver Fibrosis)  | FIBT  | B  | 2 weeks   |
| Fluoride (Urine)  | UFL   | RU   | 5 days  |
| Folate (Red Cell)   | RBCF  | A  | 2 days  |
| Folate (Serum)  | F0LA  | B  | 1 day   |
| Free Fatty Acids  | FFA   | (Frozen) 1   | 10 days   |
| Fructosamine  | FRUC  | B  | 1 day   |
| Galactose-1-Phosphate Uridyltransferase   | GAL1  | 5,6  | 2 weeks   |
| Galactosidase — Alpha* *Sample must reach TDL Referrals Dept. urgently, to be tested within 24 hours of collection. Monday— Thursday only. Referrals to send Immediately.   | GALA  | J*   | 6 weeks   |
| Gall Stone Analysis   | RSTA  | STONE  | 10 days   |
| Gamma GT  | GGT   | B  | 4 hours   |
|   |   |  |   |
| Gastrin   | GAST  | (Plasma)   | 5 days  |
| Gastrin<br>Globulin   | GAST<br>GLOB                                      | A (Plasma)   | 5 days<br>4 hours   |
| -   |   |  |   |
| Globulin  | GLOB  | B  | 4 hours   |
| Globulin<br>Glucagon  | GLOB<br>GLUG                                      | B<br>(Plasma)  | 4 hours<br>10 days  |
| Globulin Glucagon Glucose Haemochromatosis –  | GLOB<br>GLUG<br>RBG                               | (Plasma)   | 4 hours<br>10 days<br>4 hours   |
| Globulin Glucagon Glucose Haemochromatosis – HFE common variants C282Y + H63D   | GLOB<br>GLUG<br>RBG<br>HMD                        | (Plasma) (G) (A) 9   | 4 hours 10 days 4 hours 3 days  |
| Globulin Glucagon Glucose Haemochromatosis – HFE common variants C282Y + H63D Haemosiderin (Urine)  | GLOB<br>GLUG<br>RBG<br>HMD                        | (Plasma) (C) (A) 9  EMU  | 4 hours 10 days 4 hours 3 days 2 weeks  |
| Globulin Glucagon Glucose Haemochromatosis – HFE common variants C282Y + H63D Haemosiderin (Urine) Haptoglobin  | GLOB<br>GLUG<br>RBG<br>HMD<br>HSID<br>HAPT        | (Plasma) (C) (A) 9  EMU (B)  | 4 hours 10 days 4 hours 3 days 2 weeks 5 days   |
| Globulin Glucagon Glucose Haemochromatosis – HFE common variants C282Y + H63D Haemosiderin (Urine) Haptoglobin HbA1c (Venous/Self-collect)  | GLOB GLUG RBG HMD HSID HAPT GHB                   | (Plasma) (Pl | 4 hours 10 days 4 hours 3 days  2 weeks 5 days 6 hours / 1 day                              |
| Globulin Glucagon Glucose Haemochromatosis - HFE common variants C282Y + H63D Haemosiderin (Urine) Haptoglobin HbA1c (Venous/Self-collect) HDL Cholesterol  | GLOB GLUG RBG HMD HSID HAPT GHB                   | (Plasma) (Pl | 4 hours 10 days 4 hours 3 days  2 weeks 5 days 6 hours / 1 day 4 hours                      |
| Globulin Glucagon Glucose Haemochromatosis – HFE common variants C282Y + H63D Haemosiderin (Urine) Haptoglobin HbA1c (Venous/Self-collect) HDL Cholesterol Homocysteine (Quantitative)  | GLOB GLUG RBG HMD HSID HAPT GHB HDL HOMO          | (Plasma) (Plasma) (Plasma) (Plasma) (Plasma) (Plasma) (Plasma)   | 4 hours 10 days 4 hours 3 days 2 weeks 5 days 6 hours / 1 day 4 hours 1 day                 |
| Globulin Glucagon Glucose Haemochromatosis - HFE common variants C282Y + H63D Haemosiderin (Urine) Haptoglobin HbA1c (Venous/Self-collect) HDL Cholesterol Homocysteine (Quantitative) Homocysteine (Urine)                         | GLOB GLUG RBG HMD HSID HAPT GHB HDL HOMO HCYS     | (Plasma) (Plasma) (Plasma) (Plasma) (Plasma) (Plasma) (Plasma) (Plasma)  | 4 hours 10 days 4 hours 3 days  2 weeks 5 days 6 hours / 1 day 4 hours 1 day 2 weeks        |
| Globulin Glucagon Glucose Haemochromatosis - HFE common variants C282Y + H63D Haemosiderin (Urine) Haptoglobin HbA1c (Venous/Self-collect) HDL Cholesterol Homocysteine (Quantitative) Homocysteine (Urine) Homovanillic Acid (HVA) | GLOB GLUG RBG HMD HSID HAPT GHB HDL HOMO HCYS HVA | (Plasma) (C) (Plasma) (C) (Plasma) (C) (Plasma) (C) (Plasma) (C) (Plasma)  | 4 hours 10 days 4 hours 3 days  2 weeks 5 days 6 hours / 1 day 4 hours 1 day 2 weeks 5 days |

| Institute   Inst   | TEST  | CODE   | SAMPLE REQS   | TAT   |
|--|---|--|---|---|
| Immunoglobulin D   IGD   IGD   IGB   Iday   Immunoglobulin E – Total   IGE   Iday   Immunoglobulin G   IGG   Iday   Immunoglobulin G   IGG   Iday   Immunoglobulin M   IGM   Iday   Immunoglobulin K   Iday   Immunoglobulin K   Iday   Immunoglobulin K   Iday   Immunoglobulin K   Iday   Iday   Immunoglobulin K   Iday   Iday   Immunoglobulin K   Iday   Iday   Immunoglobulin K   Iday   I    | IgG Subclasses  | IGSC   | В   | 5 days  |
| Immunoglobulin E – Total IGE IG 1 day Immunoglobulin G IGG IGG IGG IGG IGGG IGGG IGGG IGGG   | lmmunoglobulin A  | IGA  | В   | 4 hours   |
| Immunoglobulin G   | Immunoglobulin D  | IGD  | В   | 5 days  |
| Immunoglobulin M IGM G A hours  Immunoglobulins (IgG, IgM, IgA) IMM G A hours  Insulin-Like Growth Factor 2 IGF2 G A 1 month  Iodide – Urine UIOD RU 1 week  Iodine – Serum IODI G A 1 week  Ionised Calcium ICPA G A 2 5 days  Iron (TIBC included) (Venous/Self-collect) FE G A 3 / G (TDL Tiny) A hours / 1 day  Iron Overload Profile IOP G G A 3 days  Iron Status Profile (Venous/Self-collect) ISP G A 3 days  Iron Status Profile (Venous/Self-collect) ISP G A 3 days  Iron Status Profile (Venous/Self-collect) ISP G A 4 hours / 1 day  Lactate (Plasma) LACT G A 1 day  Lactate Dehydrogenase (LDH) LDH G A 1 day  Lactate Pyruvate Ratio LPR J A 4 hours  Lactose Tolerance Test LTT By appointment only 1 day  Collection timings and sample requirements:  Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions LDL7 G 10 days  Lead (Blood) LEAD A 5 days  Lead (Urine) URPB RU 5 days  Leptin LEPT G (height and weight required) 49  Lipase (Venous/Self-collect) LIPA G G (TDL Tiny) A hours / 1 day  Lipase (Venous/Self-collect) LIPP G G (TDL Tiny) A hours / 1 day  Lipoprotein (a) (Venous/Self-collect) LIPP G G (TDL Tiny) A hours / 1 day  Lipoprotein (a) (Venous/Self-collect) LIPP G G (TDL Tiny) A hours / 1 day  Lipoprotein Electrophoresis LEL G 5 days  Lithium (take 12 hours after dose) LITH G 4 hours  Liver Fibrosis (Enhanced Liver Fibrosis ELF) ELF G 5 days  Liver Fibrosis (Enhanced Liver Fibrosis ELF) ELF G 5 days  Liver Fibrosis (Enhanced Liver Fibrosis ELF) ELF G 5 days  Liver Fibrosis Fibrotest FIBT G 2 weeks  Liver Fibrosis Fibrotest FIBT G 2 weeks  Liver Fibrosis Fibrotest FIBT G 2 days  Lysosomal Enzyme Screen LE J 1 2 months  | Immunoglobulin E – Total  | IGE  | В   | 1 day   |
| Immunoglobulins (IgG, IgM, IgA) IMM G A hours  Insulin-Like Growth Factor 2 IGF2 G A 1 month  Iodide – Urine UIIOD RU 1 week  Iodine – Serum IODI G A 1 week  Ionised Calcium ICPA G A 3 5 days  Iron (TIBC included) (Venous/Self-collect) FE G A 3 / G (TDL Tiny) 4 hours / 1 day  Iron Overload Profile IOP G G A 3 days  Iron Status Profile (Venous/Self-collect) ISP G A 3 days  Iron Status Profile (Venous/Self-collect) ISP G A 3 days  Iron Status Profile (Venous/Self-collect) ISP G A 4 hours / 1 day  Lactate (Plasma) LACT G A 1 day  Lactate Dehydrogenase (LDH) LDH G A 1 day  Lactate Pyruvate Ratio LPR J A 4 hours  Lactose Tolerance Test LTT By appointment only 1 day  Collection timings and sample requirements:  Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions LDL7 G 10 days  Lead (Blood) LEAD A 5 days  Lead (Urine) URPB RU 5 days  Leptin LEPT G (height and weight required) 40 days  Lipase (Venous/Self-collect) LIPA G G (TDL Tiny) 4 hours / 1 day  Lipad Profile (Venous/Self-collect) LIPP G G (TDL Tiny) 4 hours / 1 day  Lipoprotein (a) (Venous/Self-collect) LIPP G G (TDL Tiny) 4 hours / 1 day  Lipoprotein (a) (Venous/Self-collect) LIPP G G (TDL Tiny) 4 hours / 1 day  Lipoprotein Electrophoresis LEL G 5 days  Lithium (take 12 hours after dose) LITH G 4 hours  Liver Fibrosis (Enhanced Liver Fibrosis ELF) ELF G 5 days  Liver Fibrosis Fibrotest FIBT G 2 weeks  Liver Fibrosis Fibrotest FIBT G 2 weeks  Liver Fibrosis Fibrotest FIBT G 2 days  Lysosomal Enzyme Screen LE J 1 days   | Immunoglobulin G  | IGG  | В   | 4 hours   |
| Insulin-Like Growth Factor 2  Iodide - Urine  Iodide - Urine  Iodide - Urine  Iodine - Serum  IoDI  I  | Immunoglobulin M  | IGM  | В   | 4 hours   |
| Indide   | Immunoglobulins (IgG, IgM, IgA)   | IMM  | В   | 4 hours   |
| Iodine - Serum   IoDI   3   1   week     Ionised Calcium   ICPA   3   5   days     Iron (TIBC included) (Venous/Self-collect)   FE   3/ (3 (TDL Tiny)   4   hours / 1   day     Iron Overload Profile   IOP   3 (3 ) 3   3   days     Iron Status Profile (Venous/Self-collect)   ISP   3/ (3 (TDL Tiny)   4   hours / 1   day     Lactate (Plasma)   LACT   3 (5 ) (1 ) (1 ) (1 ) (1 ) (1 ) (1 ) (1 )   | Insulin-Like Growth Factor 2  | IGF2   | <b>B</b> 6  | 1 month   |
| IcPA   3   | lodide – Urine  | UIOD   | RU  | 1 week  |
| Iron (TIBC included) (Venous/Self-collect)  Iron Overload Profile  IOP  ③ ③ ③ 3 days  Iron Status Profile (Venous/Self-collect)  ISP  ③ / ⑥ (TDL Tiny)  4 hours / 1 day  Lactate (Plasma)  LACT  ⑥ 16  1 day  Lactate Dehydrogenase (LDH)  LDH  ③ 4 hours  Lactate Pyruvate Ratio  LPR  J¹  4-6 weeks  Lactose Tolerance Test  LTT  By appointment only  LOLT Subfractions  LDL7  IO days  Lead (Blood)  LEAD  ④ 5 days  Lead (Urine)  LEPT  ② (height and weight required) 19  Lipase (Venous/Self-collect)  LIPA  ③ / ⑥ (TDL Tiny)  4 hours / 1 day  Lipoprotein (a) (Venous/Self-collect)  LIPP  ③ / ⑥ (TDL Tiny)  4 hours / 1 day  Lipoprotein Electrophoresis  LEL  ⑤ 5 days  Lithium (take 12 hours after dose)  Lithium (take 12 hours after dose)  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  Liver Fibrosis Fibrotest  FIBT  ⑤ (TDL Tiny)  4 hours / 1 day  Lip-PLA2 (PLAC) Test  PLA2  Q anonths  | lodine – Serum  | IODI   | В   | 1 week  |
| Iron Overload Profile   IOP   3 3 days     Iron Status Profile (Venous/Self-collect)   ISP   3 / 3 (TDL Tiny)   4 hours / 1 day     Lactate (Plasma)   LACT   6 16   1 day     Lactate Dehydrogenase (LDH)   LDH   3   4 hours     Lactate Pyruvate Ratio   LPR   J  | Ionised Calcium   | ICPA   | В   | 5 days  |
| Iron Status Profile (Venous/Self-collect)   ISP   3/ 3 (TDL Tiny)   4 hours / 1 day  | Iron (TIBC included) (Venous/Self-collect)  | FE   | B / B (TDL Tiny)  | 4 hours / 1 day   |
| Lactate (Plasma)  Lactate Dehydrogenase (LDH)  Lactate Pyruvate Ratio  LPR  J¹  4-6 weeks  Lactate Pyruvate Ratio  LIT  By appointment only  1 day  Louding Suppointment only  LDL7 Subfractions  LDL7 3 10 days  Lead (Blood)  LEAD  LIPA  LIPA | Iron Overload Profile   | IOP  | <b>A B</b> <sup>9</sup>   | 3 days  |
| Lactate Dehydrogenase (LDH)  Lactate Pyruvate Ratio  LPR  J¹  4-6 weeks  Lactose Tolerance Test  Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  LDL7  LEAD  LEPT  (Ineight and weight required) 19  Lipase (Venous/Self-collect)  LIPA  LIPA | Iron Status Profile (Venous/Self-collect)   | ISP  | B / B (TDL Tiny)  | 4 hours / 1 day   |
| Lactate Pyruvate Ratio  Lactose Tolerance Test Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  LDL7   | Lactate (Plasma)  | LACT   | <b>G</b> 16   | 1 day   |
| Lactose Tolerance Test Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions LEAD LEAD LEAD LEAD LEAD LEAD LEAD LEAD   | Lactate Dehydrogenase (LDH)   | LDH  | В   | 4 hours   |
| Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7   | Lactate Pyruvate Ratio  | LPR  | <b>J</b> <sup>1</sup>   | 4-6 weeks   |
| Lead (Blood)  LEAD  URPB  RU  5 days  Leptin  LEPT  (1) (height and weight required) 19  Lipase (Venous/Self-collect)  LipA  Lipid Profile (Venous/Self-collect)  LipP  (2) (3) (TDL Tiny)  4 hours / 1 day  Lipoprotein (a) (Venous/Self-collect)  LipO  LipO  (3) (3) (TDL Tiny)  4 hours / 1 day  Lipoprotein (a) (Venous/Self-collect)  LPOA  (3) (3) (TDL Tiny)  4 hours / 1 day  Lipoprotein Electrophoresis  LEL  (3)  5 days  Lithium (take 12 hours after dose)  LITH  (3)  4 hours  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  ELF  (3)  5 days  Liver Fibrosis Fibrotest  FIBT  (3)  2 weeks  Liver Function Tests (Venous/Self-collect)  LFT / TLFT  (3) (3) (TDL Tiny)  4 hours / 1 day  Lp-PLA2 (PLAC) Test  PLA2  (3)  2 days  Lysosomal Enzyme Screen  LE  J 1  2 months  |   | LTT  |   | 4 44  |
| Leptin  LEPT  (3) (height and weight required) 19  Lipase (Venous/Self-collect)  Lipase (Venous/ | Collection timings and sample requirements:   | LII  | By appointment only   | i day   |
| Leptin  LEPT  (3) (height and weight required) 19  Lipase (Venous/Self-collect)  LipA  (3) (3) (TDL Tiny)  4 hours / 1 day  Lipid Profile (Venous/Self-collect)  LipP  (3) (3) (TDL Tiny)  4 hours / 1 day  Lipoprotein (a) (Venous/Self-collect)  LPOA  (3) (3) (TDL Tiny)  4 hours / 1 day  Lipoprotein Electrophoresis  LEL  (3)  5 days  Lithium (take 12 hours after dose)  LITH  (3)  4 hours  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  ELF  (3)  5 days  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  ELF  (3)  5 days  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  ELF  (3)  5 days  Liver Fibrosis (Venous/Self-collect)  LFT / TLFT  (3) (3) (TDL Tiny)  4 hours / 1 day  Lp-PLA2 (PLAC) Test  PLA2  (3)  2 days  Lysosomal Enzyme Screen  LE  J¹  2 months  | Collection timings and sample requirements:<br>Contact 020 7307 7383 (Phlebotomy)   |  |   |   |
| Lipase (Venous/Self-collect) Lipase (Venous/Self-collect) Lipid Profile (Venous/Self-collect) Lipoprotein (a) (Venous/Self-collect) Lipoprotein (a) (Venous/Self-collect) Lipoprotein Electrophoresis LEL 3 5 days Lithium (take 12 hours after dose) LiTH 4 hours Liver Fibrosis (Enhanced Liver Fibrosis ELF) Liver Fibrosis Fibrotest FIBT 5 days Liver Function Tests (Venous/Self-collect) LFT/TLFT 7 (TDL Tiny) 4 hours / 1 day Lipoprotein Electrophoresis LITH 5 days Liver Fibrosis Fibrotest FIBT 7 2 weeks Liver Function Tests (Venous/Self-collect) LFT/TLFT 7 (TDL Tiny) 4 hours / 1 day Lp-PLA2 (PLAC) Test PLA2 2 days Lysosomal Enzyme Screen LE J¹ 2 months  | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions   | LDL7   | <b>3</b>  | 10 days   |
| Lipid Profile (Venous/Self-collect) Lipoprotein (a) (Venous/Self-collect) Lipoprotein (a) (Venous/Self-collect) Lipoprotein Electrophoresis LEL Solution Sol | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)   | LDL7<br>LEAD   | B<br>A  | 10 days<br>5 days   |
| Lipoprotein (a) (Venous/Self-collect) LPOA 3 / 3 (TDL Tiny) 4 hours / 1 day Lipoprotein Electrophoresis LEL 3 5 days Lithium (take 12 hours after dose) LITH 3 4 hours Liver Fibrosis (Enhanced Liver Fibrosis ELF) ELF 3 5 days Liver Fibrosis Fibrotest FIBT 3 2 weeks Liver Function Tests (Venous/Self-collect) LFT / TLFT 3 / 3 (TDL Tiny) 4 hours / 1 day Lp-PLA2 (PLAC) Test PLA2 3 2 days Lysosomal Enzyme Screen LE J1 2 months   | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)   | LDL7<br>LEAD<br>URPB   | B RU (height and  | 10 days<br>5 days<br>5 days   |
| Lipoprotein Electrophoresis LEL 3 5 days Lithium (take 12 hours after dose) LITH 3 4 hours Liver Fibrosis (Enhanced Liver Fibrosis ELF) ELF 3 5 days Liver Fibrosis Fibrotest FIBT 2 weeks Liver Function Tests (Venous/Self-collect) LFT / TLFT 3 / 3 (TDL Tiny) Lp-PLA2 (PLAC) Test PLA2 3 2 days Lysosomal Enzyme Screen LE J1 2 months   | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin   | LDL7<br>LEAD<br>URPB<br>LEPT                                       | B  RU  B (height and weight required) 19  | 10 days<br>5 days<br>5 days<br>5 days   |
| Lithium (take 12 hours after dose)  Lithium (take 12 hours after dose)  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  Liver Fibrosis Fibrotest  FIBT  2 weeks  Liver Function Tests (Venous/Self-collect)  LFT/TLFT  (TDL Tiny)  4 hours / 1 day  Lp-PLA2 (PLAC) Test  PLA2  2 days  Lysosomal Enzyme Screen  LE  J  2 months  | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin  Lipase (Venous/Self-collect)   | LDL7 LEAD URPB LEPT LIPA   | B RU B (height and weight required) 19 B / B (TDL Tiny)   | 10 days 5 days 5 days 5 days 4 hours / 1 day  |
| Liver Fibrosis (Enhanced Liver Fibrosis ELF)     ELF     5 days       Liver Fibrosis Fibrotest     FIBT     2 weeks       Liver Function Tests (Venous/Self-collect)     LFT / TLFT     (CTDL Tiny)     4 hours / 1 day       Lp-PLA2 (PLAC) Test     PLA2     2 days       Lysosomal Enzyme Screen     LE     J¹     2 months   | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  | LDL7 LEAD URPB LEPT LIPA LIPP                                      | B (height and weight required) 19 B / B (TDL Tiny) B / B (TDL Tiny)   | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day  |
| Liver Fibrosis Fibrotest FIBT 3 2 weeks  Liver Function Tests (Venous/Self-collect) LFT / TLFT 3 / 3 (TDL Tiny) 4 hours / 1 day  Lp-PLA2 (PLAC) Test PLA2 3 2 days  Lysosomal Enzyme Screen LE J1 2 months   | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  Lipoprotein (a) (Venous/Self-collect)   | LDL7 LEAD URPB LEPT LIPA LIPP LPOA                                 | B RU B (height and weight required) 19 B / B (TDL Tiny) B / B (TDL Tiny) B / B (TDL Tiny)   | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day 4 hours / 1 day  |
| Liver Function Tests (Venous/Self-collect)     LFT / TLFT 3 / 3 (TDL Tiny)     4 hours / 1 day       Lp-PLA2 (PLAC) Test     PLA2     3 2 days       Lysosomal Enzyme Screen     LE     J¹     2 months  | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  Lipoprotein (a) (Venous/Self-collect)  Lipoprotein Electrophoresis  | LDL7 LEAD URPB LEPT LIPA LIPP LPOA LEL                             | B (A)  RU  B (height and weight required) 19  B / B (TDL Tiny)  C / B (TDL Tiny)  B / B (TDL Tiny)  B / B (TDL Tiny)  | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day 4 hours / 1 day 5 days   |
| Lp-PLA2 (PLAC) Test     PLA2     3     2 days       Lysosomal Enzyme Screen     LE     J¹     2 months   | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  Lipoprotein (a) (Venous/Self-collect)  Lipoprotein Electrophoresis  Lithium (take 12 hours after dose)  | LDL7 LEAD URPB LEPT LIPA LIPP LPOA LEL LITH                        | B (A)  RU (B) (height and weight required) 19 (B) / (B) (TDL Tiny) (B) / (B) / (CDL Tiny) (CDL | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day 4 hours / 1 day 5 days 4 hours                                       |
| Lysosomal Enzyme Screen LE J¹ 2 months   | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  Lipoprotein (a) (Venous/Self-collect)  Lipoprotein Electrophoresis  Lithium (take 12 hours after dose)  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  | LDL7 LEAD URPB LEPT LIPA LIPP LPOA LEL LITH ELF                    | B (height and weight required) 19 B / B (TDL Tiny)  | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day 4 hours / 1 day 5 days 4 hours 5 days                                |
|  | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  Lipoprotein (a) (Venous/Self-collect)  Lipoprotein Electrophoresis  Lithium (take 12 hours after dose)  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  Liver Fibrosis Fibrotest  | LDL7 LEAD URPB LEPT LIPA LIPP LPOA LEL LITH ELF FIBT               | B (A)  RU  B (height and weight required) 19  B / B (TDL Tiny)  C / B (TDL Tiny)  B / B (TDL Tiny)  B  B  B  B  | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day 4 hours / 1 day 5 days 4 hours 5 days 2 weeks                        |
| Lysozyme LYSO 🕒 5 days   | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Leptin  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  Lipoprotein (a) (Venous/Self-collect)  Lipoprotein Electrophoresis  Lithium (take 12 hours after dose)  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  Liver Function Tests (Venous/Self-collect)  | LDL7 LEAD URPB LEPT LIPA LIPP LPOA LEL LITH ELF FIBT LFT/TLFT      | B (height and weight required) 19 B / B (TDL Tiny) B / B (TDL Tiny) C (TDL Tiny)   | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day 4 hours / 1 day 5 days 4 hours 5 days 2 weeks 4 hours / 1 day        |
|  | Collection timings and sample requirements: Contact 020 7307 7383 (Phlebotomy)  LDL7 Subfractions  Lead (Blood)  Lead (Urine)  Lipase (Venous/Self-collect)  Lipid Profile (Venous/Self-collect)  Lipoprotein (a) (Venous/Self-collect)  Lipoprotein Electrophoresis  Lithium (take 12 hours after dose)  Liver Fibrosis (Enhanced Liver Fibrosis ELF)  Liver Fibrosis Fibrotest  Liver Function Tests (Venous/Self-collect)  Lp-PLA2 (PLAC) Test | LDL7 LEAD URPB LEPT LIPA LIPP LPOA LEL LITH ELF FIBT LFT/TLFT PLA2 | B (height and weight required) 19 B / B (TDL Tiny)  | 10 days 5 days 5 days 5 days 4 hours / 1 day 4 hours / 1 day 4 hours / 1 day 5 days 4 hours 5 days 2 weeks 4 hours / 1 day 2 days |

| TEST  | CODE | SAMPLE REQS   | TAT       |
|---|------|---|-----------|
| Magnesium (Serum)                                   | MG   | B   | 4 hours   |
| Magnesium (Urine)                                   | URMG | PU  | 1 day     |
| Manganese (Serum)                                   | MANG | B   | 5 days    |
| Mercury (Blood)                                     | MERC | A or (1)  | 5 days    |
| Mercury (Urine)                                     | URHG | RU <sup>1</sup>                                       | 5 days    |
| Methaqualone  | METQ | RU  | 5 days    |
| Methylmalonic Acid – Serum                          | MMAS | В   | 5 days    |
| Methylmalonic Acid – Urine                          | MMA  | CU  | 2 weeks   |
| Mucopolysaccharides                                 | MPS  | RU (Frozen)   | 3 weeks   |
| Myeloma Screen                                      | MYEL | <b>△ B G</b> RU                                       | 5 days    |
| Myoglobin (Serum)                                   | SMY0 | В   | 4 hours   |
| Myoglobin (Urine)                                   | UMY0 | RU  | 5-10 days |
| Newborn Screening Panel                             | GUTH | <b>J</b> <sup>1</sup>                                 | 2 weeks   |
| Nickel (Serum)                                      | NICK | В   | 5 days    |
| Nickel (Urine)                                      | NICU | RU  | 4 weeks   |
| Oligosaccharides                                    | UOLI | RU  | 6 weeks   |
| Orosomucoid (A1AG – Alpha 1 Glycoprotein)           | OROS | (Frozen)  | 5 days    |
| Osmolality (Serum)                                  | OSM0 | B   | 1 day     |
| Osmolality (Urine)                                  | ROSM | RU  | 1 day     |
| Osteoporosis Screen                                 | 0PS  | ВВ  | 4 days    |
| Oxalate (Plasma)                                    | POXA | (Frozen)  | 7 days    |
| Oxalate (Urine)                                     | UOXA | PU  | 5 days    |
| Pancreatic Peptide                                  | PP   | J   | 4 weeks   |
| Parathyroid Related Peptide                         | PTRP | 2ml A Plasma frozen (Freeze immediately) <sup>1</sup> | 2 weeks   |
| PEth (Phosphatidylethanol)<br>(Venous/Self-collect) | PETH | (TDL Tiny) <sup>38</sup>                              | 5-7 days  |
| Phencyclidine (PCP)                                 | DUST | RU  | 5 days    |
| Phosphate   | PHOS | В   | 4 hours   |
| Phosphate (24 hour Urine)                           | UPH  | PU  | 4 hours   |
| PLAC Test (Lp-PLA2) (Venous/Self-collect)           | PLA2 | B / B (TDL Tiny)                                      | 2 days    |
| Plasminogen   | PLAS | (Frozen plasma) <sup>4</sup>                          | 5 days    |
| Plasminogen Activator Inhibitor – 1                 | PAI1 | (Frozen plasma)                                       | 2 weeks   |
| Porphyrin (Blood)                                   | PORP | <b>A</b> 3  | 15 days   |
| Porphyrin (Stool)                                   | FP0R | RF <sup>3</sup>                                       | 3 weeks   |
| Porphyrin (Urine)                                   | RPOR | RU <sup>3</sup>                                       | 3 weeks   |
|   |      |   |           |

| TEST  | CODE | SAMPLE REQS             | TAT     |
|---|------|-------------------------|---------|
| Porphyrin Full Screen<br>(Total: Urine, Stool, Blood) | PORS | A RU, RF <sup>3</sup>   | 3 weeks |
| Potassium   | K    | B                       | 4 hours |
| Pregnancy (Serum) [Quantitative]                      | QHCG | B                       | 4 hours |
| Pregnancy Test (Urine)                                | PREG | RU                      | 4 hours |
| Procalcitonin   | PCAL | (Frozen) <sup>4,7</sup> | 1 day   |
| Procollagen 1 Peptide N-Terminal (NTX)                | P1NP | В                       | 5 days  |
| Procollagen 3 Peptide                                 | PRC0 | В                       | 5 days  |
| Propoxyphene  | DPR0 | RU                      | 5 days  |
| Prostatic Acid Phosphatase                            | PACP | (Frozen)                | 3 days  |
| Protein (Urine)                                       | UPRT | CU                      | 4 hours |
| Protein 14.3.3 (Creutzfeldt–Jakob Disease)            | CJD  | J                       | 5 weeks |
| Protein Electrophoresis incl. immunoglobulin          | PRTE | <b>B</b>                | 5 days  |
| Protein Total (Blood)                                 | PROT | В                       | 4 hours |
| Protein/Creatinine Ratio (Urine)                      | UCPR | RU                      | 4 hours |
| Renal Calculi Screen (Metabolic)                      | RSPR | <b>J</b> 6              | 5 days  |
| Renal Stone Analysis                                  | RSTA | STONE                   | 10 days |
| Retinol Binding Protein                               | RBP  | B                       | 3 days  |
| Salicylates   | SALI | B                       | 4 hours |
| Selenium (Serum) (Venous/Self-collect)                | SELE | 3 (TDL Tiny)            | 4 days  |
| Serum Free Light Chains                               | SLC  | B                       | 5 days  |
| Silver (Blood)  | SILV | B                       | 5 days  |
| Silver (Urine)  | USIL | RU                      | 5 days  |
| Sodium  | NA   | B                       | 4 hours |
| Superoxide Dismutase Inhibitor                        | SODI | <b>A</b> / <b>(</b>     | 5 days  |
| Thiopurine Methyl Transferase                         | TPMT | <b>A</b> 5              | 5 days  |
| Tissue Polypeptide Antigen                            | TPA  | В                       | 1 week  |
| Total Acid Phosphatase                                | APT  | В                       | 5 days  |
| Total Bile Acid/Bile Salts                            | BILS | В                       | 1 week  |
| Total IgE   | IGE  | В                       | 1 day   |
| Transferrin   | TRAN | В                       | 1 day   |
| Transferrin Electrophoresis                           | TREL | В                       | 2 weeks |
| Triglycerides   | TRI  | В                       | 4 hours |
| Trimethylaminuria (Fish Odour Syndrome)               | F0S  | J                       | 6 weeks |
| Troponin T (High sensitive)                           | TROT | B                       | 4 hours |
|   |      |                         |         |

| Tumour Necrosis Factor – Alpha  TNF  (3) (Frozen) 4 2 weeks  Urate (Uric acid)  UA  (3) 4 hours  Urea (Venous/Self-collect)  UREA  (3) (3) (TDL Tiny)  4 hours / 1 day  Urea (Urine)  UURE  UURE | TEST  | CODE | SAMPLE REQS     | TAT             |
|--|---|------|-----------------|-----------------|
| Urate (Uric acid)  Urae (Venous/Self-collect)  UREA  ①/②(TDL Tiny)  4 hours  4 hours  Urea (Urine)  UURE  CU  4 hours  Urea and Electrolytes  U/E  ① (TDL Tiny)  1 day  Urea/Creatinine/eGFR (Self-collect)  Uric Acid (Serum)  Uric Acid (Urine)  UURI  UURI  CU  4 hours  Uric Acid (Urine)  UURI  CU  4 hours  Uric Acid (Urine)  UURI  CU  4 hours  Uric Acid (Urine)  UURI  CU  4 hours  URIC  URIC  URIC  URIC  URIC  UURI  URIC  UURI  UURI  CU  4 hours  5 days  48 hours)***  Urine Microalbumin/Creatinine Ratio  UMA  RU  4 hours  URIC  URIC CU  5 days  4 hours  5 days  4 hours  5 days  4 hours  Treatment or 1-2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio  UMA  RU  4 hours  URIC  URIC  UMA  RU  4 hours  URIC  U | Tryptase  | STRY | <b>B</b>        | 2 days          |
| Urea (Venous/Self-collect) UREA  ②/③(TDL Tiny) 4 hours/1 day Urea (Urine) UURE CU 4 hours Urea and Electrolytes U/E 3 4 hours Urea Electrolytes (Urine) UELE CU 4 hours Urea/Creatinine/eGFR (Self-collect) TCU 3 (TDL Tiny) 1 day Uric Acid (Serum) UA 3 4 hours UURI CU 4 hours UBC RU (Freeze within 48 hours)**  Uric Acid (Urine) UBC RU (Freeze within 48 hours)**  Urine Microalbumin/Creatinine Ratio UMA RU Urine Organic Acids UORG RU (Frozen) 3 weeks Urine Steroid Screen (Steroid Hormones) UCRO RU (Frozen) 3 weeks Very Long Chain Fatty Acids VICF 4 hours  2 (TDL Tiny) 4 hours URIC U 4 hours URIC UNA RU 4 hours   | Tumour Necrosis Factor – Alpha  | TNF  | (Frozen) 4      | 2 weeks         |
| Urea (Urine) Urea and Electrolytes U/E 3 4 hours Urea Electrolytes (Urine) UELE CU 4 hours Urea/Creatinine/eGFR (Self-collect) Uric Acid (Serum) Uric Acid (Urine) UURI URI UURI UURI UURI CU 4 hours Uric Acid (Urine) UURI CU 4 hours UBC RU (Freeze within 48 hours)**  ** It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio UMA RU 4 hours  Urine Organic Acids UORG RU (Frozen) 3 weeks Urine Steroid Screen (Steroid Hormones) USTE CU 9 2 weeks Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks Very Long Chain Fatty Acids VLCF Or (Frozen) 9 4-6 weeks Vitamin B12 (Active) (Venous/Self-collect) B12 (IDL Tiny) 1 day  | Urate (Uric acid)   | UA   | <b>B</b>        | 4 hours         |
| Urea and Electrolytes (Urine) UELE CU 4 hours  Urea/Creatinine/eGFR (Self-collect) Uric Acid (Serum) Uric Acid (Urine) UURI CU 4 hours  Uric Acid (Urine) UURI CU 4 hours  Urinary Bladder Cancer Antigen ** It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio UMA RU 4 hours  Urine Organic Acids UORG RU (Frozen) 3 weeks  Urine Steroid Screen (Steroid Hormones) USTE CU 9 2 weeks  Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks  Very Long Chain Fatty Acids VLCF A or (Frozen) 4-6 weeks  Vitamin B12 (Active) (Venous/Self-collect) B12 (TDL Tiny) 1 day   | Urea (Venous/Self-collect)  | UREA | 3 (TDL Tiny)    | 4 hours / 1 day |
| Urea Electrolytes (Urine) UFLE CU 4 hours  Urea/Creatinine/eGFR (Self-collect) TCU 3 (TDL Tiny) 1 day  Uric Acid (Serum) UA 3 4 hours  Uric Acid (Urine) UURI CU 4 hours  Urinary Bladder Cancer Antigen Wit is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio UMA RU 4 hours  Urine Organic Acids UORG RU (Frozen) 3 weeks  Urine Steroid Screen (Steroid Hormones) USTE CU 9 2 weeks  Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks  Very Long Chain Fatty Acids VLCF Or (Frozen) 4-6 weeks  Vitamin B12 (Active) (Venous/Self-collect) B12 3 (TDL Tiny) 1 day  | Urea (Urine)  | UURE | CU              | 4 hours         |
| Urea/Creatinine/eGFR (Self-collect)  Uric Acid (Serum)  Uric Acid (Urine)  UURI  UURI  UURI  UBC  RU (Freeze within 48 hours)**  *** It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio  UMA  RU  4 hours  48 hours)**  UMA  RU  4 hours  UMA  RU  4 hours  Urine Organic Acids  UORG  RU (Frozen)  3 weeks  Urine Steroid Screen (Steroid Hormones)  UCRO  RU (Frozen)  3 weeks  Very Long Chain Fatty Acids  VLCF  Or (Frozen)  4-6 weeks  Vitamin B12 (Active) (Venous/Self-collect)  B12  3 (TDL Tiny)  1 day   | Urea and Electrolytes   | U/E  | <b>B</b>        | 4 hours         |
| Uric Acid (Serum)  Uric Acid (Urine)  UURI  Freeze within  48 hours)**  5 days  48 hours)**  URI  URI  URI  URI  URI  URI  URI  U  | Urea Electrolytes (Urine)   | UELE | CU              | 4 hours         |
| Uric Acid (Urine)  Urinary Bladder Cancer Antigen  **It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio  Urine Organic Acids  UORG  RU (Frozen)  3 weeks  Urine Steroid Screen (Steroid Hormones)  UCRO  RU (Frozen)  3 weeks  UCRO  RU (Frozen)  3 weeks  Very Long Chain Fatty Acids  VLCF  Or (Frozen)  4-6 weeks  Vitamin B12 (Active) (Venous/Self-collect)  B12  3 / (CTDL Tiny)  1 day   | Urea/Creatinine/eGFR (Self-collect)   | TCU  | (TDL Tiny)      | 1 day           |
| Urinary Bladder Cancer Antigen *** It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio UMA RU 4 hours  Urine Organic Acids UORG RU (Frozen) 3 weeks  Urine Steroid Screen (Steroid Hormones) USTE CU 9 2 weeks  Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks  Very Long Chain Fatty Acids VLCF Or (Frozen) 4-6 weeks  Vitamin B12 (Active) (Venous/Self-collect) B12 3 / 3 (TDL Tiny) 1 day   | Uric Acid (Serum)   | UA   | <b>B</b>        | 4 hours         |
| ** It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.  Urine Microalbumin/Creatinine Ratio  UMA  RU  4 hours  Urine Organic Acids  UORG  RU (Frozen)  3 weeks  Urine Steroid Screen (Steroid Hormones)  USTE  CU  2 weeks  Urine Sugar Chromatography  UCRO  RU (Frozen)  3 weeks  Very Long Chain Fatty Acids  VLCF  A or (Frozen)  4 -6 weeks  Vitamin B12 (Active) (Venous/Self-collect)  B12  3 / 3 (TDL Tiny)  1 day  | Uric Acid (Urine)   | UURI | CU              | 4 hours         |
| Urine Organic Acids UORG RU (Frozen) 3 weeks Urine Steroid Screen (Steroid Hormones) USTE CU 9 2 weeks Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks Very Long Chain Fatty Acids VLCF or (Frozen) 9 4-6 weeks Vitamin B12 (Active) (Venous/Self-collect) B12 (CTDL Tiny) 1 day   | <b>Urinary Bladder Cancer Antigen</b> ** It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter. | UBC  | ,               | 5 days          |
| Urine Steroid Screen (Steroid Hormones) USTE CU® 2 weeks Urine Sugar Chromatography UCRO RU (Frozen) 3 weeks Very Long Chain Fatty Acids VLCF A or (Frozen) 4-6 weeks Vitamin B12 (Active) (Venous/Self-collect) B12 3 / 3 (TDL Tiny) 1 day  | Urine Microalbumin/Creatinine Ratio   | UMA  | RU              | 4 hours         |
| Urine Sugar Chromatography     UCRO     RU (Frozen)     3 weeks       Very Long Chain Fatty Acids     VLCF     A or (1) (Frozen)     9 4-6 weeks       Vitamin B12 (Active) (Venous/Self-collect)     B12     (1) (TDL Tiny)     1 day   | Urine Organic Acids   | UORG | RU (Frozen)     | 3 weeks         |
| Very Long Chain Fatty Acids     VLCF     ♠ or ♠ (Frozen) 9     4-6 weeks       Vitamin B12 (Active) (Venous/Self-collect)     B12     ♠ (TDL Tiny)     1 day   | Urine Steroid Screen (Steroid Hormones)   | USTE | CU <sup>9</sup> | 2 weeks         |
| Vitamin B12 (Active) (Venous/Self-collect) B12 (TDL Tiny) 1 day  | Urine Sugar Chromatography  | UCR0 | RU (Frozen)     | 3 weeks         |
|  | Very Long Chain Fatty Acids   | VLCF | A or (Frozen) 9 | 4-6 weeks       |
| Vitamin B12 (Active)/Red Cell Folate B12F (1) (B) 2 days   | Vitamin B12 (Active) (Venous/Self-collect)  | B12  | 3 (TDL Tiny)    | 1 day           |
|  | Vitamin B12 (Active)/Red Cell Folate  | B12F | <b>A</b> B      | 2 days          |
| Vitamin B12 (Total) TB12 🕕 1 day   | Vitamin B12 (Total)   | TB12 | <b>B</b>        | 1 day           |
| Vitamin D (25-0H) (Venous/Self-collect) VITD 3 (TDL Tiny) 4 hours / 1 day  | Vitamin D (25-OH) (Venous/Self-collect)   | VITD | 3 (TDL Tiny)    | 4 hours / 1 day |
| VLDL Cholesterol VLDL <sup>13</sup> 1 week   | VLDL Cholesterol  | VLDL | <b>B</b> 13     | 1 week          |
| VMA UVMA PU 1 5 days   | VMA   | UVMA | <b>PU</b> 1     | 5 days          |

#### **Bone Screen**

Calcium (24 hour Urine) Phosphate (24 hour Urine) Urea and Electrolytes Alkaline Phosphatase Total Protein Albumin Globulin Calcium

#### TAT: 4 hours

BONE

(E) CU

#### **Bone Screen** (Bloods only)

Urea and Electrolytes **LFTs** Calcium Phosphate Vitamin D (25 OH)

#### TAT: 4 hours

BON<sub>2</sub>

B

#### **Chest Pain Profile**

Myoglobin CK MB Fraction Troponin T

TAT: STAT

**CPP** 

8

#### Cardiovascular **Risk Profile 1**

Lipid Profile (Cholesterol, Triglycerides, HDL Cholesterol. LDL Cholesterol. Non-HDL Cholesterol) Apolipoprotein A1 Apolipoprotein B Lipoprotein (a) hsCRP Lp-PLA2 (PLAC) Test

#### TAT: 3 days

**PP10** 



#### Cardiovascular **Risk Profile 2**

Lipid Profile (Cholesterol, Triglycerides, HDL Cholesterol, LDL Cholesterol. Non-HDL Cholesterol) Apolipoprotein A1 Apolipoprotein B Lipoprotein (a) Fibrinogen hsCRP Lp-PLA2 (PLAC) Test Homocysteine

#### TAT: 3 days

PP11





#### **Diabetic Profile 1**

Glucose HbA1c

TAT: 8 hours

DIAB



#### **Diabetic Profile 2**

Glucose HbA1c Microalbumin

TAT: 2 days

DIA2



#### **Iron Overload Profile**

Iron (TIBC included) Ferritin Transferrin Saturation Haemochromatosis C282Y, H63D

#### TAT: 3 days

10P



#### **Iron Status Profile** (Venous/Self-collect)

Iron (TIBC included) Ferritin Transferrin Saturation

TAT: 4 hours / 1 day

ISP

(TDL Tiny)

#### **Lipid Profile** (Venous/Self-collect)

Triglycerides Cholesterol **HDL Cholesterol** LDL Cholesterol Non-HDI Cholesterol

#### TAT: 4 hours / 1 day

LIPP

(B) / (B) (TDL Tiny)

#### Calcium

Alkaline Phosphatase Albumin Phosphate

**Osteoporosis Screen** 

Serum Crosslaps (DPD) Vitamin D (25 OH)

#### TAT: 4 days

0PS



#### **Liver Function Tests** (Venous/Self-collect)

ALT (Venous only) AST (Venous only) Bilirubin Total Protein Alkaline Phos Albumin Globulin

Gamma-GT

#### TAT: 4 hours / 1 day

LFT / TLFT

#### (TDL Tiny)

#### **Myeloma Screen**

FBC and ESR Biochemistry Profile Protein Electrophoresis Immunoglobulins (IgA, IgG, IgM) Bence-Jones Protein

#### TAT: 5 days

MYEL

#### A B G RU

#### **Porphyrin Full Screen** (Total: Blood, Stool, Urine)

Porphyrin Blood Porphyrin Stool Porphyrin Urine

#### TAT: 3 weeks

**PORS** 

#### A RU, RF<sup>3</sup>

#### **Urea and Electrolytes**

Sodium Potassium Chloride Bicarbonate Urea Creatinine

#### TAT: 4 hours

U/E



All citrate samples co sent by post or with an overnight delay must be double spun and sent frozen.

| TEST   | CODE | SAMPLE REQS                | TAT     |
|--|------|----------------------------|---------|
| Anaemia Profile  | ANAE | AAB                        | 2 days  |
| Antenatal Profile  | ANTE | <b>A A</b> 33 <b>B B G</b> | 3 days  |
| APTT/KCCT  | KCCT | <b>C</b> 18                | 4 hours |
| Atypical Antibody Screen (handwritten tube label)  | AASC | <b>A</b> 22,33             | 2 days  |
| Blood Film Examination   | FILM | A                          | 1 day   |
| Blood Group † † The tube's own label must be completed by hand. This must correspond with same name and date of birth details as given on the request form. Do not affix additional computerised or hand written labels. | AB0  | <b>A</b> 22,33             | 2 days  |
| Carboxyhaemoglobin   | СВНВ | A                          | 1 week  |
| Coagulation Profile 1  | CLPF | <b>(</b> ) 18              | 4 hours |
| Coagulation Profile 2  | CLOT | <b>A C</b> 18              | 4 hours |
| D-Dimers (Fibrinogen Degradation Products)   | DDIT | <b>©</b> 4                 | 4 hours |
| DVT/Pre-travel Screen  | DVT1 | <b>A A B</b> <sup>9</sup>  | 5 days  |
| ESR  | ESR  | A                          | 4 hours |
| Fibrinogen   | FIB  | C 4,18                     | 4 hours |
| Full Blood Count   | FBC  | A                          | 4 hours |
| Haematology Profile  | PP3  | A                          | 4 hours |
| Haemoglobin  | НВ   | A                          | 4 hours |
| Immune Function Evaluation (Total)   | TIE  | A + B 5,10                 | 7 days  |
| INR  | PTIM | <b>C</b> 18                | 4 hours |
| Lymphocyte Subsets (CD3/CD4/CD8)   | LYSS | <b>A</b> 10                | 1 day   |
| Malarial Parasites   | MALP | <b>A</b> 4,9,14            | STAT    |
| Malarial Parasites (visa, non-urgent)  | MP48 | A                          | 2 days  |
| Mean Cell Volume (MCV)   | MCV  | A                          | 4 hours |
| Microfilaria Blood Film  | MICF | A                          | STAT    |
| Natural Killer Profile 2   | NKP2 | <b>A</b> 10                | 2 days  |
| PAI-1 4G/5G Polymorphism   | PAIP | A                          | 10 days |
| Paul Bunnell (Monospot)  | PAUL | A or 3                     | 8 hours |
| Pre-Travel Screen (DVT)  | DVT1 | <b>A B</b> <sup>9</sup>    | 5 days  |
| Prothrombin Time   | PTIM | <b>(</b> ) 18              | 4 hours |
| Prothrombin Time + Dose  | PT+D | <b>(</b> ) 18              | 4 hours |
| Reticulocyte Count   | RETC | Δ                          | 4 hours |
|  |      |                            |         |

| TEST                      | CODE | SAMPLE REQS   | TAT     |
|---------------------------|------|---------------|---------|
| Thrombin Time             | THR0 | <b>(</b> ) 18 | 4 hours |
| Vitamin K (With PIVKA II) | VITK | B 13          | 10 days |

#### **Special Haemostasis**

| TEST  | CODE | SAMPLE REQS                | TAT     |
|---|------|----------------------------|---------|
| Activated Protein C Resistance  | APCR | © (Frozen) <sup>4,18</sup> | 3 days  |
| ADAMTS-13 Antibody  | A13A | © (Frozen) <sup>9,18</sup> | 1 month |
| Anti-Xa Apixaban Monitoring  * Please state drug and time of dose on request.   | APIX | (Frozen)*18                | 3 days  |
| Anti-Xa Edoxaban Monitoring   | EDOX | C (Frozen)*18              | 3 days  |
| *Please state drug and time of dose on request.   | LDOX | (1102011)                  | o dayo  |
| Anti-Xa Fondapariux Monitoring  * Please state drug and time of dose on request.  | FOND | ○ Frozen)*18               | 3 days  |
| Anti-Xa LMWH Monitoring   | LMWX | C (Frozen)*18              | 3 days  |
| * Please state drug and time of dose on request.  |      |                            |         |
| Anti-Xa Rivaroxaban Monitoring * Please state drug and time of dose on request.   | RIVA | (Frozen)*18                | 3 days  |
| Antithrombin III  | A111 | (Frozen) <sup>4,9,18</sup> | 3 days  |
| Factor II Assay   | FAC2 | © (Frozen) <sup>9,18</sup> | 5 days  |
| Factor V Assay  | FAC5 | C (Frozen) <sup>9,18</sup> | 5 days  |
| Factor VII Assay  | FAC7 | © (Frozen) <sup>9,18</sup> | 5 days  |
| Factor VIII Assay   | FAC8 | © (Frozen)9,18             | 5 days  |
| Factor VIII Inhibiting Antibody   | F8IA | <b>C C</b> 18              | 2 weeks |
| Factor IX Assay   | F1X  | © (Frozen) <sup>9,18</sup> | 5 days  |
| Factor IX Inhibiting Antibody   | F9IA | <b>C C</b> 18              | 2 weeks |
| Factor X Assay  | FX   | (Frozen) 9,18              | 5 days  |
| Factor XI Assay   | FX1  | (Frozen) 9,18              | 5 days  |
| Factor XII Assay  | FX11 | (Frozen) 9,18              | 5 days  |
| Factor XIII Assay   | FA13 | (Frozen) 9,18              | 5 days  |
| FXIII A Subunit   | F13S | © (Frozen) <sup>9,18</sup> | 14 days |
| Hughes Syndrome   | LUPA | <b>B C C</b> 4,18          | 2 days  |
| Lupus Anticoagulant and Anticardiolipin Abs   | LUPA | <b>B C C</b> 4,9,18        | 2 days  |
| Lupus Anticoagulant only  | LUPC | <b>© ©</b> 9,18            | 2 days  |
| Miscarriage/Thrombotic Risk Profile   | PROP | <b>AABCC</b> <sup>18</sup> | 5 days  |
| P2Y12 Receptor Platelet Function Analysis (Clopidogrel Resistance) **Samples not processed at Halo, please contact laboratory prior to sample taking. | P2Y  | <b>J</b> **1               | 1 day   |

| TEST   | CODE | SAMPLE REQS                | TAT      |
|--|------|----------------------------|----------|
| Platelet Aggregation Studies  **Samples not processed at Halo, please contact laboratory prior to sample taking.               | PLAG | <b>J</b> ** 1              | 3 days   |
| Platelet Function Test Screen – PFA-100/200 ** Samples not processed at Halo, please contact laboratory prior to sample taking | PFAT | <b>J**</b> 1               | 1 day    |
| Protein C  | PRC  | (Frozen) 4,9,18            | 3 days   |
| Protein S Activity   | PS1  | (Frozen) <sup>4,9,18</sup> | 5 days   |
| Protein S Free Ag  | FPRS | (Frozen) 4,9,18            | 3 days   |
| Taipan Snake Venom Time  | TTVT | <b>C C</b> 9,18            | 1 week   |
| Thrombotic Risk Profile  | PROP | <b>A B C C 1</b> 8         | 5 days   |
| Viscosity (Plasma) *EDTA plasma must be separated within 24 hours of collection and sent at room temperature.                  | VISC | <b>A</b> 4*                | 3 days   |
| Von Willebrand Profile   | FVWF | <b>C C C</b> 4,9,12        | 5 days   |
| Von Willebrands Multimers  | VWM  | <b>C C C</b> 18            | 3 months |

#### **Special Haematology**

| TEST  | CODE | SAMPLE REQS | TAT    |
|---|------|-------------|--------|
| Coombs (Direct Antiglobulin Test)   | COOM | A           | 2 days |
| Eosin-5 Maleimide Dye binding test for<br>Hereditary spherocytosis (EMA)*   | EMA  | A           | 2 days |
| *Sample to be received by laboratory within 24 hours of being<br>taken and the test is done Tuesday to Thursday (test must<br>be performed within 48 hours of sample being taken. |      |             |        |
| Erythropoietin  | ERY  | B           | 4 days |
| G6PD  | G6PD | A           | 4 days |
| Haemoglobin Electrophoresis   | HBEL | A           | 4 days |
| HFE gene (Haemochromatosis) –<br>common variants C282Y + H63D   | HMD  | <b>A</b> 9  | 3 days |
| Thalassaemia Screen   | HBEL | A           | 4 days |

#### **Flow Cytometry**

| TEST                          | CODE | SAMPLE REQS           | TAT     |
|-------------------------------|------|-----------------------|---------|
| Bone Marrow (Aspirate)        | BMAS | <b>J</b> <sup>1</sup> | 14 days |
| Bone Marrow (Trephine Biopsy) | BMI  | <b>J</b> <sup>1</sup> | 3 days  |
| CD3/CD4/CD8                   | LYSS | <b>A</b> 10           | 1 day   |
| CD16                          | CD16 | <b>A</b> 4            | 1 day   |
| CD19 B Cells                  | CD19 | <b>A</b> 4            | 1 day   |
| CD20                          | CD20 | <b>A</b> 10           | 2 days  |
| CD25                          | CD25 | <b>A</b> 10           | 2 days  |
| CD56                          | CD56 | <b>A</b> 4            | 1 day   |
| CD57                          | CD57 | A                     | 1 day   |
| Leukaemia Immunophenotyping   | LYPT | <b>A</b> 4,5          | 5 days  |

#### **Anaemia Profile**

FBC ESR

Iron (TIBC included)
Ferritin
B12 (Active)

## Folate (RBC) **TAT: 2 days**

#### ANAE



#### **Antenatal Profile**

FBC

Blood Group and Rh Type Atypical Antibody Screen Haemoglobin electrophoresis Syphilis IgG/IgM

Glucose

FT4/TSH

Rubella Antibodies (IgG) Toxoplasma (IgG/IgM)

Hep B sAg Hep C Abs

Hep C Abs

Varicella zoster IgG (Immunity) HIV 1 & 2 Abs

Please ensure the blood group (EDTA) tube label is handwritten. Do not affix a secondary label.

TAT: 3 days

ANTE



#### **Coagulation Profile 1**

Prothrombin Time APTT Fibrinogen

#### TAT: 4 hours

**CLPF** 



#### **Coagulation Profile 2**

FBC

Prothrombin Time APTT

Fibrinogen

**TAT: 4 hours** 

CLOT



#### **DVT/Pre-travel Screen**

**FBC** 

Factor II Prothrombin Gene Factor V Leiden Anticardiolipin Antibodies

TAT: 5 days

DVT1



#### **Haematology Profile**

FBC **FSR** 

TAT: 4 hours

PP3



#### Miscarriage/ **Thrombotic Risk Profile**

FBC

Coagulation Profile Antithrombin III Factor V Leiden gene Factor II Prothrombin gene MTHFR gene Lupus Anticoagulant Protein C Free Protein S Ag Anticardiolipin Abs

TAT: 5 days

PROP



#### **Natural Killer Profile 2**

CD3

CD4

CD8

CD16/CD56 CD19

TAT: 2 days

NKP2



#### Von Willebrand Profile

Von Willebrand Factor Von Willebrand Activity (Ristocetin Cofactor) Factor VIII Assay

TAT: 5 days

**FVWF** 



#### **Pre-Travel Screen (DVT)**

FBC

Factor II Prothrombin Gene Factor V Leiden Anticardiolipin Antibodies

TAT: 5 days

DVT1





#### **Thrombotic Risk Profile**

FBC

Coagulation Profile Antithrombin III

Factor V Leiden Common Variant

Factor II Prothrombin Common Variant

MTHER Common Variants

Lupus Anticoagulant

Protein C

Free Protein S Aa

Anticardiolipin Abs

#### TAT: 5 days

PR<sub>OP</sub>



| TEST                    | CODE | SAMPLE REQS                | TAT      |  |
|-------------------------|------|----------------------------|----------|--|
| 16S rRNA Bacterial Gene | 16S  | J                          | 1 week   |  |
| 18S rRNA Fungal Gene    | 18S  | J                          | 1 week   |  |
| Aspergillus Precipitins | ASPP | В                          | 5 days   |  |
| Beta D Glucan           | XBDG | В                          | 3 days   |  |
| Blood Culture#          | BCUL | 2 x <b>BC</b> <sup>4</sup> | 6 days + |  |

#Please contact the Phlebotomy at Patient Reception 020 7307 7383 for further details, as needed.
Blood cultures must be taken prior to any other blood samples. The aerobic bottle must be collected first, followed by the anaerobic bottle. Each bottle should be filled with 8-10 ml of blood, use the markings on the bottles to achieve this.

- Other bloods can be collected but must be collected after the blood cultures.
- Bottles must be labelled with the patient's identification details.
- Bottles and Request Form need to give the time taken and the body site that the blood was taken from. Ensure that the bottle barcodes are not obscured when adding patient labels.
- . Send the blood cultures to the laboratory without delay.

| Calprotectin/QFIT Profile (Combined)   | QCAL | QFIT sample collection device                    | 5 days       |
|--|------|--|--------------|
| Campylobacter Jejuni Antibodies  | CJAB | В  | 5 days       |
| Candida (Culture)  | CANC | STM/CS   | 2-4 days     |
| Candida Antibodies   | CANA | В  | 5 days       |
| Carbapenemase producing organism screen<br>‡ Presumptive positive isolates will be sent to<br>the PHE reference laboratory for confirmation.   | MDR  | STM (rectal)                                     | 4-5 days ‡   |
| Clostridium Difficile Toxin by PCR * Not performed on formed stool specimens.  | CLOS | RF*  | 2 days       |
| Cryptococcal Antigen   | CRYC | Serum or CSF                                     | 1 day        |
| Cryptosporidium  | CRP0 | RF   | 2 days       |
| CSF for Microscopy and Culture   | CSF  | CSF  | 1-3 days     |
| Culture (Any site)   | CULT |  | up to 5 days |
| Fluid Culture  | FLUD | SC   | 2-7 days     |
| Fluid for Crystals + Culture   | FLU2 | SC   | 1 day        |
| Fungal ID + Sens   | FUID | Fungal sample / STM                              | 14 days      |
| Fungal investigations<br>(non-superficial extended culture)  | FUN  | All specimens other than<br>Skin, Hair and Nails | From 3 days  |
| Fungal investigations (superficial/dermatophyte PCR test)  | DERM | Skin, Hair, Nails                                | 3-7 days     |
| Galactomanan (Aspergillus Antigen)   | SGAL | B  | 2 weeks      |
| Gonorrhoea – Culture  ‡ ‡ ‡ The optimal sample type from the female genital tract is an endocervical swab. Gonorrhoea does not survive well outside the endocervical epithelium; a negative gonorrhoea culture result from a vaginal swab is not reliable for excluding infection. | GONN | CS***  | 2-3 days     |

| TEST  | CODE | SAMPLE REQS                                | TAT        |
|---|------|--|------------|
| Group B Strep – Vaginal and Rectal (STM/Self-collect)   | GBSX | 2 x <b>STM</b> / Blue gel<br>Amies swab x2 | 3-5 days   |
| H. pylori Antigen – Stool (RF/Self-collect)   | HBAG | RF / Stool or faecal container             | 3 days     |
| H. pylori Culture   | HPCU | J  | 3 weeks    |
| HVS  ‡ ‡ ‡ ‡ Culture for Mycoplasma, Ureaplasma and Trichomonas vaginalis has been discontinued due to the superiority of molecular methods. If investigations for Mycoplasma genitalium, Ureaplasma or Trichomonas vaginalis are required please request PCR testing (see Sexual Health section of Lab Guide). |      | STM/CS****                                 | 2-4 days   |
| IUCD for Culture  | IUCD | Send Device                                | 11-12 days |
| Legionella Urine Antigen  | LEGA | RU   | 1 day      |
| MRSA (Rapid PCR) one swab per site  | MRSA | Blue Micro Swab                            | 4 hours    |
| MRSA (Rapid PCR) one swab per site x 2  | MRS2 | Blue Micro Swab x 2                        | 4 hours    |
| MRSA Culture one swab per site  | MRSW | Blue Micro Swab                            | 2 days     |
| MRSA Culture one swab per site x 2  | MRW2 | Blue Micro Swab x 2                        | 2 days     |
| MRSA Culture (Self-collect)  – Nose/Groin   | MRW2 | Purple liquid<br>Amies swab x2             | 2 days     |
| MRSA Culture (Self-collect)  – Nose/Groin/Axilla  | MRW3 | Purple liquid<br>Amies swab x3             | 2 days     |
| MRSA PCR (Self-collect)  - Nose/Groin   | MRS2 | Purple liquid<br>Amies swab x2             | 1 day      |
| MRSA PCR (Self-collect)  - Nose/Groin/Axilla  | MRS3 | Purple liquid<br>Amies swab x3             | 1 day      |
| Mycology/Skin Scrapings by PCR  | DERM | Submit Sample                              | 3-7 days   |
| Nail Clippings  | DERM | Nail clippings                             | 3-7 days   |
| Pleural Fluid for Culture   | FLUP | SC   | 7 days     |
| Pneumococcal Antigen  | PNAG | RU   | 1 day      |
| Pneumocystis Jiroveci (PCP) Examination<br>‡ ‡ BAL: Induced sputum or bronchoalveolar lavage.   | PCYS | BAL <sup>‡‡</sup>                          | 2-3 days   |
| QFIT/Calprotectin Profile (Combined)  | QCAL | QFIT sample collection device              | 5 days     |
| Quantitative Faecal Immunochemical<br>Test (QFIT) (Self-collect)  | QFIT | QFIT sample collection device              | 1 day      |
| Rapid Strep (incl. m/c/s)  ** Do not use a black swab for RAPS. Use Blue only. Rapid antigen is reported within 4 hours with full culture to follow.  | RAPS | STM**                                      | 1-3 days** |

| TEST  | CODE | SAMPLE REQS   | TAT  |
|---|------|---|--|
| Schistosoma (Urine)   | USCH | Mid-morning terminal<br>urine following<br>exercise <sup>14</sup> | 1-2 days   |
| Sellotape Test  *** Use clear Sellotape only and attach to slide.   | SELL | Send Sample***  | 1 day  |
| Semen Culture   | SPCU | Semen   | 2-4 days   |
| Skin Scrapings/Mycology by PCR  | DERM | Send Sample   | 3-7 days   |
| Specific Gravity (Urine)  | USG  | RU  | 24 hours   |
| Sputum for Routine Culture  | SPU1 | SC  | 2-4 days   |
| Sputum for TB Culture (AFB)   | SPU2 | SC  | up to 8 weeks  |
| Stool for OCP and Culture  † † Please provide relevant travel history. If travel history is not provided, stool will be investigated for endemic pathogens only [Campylobacter, Salmonella, Shigella, Shigatoxin-producing E coli (VTEC), Cryptosporidium and Giardia]. | PENT | RF  | 2-3 days   |
| Stool for OVA Cysts & Parasites by PCR  | MOCP | RF  | 2 days   |
| Stool Reducing Substances   | STRS | RF <sup>7</sup>   | 5 days   |
| Swab (Cervical)   | CERS | STM / CS  | 2-4 days   |
| Swab (Ear)  | EARS | STM   | 2-4 days (Culture)<br>8-9 days (Fungal)<br>– same swab |
| Swab (Eye)  | EYES | STM   | 2-4 days   |
| Swab (Nasal)  | NASS | STM   | 2-4 days   |
| Swab (0ral)   | ORSW | STM/CS  | 2-4 days   |
| Swab (Penile)   | PENS | STM/CS  | 2-4 days   |
| Swab (Rectal)   | RECG | STM/CS  | 2-4 days   |
| Swab (Skin)   | SKIS | STM   | 2-4 days   |
| Swab (Throat)   | THRS | STM   | 2-4 days   |
| Swab (Urethral)   | URES | STM/CS  | 2-4 days   |
| Swab (Vaginal)  | VAGS | STM/CS  | 2-4 days   |
| Swab (Vulval)   | VULV | STM/CS  | 2-4 days   |
| Swab (Wound)  | WOUS | STM   | 2-4 days   |
| Synovial Fluid (for microscopy and culture)<br>††† If prosthetic joint is present please state<br>in clinical details to ensure that enrichment<br>culture is prolonged for 14 days.  | FLU2 | SC <sup>†††</sup>   | 14 days  |
| TB (Pleural Fluid)  | TBCU | SC  | up to 8 weeks  |
| TB Culture  | SPU2 | SC  | up to 8 weeks  |
| TB Culture (Urine)  | TBUR | 3 x EMU   | up to 8 weeks  |

| TEST   | CODE | SAMPLE REQS                                    | TAT           |
|--|------|--|---------------|
| TB Slopes – Confirmation and Sensitivity   | TBSL | <b>TB slope</b> (LJ medium-green) <sup>6</sup> | up to 8 weeks |
| Tissue for culture   | TISS | Tissue sample                                  | up to 14 days |
| Urine (Microscopy Only)  | UMIC | RU   | 1 day         |
| Urine Chemistry and Microscopy (Self-collect) Mid-stream urine.  | UMIC | Urine (Universal).<br>Mid stream.              | 1-2 days      |
| Urine Chemistry, Microscopy<br>and Culture (Self-collect)<br>Mid-stream urine.   | UCEM | Urine (Universal &<br>Boric). Mid stream.      | 1-2 days      |
| Urine for Extended Culture   | UCXD | MSU  | up to 7 days  |
| Urine for Microscopy and Culture † † † † Optimal sample type for urine culture is a mid-stream clean catch urine sent in a sterile pot containing boric acid preservative. | UCEM | MSU ††††                                       | 1-2 days      |

# Calprotectin/QFIT Profile (Combined) Calprotectin QFIT TAT: 5 days QCAL

QFIT sample collection device

## Urine culture processing and results

All urine culture testing is performed using manual methods. The culture pathway adheres to national guidance and is a fully UKAS-accredited method.

Manual testing allows a larger amount of urine to be tested than previous automated method, which enables the laboratory to detect lower bacterial counts (as low as 103 cfu/mL) and also facilitates the follow up of significant organisms grown from mixed cultures.

If the culture result is indicative of urinary tract infection, antibiotic susceptibilities will be tested from the culture growth and will be available 24 hours after the culture result. 'Direct sensitivities' are no longer performed. Direct susceptibility testing is not inoculum-controlled, produces inaccurate results and is not UKAS-accredited.

Culture results should be interpreted alongside the microscopy WBC count and clinical signs and symptoms. Significant growth on culture in the absence of pyuria may be suggestive of contamination with regional flora rather than true infection. It should be noted, however, that WBC degrade in urine quite rapidly and delays between sample collection and microscopy may lead to falsely low WBC readings which may account for these findings.

## What does the result 'No significant growth' mean?

The amount of growth falls below the threshold for urinary tract infection (<103 cfu/mL). There is no laboratory evidence of urinary tract infection. Occasionally, this may be seen in very early stages of infection or in a partially treated urinary tract infection. Therefore, please send a repeat specimen if symptoms persist.

## What does the result 'mixed growth doubtful significance' mean?

This means that the culture revealed a heavy growth of at least 3 organisms with no predominating organism; this represents contamination of the urine with the patient's flora during collection.

This result does not exclude urinary tract infection but it is not possible to determine the causative organism among the mixture of organisms.

If symptoms persist, please send a repeat urine specimen and ensure that patient understands optimal collection technique.

If you are receiving a lot of 'mixed growth of doubtful significance' results, please consider the following:

#### The instructions that patients are given to collect their urine sample

Poor collection technique is the most common reason for a heavily mixed growth in a urine sample. It is almost impossible to collect a urine sample without any contamination from the normal bacterial flora which inhabits the area surrounding the urethral opening, but optimal collection technique will minimise this contamination and allow the true infective cause to stand out and be identified (a patient instruction leaflet is available).

#### Delays between sample collection and laboratory processing

The time between sample collection and laboratory processing can allow small amounts of contaminating bacterial flora to multiply up to higher amounts prior to laboratory testing, which can result in heavy mixed growth of bacteria on culture. Using a red topped specimen pot containing boric acid preservative will minimise this.

If, despite these measures, a patient has recurrent mixed growth reports from multiple urines, it may suggest that your patient has abnormal urinary tract architecture, immunosuppression or other non-infective cause that requires different laboratory investigations or referral to a specialist. If further information is required, please telephone the laboratory and ask to discuss the case with one of our consultant Microbiologists.

#### **Red topped boric acid containers**

The preservative reduces the overgrowth of organisms and, to a lesser extent, reduces the degradation of white cells during transit leading to a more accurate laboratory result for both microscopy and culture. UKAS recommends the use of boric acid containers for all urine sample for microscopy and culture (Urine M,C&S) to improve the quality of microbiological results.

# Red topped boric acid containers are for requests for urine microscopy and culture (MC&S) ONLY. Boric acid container should NOT be used for:

- Other urine microbiology tests (e.g. investigations for Chlamydia, Mycobacterium, Schistosomiasis, urinary antigen testing)
- Urine samples being analysed by PCR methodology
- Urine samples for non-microbiology tests (e.g. biochemistry, virology, pregnancy testing)
- Very small urine volumes (<20ml) e.g. neonates

Use of urinary dipsticks: boric acid may inhibit leukocyte esterase dipstick readings; dipstick testing performed on a sample in a boric acid container should be interpreted with caution.

If additional tests are required in addition to urine microscopy and culture, an additional sample in a white-topped universal container should be sent. In this case, it is advised that the mid-stream clean catch urine is collected in a sterile bowl and then transferred to the necessary specimen containers.

#### **Group B Streptococcus (GBS)**

Group B Streptococcus (GBS or group B Strep) is the most common cause of severe infection in newborn babies, and of meningitis in babies under age 3 months. On average in the UK:

- 2 babies a day develop group B Strep infection
- 1 baby a week dies from group B Strep infection
- 1 baby a week survives group B Strep infection with long term disability

Most GBS infection is of early onset, presenting in babies within the first 6 days of life, and usually within the first 12 hours after birth. Between age 7 days and 3 months, these infections are rare, and in babies over 3 months they are very rare indeed.

Most early-onset GBS infections (in babies aged 0-6 days) can be prevented by giving intravenous antibiotics in labour to women whose babies are at raised risk of developing GBS infection. In the UK, women are offered IV antibiotics in labour based on specific risk factors.

GBS is normal flora of the distal GI tract. Up to 30% of women carry it harmlessly in their vaginal tract. Vaginal carriage at the time of vaginal delivery can result in transmission of GBS to baby. Babies are more vulnerable to infection as their immature immune systems cannot fight off the multiplying bacteria. If untreated, GBS can cause serious infections.

such as meningitis and septicaemia, which may lead to stillbirths, and newborn and infant deaths. If they survive, babies can develop permanent problems including hearing or vision loss, or cerebral palsy.

Current GBS prevention focuses on giving intravenous antibiotics to women in labour, aiming to reduce disease in infants at delivery. 2 x **Blue culture swabs** (lower vaginal and lower rectal) should ideally be taken from 35 weeks. Swabs will be placed in enrichment culture in the microbiology laboratory fto ensure maximal detection.



#### **Swabs: Types and Codes**

**Patient Request Forms** and **Swabs** should be labelled with the body site from which the sample was taken. **This is important**. The swab site determines the appropriate culture media required to target the most likely pathogens.

#### **Culture Swabs**

| SITE              | CODE | SAMPLE TYPE                |
|-------------------|------|----------------------------|
| Candida only swab | CANC | Black or Blue Micro Swab   |
| Cervical swab     | CERS | Black or Blue Micro Swab   |
| Ear swab          | EARS | Blue or Orange Micro Swab  |
| Eye swab          | EYES | Blue or Orange Micro Swab  |
| Gonorrhoea        | GONN | Black Charcoal Swab        |
| High vaginal swab | HVS  | Black or Blue Micro Swab   |
| Nasal swab        | NASS | Blue or Orange Micro Swab  |
| Oral swab         | ORSW | Black or Blue Micro Swab   |
| Penile swab       | PENS | Black or Orange Micro Swab |
| Rectal swab       | RECG | Black or Blue Micro Swab   |
| Skin swab         | SKIS | Blue Micro Swab            |
| Throat swab       | THRS | Blue Micro Swab            |
| Urethral swab     | URES | Black or Orange Micro Swab |
| Vaginal swab      | VAGS | Black or Blue Micro Swab   |
| Vulval swab       | VULV | Black or Blue Micro Swab   |
| Wound swab        | WOUS | Black or Blue Micro Swab   |

#### **MRSA by Culture**

| ,    |  |
|------|--|
| CODE | SAMPLE TYPE                              |
| MRSW | Blue Micro Swab x 1 – state site         |
| MRW2 | Blue Micro Swab x 2 – state sites        |
| MRW3 | Blue Micro Swab x 3 – state sites        |
| MRW4 | Blue Micro Swab x 4 – state sites        |
| MRW5 | <b>Blue</b> Micro Swab x 5 – state sites |

#### **Rapid MRSA by PCR**

| CODE | SAMPLE TYPE                              |
|------|--|
| MRSA | Blue Micro Swab x 1 – state site         |
| MRS2 | <b>Blue</b> Micro Swab x 2 – state sites |
| MRS3 | <b>Blue</b> Micro Swab x 3 – state sites |
| MRS4 | <b>Blue</b> Micro Swab x 4 – state sites |
| MRS5 | <b>Blue</b> Micro Swab x 5 – state sites |

#### PCR methods for the detection of Dermatophyte Fungal Cultures

The detection of Dermatophyte fungal cultures uses High Sensitivity PCR testing. This reduces the overall turnaround time by up to three weeks, and increases the detection of fungal infection compared to combined microscopy and culture. Furthermore the specific targeting pathogens associated with superficial fungal infection is increased which assists in preventing the over reporting of insignificant fungi that are contaminants.

#### **Fungal test codes**

|                    | Investigation of<br>Superficial Fungal Infection  | Investigation of<br>Non-Superficial Fungal Infection  |
|--------------------|---|---|
| Test code          | DERM*   | FUN*  |
| Sample type        | Skin, Hair and Nail.  | All specimens other than<br>Skin, Hair and Nail.  |
| Turnaround<br>time | 72 hours for interim PCR report, and 7 days for final culture (unless the fungal culture needs to be extended for significant growth).                      | 7 days (non-sterile e.g. ear swab) and 3 weeks (sterile i.e. CSF).  |
| Notes              | <ul> <li>Dermatophyte PCR has replaced microscopy<br/>for Skin, Hair and Nail (72 Hour TAT).</li> <li>Non-dermatophyte culture will take 7 days.</li> </ul> | Non-sterile specimen fungal cultures<br>are performed on Sabouraud's agar<br>plates for 7 days with no microscopy.  |
|                    | significance of rare fungi.  Pseudomonas investigation in Nail specimens is available on request  and culture   | Sterile specimen fungal cultures<br>have microscopy (Calcafluor)<br>reported on the day of processing<br>and culture on a Sabouraud's agar<br>slope, incubated for 21 days. |

#### **Stool test codes**

Traditional culture methods have been replaced by Real Time PCR for enteric pathogen testing. The benefits are increased sensitivity and a higher detection rate. Once received and processed in the microbiology lab, negative results will be available within 24 hours. Positive results will be followed up with culture and sensitivities for final reporting.

#### **Stool OCP and Culture**

| Sample typ | e                             | Comments  |
|------------|-------------------------------|---|
| Stool      | Please request as <b>PENT</b> | All stool samples will be tested for UK Pathogens.  |
|            | Serosep EntericBio PCR        | Overseas pathogens will only be tested if specifically  |
|            | Bacteria/Bacterial Toxins     | requested and travel history and clinical details   |
|            | • Salmonella • Campylobacter  | are provided. Samples that are positive for the bacterial pathogens will be cultured to provide |
|            | • Shigella • VTEC             | sensitivities and, if indicated, for PHE referral.  |
|            | Parasites                     | Samples will be kept for 7 days after receipt   |
|            | • Cryptosporidium • Giardia   | to allow for additional testing if required.  |

#### **Stool for OCP**

| Sample type |   | Comments  |
|-------------|---|---|
| Stool       | Please request as <b>OCP</b>  | Overseas pathogens will only be   |
|             | Requests for OCP only will include testing for cryptosporidium and giardia by PCR | tested if requested and travel history and clinical details are provided. |

#### C. Difficile detection

| Sample ty  | уре                              | Comments |
|--|----------------------------------|----------|
| Stool Please request as CLOS Serosep Enteric Bio PCR | Two tier PCR and Toxin c.diff    |          |
|  | screening based on PHE guidance. |          |
|  | Alere Techlab EIA (Toxin)        |          |

**Enteric Organism Rapid Detection – see Tropical Immunology page 90** 

| TEST   | CODE           | SAMPLE REQS  | TAT             |
|--|----------------|--|-----------------|
| 11 Deoxycorticosterone   | DEOX           | B  | 10 days         |
| 11 Deoxycortisol   | 11DC           | (Frozen)   | 10 days         |
| 17 Hydroxyprogesterone   | 170H           | B  | 5 days          |
| ACTH (Adrenocorticotropic Hormone)   | ACTH           | (Plasma, spun and frozen within 2 hours) <sup>41</sup> | 1 day           |
| Aldosterone  | ALDN           | A or B   | 5 days          |
| Aldosterone (Urine)  | UALD           | PU   | 5 days          |
| Alpha-Fetoprotein  | AFP            | B  | 4 hours         |
| Amenorrhoea Profile<br>(Venous/Self-collect) CHANGE  | AMEN /<br>TAME | B / (F) (TDL Tiny) (TDL Tiny)                          | 4 hours / 1 day |
| Andropause Profile   | ANDP           | 88   | 8 hours         |
| Androstenedione  | ANDR           | (Frozen)   | 5 days          |
| Antidiuretic Hormone   | ADH            | (Plasma Frozen) <sup>4</sup>                           | 10 days         |
| Antimullerian Hormone (AMH) (Venous/Self-collect) Samples can be taken, at any time during a patient's monthly cycle. Ambient, unspun sample stability has been validated for up to 5 days (Venous). | АМН            | 3 / (TDL Tiny)   | 4 hours / 1 day |
| BNP (NT-pro BNP)   | BNP            | B  | 4 hours         |
| C Peptide  | CPEP           | B  | 3 days          |
| Calcitonin   | CAT0           | (Frozen) <sup>4</sup>                                  | 1 day           |
| Catecholamines (Plasma)  | CATE           | (Plasma Frozen) <sup>4</sup>                           | 5 days          |
| Catecholamines (Urine)   | UCAT           | PU (collect on acid) <sup>1</sup>                      | 5 days          |
| Cortisol (Venous/Self-collect)   | CORT           | B / B (TDL Tiny)                                       | 4 hours / 1 day |
| Cortisol (Urine)   | UCOR           | CU   | 5 days          |
| DHEA   | DHEX           | B  | 7-10 days       |
| DHEA – Urine (Dehydroepiandrosterone)  | UDHE           | CU   | 3 weeks         |
| DHEA Sulphate (Venous/Self-collect)  | DHEA           | B (TDL Tiny)   | 4 hours / 1 day |
| Dihydrotestosterone  | DHT            | 88   | 7 days          |
| Down Syndrome Risk Bloods only (Risk to be calculated by clinician)  | HCGF/<br>Papa  | В  | 4 hours         |
| Down Syndrome Risk Profile<br>(2nd trimester) Quad   | DRP            | B DRP form <sup>7,8</sup>                              | 5 days          |
| Down Syndrome Risk Profile with risk calculation first trimester   | DRP            | B DRP form + image of scan <sup>7,8</sup>              | 5 days          |
| Erectile Dysfunction Profile   | IMP0           | ABBG   | 3 days          |
| Fasting Insulin Resistance Index (FIRI)  | FIRI           | BG   | 4 hours         |
|  |                |  |                 |

| TEST  | CODE           | SAMPLE REQS                                    | TAT             |
|---|----------------|--|-----------------|
| Female Hormone Profile<br>(Venous/Self-collect)   | FIP /<br>TFIP  | B / F (TDL Tiny) B (TDL Tiny)                  | 4 hours / 1 day |
| First Trimester Antenatal Screen (Risk to be calculated by requesting clinician)  | HCGF/<br>PAPA  | В  | 4 hours         |
| Free T3 (Venous/Self-collect)   | FT3            | B (TDL Tiny)                                   | 4 hours / 1 day |
| Free T4 (Venous/Self-collect)   | FT4            | B (TDL Tiny)                                   | 4 hours / 1 day |
| FSH (Venous/Self-collect)   | FSH            | 3 (TDL Tiny)                                   | 4 hours / 1 day |
| Growth Hormone (Fasting)  | GH             | B 7,35   | 4 hours         |
| Gut Hormone Profile   | GUTP           | (Frozen within 15 minutes) <sup>41</sup>       | 3 weeks         |
| HCG (Quantitative)  | QHCG           | <b>B</b>                                       | 4 hours         |
| Hirsutism Profile   | HIRP           | <b>B</b>                                       | 4 hours         |
| HRT Profile 1   | HRT            | <b>B</b>                                       | 4 hours         |
| HRT Profile 2   | HRT2           | <b>B G</b>                                     | 4 hours         |
| IGF-1 (Somatomedin)   | SOMA           | □ (Frozen) <sup>4</sup>                        | 1 day           |
| IGF-BP3   | IGF3           | □ (Frozen) <sup>4</sup>                        | 5 days          |
| Impotence Profile   | IMP0           | ABBG   | 3 days          |
| Inhibin A   | INIA           | В  | 1 month         |
| Inhibin B   | INIB           | (Day 3 of cycle, frozen)                       | 5 days          |
| Insulin   | INSU           | <b>B</b>                                       | 4 hours         |
| Luteinising Hormone (LH)<br>(Venous/Self-collect)   | LH             | B / B (TDL Tiny)                               | 4 hours / 1 day |
| Macroprolactin  | PRLD           | В  | 4 days          |
| Male Hormone Profile  | MIPR           | <b>B</b>                                       | 4 hours         |
| Melatonin (Serum)   | MEL            | (Frozen)                                       | 5 days          |
| Melatonin (Urine)   | UMEL           | CU <sup>13</sup>                               | 2 weeks         |
| Menopause Profile (Venous/Self-collect)   | MENO /<br>TMEN | B (TDL Tiny) (TDL Tiny)                        | 4 hours / 1 day |
| Metabolic Syndrome Profile  | METS           | ABBG   | 9 days          |
| Metanephrines (Plasma) Must be frozen within 2 hours.   | PMET           | (Frozen plasma, must be frozen within 2 hours) | 7 days          |
| Metanephrines (Urine)   | UMEX           | <b>PU</b> (collect on acid) <sup>1</sup>       | 5 days          |
| Oestradiol (Venous/Self-collect) Requests for a single self-collect Oestradiol [TOES] requires 1 x (3) (TDL Tiny) only. | 0EST /<br>T0ES | 3 (TDL Tiny)                                   | 4 hours / 1 day |
| Oestriol (Estriol)  | E3             | BB   | 4 days          |
|   |                |  |                 |

| TEST  | CODE | SAMPLE REQS                       | TAT             |
|---|------|-----------------------------------|-----------------|
| Oestrone  | E1   | BB                                | 4 days          |
| Osteocalcin   | 0ST  | ⊕ (Frozen)⁴                       | 4 days          |
| Parathyroid Hormone (Whole)   | PTHI | <b>A</b> 4                        | 1 day           |
| Pituitary Function Profile CHANGE   | PITF | <b>BB</b> <sup>7</sup>            | 1 day           |
| Polycystic Ovary Syndrome Profile   | PC0P | <b>ABBB G</b> <sup>7</sup>        | 5 days          |
| Polycystic Ovary Syndrome SHORT   | PCOS | BG                                | 4 hours         |
| Pregnancy (Serum) [Quantitative]  | QHCG | B                                 | 4 hours         |
| Pregnenolone  | PREN | B                                 | 15 days         |
| Progesterone (Venous/Self-collect)  | PROG | B / B (TDL Tiny)                  | 4 hours / 1 day |
| Proinsulin  | PROI | (Frozen plasma)4                  | 5 days          |
| Prolactin (Macro)   | PRLD | B                                 | 4 days          |
| Prolactin (Venous/Self-collect)   | PROL | B / B (TDL Tiny)                  | 4 hours / 1 day |
| Renin   | RENI | (Frozen plasma) <sup>36</sup>     | 5 days          |
| Reverse T3  | RT3  | <b>B</b> 7,37                     | 15 days         |
| Serotonin   | SERT | (Frozen whole blood) <sup>1</sup> | 10 days         |
| Serotonin (Urine)   | USER | PU 50mls (Frozen) <sup>1</sup>    | 5 days          |
| Sex Hormone Binding Globulin<br>(Venous/Self-collect)                         | SHBG | B / B (TDL Tiny)                  | 4 hours / 1 day |
| Somatomedin (IGF-1)   | SOMA | ⊕ (Frozen) <sup>4</sup>           | 1 day           |
| ТЗ  | T3   | В                                 | 4 hours         |
| T3 (Reverse)  | RT3  | <b>B</b> 7,37                     | 15 days         |
| Testosterone (Venous/Self-collect)  | TEST | B / B (TDL Tiny)                  | 4 hours / 1 day |
| Testosterone (Free)<br>(Venous/Self-collect)                                  | FTES | B / B (TDL Tiny)                  | 3 days          |
| Thyroglobulin Abs   | TGAB | B                                 | 1 day           |
| Thyroglobulin Assay   | TGA  | В                                 | 1 day           |
| Thyroid Abs (Thyroglobulin + Thyroid<br>Peroxidase Abs) (Venous/Self-collect) | THAB | 3 / (TDL Tiny)                    | 1 day / 2 days  |
| Thyroid Peroxidase Antibodies/Anti TPO  | TPEX | B                                 | 1 day           |
| Thyroid Profile 1 (FT4/TSH)<br>(Venous/Self-collect)                          | TF   | 3 / (TDL Tiny)                    | 4 hours / 1 day |
| Thyroid Profile 2   | TF2  | В                                 | 2 days          |
| Thyroid Profile 3 (FT3/FT4/TSH) (Venous/Self-collect)                         | TF3  | B / B (TDL Tiny)                  | 4 hours / 1 day |
| Thyroxine (T4)  | T4   | В                                 | 4 hours         |
|   |      |                                   |                 |

| TEST                       | CODE | SAMPLE REQS      | TAT             |
|----------------------------|------|------------------|-----------------|
| Thyroxine Binding Globulin | TBG  | (Frozen)         | 10 days         |
| TSH (Venous/Self-collect)  | TSH  | 3 / B (TDL Tiny) | 4 hours / 1 day |
| TSH-Receptor Antibodies    | TSI  | B                | 4 days          |

#### Reproductive Immunology at Rosalind Franklin Laboratory, Chicago, USA

| CODE | SAMPLE REQS   | TAT       |
|------|---|-----------|
| 3RF  | 000   | 1 week    |
| 4RF  | 000   | 1 week    |
| 5RF  | 000   | 1 week    |
| 6RF  | <b>000</b> 5  | 1 week    |
| 7RF  | <b>(1)</b> (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)                            | 1 week    |
| 8RF  | B   | 1 week    |
| 9RF  | AA  | 2 weeks   |
| 10RF | AA  | 2 weeks   |
| 11RF | AA  | 2 weeks   |
| 14RF | AA  | 2 weeks   |
| 16RF | 000   | 1 week    |
| 17RF | AAA   | 2-3 weeks |
| 20RF | <b>999</b> <sup>5</sup>   | 1 week    |
| 21RF | <b>000</b> 5  | 1 week    |
| 22RF | <b>999</b> <sup>5</sup>   | 1 week    |
| 23RF | J (Contact Referrals)   | 2 weeks   |
| 25RF | 0   | 3 days    |
| 26RF | AA  | 2 weeks   |
| PAIP | A   | 10 days   |
|      | 3RF 4RF 5RF 6RF 7RF 8RF 9RF 10RF 11RF 14RF 16RF 20RF 22RF 22RF 23RF 25RF 26RF | 3RF       |

Patients who have samples taken at TDL's Patient Reception at 76 Wimpole Street may attend any time during hours of opening on Mondays or Tuesdays, and by NOON on Wednesdays to allow for same day shipping to Chicago by Fed Ex. Samples for Rosalind Franklin are not accepted on Thursdays, Fridays or Saturdays. Fed Ex charges are included in these charges.

#### **Reproductive Immunology from St Helier**

| TEST  | CODE | SAMPLE REQS  | TAT                 |
|---|------|--------------|---------------------|
| NK (CD69) Cell Assay  | CD69 | <b>()</b> *  | Send Mon-Thurs only |
| NK (CD69) and NK Cytotoxicity   | 69C  | <b>•••</b>   | Send Mon-Thurs only |
| NK Cytotoxicity Assay   | HSNK | <b>•••</b>   | Send Mon-Thurs only |
| NK Cytotoxicity with suppression with steroid, IVIg and intralipin, and NK (CD69) cell assay  | 69CI | <b>000</b> * | Send Mon-Thurs only |
| NK Cytotoxicity with suppression, steroid, IVIg & Intralipin                                  | NKCY | 000*         | Send Mon-Thurs only |
| Suppression with steroid, IVIg and intralipin, NK (CD69) cell assay, TH1/TH2 cytokines CHANGE | NCIT | 0000*        | Send Mon-Thurs only |
| TH1/TH2 Cytokine Profile  | 1TH2 | <b>000</b> * | Send Mon-Thurs only |

Patients need to attend Patient Reception at 76 Wimpole Street by 11.00am latest Mondays – Thursdays. Samples cannot be accepted on Fridays, Saturdays or Sundays. Allow 2 days for results.

## Amenorrhoea Profile (Venous / Self-collect)

#### CHANGE

LH FSH Prolactin

Testosterone

Oestradiol – 17 Beta (Venous) Oestradiol – 17 Beta (Self-collect) SHBG

Free Androgen Index

TAT: 4 hours / 1 day

AMEN / TAME

(TDL Tiny) (TDL Tiny)

#### Andropause Profile

DHEAs FSH

Testosterone Free Androgen Index

LH SHBG

TAT: 8 hours

ANDP

**BB** 

## **Erectile Dysfunction Profile**

Lipid Profile

Glucose HbA1C

FT4/TSH Prolactin

Total Testosterone

Free Testosterone

PSA SHBG

Free Androgen Index

TAT: 3 days

IMP0

**ABBG** 

## Female Hormone Profile (Venous/Self-collect)

LH ESH

Prolactin

Oestradiol – 17-Beta (Venous)
Oestradiol – 17-Beta (Self-collect)

#### TAT: 4 hours / 1 day

FIP / TFIP

3 (TDL Tiny) (TDL Tiny)

#### First Trimester Antenatal Screen (Risk to be calculated by requesting clinician)

Free β-hCG PAPP-A

Free β-hCG and PAPP-A in serum and sonographic determination of nuchal translucency (NT) are markers of choice to identify women at increased risk of Down Syndrome during the first trimester (week 11-13) of pregnancy.

#### TAT: 4 hours

#### HCGF/PAPA

₿

#### **Hirsutism Profile**

FSH LH Testosterone DHEAs SHBG

#### TAT: 4 hours

HIRP

#### B

#### **HRT Profile 1**

FSH

Oestradiol – 17-Beta Progesterone

#### **TAT: 4 hours**

HRT



#### **HRT Profile 2**

Lipid Profile Glucose FT4 TSH FSH OEST

#### TAT: 4 hours

HRT2



#### **Impotence Profile**

Lipid Profile Glucose HbA1C TSH Prolactin Total Testosterone

Free Testosterone PSA

PSA SHBG

Free Androgen Index

#### TAT: 3 days

IMP0



#### **Male Hormone Profile**

FSH

LH Testosterone Free Androgen Index Prolactin

SHBG

#### TAT: 4 hours

**MIPR** 



## Menopause Profile (Venous/Self-collect)

FSH

LH

Oestradiol – 17-Beta (Venous)
Oestradiol – 17-Beta (Self-collect)
TSH
FT4

#### TAT: 4 hours / 1 day

MENO / TMEN

3 (TDL Tiny) (TDL Tiny)


#### Metabolic Syndrome Profile

Lipid Profile Glucose HbA1C Insulin hsCRP Adiponectin

#### TAT: 9 days

**METS** 





#### **Pituitary Function Profile**

#### CHANGE

TSH

**FSH** 

LH Prolactin

IGF-1 (Somatomedin)

Cortisol

Please provide details of time of day sample is taken. Patient should be resting for 30 mins before sample taking.

#### TAT: 1 day

**PITF** 



#### **Polycystic Ovary Syndrome SHORT**

Testosterone

SHBG

FAI

**FSH** 

LH Glucose

Insulin

Lipid Profile

FT4/TSH

#### TAT: 4 hours

**PCOS** 



#### **Polycystic Ovary Syndrome Profile**

Testosterone

TSH

Glucose

HbA1C

**FSH** 

**DHFAs** 

Insulin

LH

17 Hydroxyprogesterone

Lipid Profile

Prolactin

Cortisol

Antimullerian Hormone Androstenedione

SHBG

A fasting 9.00am sample is recommended.

#### TAT: 5 days

**PCOP** 



#### **Thyroid Profile 1** (FT4/TSH) (Venous/Self-collect)

FT4 **TSH** 

#### TAT: 4 hours / 1 day

TF

B/ B (TDL Tiny)

#### **Thyroid Profile 2**

T4

**TSH** Free T3

Free T4

Thyroglobulin Abs

Thyroid Peroxidase

#### TAT: 2 days

TF2



#### **Thyroid Profile 3** (FT3/FT4/TSH) (Venous/Self-collect)

FT3 FT4

**TSH** 

#### TAT: 4 hours / 1 day

TF3

B (TDL Tiny)

The single most important factor determining a man's fertility potential is the production of healthy sperm. A semen analysis has classically been used as the marker of this potential, by providing information about the sperm count, motility and morphology. However, there are other parameters given in a semen analysis that are often neglected or overlooked, which may indicate important pathologies — such as infection, prostatic disease, immunological infertility, retrograde ejaculation, malformation or obstruction of the genital tract, tumour, and congenital or endocrine disorders.

Early diagnosis of the male factor is important in order to detect any underlying pathology, determine the extent of infertility and ensure appropriate treatment. It may also avoid unnecessary investigations for the female partner, particularly if her age is a limiting factor.

For men who have had a vasectomy, clearance should only be given when there is no evidence of presence of sperm in two consecutive semen samples. It is therefore vital to ensure that results are reported according to best practice guidelines. Special clearance may be given at the doctor's discretion when there are persistent non-motile sperm present.

#### **Guidelines for Producing Samples**

Ideally semen samples should be produced on-site at TDL's Patient Reception at 76 Wimpole Street. Ideally patients must abstain from ejaculation for 2-3 days prior to the test, generally no less than 2 days and no longer than 7 days before the test is acceptable. This requirement is important for semen analyses and post vasectomy analyses to ensure reliability of results. It is possible that samples that do not comply with guidelines for abstinence and collection may not be able to be processed. All semen samples must be produced directly into the sterile containers provided by The Doctors Laboratory.

All containers are weighed and batch tested for sperm cytotoxicity. In exceptional circumstances when semen samples are produced off-site, they can only be accepted by the Andrology Department in sample containers provided by TDL.

TDL Andrology provides reference values to those given in the most recent WHO guidelines (2021). WHO 2021 guidelines state that two semen analyses should be performed before any diagnosis is confirmed. This may require requests for two (separate) semen analyses.

#### **Appointments**

It is important to make an appointment for all semen samples (on or off site) whether for a comprehensive semen analysis or post vasectomy analysis. It may be necessary to give patients who attend without an appointment a specific time to re-attend. The first appointments for post vasectomy samples should usually be 12 weeks and 20 ejaculations after surgery.

Appointments can be made by calling **020 7025 7940**. There is an attendance fee of £50.00 in addition to pathology charges.

Please complete a Pathology Request Form for your patient. If you would like to request other pathology, you can use the same form or complete a second additional form. Results will usually be reported to you within 48 hours.

If you would like to discuss these tests, or any aspect of this service including clinical interpretation by the consultant please contact TDL Andrology on **020 7025 7940** or email **andrology@tdlpathology.com** for further information.



Book an appointment online:

www.tdlpathology.com/ andrologybooking

SCAN ME

| TEST   | CODE | SAMPLE REQS        | TAT     |
|--|------|--------------------|---------|
| Individual Semen Parameters***  *** Semen parameters may be requested individually (e.g. count only, vitality only, motility etc.). Please request as SPOD and indicate on the request form which parameter is required. | SPOD | Semen <sup>1</sup> | 1 day   |
| Oxidative Stress in Semen (ROS + MIOXSYS)  | SROS | Semen 1            | 1 day   |
| Retrograde Ejaculation   | RTR0 | Contact lab        | 2 days  |
| Semen Analysis, Comprehensive* * If required, comprehensive semen analysis can be reported within 4 hours, with morphology to follow.  | SPER | Semen <sup>1</sup> | 2 days* |
| Semen Analysis, Post-Vasectomy**   | PVAS | Semen 1            | 2 days  |

<sup>\*\*</sup> For men who have had a vasectomy, clearance should only be given when there is no evidence of presence of sperm in a single ejaculate when recommendations are met. It is rare that a 'diagnosis' is made without confirmation, therefore patients/clinicians should be able to freely request a second confirmatory sample. Special clearance may be given at the doctor's discretion, when there are <100 000/ml non-motile sperm present after the assessment of two specimens in full accordance with recommendations. Recommendations, as given by the Association of Biomedical Andrologists, the British Andrology Society and the British Association of Urological Surgeons 2016, are as follows:

- · Analysis of post vasectomy semen samples should not occur until 12 weeks post-surgery and after a minimum of 20 ejaculates
- Semen samples must be analysed within 4 hours of production, and in cases where sperm is found a repeat analysis must be performed within 1 hour of production
- . Semen should be provided in weighed specimen containers provided by TDL Andrology
- . Sexual abstinence should be between 2 and 7 days.

| Semen Analysis, Vasectomy Reversal* * If required, comprehensive semen analysis can be reported within 4 hours, with morphology to follow. | SPER | Semen 1 | 2 days*       |
|--|------|---------|---------------|
| Semen Culture  | SPCU | Semen   | 2-4 days      |
| Semen Fructose   | SPCF | Semen   | 2 days        |
| Semen Leucocytes   | PMNS | Semen   | 2 days        |
| Semen Zinc   | SPCZ | Semen   | up to 10 days |
| Sperm Aneuploidy   | SPPL | Semen 1 | 4 weeks       |
| Sperm Antibodies (Serum)   | ASAB | B       | 5 days        |
| Sperm Antibodies/MAR Test (Semen) <sup>†</sup> † Sperm antibodies in semen are measured as part of the routine semen analysis.             | ASPA | Semen   | 1 day         |
| Sperm Comet®   | CMET | Semen 1 | 1-2 weeks     |
| Sperm Count (Post-Vasectomy)   | PVAS | Semen 1 | 2 days        |
| Sperm DNA Fragmentation (SCSA)   | SEXT | Semen 1 | 1-2 weeks     |
| Sperm Morphology (Kruger strict criteria)  | MRPH | Semen 1 | 2 days        |
|  |      |         |               |

#### By special arrangement

- Sperm swim test
- Sperm preparation for overnight survival
- Sperm motility and vitality testing for epididymal toxicity
- Sperm retrieval procedures (biopsy, PESA, MESA)
- Sperm cryopreservation and storage (undertaken by Andrology Solutions – HFEA licensed)

All men who store sperm must be screened for HIV 1&2, Hepatitis B, Hepatitis C and HTLV. Under HFEA regulations, sperm can be stored for an initial period of 10 years with formal consent. All patients are offered counselling prior to sperm cryopreservation.

These arrangements, and details for other specialist semen tests, are available on request. Please contact TDL Andrology on **020 7025 7940** or email **sheryl.homa@tdlpathology.com** for further information.

#### **Sperm DNA fragmentation**

High sperm DNA fragmentation is associated with reduced natural pregnancy rates and assisted conception pregnancy rates as well as live birth rates. In addition, DNA fragmentation leads to higher miscarriage rates as published in the ESHRE Recurrent Pregnancy Loss 2017 Guideline. High levels of DNA fragmentation may be reduced by considering varicocele repair, treatment of underlying infections or inflammation, changes in lifestyle or with antioxidant supplements.

When requesting Sperm DNA Fragmentation there are two options. Please specify whether the request is for sperm DNA fragmentation by **SCSA** or **COMET**.

## Sperm Chromatin Structure Assay (SCSA®) [SEXT]

This test has the ability to measure large numbers of cells (between 5,000 and 10,000 sperm), rapidly in an ejaculate. The SCSA® test monitors the changes in fluorescence of a probe, acridine orange, to detect both single and double DNA strand breaks using flow cytometry. It has been developed using human and animal models over the last 35 years and is one of the most statistically robust tests available for sperm DNA fragmentation. It is a standardised, validated CLIA approved test with high reproducibility and low variability. The test requires a minimum sperm count of approximately 100,000/ml.

#### Sperm COMET® Assay [CMET]

Exact® tests, powered by SpermComet® technology measure sperm DNA damage. The Exact range of tests are available via healthcare professionals only. Sperm DNA can be damaged when sperm are being made in the testes or as they mature before ejaculation. This damage breaks the DNA into fragments, so sperm DNA tests are also known as sperm DNA fragmentation tests. Men with high levels of sperm DNA damage are less likely to get their partner pregnant and have increased risk of miscarriage. Even if semen analysis results are 'normal', the sperm DNA could be damaged and therefore poor quality. Sperm DNA damage can reduce your chances of having a baby. The Comet® assay can measure both single and double strand breaks. Only a small number of sperm (a minimum of 5,000) sperm are required to perform the assay.

It is a standardized ISO 13485 certified test with high reproducibility and low variability.

It also has the advantage of requiring only 5000 sperm so it can be used for men with low sperm counts and also for surgically retrieved sperm samples.

#### **Sperm Aneuploidy**

Chromosomal abnormalities may be somatic cell in origin, in which case they can be detected by a simple blood karyotype analysis. However, most sperm chromosome anomalies arise as a result of errors during meiosis, which cannot be detected by a blood karyotype analysis. These anomalies can only be detected by looking at the sperm chromosomes directly. Studies have shown that sperm with a high rate of aneuploidy have a negative impact on pregnancy rate and are associated with recurrent pregnancy loss.

This test uses fluorescent in situ hybridisation (FISH) to label individual chromosomes with specific probes. Hundreds of sperm are assessed from one ejaculate. There are limitations to the test as only 5 probes are currently used routinely for analysis (three of the 22 autosomes: chromosomes 13, 18 and 21, and the sex chromosomes, X and Y), although others are available upon specific request. The results are reported showing incidence of disomy or nullisomy for each of the autosomes and for both sex chromosomes. A sex chromosome ratio is also reported. It is CE marked.

## Instructions for collection of Sperm DNA and Aneuploidy specimens

Sperm DNA Fragmentation or Sperm Aneuploidy testing are not part of the Comprehensive Semen Analysis and need to be requested as a separate test, test code SEXT and SPPL, respectively.

Semen samples ideally need to be frozen as soon as possible after liquefaction, but not longer than 60 minutes post ejaculation. Samples must be snap-frozen for Sperm DNA Fragmentation and cryopreserved in TYB for Sperm Aneuploidy. If samples are prepared by another laboratory. Two cryovials containing not less than 0.25 mls of semen is required. Frozen samples can be sent to, or collected by TDL, by arrangement, and must be accompanied with relevant patient details, the sperm count and GDPR consent form.

A count of a minimum 0.1 million/ml is required for accurate DNA and aneuploidy reporting.

## Oxidative Stress in Semen (ROS + MIOXSYS) and Male infertility

There is now growing evidence to support a link between oxidative stress and male infertility. It is the underlying cause of sperm DNA damage and impairs semen parameters and fertilisation, adversely affects embryo development and is associated with reduced pregnancy rates. It may also increase the risk of miscarriage. High levels of ROS may be reduced by considering varicocele repair, treatment of underlying infections or inflammation, changes in lifestyle or with antioxidant supplements.

TDL provides a comprehensive assessment of oxidative stress by **combined measurement of Reactive Oxygen Species and Redox Potential**.

Please request as oxidative stress test (code ROS).

The test includes combined testing for:

- Chemiluminescence Assay for Reactive Oxygen Species: Reactive Oxidative stress may be measured by a simple chemiluminescence test in semen, which measures the level of reactive oxygen species.
- MIOXSYS Electrochemical Assay for Redox Potential: Oxidative stress may be determined by an electrochemical assay which measures the redox potential in semen. This test measures the overall difference between total oxidants and antioxidants in the system.

If you would like to discuss these tests, or any aspect of this service, please contact TDL Andrology on **020 7025 7940** or **020 7307 7373**, or email **andrology@tdlpathology.com**.

#### References

Vassiliou A, Martin CH, Homa ST, Stone J, Dawkins A, Genkova MN, Skyla Dela Roca H, Parikh S, Patel J, Yap T, Killeen AP. Redox potential in human semen: Validation and qualification of the MiOXsys assay. Andrologia. 2021 Mar;53(2):e13938. doi: 10.1111/and.13938. Epub 2020 Dec 30. PMID: 33377541.

Semen samples need specialist handling — for this reason all requests for semen analyses should be made by appointment. Practices or patients should contact TDL Andrology on **020 7025 7940** to make appointments and to confirm instructions for sample collection.

#### Effects of ROS-induced Oxidative Stress on Sperm

- Lipid peroxidation which damages the sperm surface causing an abnormal morphology and impaired motility.
- Damage to proteins on cell surface responsible for cell signalling and may affect enzyme function inside the cell.
- Increased semen viscosity.
- Peroxidation of DNA and subsequent unravelling or fragmentation.
- Possible mutagenic effects.
- Damage to seminiferous epithelium, damage to tubules, testicular atrophy, reduced spermatogenesis.
- Decrease in sperm vitality, motility.
- Impaired fertilization by affecting sperm capacitation and the acrosome reaction.

#### Causes of Elevated ROS Levels

- Genito-urinary tract infection
- Prostatitis
- Vasectomy reversal
- Varicocoele
- Cryptorchidism
- Chronic disease
- Xenobiotics
- Chemical pollutants and occupational hazards
- Heavy metal exposure
- Removal of seminal plasma during sperm preparation for assisted conception
- Drugs cyclophosphamide, aspirin, paracetamol
- Smoking
- Excessive exercise
- Heat exposure
- Obesity
- Age

#### **Sexual Health**

| TEST   | CODE           | SAMPLE REQS   | TAT                |
|--|----------------|---|--------------------|
| 7 STI Profile by PCR<br>(7 tests from 1 Sample)  | DL12           | FCRU / PCR Swab / TPV or<br>Aptima urine / multisite swab | 2 days             |
| Chlamydia – PCR swab   | SPCR           | PCR   | 2 days             |
| Chlamydia – Thin Prep  | TPCR           | TPV   | 2 days             |
| Chlamydia – Urine  | CPCR           | FCRU  | 2 days             |
| Chlamydia/Gonorrhoea – PCR Swab  | SCG            | PCR   | 2 days             |
| Chlamydia/Gonorrhoea – Rectal (PCR/Self-collect)   | RSCG           | PCR / Aptima multisite swab                               | 2 days             |
| Chlamydia/Gonorrhoea – Thin Prep   | TCG            | TPV   | 2 days             |
| Chlamydia/Gonorrhoea – Throat (PCR/Self-collect)   | TSCG           | PCR / Aptima multisite swab                               | 2 days             |
| Chlamydia/Gonorrhoea – Urine<br>(FCRU/Self-collect)  | CCG            | FCRU / Aptima urine                                       | 2 days             |
| Chlamydia/Gonorrhoea – Vaginal<br>(Self-collect)   | SCG            | Aptima multisite swab                                     | 2 days             |
| Chlamydia/Gonorrhoea/Trichomonas<br>– PCR Swab   | SCGT           | PCR   | 2 days             |
| Chlamydia/Gonorrhoea/Trichomonas<br>– Thin Prep  | TCGT           | TPV   | 2 days             |
| Chlamydia/Gonorrhoea/Trichomonas<br>– Urine  | CCGT           | FCRU  | 2 days             |
| CT/GC/Trichomonas/Mgen – PCR Swab  | SGTM           | PCR Swab  | 2 days             |
| CT/GC/Trichomonas/Mgen – Thin Prep   | TGTM           | TPV   | 2 days             |
| CT/GC/Trichomonas/Mgen – Urine   | CGTM           | FCRU  | 2 days             |
| Gardnerella vaginalis by PCR   | GVPC           | FCRU / PCR / TPV  | 2 days             |
| Gonorrhoea – Culture  † † † The optimal sample type from the female genital tract is an endocervical swab. Gonorrhoea does not survive well outside the endocervical epithelium; a negative gonorrhoea culture result from a vaginal swab is not reliable for excluding infection. | GONN           | CS***   | 2-3 days           |
| Gonorrhoea – PCR swab  | SGON           | PCR   | 2 days             |
| Gonorrhoea – Thin Prep   | TGON           | TPV   | 2 days             |
| Gonorrhoea – Urine   | CGON           | FCRU  | 2 days             |
| Haemophilus ducreyi by PCR   | DUCR           | PCR   | 7 days             |
| Hepatitis A Profile  | HEPA           | B   | 4 hours            |
| Hepatitis B Surface Antigen<br>(Venous/Self-collect)   | AUAG /<br>THBA | 3 (TDL Tiny)  | 4 hours /<br>1 day |
| Hepatitis C Antibodies<br>(Venous/Self-collect)  | HEPC /<br>THCV | 3 (TDL Tiny)  | 4 hours /<br>1 day |

#### **Sexual Health**

| TEST  | CODE           | SAMPLE REQS                    | TAT                |
|---|----------------|--------------------------------|--------------------|
| Herpes Simplex (HSV) 1 & 2<br>(PCR/Self-collect) (Oral or Genital)  | HERS           | PCR / Aptima multisite swab    | 5 days             |
| Herpes Simplex I/II by PCR (Urine)  | HERD           | FCRU                           | 5 days             |
| HIV 1 & 2/p24Ag (Venous/Self-collect)   | HDUO /<br>Thiv | 3 (TDL Tiny)                   | 4 hours /<br>1 day |
| HIV/HBV/HCV Screen by PCR/<br>NAAT (10 days post exposure)  | STDX           | (Vacutainer only)              | 3 days             |
| HIV/HBV/HCV (Early detection by PCR/NAAT) with Syphilis   | STXX           |                                | 3 days             |
| HIV Rapid RNA HIV-1 QUALITATIVE   | LHIV           | (Vacutainer only)              | 4 hours            |
| HIV Rapid RNA HIV-1 QUANTITATIVE  | RHIV           | (Vacutainer only)              | 4 hours            |
| HPV (DNA and reflexed mRNA)   | HPVT           | TPV                            | 5 days             |
| HPV (HR mRNA types 16, 18 + others)   | HPVH           | TPV                            | 3 days             |
| HPV (Individually typed low & high risk DNA subtypes)   | HP20           | TPV / PCR swab                 | 3 days             |
| HPV (Individually typed high risk DNA subtypes) (Self-collect)  | HPVZ           | Qvintip vaginal swab           | 3 days             |
| HPV (mRNA all high risk subtypes)<br>(Self-collect)   | HPVY           | Qvintip vaginal swab           | 3 days             |
| Lymphogranuloma Venerium (LGV)  - Rectal (Self-collect)*  * This test can be configured to be   | LGVP           | Aptima multisite swab          | 1-2 weeks          |
| automatically reflexed as required.   |                |                                |                    |
| Lymphogranuloma Venerium (LGV) (PCR)  | LGVP           | PCR <sup>42</sup>              | 1-2 weeks          |
| Macrolide Resistance Test (Mgen)  | MGR            | FCRU / PCR                     | 1-2 weeks          |
| Monkeypox Virus – Lesion (Self-collect)   | MPXV           | Aptima multisite swab          | 2 days             |
| Mycoplasma genitalium by PCR  | MGEN           | FCRU / PCR / TPV               | 2 days             |
| Mycoplasma genitalium Detection<br>– Urine or Vaginal (Self-collect)  | MGEN           | Aptima urine or multisite swab | 2 days             |
| Mycoplasma genitalium Resistance  – Urine or Vaginal (Self-collect)*  * This test can be configured to be automatically reflexed as required. | MGR            | Aptima urine or multisite swab | 1-2 weeks          |
| Mycoplasma genitalium/<br>Ureaplasma by PCR   | MUPC           | FCRU / PCR / TPV               | 2 days             |
| Rapid Xpert HIV-1 RNA Qualitative<br>– Early Detection from 10 days   | LHIV           | (Vacutainer only)              | 4 hours            |
| Rapid Xpert HIV-1 RNS Viral Load – Rapid<br>Testing for HIV-Positive Patient Prognosis<br>and Response To Antiretroviral Therapy              |                | (Vacutainer only)              | 4 hours            |
| RPR (Syphilis)  | RPR            | 3                              | 2 days             |
| (0) p   |                |                                |                    |

| TEST  | CODE           | SAMPLE REQS  | TAT                  |
|---|----------------|--|----------------------|
| STD1 M/F STD Quad (Urine and Serology)  | STD1           | 3 FCRU   | 2 days               |
| STD2 M/F STI Profile Plus<br>(Urine and Serology)                                     | STD2           | <b>3 FCRU</b> (If culture swabs are needed please request separately)  | 4 days               |
| STD3 Female STD Quad<br>(PCR Swab and Serology)                                       | STD3           | □ PCR  | 2 days               |
| STD4 Female STI Profile Plus<br>(PCR Swab and Serology)                               | STD4           | PCR (If culture swabs are needed please request separately)  | 4 days               |
| STD5 Serology only  | STD5           | B  | 4 hours              |
| STD6 Serology only without HIV  | STD6           | B  | 4 hours              |
| STD8 Vaginitis/BV Profile using Culture & PCR Swab                                    | STD8           | PCR and STM  | 3 days               |
| STD9 Symptomatic lesion sample using PCR Swab from lesion & PCR Swab                  | STD9           | 2 x PCR Swab   | 7 days               |
| STI Profile by PCR<br>(7 tests from 1 Sample) (Self-collect)                          | DL12           | Aptima urine or multisite swab   | 2 days               |
| STI Profile: MSM1 (Venous/Self-collect)   | MSM1           | 3 / FCRU / PCR Swab<br>Throat / PCR Swab Rectal<br>or (3 (TDL Tiny) / Aptima Urine<br>/ Aptima multisite swab x 2  | 2 days               |
| STI Profile: MSM2 (Venous/Self-collect)   | MSM2           | [] / FCRU / PCR Swab<br>Throat / PCR Swab Rectal<br>or [] (TDL Tiny) / Aptima urine<br>/ Aptima multisite swab x 2 | 3 days               |
| Syphilis by PCR (chancre)   | SYPS           | PCR  | 5 days               |
| Syphilis IgG/IgM (Venous/Self-collect)  | SERJ /<br>TSYP | 3 (TDL Tiny)   | 4 hours /<br>1 day   |
| ТРРА  | TPPA           | B  | 2 days               |
| Trichomonas vaginalis   | TVPC           | FCRU / PCR / TPV   | 2 days               |
| Trichomonas Vaginalis (TV) –<br>Urine or Vaginal (Self-collect)                       | TVPC           | Aptima urine or multisite swab   | 2 days               |
| Triple Swab Female STI Profile<br>(Vaginal/Throat/Rectal Swabs)<br>(PCR/Self-collect) | 3SWA           | PCR swab x 3 (label by site) or Aptima multisite swab x 3 (label by site)  | 2 days               |
| Ureaplasma urealyticum by PCR   | UGEN           | FCRU / PCR / TPV   | 2 days               |
| Vaginitis/BV Profile<br>(Culture & PCR/Self-collect)                                  | STD8           | PCR and STM or Aptima<br>multisite swab and Blue<br>gel Amies swab   | 3 days /<br>3-5 days |

# STD1 M/F STD Quad (Urine and Serology)

#### SEROLOGY

HIV 1&2/p24 Antigen Syphilis IgG/IgM

#### URINE

Chlamydia Gonorrhoea

### TAT: 2 days

STD1

FCRU

# STD2 M/F STI Profile Plus (Urine and Serology)

#### **SEROLOGY**

HIV 1&2/p24 Antigen Hep B Surface Antigen Hep C Abs Hep C Ag Syphilis IgG/IgM

#### URINE

Chlamydia/Gonorrhoea Mycoplasma genitalium Ureaplasma Trichomonas vaginalis Gardnerella vaginalis Herpes Simplex I/II

### TAT: 4 days

STD2

**B FCRU** (If culture swabs are needed please request separately)

# STD3 Female STD Quad (PCR Swab and Serology)

#### **SEROLOGY**

HIV 1&2/p24 Antigen Syphilis IgG/IgM

#### **VAGINAL PCR SWAB**

Chlamydia Gonorrhoea

### TAT: 2 days

STD3

PCR

# STD4 Female STI Profile Plus (PCR Swab and Serology)

#### **SEROLOGY**

HIV 1&2/p24 Antigen Hep B Surface Antigen Hep C Abs Hep C Ag Syphilis IgG/IgM

#### **VAGINAL PCR SWAB**

Chlamydia/Gonorrhoea Mycoplasma genitalium Ureaplasma Trichomonas vaginalis Gardnerella vaginalis Herpes Simplex I/II

### TAT: 4 days

### STD4

**E PCR** (If culture swabs are needed please request separately)

# STD5 Serology only

HIV 1&2/p24 Antigen Hepatitis B Surface Antigen Hep C Abs Hep C Ag Syphilis IgG/IgM

#### TAT: 4 hours

STD5



# STD6 Serology only without HIV

Hepatitis B Surface Antigen Hep C Abs Hep C Ag Syphilis IgG/IgM

### TAT: 4 hours

STD6



# STD8 Vaginitis/BV Profile using Culture & PCR Swab

Candida species Gardnerella vaginalis by PCR Trichomonas vaginalis by PCR

### TAT: 3 days

STD8

PCR and STM

# STD9 Symptomatic lesion sample using PCR Swab from lesion & PCR Swab

Syphilis by PCR Herpes Simplex I/II by PCR (from single swab)

TAT: 7 days

STD9

2 x PCR Swab

# 7 STI Profile by PCR (7 tests from 1 Sample)

Chlamydia trachomatis Neisseria gonorrhoea Mycoplasma genitalium Ureaplasma species Trichomonas vaginalis Gardnerella vaginalis Herpes Simplex I/II

All tests can be requested individually

TAT: 2 days

DL<sub>12</sub>

FCRU / PCR / TPV

or Aptima urine or multisite swab

### CT/GC/Trichomonas/ Mgen – PCR Swab

Chlamydia Gonorrhoea Trichomonas vaginalis Mycoplasma genitalium

All tests can be requested individually

TAT: 2 days

**SGTM** 

**PCR Swab** 

# CT/GC/Trichomonas/ Mgen – Urine

Chlamydia Gonorrhoea Trichomonas vaginalis Mycoplasma genitalium

All tests can be requested individually

TAT: 2 days

**CGTM** 

**FCRU** 

# HIV/HBV/HCV Screen by PCR/NAAT (10 days post exposure)

Positive findings will be reflexed for confirmatory testing

HIV1 and HIV2 (RNA) Hepatitis B Virus (HBV DNA) Hepatitis C Virus (HCV RNA)

Samples must be received in the laboratory within 2 days of sample taking

STDX provides diagnostic confirmatory testing only when used in addition to serology for Ag/Ab HIV-1&2, HBV, HCV

TAT: 3 days

STDX

A 10mls or 2 x 4mls (Vacutainer only)

# HIV/HBV/HCV (Early detection by PCR/ NAAT) with Syphilis

HIV1 and HIV2 (RNA) Hepatitis B Virus (HBV DNA) Hepatitis C Virus (HCV RNA) Syphilis IgG/IgM

Samples must be received in the laboratory within 2 days of sample taking

TAT: 3 days

STXX

(3) A 10mls or 2 x 4mls

# HIV Rapid RNA HIV-1 QUALITATIVE

Early detection from 10 days HIV-1 RNA

Sample must be received in the laboratory within 24 hours of sample taking

#### TAT: 4 hours

LHIV

(Vacutainer only)

# HIV Rapid RNA HIV-1 QUANTITATIVE

Rapid testing for HIV-positive patient prognosis and response to antiretroviral therapy HIV-1 RNA VIRAL LOAD (40 copies/ml)

Sample must be received in the laboratory within 24 hours of sample taking

#### TAT: 4 hours

RHIV

(Vacutainer only)

# STI Profile: MSM1 (Venous/Self-collect)

HIV 1&2/p24 Ag Syphilis IgG/IgM Urine for CT/GC Throat Swab CT/GC Bectal Swab CT/GC

### TAT: 2 days

MSM<sub>1</sub>

3 / FCRU / PCR Swab
Throat / PCR Swab Rectal
or (TDL Tiny) / Aptima Urine
/ Aptima multisite swab x 2

# STI Profile: MSM2 (Venous/Self-collect)

HIV 1&2/p24 Ag Syphilis IgG/IgM Hep B sAg Hep C Abs 7 STI by PCR Screen Throat Swab CT/GC Rectal Swab CT/GC Macrolide Resistance Test (M.gen)

### TAT: 3 days

MSM<sub>2</sub>

(3) / FCRU / PCR Swab Throat / PCR Swab Rectal or (3) (TDL Tiny) / Aptima Urine / Aptima multisite swab x 2

# Triple Swab Female STI Profile (Vaginal/ Throat/Rectal Swabs) (PCR/Self-collect)

CT/GC Vaginal CT/GC Throat CT/GC Rectal

### TAT: 2 days

3SWA

**PCR Swab** x 3 (label by site) or Aptima multisite swab x 3 (label by site)

# **FASTest Test Now: Sexual Health screening ahead of expected time**

| TEST                         | CODE | SAMPLE REQS | TAT     |
|------------------------------|------|-------------|---------|
| FAST Chlamydia – PCR Swab    | FSCT | PCR Swab    | 4 hours |
| FAST Chlamydia – Urine       | FCT  | FCRU        | 4 hours |
| FAST CT/GC – PCR Swab        | FSCG | PCR Swab    | 4 hours |
| FAST CT/GC – Rectal PCR Swab | FRCG | PCR Swab    | 4 hours |
| FAST CT/GC – Throat PCR Swab | FTCG | PCR Swab    | 4 hours |
| FAST CT/GC – Urine           | FCG  | FCRU        | 4 hours |
| FAST Gonorrhoea – PCR Swab   | FSGN | PCR Swab    | 4 hours |
| FAST Gonorrhoea – Urine      | FGN  | FCRU        | 4 hours |
| FAST Screen SHORT with Swab  | FSSS | B PCR Swab  | 4 hours |
| FAST Screen SHORT with Urine | FSSC | ■ FCRU      | 4 hours |
| FAST Screen with Swab        | FSWS | B PCR Swab  | 4 hours |
| FAST Screen with Urine       | FUSC | ■ FCRU      | 4 hours |
|                              |      |             |         |

### **FAST Screen SHORT with Urine**

HIV 1&2/p24 Ag Syphilis IgM/IgG FAST Urine CT/GC

### TAT: 4 hours

**FSSC** 

FCRU

### **FAST Screen SHORT with Swab**

HIV 1&2/p24 Ag Syphilis IgM/IgG FAST Swab CT/GC

### TAT: 4 hours

**FSSS** 

PCR Swab

### **FAST Screen with Urine**

HIV 1&2/p24 Ag Hep B sAg Hep C Abs Syphilis IgG/IgM FAST Urine CT/GC

### TAT: 4 hours

**FUSC** 

FCRU

### **FAST Screen with Swab**

HIV 1&2/p24 Ag Hep B sAg Hep C Abs Syphilis IgG/IgM FAST Swab CT/GC

### TAT: 4 hours

**FSWS** 

PCR Swab

| STI  | INCUBATION<br>PERIOD   | SAMPLE<br>SITE  | TEST   | TEST<br>CODE                         | SAMPLE<br>TYPE  | TAT  |
|--|--|---|--|--------------------------------------|---|--|
| Chlamydia CT<br>(Bacterial)  | 1-3 weeks,<br>up to 6 weeks  | Urine<br>Cervix/Vagina<br>Cervix/Vagina                     | Chlamydia<br>Chlamydia<br>Chlamydia  | CPCR<br>SPCR<br>TPCR                 | First catch Urine<br>PCR Swab<br>Thin Prep Vial                         | 2 days<br>2 days<br>2 days                               |
| Gonorrhoea<br>GC (Bacterial)   | 2-7 days,<br>up to 1 month   | Urine<br>Cervix/Vagina<br>Cervix/Vagina<br>Cervix/Vagina    | Gonorrhoea by PCR<br>Gonorrhoea by PCR<br>Gonorrhoea by PCR<br>Gonorrhoea by CULTURE                                       | CGON<br>SGON<br>TGON<br>GONN         | First Catch Urine<br>PCR Swab<br>Thin Prep Vial<br>Black Charcoal swab  | 2 days<br>2 days<br>2 days<br>2-3 days                   |
| CT/GC Combined<br>(Bacterial)  | 1–3 weeks,<br>up to 6 weeks  | Urine<br>Cervix/Vagina<br>Cervix/Vagina<br>Rectum<br>Throat | CT/GC<br>CT/GC<br>CT/GC<br>CT/GC<br>CT/GC  | CCG<br>SCG<br>TCG<br>RSCG<br>TSCG    | First Catch Urine<br>PCR Swab<br>Thin Prep Vial<br>PCR Swab<br>PCR Swab | 2 days<br>2 days<br>2 days<br>2 days<br>2 days<br>2 days |
| Mycoplasma<br>genitalium<br>(Bacterial)<br>Ureaplasma<br>urealyticum | Symptoms develop at 1–3 weeks Symptoms develop at 1–3 weeks                    | Urine<br>GU Site<br>Cervix/Vagina<br>Urine<br>GU Site       | Mycoplasma genitalium by PCR Mycoplasma genitalium by PCR Mycoplasma genitalium by PCR Ureaplasma by PCR Ureaplasma by PCR | MGEN<br>MGEN<br>MGEN<br>UGEN<br>UGEN | First Catch Urine PCR Swab Thin Prep Vial First Catch Urine PCR Swab    | 2 days 2 days 2 days 2 days 2 days 2 days                |
| Trichomonas<br>vaginalis<br>(Parastitc)                              | 4–28 days, many Urine patients are GU Site asymptomatic carriers Cervix/Vagina | Urine<br>GU Site<br>Cervix/Vagina                           | Trichomonas vaginalis by PCR<br>Trichomonas vaginalis by PCR<br>Trichomonas vaginalis by PCR                               | TVPC<br>TVPC<br>TVPC                 | First Catch Urine<br>PCR Swab<br>Thin Prep Vial                         | 2 days<br>2 days<br>2 days<br>2 days                     |
| Gardnerella<br>vaginalis<br>(Bacterial)                              | Imbalance of<br>normal flora   | Urine<br>GU Site<br>Cervix/Vagina                           | Gardnerella vaginalis by PCR<br>Gardnerella vaginalis by PCR<br>Gardnerella vaginalis by PCR                               | GVPC<br>GVPC<br>GVPC                 | First Catch Urine<br>PCR Swab<br>Thin Prep Vial                         | 2 days<br>2 days<br>2 days                               |
| Bacterial<br>Vaginosis (BV)<br>(Bacterial)                           | Imbalance of normal<br>flora   | Cervix/Vagina   | Bacterial Vaginosis (BV) Profile<br>by both MICROSCOPY and PCR   | STD8                                 | Both Microscopy<br>& PCR swab   | 3 days   |

| Herpes Simplex               | 2-14 days, testing                    | Herpes lesion             | Herpes by PCR  | HERS | PCR Swab          | 5 days |
|------------------------------|---------------------------------------|---------------------------|--|------|-------------------|--------|
| <b>Viral I/II</b><br>(Viral) | is most appropriate for patients with |                           | Herpes by PCR  | HERD | First Catch Urine | 5 days |
| Human                        | HPV is the most                       | Cervical cells            | HPV (DNA and reflexed mRNA)                              | HPVT | Thin Prep Vial    | 5 days |
| <b>Papillomavirus</b>        | common sexually                       | Cells/papilloma from site | Cells/papilloma from site HPV (Individually typed low    | HP20 | PCR Swab          | 3 days |
| (Viral)                      | transmitted                           | (throat/penile/anal)      | & high risk DNA subtypes)                                | HP20 | Cells/Papilloma   | 3 days |
|                              | infection – usually<br>asymptomatic   |                           | HPV (Individually typed low<br>& high risk DNA subtypes) |      |                   | ,      |
| Genital warts                | Weeks/months                          | GU Warts                  | HPV (DNA and reflexed mRNA)                              | HPVT | Thin Prep Vial    | 5 days |
| (Viral)                      | after exposure                        |                           | HPV (Individually typed low                              | HP20 | PCR Swab          | 3 days |
|                              |                                       |                           | & high risk DNA subtypes)                                | HP20 | Cells/Papilloma   | 3 days |
|                              |                                       |                           | HPV (Individually typed low & high risk DNA subtypes)    |      |                   |        |
| Syphilis/Herpes              | Whenever active                       | Symptomatic lesion        | Syphilis/Herpes Lesion Profile                           | STD9 | PCR Swab          | 7 days |
| (Bacterial/Viral)            | lesions are present                   |                           |  |      |                   |        |

| BLOOD                                | INCUBATION<br>PERIOD  | SAMPLE<br>SITE            | TEST  | TEST<br>CODE | SAMPLE<br>TYPE  | TAT              |
|--------------------------------------|---|---------------------------|---|--------------|---|------------------|
| Syphilis (Bacterial)                 | 9–21 days, but<br>up to 90 days   | Blood                     | Syphilis IgG/IgM  | SERJ         | <b>@</b>  | 4 hours          |
| Herpes Simplex<br>Virus I/II (Viral) | IgG 4–6 weeks after<br>exposure, IgM 5–35<br>days after exposure,<br>after which test IgG | Blood                     | Herpes IgG (past infection<br>Herpes IgM (current/recent)   | HERP<br>HERM | <b>@ @</b>  | 2 days<br>2 days |
| HIV (Viral)                          | Usually 10–90 days,<br>but up to 180 days   | Blood                     | HIV I&II / p24 antigen<br>(screening from 45 days<br>post exposure (BHIVA))   | НВПО         | <b>@</b>  | 4 hours          |
| Hep B (Viral)                        | Usually 45–180 days,<br>average of 60–90 days   | Blood                     | Hep B surface antigen   | AUAG         | <b>B</b>  | 4 hours          |
| Hep C Ab (Viral)                     | Usually 9–180 days,<br>average of 45–65 days  | Blood                     | Hep C Antibodies  | НЕРС         | <b>©</b>  | 4 hours          |
| EARLY DETECTION<br>Profiles by PCR   | INCUBATION<br>PERIOD  | SAMPLE                    | TEST  | TEST<br>CODE | SAMPLE<br>TYPE  | TAT              |
| 7 STIs by PCR                        | One sample for 7 STI Tests  | Urine<br>Cervix<br>Vagina | Chlamydia<br>Gonorrhoea<br>Mycoplasma genitalium<br>Ureaplasma genitalium<br>Trichomonas vaginalis<br>Gardnerella vaginalis | PP12         | Thin Prep Vial  or  First Catch Urine  or  PCR Swab  or  Aptima urine  or  multisite swab | 2 days           |
| ніу/нву/нсу                          | Early Detection Screen<br>by PCR Multiplex  | Blood                     | HIV 1&2 RNA<br>Hepatitis B (HBV DNA)<br>Hepatitis C (HCV RNA)   | STDX         | 4 10mls or 2x4mls<br>(Vacutainer only)  | 3 days           |

| TEST   | CODE | SAMPLE REQS                   | TAT       |
|--|------|-------------------------------|-----------|
| Acute Viral Hepatitis Screen                                 | AHSC | B                             | 4 hours   |
| Adrenal Cortex Antibodies                                    | ACTX | B                             | 2 days    |
| ANCA (Anti-Neutrophil Cytoplasmic Abs)                       | ANCA | B                             | 2 days    |
| Anti-Actin Antibodies  | AAA  | B                             | 5 days    |
| Anti-Basal Ganglia Antibodies                                | ABGA | B                             | 3 weeks   |
| Anti-CCP Antibodies  | CCP  | B                             | 2 days    |
| Anti-Liver Cytosol Antibodies                                | ALCA | B                             | 5 days    |
| Anti-MOG [Myelin Oligodendrocyte<br>Glycoprotein] Antibodies | AMOG | B                             | 3 weeks   |
| Anti-MUSK Antibodies   | MUSK | B                             | 2 weeks   |
| Anti-Nuclear Antibodies (titre & pattern)                    | ANAB | B                             | 2 days    |
| Anti-Phosphatidylserine Antibodies                           | PHTS | B                             | 5 days    |
| Anti-Phospholipase A2 Receptor                               | AA2R | B                             | 6 weeks   |
| Anti-Ri Antibodies   | RIAB | B                             | 3 days    |
| Anti-SLA (Soluble Liver Antigen) Abs                         | LSA  | B                             | 10 days   |
| Anti-Staphylolysin Titre (SGOT)                              | ASTT | B                             | 3 days    |
| Anti-Streptolysin Titre/ASOT                                 | ASLT | B                             | 2 days    |
| Anti-Sulfatide Antibodies                                    | ASA  | B                             | 5 weeks   |
| Aquaporin 4 Antibodies (Neuromyelitis Optica)                | AQUA | B                             | 2 weeks   |
| Ascariasis Serology  | ASC  | B                             | 5 days    |
| Autoantibody Profile I                                       | AUT0 | B                             | 2 days    |
| Autoantibody Profile II                                      | END0 | B                             | 2 days    |
| Avian Precipitins (11 Species)                               | AVIA | B                             | 5 days    |
| Babesia PCR  | PCRB | A                             | 7 days    |
| Beta 2 Glycoprotein 1 Abs                                    | B2GP | B                             | 5 days    |
| Borrelia Antibodies (Lyme Disease) IgG, IgM                  | BORR | <b>B</b> 9,14                 | 2 days    |
| Borrelia Antibodies (Lyme Disease) IgM                       | BORM | B                             | 2 days    |
| Borrelia Confirmation (Immunoblot)                           | BORC | <b>B</b> 9,14                 | 10 days   |
| Brucella Serology  | BRUC | <b>B</b> 9                    | 2-3 weeks |
| C1 Esterase Inhibitor  | C1EI | B                             | 5 days    |
| C3 Complement  | C3   | B                             | 4 hours   |
| C3/C4 Complement   | COMP | B                             | 4 hours   |
| C4 Complement  | C4   | B                             | 4 hours   |
| Calprotectin   | CALP | QFIT sample collection device | 5 days    |

| TEST  | CODE | SAMPLE REQS                             | TAT     |
|---|------|---|---------|
| Calprotectin/QFIT Profile (Combined)  | QCAL | QFIT sample collection device           | 5 days  |
| Cardiolipin Antibodies (IgG+IgM)  | ACAB | B                                       | 2 days  |
| CCP Antibodies (RF)   | CCP  | B                                       | 2 days  |
| Centromere Autoantibodies   | CENT | B                                       | 2 weeks |
| CH50 (Classical pathway)  | CH50 | (Frozen) <sup>4</sup>                   | 4 days  |
| Chagas Disease Serology<br>(S.American Trypanosomiasis) T. Cruzi                          | CHGA | <b>B</b> 9,14                           | 10 days |
| Chlamydia Species Specific (MIF) Ab Screen  | CHAB | В                                       | 2 days  |
| Chronic Fatigue Syndrome Profile  | VIP1 | A + B 10                                | 5 days  |
| Coeliac Disease – HLA DQ2/DQ8 Genotype  | Q2Q8 | <b>A</b> 9                              | 10 days |
| Coeliac/Gluten Genetic Profile 2** CHANGE **See page 87                                   | GSA2 | AB                                      | 10 days |
| Coeliac/Gluten Sensitivity Profile** CHANGE  **See page 87                                | GSA  | <b>B</b>                                | 2 days  |
| Colloid Antigen-2 Antibodies  | CA2A | В                                       | 2 weeks |
| Cotinine (Serum)  | СОТ  | В                                       | 4 days  |
| COVID-19 (SARS-CoV-2) Roche Elecsys<br>Anti-SARS-CoV-2 S (SPIKE)<br>(Venous/Self-collect) | SCOV | SST/Serum (3) (Venous) / (3) (TDL Tiny) | 1 day   |
| Diphtheria Antibodies   | DIPH | В                                       | 5 days  |
| DNA (Double Stranded) Antibodies IgG  | DNAA | В                                       | 2 days  |
| DNA (Single Stranded) Antibodies  | DNAS | В                                       | 5 days  |
| Echinococcus (Hydatid) Antibodies   | EFAT | B 9,14                                  | 5 days  |
| Ehrlichiosis Antibodies   | EHRL | B 9,14                                  | 10 days |
| Endomysial Antibodies (IgA)<br>(Venous/Self-collect)                                      | AEAB | 3 (TDL Tiny)                            | 2 days  |
| Extractable Nuclear Antibodies<br>(nRNP, Sm, Ro, La, Jo1, ScI70) CENP-B                   | ENA  | B                                       | 2 days  |
| Farmers Lung Precipitins  | FARM | B                                       | 5 days  |
| Fasciola Hepatica Antibodies (Liver Fluke)  | FASC | B                                       | 2 weeks |
| Ganglionic Acetylcholine Receptor Antibodies  | GACA | B                                       | 1 month |
| Ganglioside GM1, GD1B, GQ1B Abs   | GANG | В                                       | 5 days  |
| Gastric Parietal Autoantibodies   | GASP | В                                       | 2 days  |
| Giardia Serology  | GIAR | В                                       | 5 days  |
| Gliadin Antibodies (IgG) (deamidated)<br>(Venous/Self-collect)                            | AGAB | B / B (TDL Tiny)                        | 2 days  |
| Glomerular Basement Membrane Abs  | AGBM | B                                       | 2 days  |
|   |      |   |         |

| TEST   | CODE | SAMPLE REQS                   | TAT       |
|--|------|-------------------------------|-----------|
| Glutamic Acid Decarboxylase<br>Antibodies (GAD 65) | GAD  | B                             | 5 days    |
| Gluten Sensitivity Evaluation CHANGE               | GSA  | В                             | 2 days    |
| Gluten Sensitivity Profile CHANGE                  | GLUT | ABB                           | 10 days   |
| Gluten/Coeliac Genetic Profile 2 CHANGE            | GSA2 | <b>A</b> B                    | 10 days   |
| Granulocyte Immunology                             | GRIM | <b>A A</b> (or 10ml) <b>B</b> | 2 weeks   |
| H. pylori Antibodies (IgG)                         | HBPA | B                             | 2 days    |
| H. pylori Antigen – Breath                         | HBQT | J                             | 5 days    |
| Haemophilus B Influenzae Antibodies                | HINF | B                             | 5 days    |
| Histamine (Blood)                                  | HITT | (Frozen plasma)               | 5 days    |
| Histamine (Urine)                                  | HITU | RU                            | 5 days    |
| Histamine Releasing Urticaria Test                 | CURT | B                             | 3 weeks   |
| Histone Antibodies                                 | HISA | B                             | 5 days    |
| Histoplasmosis                                     | HISP | B                             | 10 days   |
| HLA B27  | HLAB | <b>A</b> 9                    | 3 days    |
| IgE (Total)  | IGE  | B                             | 1 day     |
| Immune-Complexes                                   | IMCP | B                             | 5 days    |
| Immunoglobulins (IgG, IgM, IgA)                    | IMM  | B                             | 4 hours   |
| Insulin Antibodies                                 | INAB | В                             | 5 days    |
| Interleukin 1 Beta                                 | ILB  | (Frozen) <sup>4,7</sup>       | 1-2 weeks |
| Interleukin 2                                      | IL2  | (Frozen) <sup>4,7</sup>       | 1-2 weeks |
| Interleukin 4                                      | IL4A | (Frozen) <sup>4,7</sup>       | 1-2 weeks |
| Interleukin 6                                      | IL6  | (Frozen)4,7                   | 1-2 weeks |
| Interleukin 8                                      | IL8  | (Frozen)4,7                   | 1-2 weeks |
| Interleukin 10                                     | IL10 | (Frozen) <sup>4,7</sup>       | 1-2 weeks |
| Interleukin 28b Genotype                           | IL28 | A                             | 2 weeks   |
| Intrinsic Factor Antibodies                        | IFAB | B                             | 2 days    |
| Islet Cell Antibodies                              | ICAB | B                             | 3 days    |
| Legionella Antibodies                              | LEG0 | B                             | 2 days    |
| Legionella Urine Antigen                           | LEGA | RU                            | 1 day     |
| Leptospirosis (Weil's Disease) Abs (IgM)           | LEP  | B                             | 5 days    |
| Leukotriene E4                                     | LTE4 | CU (Frozen)                   | 3 weeks   |
| Liver Immunoblot                                   | LIVI | B                             | 3 days    |
| Liver Kidney Microsomal Antibodies                 | LKM  | B                             | 2 days    |
| Lupus Anticoagulant and Anticardiolipin Abs        | LUPA | <b>3 6 6</b> 4,9,18           | 2 days    |
|  |      |                               |           |

| TEST  | CODE | SAMPLE REQS                   | TAT     |
|---|------|-------------------------------|---------|
| Lyme Disease (Borrelia Abs) IgG, IgM        | BORR | <b>B</b> 9,14                 | 2 days  |
| Lyme Disease (Borrelia Abs) IgM             | BORM | B                             | 2 days  |
| Meningococcal Serology (only serogroup C)   | MENI | B                             | 6 weeks |
| Mitochondrial Antibodies                    | AMIT | B                             | 3 days  |
| Mitochondrial Antibodies M2                 | MAM2 | B                             | 2 days  |
| Myasthenia Gravis Evaluation                | MGE  | B                             | 5 days  |
| Myelin Associated Glycoprotein Antibodies   | MAG  | B                             | 5 days  |
| Myelin Basic Protein Antibodies             | MBPA | B                             | 2 weeks |
| Myeloperoxidase Antibodies                  | MPO  | B                             | 2 days  |
| Myocardial Antibodies                       | MYO  | B                             | 1 week  |
| Myositis Panel                              | MYOS | B                             | 3 days  |
| Neuronal Antibody (Hu, Ri, Yo, Cv2, Ma2)    | NEUR | B                             | 10 days |
| NMDA Receptor Antibodies                    | NMDA | B                             | 3 weeks |
| Nucleic Acid Antigen Antibodies             | DNA  | B                             | 2 days  |
| Oligoclonal Bands                           | CSF0 | CSF + B                       | 5 days  |
| Ovarian Autoantibodies                      | OVAB | B                             | 2 days  |
| Paragomius Serology                         | PRGM | B                             | 2 weeks |
| Parathyroid Antibodies                      | PTHA | B                             | 1 week  |
| Pemphigus/Pemphigoid Autoantibodies         | SKAB | B                             | 2 days  |
| Pertussis (Whooping Cough) Antibodies       | PERS | B                             | 5 days  |
| Pituitary Antibodies                        | PITU | <b>B</b> 4                    | 1 month |
| Pneumococcal Antibodies – Serotype Specific | PASS | B                             | 5 weeks |
| Pneumococcal Antibody Screen                | PNEU | B                             | 5 days  |
| Proteinase 3 Ab                             | PR3  | B                             | 2 days  |
| Purkinje Cell Antibody (Hu and Yo)          | PURK | B                             | 10 days |
| Q Fever (C Burnetti) Antibodies             | QFEV | <b>B</b> 9                    | 10 days |
| QFIT/Calprotectin Profile (Combined)        | QCAL | QFIT sample collection device | 5 days  |
| Rheumatoid Factor (Latex Test)              | RF   | B                             | 1 day   |
| Rheumatology Profile 1 (Screen)             | RH   | AB                            | 2 days  |
| Rheumatology Profile 2 (Connective tissue)  | RH2  | AABB                          | 3 days  |
| Rheumatology Profile 3 (Rheumatoid/Basic)   | RH3  | <b>A</b> B                    | 2 days  |
| Rheumatology Profile 4 (Systemic Lupus)     | RH4  | ABB                           | 2 days  |
| Rheumatology Profile 5 (Mono Arthritis)     | RH5  | AABB                          | 3 days  |
| Rheumatology Profile 6 (Rheumatoid Plus)    | RH6  | В                             | 2 days  |
|   |      |                               |         |

| TEST   | CODE          | SAMPLE REQS          | TAT                |
|--|---------------|----------------------|--------------------|
| Rheumatology Profile 7 (Sjogren's Syndrome)  | RH7           | В                    | 10 days            |
| Rickettsial Species Antibody Profile   | RICK          | В                    | 7 days             |
| RNA Polymerase Antibodies  | RNAP          | В                    | 3 days             |
| RPR (Syphilis)   | RPR           | В                    | 2 days             |
| Saccharomyces Cerevisiae Antibodies  | ASCA          | B                    | 2 weeks            |
| Salivary Duct Antibodies   | SAB           | B                    | 12 days            |
| Scleroderma Immunoblot   | SCLI          | В                    | 3 days             |
| Sjogren's Syndrome   | RH7           | B                    | 10 days            |
| Skin (Pemphigus/Pemphigoid) Autoantibodies   | SKAB          | B                    | 2 days             |
| Skin Antibodies by Immunofluorescence  | STSK          | B                    | 1 month            |
| Sleeping Sickness Serology<br>(African Trypanosomiasis)  | TRYP          | <b>B</b> 9           | 10 days            |
| Smooth Muscle Antibodies   | ASM0          | B                    | 2 days             |
| Sperm Antibodies (Serum)   | ASAB          | B                    | 5 days             |
| Steroid Cell Antibody  | SCA           | B                    | 2 days             |
| Striated/Skeletal Muscle Antibody  | STRA          | B                    | 2 days             |
| Strongyloides Antibodies   | STGA          | B                    | 10 days            |
| Syphilis IgG/IgM (Venous/Self-collect)   | SERJ/<br>TSYP | B/B (TDL Tiny)       | 4 hours /<br>1 day |
| TB Quantiferon®-TB Gold*  * Please indicate clearly if samples have/have not been incubated prior to sending to the laboratory. If Lith Hep (green top) tube is used, please request as TBQ4 and ensure sample is received in the laboratory within 16 hours of sample taking. | TBQ4          | Special tubes or (1) | 3 days             |
| Tetanus Antibody   | TETA          | В                    | 5 days             |
| Thyroid Abs (Thyroglobulin + Thyroid<br>Peroxidase Abs) (Venous/Self-collect)  | THAB          | B/B (TDL Tiny)       | 1 day /<br>2 days  |
| Thyroid Peroxidase Antibodies/Anti TPO   | TPEX          | B                    | 1 day              |
| Tissue Transglutaminase IgA (Coeliac)<br>(Venous/Self-collect)**<br>**See page 87  | TAA           | B/B(TDL Tiny)        | 2 days             |
| Tissue Transglutaminase IgG  | TAAG          | B                    | 5 days             |
| Total Immune Function Function   |               |                      |                    |
| Total Immune Function Evaluation   | TIE           | A + B 5,10           | 7 days             |
| Total Immunoglobulin E   | TIE<br>IGE    | A + B 5,10           | 1 days             |
|  |               |                      |                    |
| Total Immunoglobulin E   | IGE           | 3                    | 1 day              |

| TEST   | CODE | SAMPLE REQS                           | TAT           |
|--|------|---------------------------------------|---------------|
| Toxoplasma by PCR  | TXAG | A                                     | 5 days        |
| ТРРА   | TPPA | B                                     | 2 days        |
| Trichinella Serology   | TRIC | В                                     | 5 days        |
| Trypanosome (Chagas) Antibodies  | CHGA | <b>B</b> 9,14                         | 10 days       |
| TSH-Receptor Antibodies  | TSI  | В                                     | 4 days        |
| Tularaemia Antibodies  | TULA | <b>B</b> 14                           | 5 days        |
| Urinary Methyl Histamine   | UHIT | RU (Frozen)                           | 2 weeks       |
| Urticaria Test (Histamine Releasing)                                       | CURT | В                                     | 3 weeks       |
| Vascular Endothelial Growth Factor   | VEGF | В                                     | 14 days       |
| Voltage Gated Calcium Channel Antibodies                                   | CCAB | В                                     | 3 weeks       |
| Voltage Gated Potassium Channel Antibodies                                 | VPCA | В                                     | 3 weeks       |
| Whooping Cough (Pertussis) Antibodies                                      | PERS | В                                     | 5 days        |
| Whooping Cough (Pertussis) by PCR  | PERP | Prenasal (posterior nasopharynx) swab | 5 days        |
| Yellow Fever Antibodies  | YELL | B 9,14                                | 10 days       |
| Yersinia Antibodies  | YERS | B                                     | 4 days        |
| Zika Abs IgM and IgG<br>- Antibody detection from 15 days                  | ZKAB | <b>3</b>                              | Up to 14 days |
| Zika RNA by PCR in Semen   | ZIKS | Semen                                 | Up to 14 days |
| Zika RT PCR – Window of detection from<br>1-14 days from onset of symptoms | ZIKU | RU                                    | Up to 14 days |
| Zika RT PCR – Window of detection from<br>1-7 days from onset of symptoms  | ZIKA | <b>B</b>                              | Up to 14 days |

## Acute Viral Hepatitis Screen

Hepatitis A IgM Abs Hepatitis B Surface Antigen Hepatitis C Abs

#### TAT: 4 hours

AHSC



### **Autoantibody Profile I**

Thyroid Abs (Thyroglobulin + Thyroid Peroxidase Abs) Anti-Nuclear Antibodies Mitochondrial Antibodies Smooth Muscle Antibodies Gastric Parietal Autoantibodies I KM

### TAT: 2 days

### AUT0



### **Autoantibody Profile II**

Thyroid Abs (Thyroglobulin + Thyroid Peroxidase Abs) Islet Cell Antibodies Adrenal Antibodies Gastric Parietal Autoantibodies Gonadal (Ovarian) Abs

#### TAT: 2 days

#### **ENDO**



# Calprotectin/QFIT Profile (Combined)

Calprotectin OFIT

# If CALP < 50ug/g then the below comment will be appended:

Calprotectin: < 50 ug/g- Not indicative of GI inflammation.
Consider IBS, or quiescent IBD if this is a known patient.

### If CALP = 50 ug/g or higher, then the below comment will be appended:

Calprotectin: 50-150 ug/g repeat calprotectin in 2 weeks (Also consider other potential causes (infection, NSAIDS, GI malignancy) depending on the magnitude of the result and clinical context.)
Repeated Calprotectin result: 100–250 ug/g routine referral

Calprotectin: >250 ug/g urgent referral to gastroenterology.

### TAT: 5 days

to gastroenterology.

### QCAL

QFIT sample collection device

# Chlamydia Species Specific (MIF) Ab Screen

Chlamydia trachomatis (serovar A-K & Delamydia pneumoniae Chlamydia psittaci

### TAT: 2 days

#### **CHAB**



# **Chronic Fatigue Syndrome Profile**

Epstein-Barr Virus Antibody Profile Lymphocyte Subsets (CD4/CD8) CRP Vitamin D (25 OH)

### TAT: 5 days

#### VIP1



# Coeliac/Gluten Genetic Profile 2

### CHANGE

Gliadin deamidated IgG Total IgA Tissue Transglutaminase (IgA) HLA DO2/DO8

### TAT: 10 days

#### GSA2



# Coeliac/Gluten Sensitivity Profile

### CHANGE

Gliadin deamidated IgG Total IgA Tissue Transglutaminase (IgA)

### TAT: 2 days

#### GSA



### **Gluten Sensitivity Profile**

#### CHANGE

Gluten Single IgE Allergen Deamidated Gliadin IgG Antibodies Tissue Transglutaminase IgA HLA DQ2/DQ8 Total IgA

### TAT: 10 days

**GLUT** 



# Rheumatology Profile 1 (Screen)

FBC ESR Uric Acid RF Anti-CCP Antibodies C Reactive Protein

### TAT: 2 days

RH



# Rheumatology Profile 2 (Connective tissue)

FBC **FSR** Uric Acid Anti-Nuclear Autoantibodies DNA (Double Stranded) Antibodies IaG Antibodies to Extractable Nuclear Antigens (ENA): Anti-nRNP Anti-Sm Anti-Ro (SS-A) Anti-La (SS-B) Anti-Jo-1 Anti-Scl 70 Anti-CFNP Anti-CCP Antibodies HI A B27 C Reactive Protein

### TAT: 3 days

CFNP-B

RH2

FBC

**FSR** 



# Rheumatology Profile 3 (Rheumatoid/Basic)

Uric Acid RF Anti-CCP Antibodies Anti-Nuclear Autoantibodies C Reactive Protein

### TAT: 2 days

RH3



# Rheumatology Profile 4 (Systemic Lupus)

FBC FSR

Anti-Nuclear Autoantibodies DNA (Double Stranded)

Antibodies IgG

Antibodies to Extractable

Nuclear Antigens (ENA):

Anti-nRNP

Anti-Sm

Anti-Ro (SS-A)

Anti-La (SS-B)

Anti-Jo-1

Anti-Scl 70

Anti-CENP

RF

Anti-CCP Antibodies

Anti-Cardiolipin Autoantibodies

Complement 3/4

C Reactive Protein

### TAT: 2 days

RH4



# Rheumatology Profile 5 (Mono Arthritis)

FBC ESR

Uric Acid

RF

Anti-CCP Antibodies

Anti-Nuclear Autoantibodies

C Reactive Protein

HI A B27

### TAT: 3 days

RH5



# Rheumatology Profile 6 (Rheumatoid Plus)

RF

Anti-CCP Antibodies C Reactive Protein

### TAT: 2 days

RH<sub>6</sub>



# Rheumatology Profile 7 (Sjogren's Syndrome)

Anti-Ro (SS-A) Anti-La (SS-B) Salivary Antibodies (SAB) C Reactive Protein

### TAT: 10 days

RH7



# **Coeliac Disease (CD)**

Coeliac Disease (CD) is an immune-mediated disease of the intestines that is triggered by the ingestion of gluten in genetically susceptible individuals. Gluten is the major protein component of wheat, rye, and barley. Genetic predisposition does play a key role in CD, and it is well known that CD is strongly associated with specific HLA class II genes known as HLA-DQ2 and HLA-DQ8. Approximately 95% of CD patients express HLA-DQ2, and the remaining patients are usually HLA-DQ8 positive. The negative predictive value for both tests is higher than 99%. However, the HLA-DQ2 allele is common and is carried by approximately 30% of Caucasian individuals. Thus, HLA-DQ2 or HLA-DQ8 is necessary for disease development but is not sufficient for disease development; its estimated risk effect is only 36-53%.

Note: History taking is important if a patient has been on a gluten-free diet for 6-12 months, approximately 80% will lose their antibody response. After 5 years this increases to >90%.

### **Coeliac pathway**

To determine the new Coeliac Pathway, a TDL audit of more than 12,000 requests for coeliac testing was carried out and results assessed within UKAS current guidelines. The purpose of these new guidelines is to reduce the risk of missing IgA deficient patients.

The new pathway covers this by adding a total IgA to all low Tissue Transglutaminase (TGG) IgA results to check for an IgA deficiency. If an IgA deficiency is identified, a reflex deamidated gliadin IgG will be carried out to determine whether the patient is likely to have coeliac disease with an IgG antibody.

The changes are as follows:

- Initial TTG IgA samples are received and tested
- If TTG IgA is LOW <0.2 U/ml reflex testing for Total IgA will be undertaken
- If Total IgA is LOW <0.1 g/L then reflex testing for Gliadin IgG test will be undertaken
- If TTG IgA is HIGH >/= 10 U/ml then reflex testing for Endomysial IgA will be undertaken as a confirmatory test for first time positive samples.

### **Endomysial IgA**

- This is no longer available as a stand-alone test.
   If requested the request will default to TTG IgA.
- However if TTG IgA is positive endomysial IgA will be carried out as a confirmatory test. This only needs to be done once in the patients history.

### **Endomysial IgG requests**

No longer available as a single test request.

### Deamidated gliadin IgA requests

 This is no longer available. If requested the request will default to TTG IgA.

### Deamidated gliadin IgG requests

This can be requested as an individual standalone test as well as being incorporated into the coeliac pathway. This may be useful when testing children's samples.

Appropriate clinical comments will be added to results automatically — see table.

| TTG IgA result<br>U/ml | Total IgA result<br>for new assay g/L | Deamidated gliadin<br>IgG result U/ml | Comment   |
|------------------------|---------------------------------------|---------------------------------------|---|
| 0.2 to 10              | N/A                                   | N/A                                   | Coeliac disease unlikely (please note that if the patient has no dietary gluten results may appear false negative)  |
| >/= 10                 | N/A                                   | N/A                                   | Suggestive of coeliac disease   |
| <0.2                   | >/= 0.1                               | N/A                                   | Coeliac disease unlikely (please note that if the patient has no dietary gluten, results may appear false negative) |
| <0.2                   | <0.1                                  | >/=10                                 | Consistent with coeliac disease in a patient with selective IgA deficiency  |
| <0.2                   | <0.1                                  | <7                                    | Coeliac disease unlikely (please note that if the patient has no dietary gluten, results may appear false negative) |
| <0.2                   | <0.1                                  | 7-10                                  | Result equivocal suggest referral to a gastroenterologist for consideration of duodenal biopsy                      |

# **Tropical and Travel-Related Immunology**

| TEST   | CODE | SAMPLE REQS   | TAT           |
|--|------|---|---------------|
| Amoebic (E. histolytica) Antibodies  | AFAT | B   | 1 week        |
| Amoebic (E. histolytica) PCR   | AMAG | RF  | 2 days        |
| Bancroftia/Oncerciasis/Filarial Antibodies                                 | TFIF | B 14  | 2 weeks       |
| Bilharzia (Schistosome) Antibody Screen                                    | BILH | <b>B</b> 14   | 10 days       |
| Bilharzia (Urine)  | USCH | Mid-morning terminal urine following exercise <sup>14</sup> | 1-2 days      |
| Borrelia Antibodies (Lyme Disease) IgG, IgM                                | BORR | B 9,14  | 2 days        |
| Borrelia Antibodies (Lyme Disease) IgM                                     | BORM | B   | 2 days        |
| Borrelia Confirmation (Immunoblot)   | BORC | B 9,14  | 10 days       |
| Cryptosporidium Detection by PCR   | CRPA | RF  | 2 days        |
| Dengue Virus Serology  | DENG | <b>B</b> 9,14   | 5 days        |
| DVT/Pre-travel Screen  | DVT1 | <b>A A B</b> <sup>9</sup>                                   | 5 days        |
| Echinococcus (Hydatid) Antibodies  | EFAT | B 9,14  | 5 days        |
| Enteric Organism Rapid Detection   | EORD | RF  | 2 days        |
| Filaria (Lymphatic and Non-Lymphatic)<br>Antibodies                        | FIFA | <b>B</b> 9,14   | 10 days       |
| Gastrointestinal Pathogen PCR (Self-collect)                               | EORD | Stool/faecal container                                      | 2 days        |
| Insect/Worm/Ova/Cysts  | FLEA | Send Specimen 9,14  | 5 days        |
| Leishmania Antibodies  | LEIS | В   | 5 days        |
| Malarial Antibodies (Pl. falciparum)                                       | MALA | <b>B</b> 9,14   | 5 days        |
| Malarial Antibodies (species specific)                                     | MALS | <b>B</b> 9,14   | 10 days       |
| Post-Travel Screen 1 (Prior to 6 weeks)                                    | PTS  | <b>A B G</b> 14   | 10 days       |
| Post-Travel Screen 2 (Prior to 6 weeks)                                    | PTS2 | <b>AABBB G</b> 14   | 10 days       |
| Pre-Travel Screen (DVT)  | DVT1 | <b>A A B</b> <sup>9</sup>                                   | 5 days        |
| Rickettsial Species Antibody Profile                                       | RICK | B   | 7 days        |
| Schistosome (Bilharzia) Antibodies   | BILH | <b>B</b> 14   | 10 days       |
| Toxoplasma Antibodies (IgG+IgM)  | TFAM | <b>B</b> 9  | 4 hours       |
| Tropical Screen (from 6 weeks post-travel)                                 | TROP | <b>B B</b> 9,14   | 10 days       |
| Zika Abs IgM and IgG –<br>Antibody detection from 15 days                  | ZKAB | В   | Up to 14 days |
| Zika RNA by PCR in Semen   | ZIKS | Semen   | Up to 14 days |
| Zika RT PCR – Window of detection from<br>1-14 days from onset of symptoms | ZIKU | RU  | Up to 14 days |
| Zika RT PCR – Window of detection from<br>1-7 days from onset of symptoms  | ZIKA | <b>B</b>  | Up to 14 days |
|  |      |   |               |

### **Tropical and Travel-Related Immunology**

# Post-Travel Screen 1 (Prior to 6 weeks)

Haematology Profile Biochemistry Profile Schistosome Abs Malarial Abs

TAT: 10 days

**PTS** 



## Post-Travel Screen 2 (Prior to 6 weeks)

Haematology Profile Biochemistry Profile Schistosome Abs Malarial Abs Hep A IgM Abs Hep B sAa Hep C Abs HIV Duo

TAT: 10 days

PTS2





# **DVT/Pre-travel Screen**

**FBC** Factor II Prothrombin Gene Factor V Leiden Anticardiolipin Antibodies

TAT: 5 days

DVT1



# **Tropical Screen** (from 6 weeks post-travel)

Amoebic Antibodies Schistosomal Antibodies (Bilharzia) Echinococcus Antibodies (Hydatid) Leishmania Antibodies Malarial Antibodies (IFA) Toxoplasma Antibodies IgG Toxoplasma Antibodies IaM

TAT: 10 days

TR0P



# **Enteric Organism Rapid Detection** (RF/Self-collect)

Detection of Bacterial, Viral and Parasitic Infection by Multiplex Real-Time PCR

### **Bacteria and Bacterial Toxins**

C. difficile Toxin A/B gene. Campylobacter spp., Enteroaggregative E.coli (EAEC), Enteroinvasive E.coli (EIEC)/ Shigella, Enterotoxigenic E.coli (ETEC), Enteropathogenic E.coli (EPEC), Plesiomonas shigelloides, Salmonella, Shiga-toxin producing E.coli (STEC) stx1/ stx2. Shiga-toxin producing E.coli (STEC) 0157:H7, Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus. Yersinia enterocolitica

#### Viruses

Adenovirus 40/41. Astrovirus. Norovirus GI, Norovirus GII, Rotavirus A, Sapovirus (I, II, IV, V)

### **Parasites**

Cyclospora cavetanensis. Cryptosporidium spp., Entamoeba histolytica, Gardia lamblia This does NOT include stool

for m/c/s - this needs to be requested as a separate test. Please provide two samples if this is required.

TAT: 2 days

FORD

RF / Stool/faecal container

# **Immune status**

| TEST  | CODE           | SAMPLE REQS          | TAT                |
|---|----------------|----------------------|--------------------|
| Hepatitis A Immunity (IgG/IgM)                      | HAIM           | В                    | 4 hours            |
| Hepatitis B Immunity (IgG)<br>(Venous/Self-collect) | HBIM /<br>Thbi | B / B (TDL Tiny)     | 4 hours /<br>1 day |
| Measles Antibodies (IgG) Immunity                   | MEAS           | В                    | 1 day              |
| Measles Antibodies (IgM)                            | MEAM           | <b>B</b> 9           | 2 days             |
| Measles, Mumps, Rubella (MMR)                       | MMR            | В                    | 1 day              |
| Mumps Antibodies (IgG)                              | MUMP           | B                    | 1 day              |
| Mumps Antibodies (IgM)                              | MUMM           | B                    | 1 day              |
| Pertussis (Whooping Cough) Antibodies               | PERS           | B                    | 5 days             |
| Pneumococcal Antibody Screen                        | PNEU           | В                    | 5 days             |
| Rabies Antibody                                     | RABI           | В                    | 20 days            |
| Rubella Antibody (IgG)                              | RUBE           | В                    | 4 hours            |
| Rubella Antibody (IgM)                              | RUBM           | B                    | 4 hours            |
| Rubella PCR   | RUBP           | (A) / Amniotic Fluid | 5 days             |
| Tetanus Antibody                                    | TETA           | B                    | 5 days             |
| Varicella zoster Antibodies (IgG)                   | VZ0S           | B                    | 1 day              |
| Varicella zoster Antibodies (IgM)                   | VZOM           | В                    | 1 day              |
|   |                |                      |                    |

# **Hepatitis testing**

| TEST  | CODE           | SAMPLE REQS      | TAT                |
|---|----------------|------------------|--------------------|
| Hepatitis (Acute) Screen                            | AHSC           | <b>B</b>         | 4 hours            |
| Hepatitis A (IgM)                                   | HAVM           | <b>B</b>         | 4 hours            |
| Hepatitis A Immunity (IgG/IgM)                      | HAIM           | B                | 4 hours            |
| Hepatitis A Profile                                 | HEPA           | B                | 4 hours            |
| Hepatitis A RNA by PCR                              | HAVR           | (A) or (B)       | 3 weeks            |
| Hepatitis A, B & C Profile                          | ABC            | B                | 4 hours            |
| Hepatitis B (PCR) Genotype                          | BGEN           | A                | 7 days             |
| Hepatitis B 'e' Antigen and Antibody                | HEPE           | <b>B</b>         | 4 hours            |
| Hepatitis B Core Antibody – IgM                     | HBCM           | <b>B</b>         | 4 hours            |
| Hepatitis B Core Antibody – Total                   | HBC            | B                | 4 hours            |
| Hepatitis B DNA (Viral load)                        | DNAB           | A                | 5 days             |
| Hepatitis B Immunity (IgG)<br>(Venous/Self-collect) | HBIM /<br>THBI | B / B (TDL Tiny) | 4 hours /<br>1 day |
|   |                |                  |                    |

| TEST  | CODE           | SAMPLE REQS      | TAT                |
|---|----------------|------------------|--------------------|
| Hepatitis B Profile   | HEPB           | B                | 4 hours            |
| Hepatitis B Resistant Mutation                              | HBRM           | A or B           | 7 days             |
| Hepatitis B Surface Antigen<br>(Venous/Self-collect)        | AUAG /<br>THBA | B/B (TDL Tiny)   | 4 hours /<br>1 day |
| Hepatitis C Abs Confirmation (RIBA)                         | RIBA           | B                | 5 days             |
| Hepatitis C Antibodies<br>(Venous/Self-collect)             | HEPC /<br>THCV | B / B (TDL Tiny) | 4 hours /<br>1 day |
| Hepatitis C Antigen (Early detection) (Venous/Self-collect) | HCAG /<br>TCAG | B / B (TDL Tiny) | 4 hours /<br>1 day |
| Hepatitis C Genotype  | CGEN           | A                | 5 days             |
| Hepatitis C Quantification (Viral Load)                     | QPCR           | A or B           | 5 days             |
| Hepatitis Delta Antibody                                    | HEPD           | B                | 5 days             |
| Hepatitis Delta Antigen                                     | HDAG           | B                | 5 days             |
| Hepatitis Delta RNA   | DRNA           | (Frozen plasma)  | 5 days             |
| Hepatitis E (PCR)   | EHEP           | A                | 2 weeks            |
| Hepatitis E IgG/IgM   | HBE            | B                | 5 days             |
| Hepatitis G (PCR)   | HEPG           | (Frozen plasma)  | 2 weeks            |

# Hepatitis viral load sample instructions

Whole blood can be stored at 2°C to 30°C and must be centrifuged within 24 hours of specimen collection. Separate the plasma or serum from the pelleted red blood cells following the manufacturer's instructions for the tube used. Plasma or serum can be tested on the Panther system in the primary tube or transferred to a secondary Aptima Specimen Aliquot Tube (SAT) for testing on the Panther system. If not tested immediately, plasma and serum can be stored in accordance with the specifications below. If transferred to the SAT, plasma may be frozen at -20°C or -70°C, and serum may be frozen at -20°C. Do not freeze specimens in EDTA, ACD, or serum primary collection tubes.

After centrifugation: In the primary collection tube at 2°C to 8°C for up to 3 days.

In the Aliquoted Tubes: at 2°C to 8°C for up to 5 days.

In the Aliquoted Tubes: at -20°C or -70°C for up to 90 days.

# Hepatitis B Immunity/ Vaccination Anti-HBs

| less than     | Non-immune            |
|---------------|-----------------------|
| 10 mIU/mI     | to Hepatitis B        |
| 10-50 mIU/mI  | Borderline –          |
|               | booster indicated     |
| 50-100 mIU/mI | Low level immunity –  |
|               | booster suggested     |
| 100 and over  | Immune to Hepatitis B |
|               |                       |

# **HAV, HBV and HCV assays**

All virology samples are processed as per manufacturers sample requirements and guidelines.

Hepatitis virus is named in order of their discovery A, B, C, D, E and G.

### **Hepatitis A**

Hepatitis A is spread through food and water that have been contaminated with the virus derived from human faeces and urine. Hepatitis A is an acute infection, not a chronic form of the disease.

### **HBV** Assays

### Hepatitis B surface antigen (HBsAg) (AUAG)

A protein on the surface of HBV; it can be detected in high levels in serum during acute or chronic HBV infection. The presence of HBsAg indicates that the person is infectious. The body normally produces antibodies to HBsAg as part of the normal immune response to infection. HBsAg is the antigen used to make Hepatitis B vaccine.

# Hepatitis B surface antibody (anti-HBs) (HBIM)

The presence of anti-HBs is generally interpreted as indicating recovery and immunity from HBV infection. Anti-HBs also develops in a person who has been successfully vaccinated against Hepatitis B.

### Total Hepatitis B core antibody (anti-HBc) (HBC)

Appears at the onset of symptoms in acute Hepatitis B and persists for life. The presence of anti-HBc indicates previous or ongoing infection with HBV in an undefined time frame.

# IgM antibody to Hepatitis B core antigen (IgM anti-HBc) (HBCM)

Positivity indicates recent infection with HBV (<6 months). Its presence indicates acute infection.

### Hepatitis B e antigen and antibody (HEPE)

**Hepatitis B e antigen (HbeAg)**: A secreted product of the nucleocapsid gene of HBV that is found in serum during acute and chronic Hepatitis B. Its presence indicates that the virus is replicating and the infected person has high levels of HBV.

### Hepatitis B e antibody (HBeAb or anti-HBe):

Produced by the immune system temporarily during acute HBV infection or consistently during or after a burst in viral replication. Spontaneous conversion from e antigen to e antibody (a change known as seroconversion) is a predictor of long-term clearance of HBV in patients undergoing antiviral therapy and indicates lower levels of HBV.

### **HBV Viral Load (DNAB)**

This assay measures the concentration of Hepatitis B viral DNA in patient serum. The test enables the viral load at the beginning of treatment to be established and, thereafter, monitored to indicate treatment success.

### **HBV Genotyping (BGEN)**

Identifies the hepatitis B genotype (A to H) in a patient's serum/plasma. This is critical for determining treatment and monitoring response.

### **HBV Drug Resistance Detection (HBRM)**

Detects Hepatitis B virus wild-type and drug-induced mutations, associated with lamivudine, entecavir and tenofovir.

### **HCV** Assays

### **HCV Antibody (HEPC)**

The test indicates exposure to virus but does not necessarily signify current infection. The HCV antibody test may therefore be used to screen patients for possible HCV infection to detect the presence of antibodies to the virus, indicating exposure to HCV. This test cannot tell if the viral infection is active, only that you were exposed to the virus in the past.

### **HCV Antigen (HCAG)**

HVC Antigen is detectable well before the occurrence of antibodies against HCV. When virus is present, but antibodies are not detectable, a negative antibody test does not rule out HCV infection. Active HCV infection, either acute or chronic is characterised by the presence of HCV Antigen. This is analogous to HepB sAg (AUAG) in active HBV Infection.

### **HCV Viral Load (QPCR)**

Measures the concentration of Hepatitis C viral RNA in patient serum. This state-of-the-art assay enables the viral load at the beginning of treatment to be established and, thereafter, monitored to indicate treatment success.

### **HCV** Genotype for Treatment (CGEN)

Determines the HCV genotype in a patient's serum. The result is presented as being of either Genotype [1, 5, 6], [4] or [2, 3]. This grouping reflects required treatment duration of the different genotypes.


### **HCV Drug Resistance**


Detects hepatitis C wild-type or drug-induced mutations associated with resistance to HCV drugs including NS5A inhibitors, NS5B inhibitors or NS3 inhibitors.

# **Hepatitis B Surface Antigen**

### **Hepatitis B**

- Transmission: Sexual, parenteral, perinatal, direct contact between individuals.
- **Clinical Signs**: Asymptomatic in 90% of cases.
- Cure: 95% of cases (adults).
- **Complications**: Cirrhosis and hepatocellular carcinoma.
- Development of chronic form: Yes (5% of adult cases).
- **Prevention**: Vaccination ++++; specific IgG.
- Main Marker: HBS Ag, anti HBc IgM, total anti HBc Ab, Anti-HBs Ab, HBe Ag, Anti-HBe Ab, HBV DNA.







# **Hepatitis C Antibodies**

### **Hepatitis C**

- **Transmission**: Parenteral, nosocomial, sexual.
- Clinical Signs: Asymptomatic in 90% of cases.
- **Cure**: 95% of cases (adults).
- **Complications**: Cirrhosis and hepatocellular carcinoma.

- Development of chronic form: Yes (80% of adult cases).
- **Prevention**: Hygiene, no vaccination.
- Main Marker: Anti HCV Ab, HCV RNA





# **HIV** testing

| TEST  | CODE | SAMPLE REQS                            | TAT     |
|---|------|--|---------|
| HIV 1 & 2 Abs/p24Ag (Self-collect)                              | THIV | (TDL Tiny)                             | 1 day   |
| HIV-1 Proviral DNA  | HIVP | Whole blood                            | 7 days  |
| HIV Confirmation of Positive Screens<br>(Using 3 methodologies) | HIVC | B                                      | 1 day   |
| HIV/HBV/HCV Screen by PCR/NAAT (10 days post exposure)          | STDX | 10mls or 2 x 4mls<br>(Vacutainer only) | 3 days  |
| HIV Rapid RNA HIV-1 QUALITATIVE                                 | LHIV | (Vacutainer only)                      | 4 hours |
| HIV Rapid RNA HIV-1 QUANTITATIVE                                | RHIV | (Vacutainer only)                      | 4 hours |
| HIV Screening: HIV1 & 2 Abs/p24 Ag (4th Gen)                    | HDU0 | В                                      | 4 hours |
| HTLV 1 & 2 Abs.<br>(Human T Lymphotropic Virus Type I-II)       | HTLV | <b>B</b>                               | 8 hours |
| HTLV by PCR   | HTLP | A Whole blood                          | 21 days |

# **HIV** positive patient monitoring

| TEST                             | CODE | SAMPLE REQS           | TAT     |
|----------------------------------|------|-----------------------|---------|
| CD3/CD4/CD8                      | LYSS | <b>A</b> 10           | 1 day   |
| HIV-1 RNA Viral Load by PCR      | HIV1 | (2 x 6ml whole blood) | 3 days  |
| HIV-2 RNA by PCR                 | HIV2 | A                     | 21 days |
| HIV Rapid RNA HIV-1 QUANTITATIVE | RHIV | (Vacutainer only)     | 4 hours |
| HIV Therapeutic Drug Monitoring  | TDM  | J                     | 21 days |

# **HIV-1** genotypic resistance testing

| TEST                                       | CODE | SAMPLE REQS           | TAT     |
|--|------|-----------------------|---------|
| HIV-1 Genotypic Resistance (Integrase)     | INTE | (2 x 6ml whole blood) | 21 days |
| HIV-1 Genotypic Resistance (RT & Protease) | HIVD | (2 x 6ml whole blood) | 21 days |
| HIV-1 Tropism                              | TRPM | (2 x 6ml whole blood) | 28 days |
| HLA B*57:01                                | HL57 | <b>A</b> 9            | 10 days |

HLA-B\*57:01 should be tested before starting patients on an Abacavir (ABC) containing regimen to reduce the risk of hypersensitivity reaction. HLA-B\*57:01-positive patients should not be prescribed ABC and a positive status should be recorded as an ABC allergy in the patient's medical record.

# **Virology - General**

| Adenovirus by PCR Arbovirus Antibodies/Abs Arbovirus Avirus Abs BK Polyoma Virus Abs Cat Scratch Fever (Bartonella IgG) Cat God/CDB Chikungunya Virus Abs Chik 100 Acy Chikungunya Virus Abs Chik 100 Acy COVID-19 (SARS-CoV-2) COSQ Rapid RNA Sequencing Please contact lisa.levett@dilpathology.com for details for referring samples to the laboratory for sequencing lesting. COVID-19 (SARS-CoV-2) (PCR/Self-collect) COVID-19 (SARS-CoV-2) COVID-19 (SARS-COV- | TEST  | CODE | SAMPLE REQS          | TAT         |
|--|---|------|----------------------|-------------|
| Atypical Pneumonia Screen  APS   | Adenovirus by PCR   | ADV  | (A) / PCR / VS / SC  | 7 days      |
| BK Polyoma Virus by PCR  BKPV  | Arbovirus Antibodies/Abs  | ARB0 | B 9,14               | 3 weeks     |
| Cat Scratch Fever (Bartonella IgG)  CD3/CD4/CD8  LYSS 10 10 1 day  Chikungunya Virus Abs  CHIK 10 0,14 10 days  COVID-19 (SARS-CoV-2)  Rapid RNA Sequencing  Please contact lisa.levett@tdiplathology.com for details for referring samples to the laboratory for sequencing testing.  COVID-19 (SARS-CoV-2) (PCR/Self-collect)  Contact Laboratory.  NCOV PCR Swab (nasal/ pharyngeal) / Throat and nose swab  CSF Screen by PCR  Cytomegalovirus (IgG/IgM) Antibodies  CMV 3 4 hours  Cytomegalovirus (PCR) Semen  Cytomegalovirus (PCR) Urine  CMVU RU 5 days  Cytomegalovirus Avidity  CMAV 3 10 days  Cytomegalovirus DNA (PCR)  Cytomegalovirus Resistance  CMVR 3 (2 x 6mls)  Cytomegalovirus Resistance  CMVR 3 (2 x 6mls)  Dengue Fever PCR  DPCR 4 or 3 14 2 weeks  Epstein-Barr Virus Antibodies IgG/IgM  EBVA 0 or 3 2 days  Epstein-Barr Virus Antibodies IgG/IgM  HANV 9 10 days  Herpes Simplex (HSV) 1 & 2 (PCR/Self-collect) (Oral or Genital)  Herpes Simplex (HSV) 1 & 2 (PCR/Self-collect) (Oral or Genital)  Herpes Simplex I/II Inthibody Profile (IgG)  HERP 5 FCRU  A 1 day  2 days  Epstein-Barr Virus Antibodies IgG/IgM  EBVA 0 or 3 2 days  HANV 9 10 days  HERP 5 days  HERP 5 days  HERP 5 days  HERP 5 days  HERP 6 days  HILL Antibody Profile (IgG)  HERP 6 days  HERP 6 days  HILL Antibody Profile (IgG)  HERP 6 days  HILL Antibody Profile (IgG)  HERP 6 days  HILL Antibody Profile (IgG)  HERP 7 day  10 days  | Atypical Pneumonia Screen   | APS  | В                    | 2 days      |
| CD3/CD4/CD8  LYSS  | BK Polyoma Virus by PCR   | BKPV | A/RU                 | 5 days      |
| Chikungunya Virus Abs  CHIK  | Cat Scratch Fever (Bartonella IgG)  | CAT  | В                    | 5 days      |
| COVID-19 (SARS-CoV-2) Rapid RNA Sequencing Please contact Lisa.levett@rdipathology.com for details for referring samples to the laboratory for sequencing testing.  COVID-19 (SARS-CoV-2) (PCR/Self-collect) Contact Laboratory.  NCOV Cortact Laboratory.  CSF Screen by PCR  Cytomegalovirus (CMV-DNA) Amnio Cytomegalovirus (IgG/IgM) Antibodies Cytomegalovirus (IgG/IgM) Antibodies Cytomegalovirus (PCR) Semen Cytomegalovirus (PCR) Urine Cytomegalovirus (PCR) Urine Cytomegalovirus Avidity Cytomegalovirus Resistance CMVP  Cytomegalovirus Resistance CMVR  Cytomegalovirus Avidity Cytomegalovirus Avidity Cytomegalovirus Resistance CMVR  Cytomegalovirus Avidity Cytomeg | CD3/CD4/CD8   | LYSS | <b>A</b> 10          | 1 day       |
| Please contact lisa.levelt@tdlpathology.com for details for referring samples to the laboratory for sequencing testing.  COVID-19 (SARS-CoV-2) (PCR/Self-collect) Contact Laboratory.  PCR Swab (nasal/ pharyngeal) / Throat and nose swab  CSF Screen by PCR  VPCR  CSF  2 days  Cytomegalovirus (CMV-DNA) Amnio  CMVD  AF  5 days  Cytomegalovirus (IgG/IgM) Antibodies  CMV  Guille Saws  Cytomegalovirus (PCR) Semen  CYUN  Cytomegalovirus (PCR) Urine  CMVU  RU  5 days  Cytomegalovirus Avidity  CMAV  Guille Saws  Cytomegalovirus Avidity  CMAV  Cytomegalovirus Avidity  CMAV  Cytomegalovirus Resistance  CMVP  Cytomegalovirus Resistance  CMVP  Cytomegalovirus Resistance  CMVR  Cytomegalovirus Resistance  CMVR  Cytomegalovirus Avidity  CMAV  Cytomegalovirus Resistance  CMVR  Cytomegalovirus Resistance  CMVR  Cytomegalovirus Avidity  CMAV  Cytomegalovirus Resistance  CMVR  Cytomegalovirus Avidity  Cytomegalovirus Resistance  CMVR  Cytomegalovirus Resistance  CMVR  Cytomegalovirus Avidity  Cytomegalovirus PCR  BEVA  Cytomegalovirus CPCR)  CMVP  Cytomegalovirus Avidity  CMAV  | Chikungunya Virus Abs   | CHIK | <b>B</b> 9,14        | 10 days     |
| Contact Laboratory.  pharyngeal) / Throat and nose swab  CSF Screen by PCR  VPCR  VPCR  CSF  2 days  Cytomegalovirus (CMV-DNA) Amnio  CMVD  AF  5 days  Cytomegalovirus (IgG/IgM) Antibodies  CMV  3 4 hours  Cytomegalovirus (PCR) Semen  SCVM  Semen  7 days  Cytomegalovirus (PCR) Urine  CMVU  RU  5 days  Cytomegalovirus Avidity  CMAV  3 10 days  Cytomegalovirus DNA (PCR)  CMVP  CMVP  CYtomegalovirus Resistance  CMVR  CMVR  CYtomegalovirus Resistance  CMVR  CMVR  CYtomegalovirus Resistance  CMVR  CYtomegalovirus  CYTOM  | Rapid RNA Sequencing Please contact lisa.levett@tdlpathology.com for details for referring samples to the | COSQ | RNA or PCR swab 43   | 48-72 hours |
| Cytomegalovirus (CMV-DNA) Amnio CMVD AF 5 days Cytomegalovirus (IgG/IgM) Antibodies CMV 3 4 hours Cytomegalovirus (PCR) Semen SCVM Semen 7 days Cytomegalovirus (PCR) Urine CMVU RU 5 days Cytomegalovirus Avidity CMAV 3 10 days Cytomegalovirus DNA (PCR) CMVP 3 5 days Cytomegalovirus Resistance CMVR 3 (2 x 6mls) Cytomegalovirus Resistance CMVR 3 or 3 9.14 2 weeks Epstein-Barr Virus Antibodies IgG/IgM EBVA 3 or 3 2 days Epstein-Barr Virus PCR EBVQ 3 or 3 10 days Hantavirus Serology HANV 3 10 days HERS PCR / Aptima multisite swab Herpes Simplex I/II Antibody Profile (IgG) HERP 3 2 days Herpes Simplex I/II Antibody Profile (IgG) HERP 3 2 days Herpes Simplex I/II IgM HERM 3 2 days HIV/HBV/HCV Screen by PCR/ NAAT (10 days post exposure) HHV6 3 5 days HHV6 3 5 days   |   | NCOV | pharyngeal) / Throat | 1 day       |
| Cytomegalovirus (IgG/IgM) Antibodies  Cytomegalovirus (PCR) Semen  Cytomegalovirus (PCR) Urine  CMVU RU  5 days  Cytomegalovirus Avidity  CMAV  Cytomegalovirus DNA (PCR)  CMVP  CMVP  Cytomegalovirus Resistance  CMVR  CYTOMEGALOVIC CMVP  | CSF Screen by PCR   | VPCR | CSF                  | 2 days      |
| Cytomegalovirus (PCR) Semen  Cytomegalovirus (PCR) Urine  CMVU  RU  5 days  Cytomegalovirus Avidity  CMAV  CMAV  CMAV  CMAV  CMAV  CYtomegalovirus DNA (PCR)  CMVP  CMVC  CMVP  CMVP  CMVP  CMVC  CMVP  CMCC  CMVP  CMCC  CMVR  CMCC  CMVC  CMCC  CMCC | Cytomegalovirus (CMV-DNA) Amnio   | CMVD | AF                   | 5 days      |
| Cytomegalovirus (PCR) Urine  CMVU RU  5 days  Cytomegalovirus Avidity  CMAV  CMVP  CMAV  C | Cytomegalovirus (IgG/IgM) Antibodies  | CMV  | В                    | 4 hours     |
| Cytomegalovirus Avidity CMAV 3 10 days  Cytomegalovirus DNA (PCR) CMVP   | Cytomegalovirus (PCR) Semen   | SCVM | Semen                | 7 days      |
| Cytomegalovirus DNA (PCR)  CMVP (A) (2 x 6mls)  21 days  Dengue Fever PCR  DPCR (A) or (B) 9.14  2 weeks  Epstein-Barr Virus Antibodies IgG/IgM  EBVA (A) or (B) 9.14  EBVA (B) ( | Cytomegalovirus (PCR) Urine   | CMVU | RU                   | 5 days      |
| Cytomegalovirus Resistance  CMVR ( (2 x 6mls) 21 days  Dengue Fever PCR  DPCR ( or ( ) 9.14 2 weeks  Epstein-Barr Virus Antibodies IgG/IgM  EBVA ( or ( ) 2 days  Epstein-Barr Virus PCR  EBVQ ( ) 5 days  Hantavirus Serology  HANV ( ) 9 10 days  Herpes Simplex (HSV) 1 & 2 HERS PCR / Aptima multisite swab  Herpes Simplex I/II Antibody Profile (IgG) HERP ( ) 2 days  Herpes Simplex I/II by PCR (Urine) HERD FCRU 5 days  Herpes Simplex I/II IgM  HERM ( ) 2 days  HIV/HBV/HCV Screen by PCR/ NAAT (10 days post exposure)  HHV6 ( ) 5 days   | Cytomegalovirus Avidity   | CMAV | В                    | 10 days     |
| Dengue Fever PCR  DPCR or 3 9.14  2 weeks  Epstein-Barr Virus Antibodies IgG/IgM  EBVA or 3 2 days  Epstein-Barr Virus PCR  EBVQ or 3 5 days  Hantavirus Serology  HANV 3 9 10 days  Herpes Simplex (HSV) 1 & 2 (PCR/Self-collect) (Oral or Genital)  Herpes Simplex I/II Antibody Profile (IgG)  HERP 3 2 days  Herpes Simplex I/II by PCR (Urine)  HERD FCRU 5 days  Herpes Simplex I/II IgM  HERM 3 2 days  HIV/HBV/HCV Screen by PCR/ NAAT (10 days post exposure)  HHV6 A 5 days  | Cytomegalovirus DNA (PCR)   | CMVP | A                    | 5 days      |
| Epstein-Barr Virus Antibodies IgG/IgM  EBVA or 3 2 days  Epstein-Barr Virus PCR  EBVQ 5 days  Hantavirus Serology  HANV 3 9 10 days  Herpes Simplex (HSV) 1 & 2 HERS PCR / Aptima multisite swab  Herpes Simplex I/II Antibody Profile (IgG)  HERP 3 2 days  Herpes Simplex I/II by PCR (Urine)  HERD FCRU 5 days  Herpes Simplex I/II IgM  HERM 3 2 days  HIV/HBV/HCV Screen by PCR/ NAAT (10 days post exposure)  HHV6 A 5 days  | Cytomegalovirus Resistance  | CMVR | ,                    | 21 days     |
| Epstein-Barr Virus PCR  Hantavirus Serology  HANV  B  10 days  Herpes Simplex (HSV) 1 & 2 (PCR/Self-collect) (Oral or Genital)  Herpes Simplex I/II Antibody Profile (IgG)  HERP  CRV  HERD  CRV  STDX  A  10 mls or 2 x 4mls (Vacutainer only)  HUMAAT (10 days post exposure)  HHV6  HHV6  HHV6  Stays  HHV6  Stays  HHV6  HHV6  Stays  HHV6  Stays  HHV6  Stays  HHV6  Stays  HHV6  Stays  HHV6  Stays   | Dengue Fever PCR  | DPCR | A or B 9,14          | 2 weeks     |
| Hantavirus Serology HANV 3 9 10 days Herpes Simplex (HSV) 1 & 2 (PCR/Self-collect) (Oral or Genital) Herpes Simplex I/II Antibody Profile (IgG) HERP 3 2 days Herpes Simplex I/II by PCR (Urine) HERD FCRU 5 days Herpes Simplex I/II IgM HERM 3 2 days HIV/HBV/HCV Screen by PCR/ NAAT (10 days post exposure)  HHV6 A 5 days   | Epstein-Barr Virus Antibodies IgG/IgM   | EBVA |                      | 2 days      |
| Herpes Simplex (HSV) 1 & 2 (PCR / Self-collect) (Oral or Genital)  Herpes Simplex I/II Antibody Profile (IgG)  Herpes Simplex I/II by PCR (Urine)  Herpes Simplex I/II IgM  HERD  FCRU  5 days  Herpes Simplex I/II IgM  HERD  STDX  10mls or 2 x 4mls (Vacutainer only)  Human Herpes Virus – 6 by PCR  HHV6  HERD  5 days  5 days  | Epstein-Barr Virus PCR  | EBVQ | A                    | 5 days      |
| CPCR/Self-collect) (Oral or Genital)   multisite swab  | Hantavirus Serology   | HANV | B 9                  | 10 days     |
| Herpes Simplex I/II by PCR (Urine) HERD FCRU 5 days Herpes Simplex I/II IgM HERM 3 2 days HIV/HBV/HCV Screen by PCR/ NAAT (10 days post exposure) STDX 10mls or 2 x 4mls (Vacutainer only) Human Herpes Virus – 6 by PCR HHV6 A 5 days   |   | HERS |                      | 5 days      |
| Herpes Simplex I/II IgM HERM  1 2 days  HIV/HBV/HCV Screen by PCR/ NAAT (10 days post exposure)  Human Herpes Virus – 6 by PCR HHV6  A 2 days  3 days  (Vacutainer only)  5 days   | Herpes Simplex I/II Antibody Profile (IgG)  | HERP | В                    | 2 days      |
| HIV/HBV/HCV Screen by PCR/ STDX 10mls or 2 x 4mls (Vacutainer only)  Human Herpes Virus – 6 by PCR HV6  5 days   | Herpes Simplex I/II by PCR (Urine)  | HERD | FCRU                 | 5 days      |
| NAAT (10 days post exposure) (Vacutainer only) Human Herpes Virus – 6 by PCR HHV6 (A) 5 days   | Herpes Simplex I/II IgM   | HERM | В                    | 2 days      |
|  | -   | STDX | (Vacutainer only)    | 3 days      |
| Human Herpes Virus – 8 (IgG) HHV8 (3) 10 days  |   | HHV6 | A                    | 5 days      |
|  | Human Herpes Virus – 8 (IgG)  | HHV8 | В                    | 10 days     |

| TEST  | CODE | SAMPLE REQS   | TAT           |
|---|------|---|---------------|
| Human Herpes Virus – 8 by PCR   | HV8D | A   | 5 days        |
| Human Parvovirus B19 – DNA  | PCRP | A   | 2 weeks       |
| JC Polyoma Virus by PCR   | JCPV | A/B/CSF   | 5 days        |
| Measles Antibodies (IgG) Immunity                                       | MEAS | <b>B</b>  | 1 day         |
| Measles Antibodies (IgM)  | MEAM | <b>B</b> 9  | 2 days        |
| Measles PCR   | MEAP | Buccal swab   | 48 hours      |
| MERS Coronavirus Test   | MERS | J   | 1 day         |
| Mumps Antibodies (IgM)  | MUMM | <b>B</b>  | 1 day         |
| Mycoplasma species – DNA  | MPCR | A   | 5 days        |
| Needle Stick Injury Profile   | NSI  | BB  | 4 hours       |
| Neurological Viral Screen   | NVIR | BB  | 2 days        |
| Parvovirus Antibodies (IgM)   | PARV | В   | 2 days        |
| Parvovirus IgG Antibodies   | PARG | В   | 2 days        |
| Parvovirus IgG/IgM Abs  | PARP | В   | 2 days        |
| Pneumonia (Atypical) Screen   | APS  | В   | 2 days        |
| Respiratory PCR Panel (COVID-19,<br>Flu A/B and RSV) (PCR/Self-collect) | FLU4 | <b>PCR</b> nasopharyngeal /<br>Throat and nose swab | 1 day         |
| Rotavirus in Stool by PCR   | ROTA | RF  | 1 day         |
| Rubella Antibody (IgG)  | RUBE | <b>B</b>  | 4 hours       |
| Rubella Antibody (IgM)  | RUBM | <b>B</b>  | 4 hours       |
| Rubella Avidity   | RUAV | В   | 1 week        |
| Torch Screen  | TORC | <b>B</b>  | 2 days        |
| Varicella zoster – DNA  | VZPC | A   | 5 days        |
| Varicella zoster Antibodies (IgG)                                       | VZ0S | <b>B</b>  | 1 day         |
| Varicella zoster Antibodies (IgM)                                       | VZOM | В   | 1 day         |
| Viral Antibody Screen   | VIRA | BB  | 2 days        |
| Viral Eye by PCR  | VPE  | PCR   | 3 days        |
| Viral Respiratory RNA Screen by PCR                                     | VPR  | <b>PCR</b> or as specified on the form              | 2 days        |
| Viral Skin/Mucosa by PCR  | VPSK | PCR   | 2 days        |
| West Nile Virus Abs   | WNV  | B   | 2 weeks       |
| Zika Abs IgM and IgG<br>– Antibody detection from 15 days               | ZKAB | <b>3</b>  | Up to 14 days |
| Zika RNA by PCR in Semen  | ZIKS | Semen   | Up to 14 days |
|   |      |   |               |

### Atypical Pneumonia Screen

Mycoplasma pneumonia Abs Chlamydia pneumoniae (MIF) Legionella pneumophila (IF)

TAT: 2 days

APS



# Respiratory PCR Panel (COVID-19, Flu A/B and RSV) (PCR/Self-collect)

Flu A Flu B Respiratory Syncytal Virus (RSV) COVID-19

TAT: 1 day

FLU4

**PCR** nasopharyngeal / Throat and nose swab

### **CSF Screen by PCR**

Herpes Simplex virus Varicella zoster virus Enterovirus

TAT: 2 days

**VPCR** 

**CSF** 

### **Hepatitis (Acute) Screen**

Hepatitis A IgM Abs Hepatitis B Surface Antigen Hepatitis C Abs

TAT: 4 hours

**AHSC** 



### Hepatitis A, B & C Profile

Hepatitis A Profile Hepatitis B Profile Hepatitis C Abs LFTs

TAT: 4 hours

ABC

3

# **Hepatitis B Profile**

Hep B Surface Antibodies Hep B Surface Antibodies Hep B Core IgG/IgM

TAT: 4 hours

**HEPB** 

**B** 

# HIV/HBV/HCV Screen by PCR/NAAT (10 days post exposure)

Positive findings will be reflexed for confirmatory testing

HIV1 and HIV2 (RNA) Hepatitis B Virus (HBV DNA) Hepatitis C Virus (HCV RNA)

Samples must be received in the laboratory within 2 days of sample taking

STDX provides diagnostic confirmatory testing only when used in addition to serology for Ag/Ab HIV-1&2. HBV, HCV

TAT: 3 days

STDX

(Vacutainer only)

# HIV Rapid RNA HIV-1 QUALITATIVE

Early detection from 10 days HIV-1 RNA

Sample must be received in the laboratory within 24 hours of sample taking

TAT: 4 hours

LHIV

(Vacutainer only)

### HIV Rapid RNA HIV-1 QUANTITATIVE

Rapid testing for HIV-positive patient prognosis and response to antiretroviral therapy

HIV-1 RNA VIRAL LOAD (40 copies/ml)

Sample must be received in the laboratory within 24 hours of sample taking

### TAT: 4 hours

#### RHIV

(Vacutainer only)

## Needle Stick Injury Profile

(Donor - Not recipient)

Hep B sAg Hep C Abs HIV 1+2 Abs/p24 Antigen Serum saved for 2 years

### TAT: 4 hours

#### NSI



## Neurological Viral Screen

Measles IgG
Measles IgM
Mumps IgG
Mumps IgM
CMV IgG
HSV 1+2 IgG
HSV 1+2 IgM
VZV IgG

### TAT: 2 days

**NVIR** 



### **Torch Screen**

Toxoplasma Antibodies (IgG, IgM) Rubella Antibody (IgG, IgM) CMV Antibody (IgG, IgM) Herpes Antibody (HSV1/HSV2 IgG)

### TAT: 2 days

**TORC** 



### **Viral Antibody Screen**

Measles IgG
Measles IgM
Mumps IgG
Mumps IgM
Mycoplasma pneumonia
CMV
HSV 1
HSV 2

### TAT: 2 days

VIRA



# Viral Eye by PCR

Herpes Simplex virus Varicella zoster virus Adenovirus

### TAT: 3 days

**VPE** 

#### PCR

### Viral Respiratory RNA Screen by PCR

Throat swabs, nasopharyngeal aspirates Adenovirus

Parainfluenza 1,2,3,4 Influenza A and B Coronavirus (seasonal) SARS-CoV-2 (COVID-19)

Parechovirus

Rhinovirus Enterovirus

Respiratory Syncytial virus A and B Human metapneumovirus

### TAT: 2 days

**VPR** 

PCR or as specified on the form

# Viral Skin/ Mucosa by PCR

If chicken pox or shingles suspected, please indicate clearly on request form

Herpes Simplex virus Varicella zoster virus

### TAT: 2 days


VPSK

### **PCR**

# **Tumour Markers/Sites**

| TEST   | CODE | SAMPLE REQS                          | TAT                |
|--|------|--------------------------------------|--------------------|
| Alpha-Fetoprotein  | AFP  | B                                    | 4 hours            |
| Breast Cancer NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9,11                      | 4 weeks            |
| CA 15-3  | C153 | В                                    | 4 hours            |
| CA 19-9  | C199 | B                                    | 4 hours            |
| CA 50  | CA50 | B                                    | 5 days             |
| CA 72-4  | C724 | B                                    | 5 days             |
| CA 125 (Venous/Self-collect)   | C125 | B / B (TDL Tiny)                     | 4 hours /<br>1 day |
| Carcino Embryonic Antigen  | CEA  | B                                    | 4 hours            |
| Complex PSA (Prostate Specific Ag)   | CPSA | B                                    | 3 days             |
| Cyfra 21-1   | CY21 | B                                    | 4 days             |
| HCG (Oncology)   | HCGQ | B                                    | 4 hours            |
| HE4 + ROMA (Earlier Detection of Ovarian Tumour)   | HE4  | B                                    | 1 day              |
| Neurone Specific Enolase   | NSE  | B                                    | 5 days             |
| Osteocalcin  | 0ST  | ③ (Frozen)⁴                          | 4 days             |
| Prostate Profile (Total & Free PSA)  | PR2  | B                                    | 4 hours            |
| Prostate Specific Antigen (Total) (Venous / Self-collect)*  * Results that fall between 4.00 ug/L and 10.00 ug/L will automatically reflex to a Free PSA with a calculated ratio. The ratio of Free to Total PSA may help discriminate between prostate cancer and benign prostatic hyperplasia. | PSPA | 3 (TDL Tiny)                         | 4 hours /<br>1 day |
| Pyruvate Kinase (M2-PK)  | M2ST | RF <sup>4</sup>                      | 5 days             |
| Pyruvate Kinase (M2-PK)  | M2PK | (Frozen plasma) <sup>7</sup>         | 5 days             |
| S100 Malignant Melanoma  | S100 | В                                    | 4 days             |
| Squamous Cell Carcinoma  | SCC  | B                                    | 4 days             |
| Testicular Tumour Profile (LDH, AFP, HCQG)   | TTP  | B                                    | 4 hours            |
| Urinary Bladder Cancer Antigen  ** It is recommended to collect mid-stream urine. Do not use first morning urine. Collection of urine specimen before any surgical intervention or treatment or 1–2 weeks after specimen shall not be collected with an instrument e.g. catheter.                | UBC  | <b>RU</b> (Freeze within 48 hours)** | 5 days             |

### **Tumour Markers/Sites**



\* NSE: Neurone Specific Enolase SCC: Squamous Cell Carcinoma

### **Tumour Markers/Sites**

# HE4 + ROMA (Earlier Detection of Ovarian Tumour)

HE4 CA 125 ROMA

Calculated Algorithm for pre and post menopausal risk of malignant disease.

### TAT: 1 day

HE4

**3** 

# Prostate Profile (Total & Free PSA)

Total PSA
Free PSA
Calculated Ratio
The ratio of Free to Total
PSA may help discriminate
between prostate cancer and
benign prostatic hyperplasia.

### TAT: 4 hours

PR2

**(3)** 

# **Testicular Tumour Profile**

LDH AFP HCQG

### TAT: 4 hours

TTP



# **TDL Genetics**

TDL Genetics is a consultant-led service which is able to provide extensive expertise in the testing, diagnosis and genetic counselling of inherited disorders. Genetic tests are performed on DNA for molecular genetic analysis and on whole chromosomes for cytogenetic analysis. Some tests are part of profiles that can be linked with assays from other TDL disciplines, such as biochemistry and haematology, to give more comprehensive results for the patient.

Genetic tests are available for:

- Prenatal diagnosis and rapid trisomy screening by Amnio-PCR
- Carrier screening
- Newborn chromosome analysis
- Confirmation of symptomatic individuals and pre-symptomatic testing
- Genetic variation that influences risk of disease
- Identity studies (paternity, zygosity, tissue typing)
- Fertility studies
- Products of conception
- Cancer

QF-PCR: DNA peaks from an unaffected fetus

QF-PCR: DNA peaks from a fetus with Down Syndrome



Genetic testing is sometimes complex and tests will vary in their ability to detect mutations or to detect all patients who have, or will develop, the disease. Some tests are diagnostic for a condition, others are indicative or are associated with an altered risk for a condition. Results can affect the lives of individuals and have implications for their family, for insurance and employment. Where testing will predict the inheritance of a disease in a healthy

person, counselling and consent are mandatory. For these tests, please complete the Genetic Request form (including informed consent). Our service provides result interpretation and risk assessment. Genetic counselling can be arranged by TDL's Consultant Clinical Geneticist.



Download TDL Request Forms from:

www.tdlpathology.com/ tests/request-forms/

To meet the increasing range and complexity of genetic testing we have developed an excellent collaboration with other specialist laboratories.

Tests marked GENE are sent to these laboratories within our network and have a fixed price.

GENE panel composition may change throughout the year to reflect new and improved developments. Turnaround times may be longer if follow-up studies are required.

Specimen Receipt at The Doctors Laboratory is 24 hours a day. Specifically, TDL Genetics results service is available Monday to Friday 8.30am – 5.30pm with the laboratory also open for processing of samples on Saturdays from 9.00am – 1.00pm.

Test codes, sample requirement codes and turnaround times may be found on the following pages.

All samples must be collected in the specified containers, as shown in the key at the back of this guide. Samples should be fresh and in good condition (e.g. not clotted if EDTA or heparinised whole blood is required) otherwise testing may be adversely affected and another sample may be required. Small DNA samples are stored routinely for one year, larger DNA samples can be stored by special arrangement.

### **TDL Genetics**

Instructions for transportation, sample labelling, and the completion of request forms can be found on the reverse of the TDL Genetics Request Form.

The locations of the Laboratory and Patient Reception are indicated on the map on the reverse of each request form. If you do not find the test you require in this directory or need more information and advice please telephone the laboratory on **020 7307 7409**.

# Sending samples to the laboratory

### **Transport arrangements**

All specimens should be kept at room temperature and despatched to the laboratory as soon as possible, by TDL/international courier, first class post, guaranteed next day delivery or a reliable alternative.

If a delay in sending the sample is unavoidable, please refrigerate overnight – DO NOT FREEZE. For NIPT sample stability see page 132, do not refrigerate or freeze NIPT bloods.

Specimens must not be allowed to come in contact with request forms, but should be kept separate by using dual — pocketed plastic bags. Specimens for inland postage must be packed in a rigid crush-proof container according to current Post Office guidelines.

IATA guidelines should be followed for international transport (advice is available from the laboratory).

# Labelling of high risk samples

Please note that it is the responsibility of the referring clinician to ensure that high-risk samples are clearly identified to reduce the risk of infection to staff and others

# Patient details on request forms and samples

Request and consent forms are available directly from TDL Genetics. In order to avoid unnecessary time spent in obtaining details please provide the following information:

### Information for request forms

- Surname, forename (not initials), date of birth and birth sex of patient for postnatal referrals
- Full name (not initials) and location of referring clinician
- Full address of clinician to whom the result should be sent
- Legible clinical summary, including details of any relevant family history
- Address for billing doctor, patient or other
- Gestation on prenatal samples
- Hospital or reference number
- Test required

# Essential information on sample container label

- Patient's surname and forename (not initials)
- Date of birth
- Hospital number or reference number

### **Consent forms**

Consent forms (see back of this guide) are available for genetic testing. As genetic testing may have implications for other family members and is regarded as personal data, it is recommended that written consent is obtained wherever possible. In cases with predictive testing for severe disorders, as indicated in the laboratory guide, it is essential that patients should also be offered formal genetic counselling. It is the responsibility of the referring clinician to obtain appropriate consent from the patient.

## **Unlabelled samples**

Unlabelled samples will ONLY be processed if the individual who took the sample can confirm the sample is from the patient in question. In the absence of this assurance, the sample will be discarded and a repeat required.

# **Genetic testing**

## The importance of clinical details

Clinical details are very important when providing genetic analysis. The more clinical information that is available (e.g. details of ultrasound information, phenotypic features or family history) the better the service we can provide. Failure to provide this information for cytogenetic studies may result in an inaccurate analysis.

## **Molecular genetics**

Clinical details can be extremely important for clinical interpretation of a molecular genetic test.

For example, the clinical comments accompanying a cystic fibrosis screening report will vary depending on whether the patient is a potential gamete donor or a person exhibiting a cystic fibrosis phenotype.

It may also be crucial, where a mutation has already been shown to be segregating in a family, to be provided with information concerning the mutation and a family pedigree to ensure the correct analysis is performed and reliable risk figures calculated.

## Cytogenetics

Cytogenetic analysis is performed according to the Professional Guidelines for the Association of Clinical Genetic Science and the recommendations provided are dependent on the clinical indications given for each case.

Clinical details inform the investigation at all stages:

- Prior to analysis, clinical details may indicate, for example, that procedures such as chromosome breakage or leukaemic studies are required, which must be referred to the oncogenomic department or specialist centre.
- During analysis they may indicate that extra cells should be screened to investigate the possibility of mosaicism, for example in a diagnosis of suspected Turner syndrome, or that particular chromosomes must be targeted for high-resolution study, for example chromosome 4 in suspected Wolf-Hirschhorn syndrome.
- When the analysis has been completed they may help to provide an accurate interpretation of the findings and in some instances prompt further investigations, for example FISH or molecular genetic studies.

When clinical details are not available a routine analysis will be performed and a conditional report issued.

# Sample Stability

### **Molecular Genetic Samples**

Whole blood collected in EDTA should be sent to the laboratory between 4°C-28°C within 48 hours.

Long term storage should be at 2-8°C.

Extracted DNA samples should be sent to the laboratory between 4°C-28°C.

## **Cytogenetic Samples**

Cytogenetic studies require living cells, please ensure that samples reach the laboratory as soon as possible. If a delay before dispatch is unavoidable, samples may be stored in a refrigerator (4°C) but they must not be frozen.

Samples sent more than 48 hours after sampling, or kept at temperatures below 4°C and greater than 38°C may have inhibited growth.

Information concerning packaging, transportation, and labelling of samples is provided on the reverse of our TDL Genetics Request Form.

## **Requesting additional tests**

Any further tests not requested at the time of sample receipt must be requested within:

- 1 week for tests requiring prenatal culture or cultured cells
- 2 weeks for DNA testing
- 2 weeks for cell culture testing
- 3 months for FISH testing

Samples can be stored for longer periods if specifically requested at the time of sample receipt.

## **Postnatal Diagnosis (Blood Culture)**

**Reasons for analysis**: Chromosome studies are requested where problems that may have a cytogenetic basis are suspected, e.g. babies with birth defects; children with developmental delay and physical handicaps, or adults with fertility problems. Additionally, prospective gamete donors are screened to detect carriers of balanced chromosome rearrangements.

Sample requirements: Lithium heparin whole blood specimens are required — gently mixed to prevent clotting and must not be frozen.

See sample stability section for cytogenetic samples. Sample volumes may be reduced for children (2-4ml) and neonates (1-2ml).

**Turnaround time**: The usual turnaround time is 2-3 weeks however the laboratory will endeavour to respond to urgent requests. Where a major trisomy is suspected, a rapid PCR screen may be performed to provide an urgent provisional result.

#### Notes

- Rarely, blood samples fail to culture (<1%);</p>
- The culture may yield chromosomes of insufficient quality. This will be indicated on the report and a repeat study suggested;
- The laboratory should be informed if the patient has recently received a blood transfusion.
- The laboratory should be informed if the patient has EVER had a bone marrow transplant.
- The patient's birth sex should be included on the request form.

## **Prenatal diagnosis**

Reasons for analysis: Chromosome studies are requested where pregnancies are identified as being at risk of a cytogenetic abnormality e.g. positive maternal serum screening combined NT test; fetal abnormalities found on ultrasound; or where a parent is a known carrier of a chromosome anomaly, or where a high risk trisomy has been found by NIPT.

## Sample requirements:

- Amniotic fluid 10ml+ in a plain sterile, leak-proof container. Suitable containers can be provided by the laboratory.
   The specimen must not be frozen. See sample stability section for cytogenetic samples.
- Chorionic villus 5mg+ in sterile transport medium. Suitable containers containing medium can be provided by the laboratory. The specimen must not be frozen. See sample stability section for cytogenetic samples.
- Fetal blood 1-2ml LITHIUM HEPARIN
   whole blood, gently mixed to prevent clotting.
   The specimen must not be frozen. See sample stability section for cytogenetic samples.

**Turnaround time**: This is dependent on the rate of cell growth, however, the usual turnaround time is approximately 2 weeks. A number of circumstances now occur more frequently, as invasive prenatal diagnosis becomes less common, that may result in delayed reporting time. These include:

- A delay in transportation in order to collect a batch of samples to reduce courier costs. Even when couriered promptly, sample growth may be slower than that seen in samples sent immediately.
- Sampling at early or late gestations, for example to confirm non-invasive tests or follow up anomaly scans.
- A tendency to take smaller quantities of sample or to take insufficient sample for multiple techniques.
- The request for karyotyping as an add-on after an initial PCR test.

Fetal blood results will usually be reported by 10 calendar days. For all other prenatal tests, please contact the laboratory prior to taking samples.

#### Notes

- Maternal contamination, and mosaicism may complicate the analysis and may lead to the suggestion that a second invasive test is performed.
- Rarely, cultures fail to grow (overall <1%)
- Very small chromosome abnormalities may not be detected (this is why the phrase 'No trisomies or major chromosome abnormalities detected...' is used in our reports).
- for TTTs or heavily blood stained amniocentesis samples, please provide a maternal EDTA blood sample for comparison studies.

#### Solid tissue

**Reasons for analysis:** Fibroblast cultures may be used in addition to blood cultures, for example where tissue specific mosaicism is suspected, or where blood samples cannot be obtained. POC samples may be requested for early spontaneous miscarriages, stillbirths, or to confirm a prenatal diagnosis.

**Sample requirements**: All specimens should be placed in a sterile container, preferably containing transport medium. This can be supplied by the laboratory. Sterile normal saline can be used if transport medium is not available. Samples must not be placed in formaldehyde or other preservative and must not be frozen. See sample stability section for cytogenetic samples.

**Turnaround time**: This is dependent on the rate of cell growth, however, the usual turnaround time is approximately 4 weeks.

#### Notes

- Material from miscarriages has a relatively high culture failure rate (around 20%). Where failure occurs, alternative molecular methods may be attempted, usually a KaryoLite Bacs-on-Beads assay that can detect whole monosomy or trisomy of any chromosome, if possible.
- If no villus or fetal parts are identified in supposedly POC material and a normal female chromosome result is found, this may indicate that maternal tissue has been cultured (this will be noted on our report).
- If a request is made for remaining pregnancy loss tissue to be returned to the patient or hospital for burial or cremation, we will return the sample as soon as possible once adequate tissues have been used for testing. Please ensure that this is communicated to the lab using a hospital consent form, noted on the referral form or by email. Patients can arrange to collect remaining tissues from TDL Patient Reception.

The lab will send all remaining tissue for samples without specific consent, for sensitive incineration. Please note that there is no distinction made between fetal and other pregnancy tissues for this process and there will be no ashes afterwards. The lab keeps detailed records of all pregnancy tissue sent for incineration and a Certificate of Destruction is available if required.

# Fluorescence in situ hybridisation (FISH)

Where FISH studies for specific microdeletion syndromes are required this must be indicated on the request form.

Note: FISH studies for a rapid pre or postnatal aneuploidy screen have now been superseded in our laboratory by multiplex-PCR technology. Subtelomeric screens are now performed by Array CGH as part of developmental delay investigations. Common microdeletion syndrome testing is now performed by BOBs analysis.

# Statement regarding Measurement Uncertainty (MU)

Measurement Uncertainty is determined for each measurement procedure in the examination phase used to report measured quantity values on patients' samples. This is determined during verification of this assay for service introduction; creation of laboratory standard operating procedures (SOP) and interpretation of the results.

Where examinations include a measurement step but do not report a measured quantity value, the laboratory calculates the uncertainty of the measurement step where it has utility in assessing the reliability of the examination procedure or has influence on the reported result.

Estimates of measurement uncertainty are regularly reviewed and are available upon request to laboratory users.

## **Key Personnel**

### **Consultant Clinical Geneticist**

Prof. Michael Patton
020 7307 7409
michael.patton@tdlpathology.com

#### **Consultant Clinical Scientist**

Elaine Holgado 020 7307 7409 elaine.holgado@tdlpathology.com

## **Head of Cytogenetics**

Rebecca Watts
020 7460 4787
rebecca.watts@hslpathology.com

## **Senior Cytogeneticist**

**Kath Masters** 020 7307 7409 kath.masters@tdlpathology.com

## Cytogenetics and Prenatal Operations Manager

Emma Wilcock 020 7307 7409 emma.wilcock@tdlpathology.com

## **Postnatal Lab Manager**

Allison Daffern 020 7307 7409 allison.daffern@tdlpathology.com

## **Director of Genetics & Molecular Pathology**

**Dr Lisa Levett** 020 7307 7409 lisa.levett@tdlpathology.com

## **Head of Genetics & Molecular Pathology**

**Dr Stuart Liddle** 020 7307 7409 stuart.liddle@tdlpathology.com

## **Operations Manager**

Oliver George 020 7307 7409 oliver.george@tdlpathology.com

## **Molecular Cytogenetics Manager**

Alessandra Callegari 020 7307 7409 alessandra.callegari@tdlpathology.com

| TEST  | CODE            | SAMPLE REQS             | TAT        |
|---|-----------------|-------------------------|------------|
| 1p36 Deletion Syndrome – karyotype + CGH  | KARY,<br>FISH   | CVS / AF / (1) 9        | 12-17 days |
| 21-Hydroxylase Deficiency<br>(Congenital Adrenal Hyperplasia)<br>Requires patient informed consent.   | GENE            | <b>A</b> 9,11           | 5 weeks    |
| 22q11 & 10p14 deletion<br>(Di George Syndrome) – BOBs only  | DGB             | CVS / AF / A 9          | 5 days     |
| 22q11 & 10p14 deletion (Di George Syndrome)<br>– BOBs (5 days) + karyotype (15 days)  | DGB,<br>KARY    | CVS / AF / (A) (1) 9    | 5-15 days  |
| Achromatopsia NGS Panel Requires patient informed consent.  | GENE            | <b>A A</b> 9            | 5 weeks    |
| Adenomatous Polyposis NGS Panel   | GENE            | <b>A</b> 9              | 4 weeks    |
| Afibrinogenemia, congenital Test code dependent on phenotype.   | R90U or<br>R97U | AA                      | 12 weeks   |
| Aicardi-Goutières Syndrome NGS Panel<br>Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 5 weeks    |
| Alagille Syndrome NGS Panel Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 8 weeks    |
| Alpha Thalassaemia – multiplex PCR for common large deletions Requires patient informed consent.  | GENE            | <b>A</b> 9              | 4 weeks    |
| Alpha-1-Antitrypsin Genotype – PI*M, PI*S, PI*Z<br>Requires patient informed consent.   | GENE            | <b>A</b> 9              | 5 weeks    |
| Alpha-2-Plasmin Inhibitor Deficiency  | R90U            | AA                      | 12 weeks   |
| Alport Syndrome NGS Panel – full sequencing with deletions and duplications Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 5 weeks    |
| AML/ALL Molecular MRD – NPM1, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, ETV6-RUNX1 Contact lab for further information. Requires patient informed consent. | GENE            | Bone Marrow / 🛕         | 5 days     |
| AmnioBOBs only – rapid aneuploidy diagnosis for all chromosomes + common microdeletion syndromes  | ABOB            | <b>AF</b> <sup>9</sup>  | 5 days     |
| Amniocentesis – rapid BOBs aneuploidy diagnosis for all chromosomes (5 days) + culture (10-15 days)   | ABK             | <b>AF</b> 9             | 5-15 days  |
| Amniocentesis – rapid PCR diagnosis<br>for common aneuploidies (2 days)<br>+ culture (10-15 days)   | APCC            | <b>AF</b> <sup>9</sup>  | 2-15 days  |
| Amniocentesis culture (karyotype) only  | ACUL            | <b>AF</b> <sup>9</sup>  | 10-15 days |
| AmnioPCR only – rapid common<br>aneuploidy diagnosis by QF-PCR  | APC             | <b>AF</b> 9             | 2 days     |
| <del>````</del>   |                 |                         |            |

| TEST   | CODE | SAMPLE REQS             | TAT        |
|--|------|-------------------------|------------|
| Amylotrophic Lateral Sclerosis<br>(Motor Neurone Disease) NGS Panel<br>Requires patient informed consent.                            | GENE | <b>A A</b> 9            | 5 weeks    |
| Androgen Insensitivity – AR gene sequencing Requires patient informed consent.   | GENE | <b>A</b> 9              | 5 weeks    |
| Angelman Syndrome (Primary Screen)  – methylation PCR  | PWAM | <b>A</b> 9              | 10 days    |
| Angelman/Rett Syndromes NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> <sup>9</sup> | 5 weeks    |
| Aniridia, Isolated – PAX6 gene sequencing + deletions/duplications Requires patient informed consent.                                | GENE | <b>A</b> 9              | 5 weeks    |
| Anophthalmia/Microphthalmia/ Coloboma NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9            | 6 weeks    |
| Apolipoprotein E genotype – E2/E3/E4   | APEG | <b>A</b> 9              | 2 weeks    |
| Array CGH (Comparative Genomic Hybridisation)  | CGH  | CVS / AF / (A) (1) 9    | 10 days    |
| Ashkenazi Breast Cancer Screen  - common variants  Requires patient informed consent.  | GENE | <b>A</b> 9,11           | 4 weeks    |
| Ashkenazi Jewish Carrier Screen Requires patient informed consent.   | GENE | <b>A</b> 9              | 4 weeks    |
| Ataxia NGS Panel Requires patient informed consent.  | GENE | <b>A A</b> <sup>9</sup> | 6 weeks    |
| Autoinflammation/Periodic Fever NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> <sup>9</sup> | 6 weeks    |
| Azoospermia – karyotype + cystic fibrosis<br>screen + polyT(5T) + Y deletions  | GRP  | <b>A (1)</b> 9          | 10-15 days |
| B cell clonality assay (IgH and IgK)   | IGHA | (A) or FFPE             | 2 weeks    |
| Bardet-Biedl Syndrome NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> <sup>9</sup> | 6 weeks    |
| Batten Disease (Neuronal Ceroid<br>Lipofuscinosis) NGS Panel<br>Requires patient informed consent.                                   | GENE | <b>A A</b> 9            | 6 weeks    |
| BCR-ABL Diagnostic Assay   | BCRD | A                       | 2 weeks    |
| BCR/ABL Quantitative – fusion<br>gene sizes p190 + p210<br>MUST arrive in the laboratory within 48 hours,<br>before 12pm on Fridays. | BCRQ | <b>A A</b> <sup>9</sup> | 10 days    |
| Becker/Duchenne Muscular Dystrophy<br>- deletions/duplications   | DMD1 | <b>A</b> 9              | 10 days    |

| TEST   | CODE       | SAMPLE REOS             | TAT       |
|--|------------|-------------------------|-----------|
| Beckwith-Wiedemann Syndrome  | GENE       | <b>A</b> 9              | 6 weeks   |
| – methylation studies on 11p15   | GLITE      | •                       | o woono   |
| imprinting domains KvDMR + H19   |            |                         |           |
| Requires patient informed consent.   |            |                         |           |
| Behcet's Disease – HLA Tissue Typing B*51  | B51        | <b>A</b> 9              | 10 days   |
| Bernard-Soulier Syndrome   | R90U       | AA                      | 12 weeks  |
| Beta Thalassaemia –  | GENE       | <b>A</b> 9              | 5 weeks   |
| beta-globin gene sequencing  |            |                         |           |
| Requires patient informed consent.   |            |                         |           |
| Bleeding and Platelet Gene Panel Contact lab. Requires patient informed consent. | R90U       | <b>A A</b> 9            | 12 weeks  |
| Bleeding Disorder of Unknown Cause   | R90U       | AA                      | 12 weeks  |
|  |            |                         |           |
| Blood PCR for Chromosome 13, 18, 21<br>and sex chromosomes                       | BPCR       | A                       | 5 days    |
|  | CENE       | •                       | 4 wooko   |
| Breast Cancer – BRCA1 + BRCA2 genes only Requires patient informed consent.      | GENE       | Δ                       | 4 weeks   |
| Breast Cancer Ashkenazi Screen   | GENE       | <b>A</b> 9,11           | 4 weeks   |
| – common variants  | GLITE      | •                       | 4 WOONG   |
| Requires patient informed consent.   |            |                         |           |
| Breast Cancer NGS Panel  | GENE       | <b>A A</b> 9,11         | 4 weeks   |
| Requires patient informed consent.   |            |                         |           |
| Brugada Syndrome/Long QT   | GENE       | <b>A A</b> <sup>9</sup> | 4-6 weeks |
| Syndrome NGS Panel Requires patient informed consent.                            |            |                         |           |
| C-KIT D816V variant – Mastocytosis   | GENE       | Bone Marrow / 🛕         | 4 weeks   |
| Requires patient informed consent.   | GENE       | bulle Marrow /          | 4 W66K5   |
| CADASIL – NOTCH3 gene sequencing   | GENE       | <b>A</b> 9              | 6 weeks   |
| Requires patient informed consent.   | U.Z.1.Z    |                         | o moone   |
| CAKUT (Congenital Anomalies of   | GENE       | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Kidney & Urinary Tract) NGS Panel  |            |                         |           |
| Requires patient informed consent.   |            |                         |           |
| CALR gene mutations – see Myeloproliferative Ne                                  | eoplasm NG | S Screening Panel       |           |
| Cancer, Comprehensive NGS Panel Requires patient informed consent.               | GENE       | <b>A A</b> 9,11         | 5 weeks   |
| Cardiomyopathy, Dilated NGS Panel  | GENE       | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Requires patient informed consent.   |            |                         |           |
| Cardiomyopathy, Hypertrophic NGS Panel Requires patient informed consent.        | GENE       | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Cardiovascular, Comprehensive NGS Panel Requires patient informed consent.       | GENE       | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Carrier Screen (Ashkenazi Jewish) Requires patient informed consent.             | GENE       | <b>A</b> 9              | 4 weeks   |
|  |            |                         |           |

| TEST  | CODE | SAMPLE REQS             | TAT           |
|---|------|-------------------------|---------------|
| Carrier Screen (Ashkenazi Jewish) – Partnered Report Requires patient informed consent. Please contact the lab for special requirements before sending.   | GENE | <b>A</b> 9              | 4 weeks       |
| Carrier Screen (Pan-Ethnic) Requires patient informed consent.  | GENE | <b>A</b> 9              | 4 weeks       |
| Carrier Screen (Pan-Ethnic) — Partnered Report Requires patient informed consent. Please contact the lab for special requirements before sending.   | GENE | <b>A</b> 9              | 4 weeks       |
| Charcot-Marie-Tooth Syndrome NGS Panel Requires patient informed consent. Contact lab prior to sending. Referral from clinical neurologist or clinical geneticist required with genetic consent form. | GENE | <b>A A</b> <sup>9</sup> | 6 weeks       |
| Charcot-Marie-Tooth Type 1A  - PMP22 duplications   | GENE | <b>A</b> 9              | 6 weeks       |
| Requires patient informed consent. Contact lab prior to sending. Referral from clinical neurologist or clinical geneticist required with genetic consent form.  |      |                         |               |
| CHARGE Syndrome – CHD7 gene sequencing Requires patient informed consent.   | GENE | <b>A</b> 9              | 6 weeks       |
| Chediak-Higashi Syndrome Requires patient informed consent.   | R90U | AA                      | 12 weeks      |
| Cholestasis NGS Panel Requires patient informed consent.  | GENE | <b>A A</b> <sup>9</sup> | 6 weeks       |
| Chromosome Analysis<br>(Amniocentesis) – culture only   | ACUL | <b>AF</b> 9             | 10-15 days    |
| Chromosome Analysis (Amniocentesis)  – rapid BOBs aneuploidy diagnosis for all chromosomes (5 days) + culture (10-15 days)  | ABK  | AF <sup>9</sup>         | 5-15 days     |
| Chromosome Analysis (Amniocentesis)  – rapid PCR diagnosis for common aneuploidies (2 days) + culture (10-15 days)  | APCC | <b>AF</b> <sup>9</sup>  | 2-15 days     |
| Chromosome Analysis (Blood)   | KARY | <b>(1)</b> 9            | 2-3 weeks     |
| Chromosome Analysis (Chorionic Villus)  – rapid BOBs aneuploidy diagnosis for all chromosomes (5 days) + culture (10-15 days)   | CBK  | CVS <sup>9</sup>        | 5-15 days     |
| Chromosome Analysis (Chorionic Villus)  – rapid PCR diagnosis for common aneuploidies (2 days) + culture (10-15 days)   | CVPC | <b>CVS</b> 1,9          | 2-15 days     |
| Chromosome Analysis<br>(Chorionic Villus) – culture only  | CVSC | CVS 1,9                 | 10-15 days    |
| Chromosome Analysis<br>(Products of Conception)   | PROC | Placental Sample 1,9    | 20-25<br>days |

| TEST  | CODE          | SAMPLE REQS             | TAT        |
|---|---------------|-------------------------|------------|
| Chromosome Analysis (Products of Conception)  – BOBs rapid aneuploidy diagnosis for all chromosomes (10 days) + culture (25 days) | PBK           | Placental Sample 1,9    | 10-25 days |
| Chromosome Analysis (Solid Tissue)  | PROC          | Fetal tissue 1,9        | 4-5 weeks  |
| Chromosome Y Deletion - AZFa, AZFb, AZFc + SRY  | YDEL          | <b>A</b> 9              | 5 days     |
| Coeliac Disease – HLA DQ2/DQ8 Genotype  | Q2Q8          | <b>A</b> 9              | 10 days    |
| Colorectal Cancer NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9,11         | 4 weeks    |
| Comparative Genomic Hybridisation<br>(Array CGH)  | CGH           | CVS / AF / (A) (1) 9    | 10 days    |
| Congenital Absence of Vas Deferens - karyotype + cystic fibrosis screen + polyT(5T) + Y deletions                                 | GRP           | <b>A (1)</b> 9          | 10-15 days |
| Congenital Adrenal Hyperplasia NGS Panel  | GENE          | <b>A</b> 9              | 6 weeks    |
| Congenital Myopathy NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> <sup>9</sup> | 6 weeks    |
| Connective Tissue Disorders NGS Panel<br>Requires patient informed consent.   | GENE          | <b>A A</b> 9            | 6 weeks    |
| Cornelia de Lange Syndrome NGS Panel<br>Requires patient informed consent.  | GENE          | <b>A A</b> <sup>9</sup> | 6 weeks    |
| Craniosynostosis NGS Panel<br>Requires patient informed consent.  | GENE          | <b>A A</b> <sup>9</sup> | 6 weeks    |
| Cri du Chat Syndrome –<br>BOBs (5 days) + karyotype (15 days)   | PBOB,<br>KARY | CVS / AF / (A) (1) 9    | 5-15 days  |
| Cri du Chat Syndrome – BOBs only  | PB0B          | CVS / AF / (A) 9        | 5 days     |
| CVS PCR for common aneuploidies<br>(2 days) + culture (10-15 days)  | CVPC          | CVS 1,9                 | 2-15 days  |
| CVSBOBs – rapid BOBs aneuploidy diagnosis for all chromosomes (5 days) + culture (10-15 days)                                     | CBK           | CVS 9                   | 5-15 days  |
| CVSBOBs only – rapid aneuploidy diagnosis for all chromosomes + common microdeletion syndromes                                    | CBOB          | CVS <sup>9</sup>        | 5 days     |
| Cystic Fibrosis (139 common variants)  – reflex to Poly T when required  Please provide relevant clinical and family history.     | CFS           | <b>A</b> 9              | 5-7 days   |
| Cytochrome P450 2C19  | 2C19          | <b>A</b> 9              | 15 days    |
| Diabetes – Obesity NGS Panel<br>Requires patient informed consent.  | GENE          | A                       | 6 weeks    |
| DiGeorge Syndrome (22q11 & 10p14 deletion)<br>– BOBs (5 days) + karyotype (15 days)   | DGB,<br>KARY  | CVS / AF / (A) (1) 9    | 5-15 days  |

| TEST   | CODE            | SAMPLE REQS             | TAT       |
|--|-----------------|-------------------------|-----------|
| DiGeorge Syndrome (22q11 & 10p14) – B0Bs only  | DGB             | CVS / AF / (A) 9        | 5 days    |
| Dihydropyrimidine Dehydrogenase deficiency screening (Fluoropyrimidine Toxicity)   | 5FU             | <b>A</b> 9              | 1-2 weeks |
| Dilated Cardiomyopathy NGS Panel Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 6 weeks   |
| DNA Extraction & Storage –<br>3 years (longer upon request)  | XDNA            | <b>A</b> 9              | 20 days   |
| DNA Identity Profile – 15 STR markers  | DNAF            | <b>A</b> 9,11           | 10 days   |
| Duchenne Muscular Dystrophy – deletions/duplications only  | DMD1            | <b>A</b> 9              | 10 days   |
| Duchenne Muscular Dystrophy –<br>full sequencing DMD1 gene<br>Requires patient informed consent.   | GENE            | <b>A</b> 9              | 6 weeks   |
| DVT/Pre-travel Screen  | DVT1            | <b>A A B</b> 9          | 5 days    |
| <b>Dysfibrinogenemia, congenital</b> Test code dependent on phenotype.   | R90U or<br>R97U | AA                      | 12 weeks  |
| Dysplasminogenemia   | R97U            | AA                      | 12 weeks  |
| Dysprothrombinemia   | R97U            | AA                      | 12 weeks  |
| Ehlers-Danlos Syndrome (associated with bleeding)  | R90U            | AA                      | 12 weeks  |
| Endometrial Cancer NGS Panel Requires patient informed consent.  | GENE            | <b>A A</b> 9,11         | 4 weeks   |
| <b>Epidermolysis Bullosa NGS Panel</b><br>Requires patient informed consent.   | GENE            | <b>A A</b> <sup>9</sup> | 6 weeks   |
| <b>Epilepsy, Adolescent/Adult Onset Panel</b> Requires patient informed consent.   | GENE            | A                       | 6 weeks   |
| <b>Epilepsy, Comprehensive NGS Panel</b> Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Fabry Disease, X-linked – GLA gene sequencing  | GENE            | <b>A</b> 9              | 4 weeks   |
| Facioscapulohumeral Muscular Dystropy<br>(FSHD) – D4Z4 repeat deletion<br>Requires patient informed consent. Contact lab prior to<br>sending. Referrals only from consultant neurologist or<br>clinical geneticist. Genetic consent form required. | GENE            | <b>A A B</b> 9          | 9 weeks   |
| Factor II Prothrombin – G20210A Variant  | FX2             | <b>A</b> 9              | 5 days    |
| Factor II Deficiency (full gene analysis) Test code dependent on phenotype.  | R90U or<br>R97U | AA                      | 12 weeks  |
| Factor V and Factor VIII, combined deficiency of   | R90U            | AA                      | 12 weeks  |
| Factor V Deficiency (full gene analysis) Test code dependent on phenotype.   | R90U or<br>R97U | AA                      | 12 weeks  |
| Factor V Leiden – G1691A Variant   | FX5             | <b>A</b> 9              | 5 days    |

| TEST  | CODE | SAMPLE REQS                        | TAT        |
|---|------|------------------------------------|------------|
| Factor VII Deficiency   | R90U | A (Whole blood 10ml) <sup>40</sup> | 12 weeks   |
| Factor X Deficiency   | R90U | (Whole blood 10ml) <sup>40</sup>   | 12 weeks   |
| Factor XI Deficiency  | R90U | (Whole blood 10ml) <sup>40</sup>   | 12 weeks   |
| Factor XII Deficiency   | R90U | AA                                 | 12 weeks   |
| Factor XIII Deficiency  | R90U | AA                                 | 12 weeks   |
| Familial Adenomatous Polyposis (FAP) NEW Requires patient informed consent.                                     | GENE | <b>A A</b> 9,11                    | 4 weeks    |
| Familial Exudative Vitreoretinopathy (FEVR) NGS Panel – full gene sequencing Requires patient informed consent. | GENE | <b>A A</b> <sup>9</sup>            | 6 weeks    |
| Familial Hypercholesterolaemia NGS panel<br>Requires patient informed consent.                                  | GENE | <b>A A</b> <sup>9</sup>            | 6 weeks    |
| Familial Hypocalciuric Hypercalcaemia (FHH) Panel Requires patient informed consent.                            | GENE | <b>A A</b> 9                       | 8 weeks    |
| Familial Medullary Thyroid Carcinoma  – hotspot sequencing RET gene Requires patient informed consent.          | GENE | <b>A</b> 9,11                      | 8 weeks    |
| Fatty Acid Oxidation Deficiency NGS Panel Requires patient informed consent.                                    | GENE | <b>A A</b> <sup>9</sup>            | 6 weeks    |
| Fletcher Factor (Prekallikrein) Deficiency  | R90U | AA                                 | 12 weeks   |
| FLT3-ITD and FLT3-TKD screening assay   | FLT3 | A                                  | 24 hours   |
| Fragile X Syndrome screen – FMR1 repeat analysis PCR Requires patient informed consent.                         | GENE | <b>AAA</b> <sup>9</sup>            | 5 weeks    |
| Friedreich Ataxia – frataxin gene repeat analysis<br>Requires patient informed consent.                         | GENE | <b>A</b> 9                         | 5 weeks    |
| Gaucher Disease   | R90U | AA                                 | 12 weeks   |
| Gaucher Disease full gene sequencing  | GDMA | <b>A</b> 40                        | 4 weeks    |
| Genetic Reproductive Profile (Male)   | GRP  | <b>A (1)</b> 9                     | 10-15 days |
| Ghosal Hematodiaphyseal Syndrome  | R90U | AA                                 | 12 weeks   |
| Giant Platelet Disorder   | R90U | AA                                 | 12 weeks   |
| Gilbert Syndrome – common UGT1A1 repeat variation Requires patient informed consent.                            | GENE | <b>A</b> 9                         | 4 weeks    |
| Glanzmann Thrombasthenia  | R90U | AA                                 | 12 weeks   |
|   |      |                                    |            |

| TEST  | CODE | SAMPLE REQS                        | TAT      |
|---|------|------------------------------------|----------|
| Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency – full G6PD gene sequencing Requires patient informed consent.  | GENE | <b>A</b> 9                         | 6 weeks  |
| Glycogen storage disease type 2<br>(Pompe) variant analysis   | POMP | A                                  | 4 weeks  |
| Gray Platelet Syndrome  | R90U | AA                                 | 12 weeks |
| Haemochromatosis –<br>HFE common variants C282Y + H63D  | HMD  | <b>A</b> 9                         | 3 days   |
| Haemophilia A (Factor VIII Deficiency) Requires patient informed consent.   | R90U | A (Whole blood 10ml) <sup>40</sup> | 12 weeks |
| Haemophilia A (Factor VIII deficiency) – CVS  | 8CVS | CVS 40                             | 3 days   |
| Haemophilia A (Severe) – Factor VIII<br>(F8) common 1/22 intron inversion   | HACD | A (Whole blood 10ml) <sup>40</sup> | 6 weeks  |
| Haemophilia B (Factor IX Deficiency)  | R90U | A (Whole blood 10ml) <sup>40</sup> | 12 weeks |
| Haemophilia B (Factor IX deficiency) – CVS  | 9CVS | CVS 40                             | 3 days   |
| Hearing Loss NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9                       | 6 weeks  |
| Hemophagocytic Lymphohistiocytosis, Familial  | R90U | AA                                 | 12 weeks |
| Hereditary Colorectal Cancer NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9,11                    | 4 weeks  |
| Hereditary Comprehensive Cancer NGS Panel<br>Requires patient informed consent.   | GENE | <b>A A</b> 9,11                    | 5 weeks  |
| Hereditary Neuropathy with Liability to Pressure Palsy – PMP22 deletion analysis Contact lab prior to sending. Referrals only from consultant neurologist or clinical geneticist. Genetic consent form required. Requires patient informed consent. | GENE | <b>A</b> 9                         | 6 weeks  |
| Hereditary Spastic Paraplegia<br>Comprehensive NGS Panel  | GENE | <b>A A</b> <sup>9</sup>            | 5 weeks  |
| Requires patient informed consent.  Hermansky-Pudlak Syndrome   | R90U | AA                                 | 12 weeks |
| HFE gene (Haemochromatosis) – common variants C282Y + H63D  | HMD  | <b>A</b> 9                         | 3 days   |
| Hirschprung Disease NGS Panel Requires patient informed consent.  | GENE | <b>A A</b> <sup>9</sup>            | 6 weeks  |
| HLA Tissue Typing A   | HLA  | <b>A</b> 9                         | 10 days  |
| HLA Tissue Typing A+B   | HLBA | <b>A</b> 9                         | 10 days  |
| HLA Tissue Typing A+B+C (Class I)   | HABC | <b>A</b> 9                         | 10 days  |
| HLA Tissue Typing A/B/DRB1/3/4/5  | HLAF | <b>A</b> 9                         | 10 days  |
| HLA Tissue Typing A/B/DRB1/3/4/5/DQB1   | HLF  | <b>A</b> 9                         | 10 days  |

| TEST  | CODE            | SAMPLE REQS             | TAT      |
|---|-----------------|-------------------------|----------|
| HLA Tissue Typing A/B/C/<br>DRB1/3/4/5/DQB1 (Class I & II)  | HLFC            | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing B   | HLB             | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing B*27 only   | HLAB            | <b>A</b> 9              | 3 days   |
| HLA Tissue Typing B*51 (Behcet's Disease)   | B51             | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing B*57:01 high resolution   | HL57            | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing C   | HLC             | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing Coeliac Disease – DQ2/DQ8   | Q2Q8            | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing DRB1/3/4/5  | DRB1            | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing DRB1/3/4/5/DQB1 (Class II)  | HLDQ            | <b>A</b> 9              | 10 days  |
| HLA Tissue Typing Narcolepsy – DQB1*06:02 Requires patient informed consent.  | GENE            | <b>A</b> 9              | 3 weeks  |
| Huntington Disease — HD gene repeat analysis PCR Contact lab prior to sending. Referrals only from consultant neurologist or clinical geneticist. Genetic consent form required. Requires patient informed consent. | GENE            | <b>A A</b> 9,11         | 5 weeks  |
| Hyperinsulinism NGS Panel Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 6 weeks  |
| Hyperparathyroidism – CASR sequencing Requires patient informed consent.  | GENE            | <b>A</b> 9              | 6 weeks  |
| Hypodysfibrinogenemia, Congenital Test code dependent on phenotype.   | R90U or<br>R97U | AA                      | 12 weeks |
| Hypoprothrombinemia   | R97U            | AA                      | 12 weeks |
| Identity Profile (DNA) – 15 STR markers   | DNAF            | <b>A</b> 9,11           | 10 days  |
| IDH1/2 screening assay Requires patient informed consent.   | GENE            | A                       | 48 hours |
| lgVH variant analysis for CLL   | IGMU            | A                       | 4 weeks  |
| Intellectual Disability NGS Panel Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 6 weeks  |
| Iron Overload Profile   | IOP             | <b>A B</b> 9            | 3 days   |
| JAK2 gene mutations – see Myeloproliferative Neo  | plasm NGS       | S Screening Panel       |          |
| Joubert/Meckel-Gruber Syndrome NGS Panel Requires patient informed consent.   | GENE            | A                       | 6 weeks  |
| Kallmann Syndrome NGS Panel Requires patient informed consent.  | GENE            | <b>A A</b> <sup>9</sup> | 6 weeks  |
| Kennedy Disease (Spinal Bulbar Muscular<br>Atrophy) – AR repeat expansion<br>Requires patient informed consent.   | GENE            | <b>A</b> 9              | 6 weeks  |

| TEST  | CODE          | SAMPLE REQS                                  | TAT        |
|---|---------------|--|------------|
| Kidney/Urinary Tract Comprehensive Cancer NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9,11                              | 4 weeks    |
| KRAS/NRAS screening assay Requires patient informed consent.  | MGP           | A  | 48 hours   |
| Lactose Intolerance Gene  | LACG          | A  | 2 weeks    |
| Langer-Giedion Syndrome –<br>BOBs (5 days) + karyotype (15 days)  | PBOB,<br>KARY | CVS / AF / (A) (1) 9                         | 5-15 days  |
| Langer-Giedion Syndrome – BOBs only   | PB0B          | CVS / AF / (A) 9                             | 5 days     |
| Leber's Hereditary Optic Neuropathy  – m.3460G>A + m.11778G>A + m.14484T>C common variants Requires patient informed consent. | GENE          | <b>A</b> 9                                   | 6 weeks    |
| Leukaemia (Rapid Acute) DNA and RNA NGS Panel Requires patient informed consent.  | ALRP          | (3mL minimum) or bone marrow aspirate sample | 3 days     |
| Leukaemia Fusion Gene Screening Assay (Q30)   | LMPX          | A  | 24 hours   |
| Leukaemia/Lymphoma RNA Sequencing<br>(Fusion Gene and SNV/Indel) Panel<br>Requires patient informed consent.                  | PHFP          | A  | 2 weeks    |
| Leukocyte Integrin Adhesion Deficiency  | R90U          | AA   | 12 weeks   |
| Li-Fraumeni Syndrome (p53-related cancer<br>predisposition) – TP53 sequencing + MLPA<br>Requires patient informed consent.    | GENE          | <b>A</b> 9,11                                | 6 weeks    |
| Limb-Girdle Muscular Dystrophy (LGMD) NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9                                 | 6 weeks    |
| Lissencephaly NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> <sup>9</sup>                      | 6 weeks    |
| Long QT Syndrome/Brugada Syndrome NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9                                 | 4-6 weeks  |
| <b>Lung Disorders NGS Panel</b> Requires patient informed consent.  | GENE          | <b>A A</b> 9                                 | 6 weeks    |
| Lynch Syndrome (HNPCC) NGS Panel NEW Requires patient informed consent.   | GENE          | <b>A</b> 9                                   | 4 weeks    |
| Lysosomal Storage Disorders NGS Panel – full gene sequencing Requires patient informed consent.                               | LSDS          | <b>A A</b> 9                                 | 4-6 weeks  |
| Macrothrombocytopenia   | R90U          | AA   | 12 weeks   |
| Male Genetic Reproductive Profile   | GRP           | <b>A ()</b> 9                                | 10-15 days |

| TEST  | CODE          | SAMPLE REQS             | TAT       |
|---|---------------|-------------------------|-----------|
| Marfan Syndrome – FBN1 sequencing<br>+ deletions/duplications<br>Requires patient informed consent.       | GENE          | <b>A</b> 9              | 6 weeks   |
| Marfan Syndrome and Aortic Aneurysm<br>and Dissection NGS Panel<br>Requires patient informed consent.     | GENE          | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Marfan Syndrome and Thoracic Aortic Aneurysm and Dissection NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Maturity-Onset Diabetes of the Young (MODY) Diabetes NGS Panel Requires patient informed consent.         | GENE          | Δ                       | 12 weeks  |
| Meckel-Gruber/Joubert Syndrome NGS Panel Requires patient informed consent.                               | GENE          | A                       | 6 weeks   |
| Medium-Chain Acyl-CoA Dehydrogenase Deficiency – ACADM sequencing Requires patient informed consent.      | GENE          | <b>A</b> 9              | 5 weeks   |
| Melanoma Comprehensive Cancer NGS Panel Requires patient informed consent.                                | GENE          | <b>A A</b> 9,11         | 4 weeks   |
| Microdeletion (common) Syndromes  – BOBs only   | PB0B          | CVS / AF / (A) 9        | 5 days    |
| Microphthalmia/Anophthalmia/ Coloboma NGS Panel Requires patient informed consent.                        | GENE          | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Miller-Dieker Syndrome – BOBs<br>(5 days) + karyotype (15 days)   | PBOB,<br>KARY | CVS / AF / (A) (1) 9    | 5-15 days |
| Miller-Dieker Syndrome – BOBs only  | PB0B          | CVS / AF / (A) 9        | 5 days    |
| Mitochondrial Genome Sequencing Requires patient informed consent.  | GENE          | <b>A</b> 9              | 6 weeks   |
| Motor Neurone Disease<br>(Amylotrophic Lateral Sclerosis) NGS Panel<br>Requires patient informed consent. | GENE          | <b>A A</b> <sup>9</sup> | 5 weeks   |
| MTHFR – common C677T + A1298C variants  | MTHF          | <b>A</b> 9              | 5 days    |
| Mucopolysaccharidosis NGS Panel<br>Requires patient informed consent.                                     | GENE          | <b>A A</b> <sup>9</sup> | 6 weeks   |
| Multiple Endocrine Neoplasia Type 1  - full MEN1 sequencing Requires patient informed consent.            | GENE          | <b>A</b> 9,11           | 7 weeks   |
| Multiple Endocrine Neoplasia Type 2  — RET gene hotspot sequencing Requires patient informed consent.     | GENE          | <b>A</b> 9,11           | 7 weeks   |

| TEST   | CODE | SAMPLE REQS                                  | TAT      |
|--|------|--|----------|
| Myeloid Gene Panel Requires patient informed consent.  | MVPS | (3mL minimum) or bone marrow aspirate sample | 2 weeks  |
| Myeloproliferative Neoplasm NGS Screening Panel NEW Requires patient informed consent.   | MPNS | (3mL minimum) or bone marrow aspirate sample | 1 week   |
| Myotonic Dystrophy Type 1 – DMPK repeat PCR Requires patient informed consent.   | GENE | <b>A</b> 9                                   | 5 weeks  |
| Myotonic Dystrophy Type 2 (PROMM)<br>– ZNF9 repeat PCR   | GENE | <b>A</b> 9                                   | 6 weeks  |
| Requires patient informed consent.   |      |  |          |
| Narcolepsy (HLA DQB1*06:02) Requires patient informed consent.   | GENE | <b>A</b> 9                                   | 3 weeks  |
| Nephrotic Syndrome,<br>Steroid-Resistant NGS Panel<br>Requires patient informed consent.   | GENE | <b>A A</b> <sup>9</sup>                      | 6 weeks  |
| Nervous System/Brain Cancer NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9,11                              | 4 weeks  |
| Neurofibromatosis Type 1 – NF1 + SPRED1 sequencing + deletions/duplications Contact lab prior to sending. Requires patient informed consent. | GENE | <b>A A</b> 9,11                              | 8 weeks  |
| Neuronal Ceroid Lipofuscinosis<br>(Batten Disease) NGS Panel<br>Requires patient informed consent.   | GENE | <b>A A</b> <sup>9</sup>                      | 6 weeks  |
| Non-Invasive Prenatal Testing (NIPT)  – common aneuploidy screening from maternal blood NEW  | NIPT | J / Special tube <sup>1</sup>                | 2-4 days |
| Noonan Syndrome and RASopathies NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9                                 | 6 weeks  |
| Nystagmus, X-linked Infantile –<br>FRMD7 gene sequencing<br>Requires patient informed consent.   | GENE | <b>A</b> 9                                   | 6 weeks  |
| Osteogenesis Imperfecta NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> <sup>9</sup>                      | 6 weeks  |
| Ovarian Cancer NGS Panel Requires patient informed consent.  | GENE | <b>A A</b> 9,11                              | 4 weeks  |
| p53-related cancer predisposition<br>(Li-Fraumeni Syndrome) –<br>TP53 sequencing + MLPA<br>Requires patient informed consent.                | GENE | <b>A</b> 9,11                                | 6 weeks  |
| Pancreatic Cancer NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9,11                              | 4 weeks  |
|  |      |  |          |

| TEST   | CODE          | SAMPLE REQS                                  | TAT                  |
|--|---------------|--|----------------------|
| Paraganglioma/Pheochromocytoma NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9,11                              | 4 weeks              |
| Paroxysmal Nocturnal Hemoglobinuria  | R97U          | AA   | 12 weeks             |
| Paternity Testing (postnatal and prenatal)  – sample required from each person being tested (3 people) Contact the genetics lab before sending the sample. | PATT          | A / AF /<br>CVS 1,12 Contact<br>Genetics lab | 5 days               |
| Pelizaeus-Merzbacher Disease –<br>PLP1 sequencing + deletions/duplications<br>Requires patient informed consent.   | GENE          | <b>A</b> 9                                   | 6 weeks              |
| Pendred Syndrome – SLC26A4 gene sequencing Requires patient informed consent.  | GENE          | <b>A</b> 9                                   | 6 weeks              |
| Periodic Fever/Autoinflammation NGS Panel Requires patient informed consent.   | GENE          | <b>A A</b> 9                                 | 6 weeks              |
| Peutz-Jegher Syndrome –<br>STK11 sequencing + deletions/duplications<br>Requires patient informed consent.   | GENE          | <b>A</b> 9                                   | 5 weeks              |
| Phelan-McDermid Syndrome –<br>karyotype + FISH   | KARY,<br>FISH | CVS / AF / 🕕 9                               | 12-17 days           |
| Pheochromocytoma/Paraganglioma NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9,11                              | 5 weeks              |
| Plasminogen Activator Inhibitor-1 Deficiency   | R97U          | AA   | 12 weeks             |
| Plasminogen Deficiency   | R97U          | AA   | 12 weeks             |
| Platelet-type Bleeding Disorder  | R90U          | AA   | 12 weeks             |
| POLG-Related Disorders – full POLG sequencing + deletions and duplications Requires patient informed consent.  | GENE          | <b>A</b> 9                                   | 6 weeks              |
| Polycystic Kidney NGS Panel Requires patient informed consent.   | GENE          | <b>A A</b> <sup>9</sup>                      | 6 weeks              |
| Pontocerebellar Hypoplasia NGS Panel<br>Requires patient informed consent.   | GENE          | <b>A A</b> 9                                 | 6 weeks              |
| Postnatal array CGH  | CGH           | <b>A H</b> <sup>9</sup>                      | 10 days              |
| Prader-Willi Syndrome<br>(Primary Screen) – methylation PCR  | PWAM          | <b>A</b> 9                                   | 10 days              |
| Prenatal array CGH   | CGH           | Amniotic fluid,<br>CVS or POC <sup>9</sup>   | 10 days              |
| Prenatal Diagnosis (BOBs + Culture)  | ABK or<br>CBK | AF / CVS <sup>9</sup>                        | 3-5 days,<br>15 days |
| Pre-Travel Screen (DVT)  | DVT1          | <b>A A B</b> <sup>9</sup>                    | 5 days               |
| Primary Ciliary Dyskinesia (PCD) NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> <sup>9</sup>                      | 6 weeks              |

| TEST  | CODE | SAMPLE REQS                          | TAT        |
|---|------|--------------------------------------|------------|
| Primary Hyperoxaluria NGS Panel Requires patient informed consent.  | GENE | A                                    | 7 weeks    |
| Products of Conception – rapid BOBs<br>aneuploidy diagnosis for all chromosomes<br>(10 days) + culture (25 days)              | PBK  | Placental Sample 1,9                 | 10-25 days |
| Products of Conception (BOBs + Culture)   | PBK  | Placental Sample 1,9                 | 10-25 days |
| Products of Conception BOBs only – rapid aneuploidy diagnosis for all chromosomes   | KB0B | Placental Sample or Solid Tissue 1,9 | 10 days    |
| Prostate Cancer NGS Panel Requires patient informed consent.  | GENE | <b>A A</b> 9,11                      | 4 weeks    |
| QF-PCR rapid common aneuploidy screen   | APC  | <b>AF</b> / <b>A</b> <sup>9</sup>    | 2 days     |
| Quebec Platelet Disorder  | R90U | AA                                   | 12 weeks   |
| Recurrent Miscarriage Profile (female)  | RMP  | <b>A A B C C C C C 1</b> 9,18        | 10-15 days |
| Renal Cysts and Diabetes (RCAD)  – HNF-1β sequencing exons 1-9 and dosage analysis by MLPA Requires patient informed consent. | GENE | <b>A</b> 9                           | 8 weeks    |
| Renal/Urinary Tract Cancer NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9,11                      | 4 weeks    |
| Retinoblastoma – RB1 sequencing + deletions/duplications Requires patient informed consent.                                   | GENE | <b>A A</b> 9,11                      | 6 weeks    |
| Rett Syndrome (MECP2 gene only)  – full sequencing + deletions/duplications Requires patient informed consent.                | GENE | <b>A</b> 9,11                        | 6 weeks    |
| Rett/Angelman Syndromes NGS Panel Requires patient informed consent.  | GENE | <b>A A</b> <sup>9</sup>              | 6 weeks    |
| Scott Syndrome  | R90U | AA                                   | 12 weeks   |
| Short-Chain Acyl-CoA Dehydrogenase Deficiency – ACADS sequencing Requires patient informed consent.                           | GENE | <b>A</b> 9                           | 6 weeks    |
| Short Stature – SHOX variant screening + deletions/duplications Requires patient informed consent.                            | GENE | <b>A</b> 9                           | 8 weeks    |
| Silver-Russell Syndrome – methylation studies on 11p15 imprinting domains KvDMR + H19 Requires patient informed consent.      | GENE | <b>A</b> 9                           | 7 weeks    |
| Sitosterolemia & Thrombocytopenia   | R90U | AA                                   | 12 weeks   |
| Skeletal Dysplasia NGS Panel Requires patient informed consent.   | GENE | <b>A A</b> 9                         | 6 weeks    |
|   |      |                                      |            |

| TEST  | CODE          | SAMPLE REQS                      | TAT       |
|---|---------------|----------------------------------|-----------|
| Smith-Lemli-Opitz Syndrome  | GENE          | <b>A</b> 9                       | 6 weeks   |
| - DHCR7 sequencing  |               |                                  |           |
| Requires patient informed consent.  | DDOD          |                                  |           |
| Smith-Magenis Syndrome –<br>BOBs (5 days) + karyotype (15 days)                   | PBOB,<br>KARY | CVS / AF / 🛕 🕕 9                 | 5-15 days |
|   |               | OVC / AF / 🔼 9                   | E dovo    |
| Smith-Magenis Syndrome – BoBs only  | PB0B          | CVS / AF / (A) 9                 | 5 days    |
| Sotos Syndrome (Cerebral Gigantism) –<br>NSD1 sequencing + deletions/duplications | GENE          | <b>A</b> 9                       | 6 weeks   |
| Requires patient informed consent.  |               |                                  |           |
| Spastic Paraplegia NGS Panel  | GENE          | <b>A A</b> 9                     | 6 weeks   |
| Requires patient informed consent.  |               |                                  |           |
| Spinal Bulbar Muscular Atrophy  | GENE          | <b>A</b> 9                       | 5 weeks   |
| (Kennedy Disease) – AR repeat analysis  |               |                                  |           |
| Requires patient informed consent.  Spinal Muscular Atrophy –                     | SMA           | <b>A</b> 9                       | 10 days   |
| SMN1 deletions/duplications   | SIVIA         |                                  | 10 days   |
| Spinocerebellar Ataxia – multiplex  | GENE          | <b>A</b> 9                       | 5 weeks   |
| SCA1+2+3+6+7+17 common repeat expansions  |               |                                  |           |
| Requires patient informed consent.  |               |                                  |           |
| Spinocerebellar Ataxia NGS Panel  | GENE          | <b>A A</b> <sup>9</sup>          | 6 weeks   |
| SRY (Sex-determining Region Y)  | SRY           | <b>A</b> 9                       | 2 days    |
| Stormorken Syndrome   | R90U          | AA                               | 12 weeks  |
| Systemic mastocystosis –  | GENE          | <b>A</b> 9                       | 4 weeks   |
| C-Kit common variants (KIT D816V)   |               |                                  |           |
| Requires patient informed consent.  | TCRA          | A or FEDE                        | 2 weeks   |
| T cell clonality assay<br>(TCR beta and TCR gamma)                                | IUNA          | A or FFPE                        | 2 WEEKS   |
| Takenouchi-Kosaki Syndrome  | R90U          | AA                               | 12 weeks  |
| Tay Sachs Screen  | GENE          | <b>A</b> 9                       | 4 weeks   |
| See also Carrier Screen (Ashkenazi Jewish/Pan-Ethnic).                            | GLINL         |                                  | 4 WGGN3   |
| Requires patient informed consent.  |               |                                  |           |
| Thrombophilia   | R97U          | AA                               | 12 weeks  |
| Thrombophilia due to Activated<br>Protein C Resistance                            | R97U          | AA                               | 12 weeks  |
|   | DOZU          | <b>0</b> 0 0 0 0                 | 40        |
| Thrombophilia due to<br>Antithrombin III Deficiency                               | R97U          | (Whole Blood 10ml) <sup>40</sup> | 12 weeks  |
| Thrombophilia due to Heparin  |               |                                  | 12 weeks  |
| Cofactor II Deficiency  | R97U          | AA                               | 12 weeks  |
| · · · · · · · · · · · · · · · · · · ·   | R97U<br>R97U  | <b>AA</b>                        | 12 weeks  |
| Cofactor II Deficiency Thrombophilia due to Histidine-rich                        |               |                                  |           |

| TEST   | CODE          | SAMPLE REQS                        | TAT       |
|--|---------------|------------------------------------|-----------|
| Thrombophilia due to Protein S Deficiency  | R97U          | AA                                 | 12 weeks  |
| Thrombophilia due to Thrombomodulin Defect   | R97U          | AA                                 | 12 weeks  |
| Thrombosis Gene Panel  | R97U          | AA                                 | 12 weeks  |
| Requires patient informed consent.   |               |                                    |           |
| Thrombotic Risk Profile  | PROP          | <b>A A B C C C 1</b> 8             | 5 days    |
| Thrombotic Thrombocytopenic<br>Purpura, Hereditary   | R97U          | AA                                 | 12 weeks  |
| Thyroid Cancer NGS Panel   | GENE          | <b>A A</b> 9,11                    | 4 weeks   |
| Requires patient informed consent.   |               |                                    |           |
| Treacher Collins Syndrome and Related Disorders NGS Panel Requires patient informed consent.             | GENE          | <b>A A</b> 9                       | 6 weeks   |
| Tuberous Sclerosis (TSC1 + TSC2) Requires patient informed consent.                                      | GENE          | <b>A A</b> 9                       | 7 weeks   |
| Urinary Tract/Renal Cancer NGS Panel Requires patient informed consent.                                  | GENE          | <b>A A</b> 9,11                    | 4 weeks   |
| Usher Syndrome NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9                       | 6 weeks   |
| Very Long-Chain Acyl-CoA Dehydrogenase Deficiency – ACADVL sequencing Requires patient informed consent. | GENE          | <b>A</b> 9                         | 6 weeks   |
| Von Hippel-Lindau Syndrome – VHL sequencing + deletions/duplications Requires patient informed consent.  | GENE          | <b>A</b> 9                         | 6 weeks   |
| Von Willebrands Disease  | R90U          | A (Whole blood 10ml) <sup>40</sup> | 12 weeks  |
| Wiskott-Aldrich Syndrome   | R90U          | AA                                 | 12 weeks  |
| Wolf-Hirschhorn Syndrome –<br>BOBs (5 days) + karyotype (15 days)  | PBOB,<br>KARY | CVS / AF / (A) (H) 9               | 5-15 days |
| Wolf-Hirschhorn Syndrome – BOBs only   | PB0B          | CVS / AF / (A) 9                   | 5 days    |
| Y chromosome microdeletions –<br>AZFa + AZFb + AZFc + SRY  | YDEL          | <b>A</b> 9                         | 5 days    |
| Zellweger Syndrome NGS Panel Requires patient informed consent.  | GENE          | <b>A A</b> 9                       | 6 weeks   |
| Zygosity testing – comparative DNA profile   | DNAC          | (From each twin and both parents)9 | 5 days    |

# Carrier Screen (Ashkenazi Jewish)

This test is optimised for individuals and couples of Ashkenazi Jewish ancestry.\*\*

Uses the same technology as the Pan-Ethnic Carrier Screen.

\*\*Male patients will not be screened for X-linked conditions (e.g., FMR1, etc.). Requires patient informed consent.

#### TAT: 4 weeks

#### **GENE**



# Carrier Screen (Pan-Ethnic)

Targets 400+ Autosomal Recessive and X-linked Inherited Disorders\*\*

\*\* Male patients will not be screened for X-linked conditions (e.g., FMR1, etc.). Requires patient informed consent.

#### TAT: 4 weeks

**GENE** 



### **DVT/Pre-travel Screen**

FBC

Factor II Prothrombin Gene Factor V Leiden Anticardiolipin Antibodies

## TAT: 5 days

DVT1



## **Iron Overload Profile**

Iron (TIBC included) Ferritin

Transferrin Saturation Haemochromatosis C282Y, H63D

#### TAT: 3 days

IOP



# Male Genetic Reproductive Profile

Chromosome Analysis Y-Chromosome Microdeletions Cystic Fibrosis Carrier Screen (139 common variants) PolyT (5T,7T,9T) if clinically indicated

#### **TAT: 10-15 days**

**GRP** 



# Products of Conception (BOBs + Culture)

Rapid Aneuploidy Diagnosis for all Chromosomes by BOBs Analysis (10 days), Chromosome Analysis (Karyotype) (25 days)

#### **TAT: 10-25 days**

**PBK** 

Placental Sample 1,9

# Recurrent Miscarriage Profile (female)

FBC

Coagulation Profile
Antithrombin III

Factor V Leiden Common Variant Factor II Prothrombin

Common Variant

MTHER Common Variants

Fibrinogen

Lupus Anticoagulant

Protein C

Free Protein S Ag

Anticardiolipin Abs Chromosome Analysis

Please request Partner's

Chromosome Analysis using a separate request form.

## **TAT: 10-15 days**

**RMP** 



## **Thrombotic Risk Profile**

FBC

Coagulation Profile
Antithrombin III
Factor V Leiden Common Variant
Factor II Prothrombin
Common Variant
MTHFR Common Variants
Lupus Anticoagulant
Protein C
Free Protein S Ag

## TAT: 5 days

Anticardiolipin Abs

PR<sub>OP</sub>



# Leukaemia (Rapid Acute) DNA and RNA NGS Panel / Myeloproliferative Neoplasm NGS Screening Panel

#### **NEW**

This NGS assay allows for rapid generation of comprehensive profile of variants (both DNA and RNA) from a single NGS run. This assay can profile both DNA and RNA targets including DNA mutations and translocations detected from RNA targets and allows for simultaneous interrogation of 45 DNA target genes and 30 RNA fusion driver genes. The broad fusion panel enables sequencing of over 700 unique fusion transcripts. The panel covers relevant targets for acute myeloid leukaemia, myelodyplastic syndromes and myeoproliferative neoplasms, including CML, CMML and JMML.

TAT: 3 days / 1 week

ALRP (DNA & RNA)

MPNS (DNA)

(3mL minimum) or bone marrow aspirate sample

# Leukaemia/Lymphoma RNA Sequencing (Fusion Gene and SNV/Indel) Panel

The Leukaemia / Lymphoma RNA Sequencing panel is an Anchored Multiplex PCR (AMP™)-based next-generation sequencing (NGS) panel to detect and identify fusions, point mutations and expression levels from ribonucleic acid (RNA) input. The panel encompasses targets in over 199 genes relating to lymphoid and myeloid malignancies. By using gene-specific primers to amplify into molecular barcodes ligated onto the cDNA fragment ends, both known and novel fusions can be identified. Requires patient informed consent.

TAT: 2 weeks

**PHFP** 



# Lysosomal Storage Disorders NGS Panel – full gene sequencing

This is a 55 gene custom NGS panel which can be used to detect both pathogenic SNP/ Indels and copy number variants (including whole exon insertions / deletions) which cause the various Lysosomal storage disorders.

All known lysosomal storage diseases are covered on this panel including:

Fabry disease, Gaucher disease, Pompe disease, metachromatic leukodystrophy, all the different mucopolysaccharidoses, fucosidosis, Krabbe disease, Tay-Sachs disease, Sandhoff disease, Danon disease, Iysosomal acid lipase deficiency, Niemann-Pick disease types A, B and C, lipfuscinoses, prosaposin deficiency and Salla disease.

Requires patient informed consent.

TAT: 4-6 weeks

LSDS

**A A** 9

# **Myeloid Gene Panel**

This is a 75 gene targeted NGS panel for acute myeloid leukaemia, myeloproliferative neoplasms, myelodysplastic syndromes, and also contains a number of targets which are useful for lymphoid malignancies (ALL and lymphoma). It uses Anchored Multiplex PCR (AMPTM) chemistry which enables deep strand-specific amplification of molecular barcoded DNA fragments for sequencing. Requires patient informed consent.

TAT: 2 weeks

**MVPS** 

(3mL minimum) or bone marrow aspirate sample

# **Array CGH testing**

Chromosome abnormalities can be associated with developmental delay, autism spectrum disorder, learning difficulties, dysmorphic features and other congenital abnormalities.

Array CGH can detect smaller genetic changes than is possible by conventional karyotyping, and can provide accurate information on the size and possible consequences of the gains (duplications) or losses (deletions) identified. Multiple studies have shown that Array CGH, when applied to appropriate patients, will detect up to three times more pathogenic chromosome imbalances than karyotyping due to its greater precision and sensitivity.

Array CGH testing is now considered to be the front line test for patients presenting with developmental delay (motor or growth), autism spectrum disorder, moderate to severe learning difficulties, dysmorphic features, with or without congenital abnormalities. Consortiums in the USA and many EU countries have adopted Array CGH as the front line test in this patient cohort.

Array CGH is now more frequently used for prenatal studies as an adjunct or replacement for conventional cytogenetic studies, particularly where structural fetal abnormalities are seen at ultrasound scan but also at a patient's or doctor's request. The technique may also be utilised as a follow up test to characterise anomalies detected by a previous study (e.g. an apparently balanced de novo rearrangement or marker chromosome).

Further information is provided by the UNIQUE website at www.rarechromo.org

## When to use Array CGH

In postnatal cases, patients should present with one or more of the following:

- Mental retardation
- Developmental delay
- Autism/autism spectrum disorder
- Dysmorphic features
- Congenital malformations

In prenatal cases, patients may present with:

 Abnormalities or increased nuchal translucency on ultrasound scan which may be associated with a chromosome imbalance.

Approximately 10-20% of results identify extra or missing DNA which may or may not be relevant to the clinical phenotype, and will require further family studies to assist with interpretation.

## What can Array CGH detect?

Deletions and duplications with greater sensitivity than conventional karyotyping.

# What does Array CGH not detect?

- Balanced chromosome rearrangements such as translocations or inversions.
   The chromosome location of duplications (this would require additional FISH testing).
- Low frequency mosaicism (<30% abnormal cells), some types of polyploidy like triploidy, Uniparental disomy (UPD) and Fragile X syndrome, imprinting defects, genetic diseases caused by point mutations or multifactorial inheritance.

| Prenatal array CGH         | CGH              | Amniotic fluid, CVS or POC 9          | 10 days         |
|----------------------------|------------------|---------------------------------------|-----------------|
| TEST                       | CODE             | SAMPLE REQS                           | TAT             |
| Blood from both parents ma | ay also be provi | ded in case of follow up studies at n | o extra charge. |
| Postnatal array CGH        | CGH              | <b>A (1)</b> 9                        | 10 days         |
| TEST                       | CODE             | SAMPLE REQS                           | TAT             |

EDTA and heparin blood from both parents should be provided at the time of prenatal sampling, if possible, in case of follow up studies at no extra charge.

# Pan-ethnic carrier screening

The Fulgent Beacon carrier panel is a comprehensive genetic screen for people of all ethnic backgrounds. The panel analyses more than 400 genes, in which mutations may cause over 440 different recessive disorders. Testing includes Cystic Fibrosis, Sickle Cell Disease, Thalassemia and Spinal Muscular Atrophy. These conditions vary in morbidity, mortality and treatment.

The Beacon carrier screen can also be filtered to report only on diseases common to the Jewish population – such as Bloom Syndrome, Canavan Disease, Gaucher Syndrome and Tay-Sachs Disease.

## Indications for use

- Pre-pregnancy screening for couples that wish to check if they are silent carriers for a disease that would have serious implications for the future health of any children.
- For patients who are concerned about a family history of a particular disease, where common mutation detections are very high – such as Tay-Sachs Disease.

The report comes with a synopsis of any diseases for which a mutation was found, including prognosis, treatment and mode of inheritance. It includes a risk assessment and recommendations for further testing.


A full list of diseases covered by this test is available from the laboratory.

Male patients will not be screened for X-linked conditions. If an X-linked condition is suspected in a male patient please contact the laboratory or a genetics specialist about diagnostic testing for that particular condition.

#### Limitations

A normal result does not rule out the possibility that the patient carries a rare mutation not detectible by this particular assay. For this reason, this test is also not appropriate to use as a direct prenatal screen (both parents must be confirmed carriers for a particular disease before we can offer prenatal diagnosis). Screening is not designed to detect somatic mutations.

| TEST  | CODE | SAMPLE REQS | TAT     |
|---|------|-------------|---------|
| Carrier Screen (Ashkenazi Jewish) Requires patient informed consent.  | GENE | <b>A</b> 9  | 4 weeks |
| Carrier Screen (Ashkenazi Jewish)  - Partnered Report  Requires patient informed consent. Please contact  | GENE | <b>A</b> 9  | 4 weeks |
| the lab for special requirements before sending.  Carrier Screen (Pan-Ethnic)   | GENE | <b>A</b> 9  | 4 weeks |
| Requires patient informed consent.  | CENE | <b>A</b> 9  | 4 wooko |
| Carrier Screen (Pan-Ethnic) – Partnered Report Requires patient informed consent. Please contact the lab for special requirements before sending. | GENE | <b>A</b> 9  | 4 weeks |



# Non-invasive prenatal testing (NIPT)

Non-invasive prenatal testing (NIPT) screens for the presence of specific chromosome disorders in the developing fetus. The test analyses fragments of cell-free DNA in maternal plasma that have been released from both maternal and placental cells.

By analysing the proportions of cell-free DNA fragments derived from different chromosomes or chromosome regions, NIPT can screen for the presence or absence of specific chromosome disorders.

NIPT is more accurate than first trimester maternal serum screening and ultrasound in identifying pregnancies with or without these disorders.

TDL Genetics uses the NIPT assay VeriSeq NIPT Solution v2, which is manufactured by Illumina and is processed at our laboratory in London.

# Targeted screening for specific common chromosome disorders

Our NIPT assay is designed to screen for:

 Trisomy 21 (Down syndrome), which is associated with moderate to severe intellectual disability, congenital heart defects and other malformations;

- Trisomy 18 (Edwards syndrome) and trisomy 13 (Patau syndrome), which are associated with severe brain and cardiac malformations. There is a high risk of stillbirth or death during infancy; and
- Sex chromosome aneuploidy (abnormalities in the number of X or Y chromosomes), which can be associated with malformations and infertility, Turner syndrome (45,X) and Klinefelter syndrome (47,XXY). Triple X syndrome and XYY syndrome can also be detected. This screen is optional (no additional cost).

In addition, NIPT can also assess fetal sex. This is optional (no additional cost).

NIPT does not screen for non-chromosome disorders, familial mutations, malformations, fetal growth or fetal viability.

# **Accuracy of NIPT**

NIPT provides fewer false-positive and false-negative results than combined first trimester screening for trisomy 21, 18 and 13.

It is important to note that NIPT is a screening test and does not provide a definitive genetic diagnosis, as NIPT cannot differentiate potential chromosome differences between the placenta and fetus.

A definitive genetic diagnosis of the fetus requires cytogenetic analysis of either amniotic fluid or chorionic villus sampling (CVS).

## When to perform NIPT

NIPT should not be performed before a gestational age of 10 weeks. However, it is suitable at any time after that, preferably while there is sufficient time for further investigation or decision-making (should this be required). An ultrasound scan is required prior to NIPT to confirm dates and fetal viability, and to check for twins. Performing first trimester screening before NIPT may provide supplementary information regarding the status of the fetus.

## Who is eligible for NIPT?

Eligible patients:

- Women who are at least ten weeks pregnant
- Women with singleton or twin pregnancies
- Women with IVF pregnancies and non-IVF pregnancies

NIPT is not suitable for patients with:

- Recent maternal blood transfusion (within the last 4 months)
- Maternal mosaicism
- Maternal prior organ transplant/stem cell transplant
- Maternal copy number variations
- Chromosomal copy number variations
- Fetoplacental mosaicism/confined placental mosaicism
- Maternal autoimmune disease excluding IVIg treatments
- Maternal neoplasms (benign and malignant)
- Pregnancies with fetal demise/vanishing twin

Patients with a twin pregnancy are not eligible for the sex chromosome aneuploidy component of the screen.

## **Reporting results**

Results will be ready within 2–4 business days upon receipt of sample in the laboratory.

TDL first checks that there is sufficient cell-free fetal DNA in the maternal sample and quality data to provide an accurate assessment. A re-collection may be recommended if the sample is not suitable or an assessment may not be feasible.

The report then summarises the screening assessment for each disorder specified by the requesting doctor (see example below).

### **Example report**

| Chromosome                | Result                    | Recommendation                             |
|---------------------------|---------------------------|--|
| Trisomy 21                | HIGH<br>Probability       | Genetic counselling and additional testing |
| Trisomy 18                | Low probability <1:10,000 | Review result with patient                 |
| Trisomy 13                | Low probability <1:10,000 | Review result with patient                 |
| Sex chromosome aneuploidy | Not requested             |  |
| Fetal sex                 | Male                      | Review result with patient                 |

A high probability NIPT result should always be confirmed by amniocentesis or CVS before making any decision regarding subsequent management of the pregnancy.

#### **Limitations of NIPT**

The VeriSeq NIPT Solution v2 is not validated for use in pregnancies with more than two fetuses, fetal demise, mosaicism, partial chromosome aneuploidy, triploidy, translocations, maternal aneuploidy, transplant or malignancy. VeriSeq NIPT Solution v2 does not detect neural tube defects. Certain rare biological conditions may also affect the accuracy of the test.

For twin pregnancies, HIGH PROBABILITY test results apply to at least one fetus; male test results apply to one or both fetuses; female test results apply to both fetuses. Due to the limitations of the test, inaccurate results are possible.

A LOW PROBABILITY result does not guarantee that a fetus is unaffected by a chromosomal or genetic condition. Some non-aneuploid fetuses may have HIGH PROBABILITY results. In cases of HIGH PROBABILITY results and/or other clinical indications of a chromosomal condition, confirmatory testing is necessary for diagnosis.

## If an assessment cannot be provided

On rare occasions, NIPT is unable to provide an assessment of the probability of specific chromosome disorders. This usually reflects the complex biology of genetics and pregnancy, and is not due to a failing in the laboratory.

If NIPT cannot provide a specific assessment after a repeat blood draw, it is not worth repeating the NIPT (unless advised by the laboratory). A decision about other tests (maternal serum screening, detailed ultrasound, amniocentesis or CVS) should be based on the doctor's assessment of all risk factors identified, and may require specialist consultation.

#### **Further information**

- TDL Genetics website: www.tdlpathology.com/tdlgenetics
- Borth H, et al. Analysis of cell-free DNA in a consecutive series of 13,607 routine cases for the detection of fetal chromosomal aneuploidies in a single center in Germany. Arch Gynecol Obstet. 2021 Jun;303(6):1407-1414.



SCAN ME

Find out more about NIPT on the TDL website:

www.tdlpathology.com/noninvasive-prenatal-testing/

| TEST | CODE | SAMPLE REQS | TAT |
|------|------|-------------|-----|
|      |      |             |     |

NIPT

Non-Invasive Prenatal Testing (NIPT)

- common aneuploidy screening
from maternal blood NEW

# **In-vivo** Tests

All *in-vivo* tests (except Glucose Challenge Test/Mini-GTT) require an appointment. Please email **phlebotomy@tdlpathology.com** or call **020 7307 7373** for details, information for patient preparation, and appointment times. Sample taking fees for Extended tests are charged at £90.00 per visit.

## **Extended Testing**

- 50g liquid glucose is consumed for the glucose challenge test/Mini-GTT.
- 75g liquid glucose is consumed for all other glucose tests.
- Each sample tube must be labelled with time of collection.

## **Glucose tolerance tests**

| TEST                                      | CODE          | SAMPLE REQS                            | TAT   | COLLECTION TIME<br>(MINUTES POST-GLUCOSE)           |
|---|---------------|--|-------|---|
| Glucose Challenge Test/Mini-GTT           | RBGM          | G                                      | 1 day | 1 at 60 mins (50gm glucose)                         |
| Glucose Tolerance Test<br>(Extended Plus) | GTTX          | 7 x <b>(3</b> , 7 x <b>RU</b>          | 1 day | 1 each at 0, 30, 60, 90, 120, 150 and 180 mins      |
| Glucose Tolerance Test (Extended)         | GTTE          | 5 x <b>G</b> , 5 x <b>RU</b>           | 1 day | 1 each at 0, 30, 60,<br>90 and 120 mins             |
| Glucose Tolerance Test (Short)            | GTTS          | 2 x 📵 , 2 x RU                         | 1 day | 1 each at 0 and 120 mins.                           |
| Glucose Tolerance Test/OGTT               | GTT           | 3 x 🕒 , 3 x RU                         | 1 day | 1 each at 0, 60 and 120<br>mins (75gm glucose load) |
| Glucose Tolerance with<br>Growth Hormone  | GTT +<br>GHDF | 3 x B <sup>35</sup> ,<br>3 x G, 3 x RU | 1 day | 1 each at 0, 60 and 120 mins.                       |
| Glucose Tolerance with Insulin            | GTTI          | 3 x B, 3 x G,<br>3 x RU                | 1 day | 1 each at 0, 60 and 120 mins                        |

## **Extended tests**

| TEST                       | CODE | SAMPLE REQS         | TAT   | COLLECTION TIME<br>(MINUTES POST-GLUCOSE) |
|----------------------------|------|---------------------|-------|---|
| Lactose Tolerance Test     | LTT  | By appointment only | 1 day | Contact 020 7307 7383<br>(Phlebotomy)     |
| Synacthen Stimulation Test | SYNA | By appointment only | 1 day | Contact 020 7307 7383<br>(Phlebotomy)     |

# **Antibiotic assays**

| TEST  | CODE | SAMPLE REQS | TAT     |
|---|------|-------------|---------|
| Amikacin Level (State dose)                 | AMIK | <b>B</b> 4  | 4 hours |
| Gentamicin Assay                            | GENT | <b>B</b> 4  | 4 hours |
| Metronidazole Level                         | METR | <b>B</b> 4  | 7 days  |
| Teicoplanin Assay                           | TEIC | B           | 5 days  |
| Tobramycin Assay (Provide Clinical Details) | TOBR | B           | 3 days  |
| Vancomycin Hydrochloride                    | VANC | В           | 4 hours |
|   |      |             |         |

# **Therapeutic Drug Assays**

There are three different collection times for Therapeutic Drug Monitoring:

- Trough Level: Blood should be collected just before the next dose.
   Trough Levels check that the appropriate drug concentration is being maintained.
- Peak Levels: Sample collection time is dependent on specific drug type and method of administration. Peak levels check that the drug level is not in the toxic range.
- Suspected Toxicity: Blood can be collected any time.

All collections should have the following noted on the request form:

- Dosage schedule including the amount and frequency and time of the last dose
- Time of specimen collection
- Clinical status of patient (e.g. routine, suspected toxicity)
- Name(s) of other drugs being taken by the patient

| TEST                               | CODE | SAMPLE REQS | TAT      |
|------------------------------------|------|-------------|----------|
| Amitriptyline                      | AMTR | <b>A</b> 4  | 5 days   |
| Anafranil (Clomipramine)           | CHLO | A           | 7 days   |
| Carbamazepine (Tegretol)           | CARB | B           | 4 hours  |
| Clobazam                           | CLOB | A           | 5 days   |
| Clomipramine (Anafranil)           | CHLO | A           | 7 days   |
| Clonazepam                         | CLON | A           | 7 days   |
| Diazepam (Valium)                  | DIAZ | A           | 7 days   |
| Digoxin                            | DIGO | B           | 4 hours  |
| Epanutin (Phenytoin)               | PHEN | В           | 4 hours  |
| Erythropoietin                     | ERY  | B           | 4 days   |
| Ethosuximide                       | ETH0 | A           | 7 days   |
| FK506 (Tacrolimus/Prograf)         | FK5  | <b>A</b> 4  | 1-2 days |
| Flecainide (Tambocor)              | FLEC | A           | 5 days   |
| Fluoxetine (Prozac)                | PROZ | <b>A</b> 4  | 5 days   |
| Gabapentin                         | GABA | <b>B</b> 4  | 5 days   |
| Imipramine                         | IMIP | <b>A</b> 4  | 4 days   |
| Lamotrigine                        | LAM0 | <b>B</b> 4  | 5 days   |
| Levetiracetam (Keppra)             | LEVE | <b>B</b> 4  | 3 days   |
| Lithium (take 12 hours after dose) | LITH | B           | 4 hours  |
| Lorazepam                          | LORA | <b>A</b> 4  | 10 days  |
| Methotrexate                       | METX | B           | 2 days   |
| Mycophenolic Acid (Cellcept)       | MYCP | A           | 5 days   |
| Mysoline (Primidone)               | PRIM | <b>B</b> 4  | 3 days   |

# **Therapeutic Drug Assays**

| Dianzapine<br>Paracetamol | OLAN<br>PARA | <b>A</b> 4 | 5 days   |
|---------------------------|--------------|------------|----------|
| Paracetamol               |              |            |          |
|                           |              | B          | 4 hours  |
| Phenobarbitone            | PHB          | <b>B</b>   | 4 hours  |
| Phenytoin (Epanutin)      | PHEN         | B          | 4 hours  |
| Primidone (Mysoline)      | PRIM         | <b>B</b> 4 | 3 days   |
| Propanalol                | PR0          | <b>B</b> 4 | 7 days   |
| Risperidone               | RISP         | <b>A</b> 4 | 7 days   |
| Sinequan (Doxepin)        | DOXE         | A          | 10 days  |
| Sirolimus                 | SIR0         | A          | 3 days   |
| Streptomycin Levels       | STRM         | 6          | 5 days   |
| Sulpiride                 | SULP         | <b>B</b> 4 | 4 days   |
| acrolimus/Prograf (FK506) | FK5          | <b>A</b> 4 | 1-2 days |
| egretol (Carbamazepine)   | CARB         | <b>B</b>   | 4 hours  |
| Temazepam                 | TEMA         | <b>B</b> 4 | 4 days   |
| Theophylline              | THE0         | B          | 4 hours  |
| opiramate (Topamax)       | TOPI         | <b>B</b> 4 | 4 days   |
| rimipramine               | TRIM         | A          | 5 days   |
| /alium (Diazepam)         | DIAZ         | A          | 7 days   |
| /alproic Acid (Epilim)    | VALP         | B          | 4 hours  |
| /igabatrin (Sabril)       | VIGA         | A          | 10 days  |

# **Allergy**

For a list of individual allergens see page 145.

| TEST  | CODE | SAMPLE REQS              | TAT      |
|---|------|--------------------------|----------|
| Allergy – Individual Allergens  | ALLE | B                        | 2 days   |
| Allergy – 5 x Single Individual Allergens   | 5AL  | B                        | 2 days   |
| Allergy – 10 x Single Individual Allergens  | 10AL | B                        | 2 days   |
| Allergy Profile 1 (Food & Inhalants)  | 1A   | BB                       | 2 days   |
| Allergy Profile 2 (UK Aero Allergen)  | 2A   | В                        | 2 days   |
| Allergy Profile 3 (Food)  | 3A   | B                        | 2 days   |
| Allergy Profile 4 (Nuts & Seeds)  | 4A   | B                        | 2 days   |
| Allergy Profile 5 (Children's Panel)  | 5A   | B                        | 2 days   |
| Allergy Profile 6 (Shellfish)   | 6A   | B                        | 2 days   |
| Allergy Profile 7 (Finfish)   | 7A   | B                        | 2 days   |
| Allergy Profile 8 (Cereal – singles)  | 8A   | B                        | 2 days   |
| Allergy Profile 9 (Antibiotics)   | 9A   | В                        | 2 days   |
| Allergy Profile 10 (Insects)  | 10A  | B                        | 2 days   |
| Allergy Profile 11 (Combined Shellfish/Finfish)   | 11A  | B                        | 2 days   |
| Allergy Profile 12 (Milk & Milk Proteins)   | 12A  | B                        | 2 days   |
| Allergy Profile 13 (Stone fruit/Rosaceae family)  | 13A  | B                        | 2 days   |
| ALEX <sup>2</sup> Allergy Test (Venous/Self-collect) 300 allergen panel, from single sample, supplemented by Total IgE, which includes pollens, mites, cat and dog, fur, insect venoms, moulds, yeasts, food and latex. | ALEX | B (Serum) / B (TDL Tiny) | 3-4 days |
| ISAC Panel (Venous/Self-collect) 112 allergen panel from single sample which includes components from 48 preselected allergen sources   | ISAC | B (TDL Tiny)             | 3 days   |
| Atopic Dermatitis/Eczema Profile (14 allergens)   | ALEC | B                        | 2 days   |
| Gluten Sensitivity Profile CHANGE   | GLUT | ABB                      | 10 days  |
| Allergic Rhinitis/Asthma Profile  | ALRN | B                        | 2 days   |
| Histamine Releasing Urticaria Test  | CURT | B                        | 3 weeks  |
| Prealbumin  | PALB | В                        | 3 days   |
| Total IgE   | IGE  | В                        | 1 day    |
| Tryptase  | STRY | В                        | 2 days   |
|   |      |                          |          |

## **Allergy**

# **Component testing**

Using ImmunoCAP Allergen Components can help refine the understanding of sensitisation, by assessing a person's sensitisation pattern at the molecular level. When used in conjunction with traditional extract-based IgE testing, these provide information at the individual component level.

For more information, please contact the Immunology Department on **020 7025 7917**.



SCAN ME

Find out more details about component testing:

www.tdlpathology.com/ specialties/allergy/ allergy-component-testing/

| TEST                                       | CODE | SAMPLE REQS | TAT    |
|--|------|-------------|--------|
| Alpha Gal Components (related to red meat) | ZZ37 | B           | 2 days |
| Alternaria Components                      | ZZ1  | B           | 2 days |
| Apple Components                           | ZZ36 | B           | 2 days |
| Aspergillus Components                     | ZZ2  | B           | 2 days |
| Birch Components                           | ZZ3  | B           | 2 days |
| Brazil Components                          | ZZ4  | B           | 2 days |
| Cashew Components                          | ZZ35 | B           | 2 days |
| Cat Components                             | ZZ5  | B           | 2 days |
| Celery Components                          | ZZ6  | B           | 2 days |
| Cow's Milk Components                      | ZZ7  | B           | 2 days |
| Dog Components                             | ZZ8  | B           | 2 days |
| Egg Components                             | ZZ9  | B           | 2 days |
| Fish Components                            | ZZ10 | B           | 2 days |
| Glycan Determinants                        | ZZ27 | B           | 2 days |
| Hazelnut Components                        | ZZ11 | B           | 2 days |
| Horse Components                           | ZZ38 | B           | 2 days |
| House Dust Mite Components                 | ZZ12 | B           | 2 days |
| Kiwi Components                            | ZZ32 | B           | 2 days |
| Latex Components                           | ZZ13 | B           | 2 days |
| Lipid Transfer Proteins                    | ZZ23 | B           | 2 days |
| Lipocalins                                 | ZZ28 | B           | 2 days |
| Olive Components                           | ZZ14 | В           | 2 days |
| Parvalbumins                               | ZZ29 | В           | 2 days |
| Peach Components                           | ZZ15 | В           | 2 days |
| Peanut Components                          | ZZ16 | B           | 2 days |
|  |      |             |        |

# **Allergy**

| TEST                      | CODE | SAMPLE REQS | TAT    |
|---------------------------|------|-------------|--------|
| Polcalcins                | ZZ25 | B           | 2 days |
| PR-10 Proteins            | ZZ22 | B           | 2 days |
| Profilins                 | ZZ24 | B           | 2 days |
| Seed Storage Proteins     | ZZ26 | B           | 2 days |
| Serum Albumins            | ZZ30 | B           | 2 days |
| Sesame Components         | ZZ39 | B           | 2 days |
| Shrimp Components         | ZZ17 | B           | 2 days |
| Soybean Components        | ZZ18 | B           | 2 days |
| Timothy Grass Components  | ZZ19 | B           | 2 days |
| Tropomyosins              | ZZ31 | B           | 2 days |
| Venom Components          | ZZ33 | B           | 2 days |
| Wall Pellitory Components | ZZ20 | B           | 2 days |
| Walnut Components         | ZZ34 | B           | 2 days |
| Wheat Components          | ZZ21 | В           | 2 days |
|                           |      |             |        |

# **Allergy Profile 1 (Food & Inhalants)**

Total IgE with individual IgE allergens for: Grass Mix, inc.: Cocksfoot, Meadow fescue, Meadow, Rye, Timothy Weed Mix, inc.: Common ragweed, Giant ragweed, Western ragweed Dust Mix, inc.: Blatella germanica, Dermatophagoides pteronyssinus.

Dermatophagoides farinae, Hollister-Stier Labs

**Mould Mix**, inc.: A. alternata, Aspergillus fumigatus, Candida albicans, Cladosporium herbarum, Helminthosporium halodes, Penicillium notatum

**Tree Mix**, inc.: Box elder, Common silverbirch, Hazel, Oak, London plane, Maple, Sycamore

Single Allergens (19): Beef, Bermuda grass, Cat dander, Clam, Common silver birch, Cow's milk, Crab, Dog dander, Egg white, Egg yolk, Fish (Cod), Hazelnut, Horse dander, Latex, Nettle, Peanut, Shrimp/Prawn, Soya bean, Wheat

### TAT: 2 days

1A



# Allergy Profile 2 (UK Aero Allergen)

Total IgE with individual IgE allergens for:

Alternaria Derma farinae
Aspergillus Dog dander
Birch pollen House dust mite
Cat dander Horse dander
Cladosporium Timothy grass
Common ragweed

#### TAT: 2 days

2A



# **Allergy Profile 3 (Food)**

Total IgE with individual IgE allergens for:

Codfish Egg yolk Sesame Cow's milk Kiwi Soya Egg white Peanut Wheat

### TAT: 2 days

3A



## Allergy Profile 4 (Nuts & Seeds)

Total IgE with individual IgE allergens for:

Almond Peanut Pumpkin seed
Brazil nut Pecan Sesame seed
Cashew Pine nut Sunflower seed
Hazelnut Pistachio Walnut
Macadamia nut Poppy seed

#### TAT: 2 days

4A



# **Allergy Profile 5 (Children's Panel)**

Total IgE with individual IgE allergens for:

Cat dander Egg white Soya bean
Cod Egg yolk Timothy grass
Cow's milk Hazelnut Wheat flour
Dog dander Peanut
Dust mite Silver birch

#### TAT: 2 days

5A



## **Allergy Profile 6 (Shellfish)**

**Total IgE** with individual IgE allergens for:

ClamLobsterScallopCrabOctopusSquid

Crawfish/Crayfish Prawns/Shrimp

TAT: 2 days

6A

**B** 

## **Allergy Profile 7 (Finfish)**

Total IgE with individual IgE allergens for:

Codfish Sardine/Pilchard Swordfish Mackerel Salmon Tuna Plaice Sole

TAT: 2 days

7A

₿

## Allergy Profile 8 (Cereal - singles)

Total IgE with individual IgE allergens for:

Barley Rye Oat Wheat

TAT: 2 days

A8

**3** 

### **Allergy Profile 9 (Antibiotics)**

**Total IgE** with individual IgE allergens for:

Amoxicilloyl Pen G Ampicilloyl Pen V Cefaclor

TAT: 2 days

9A

**3** 

### Allergy Profile 10 (Insects)

Total IgE with individual IgE allergens for:

Common wasp – Paper wasp yellow jacket Yellow hornet Bee White faced hornet

TAT: 2 days

10A

**B** 

## Allergy Profile 11 (Combined Shellfish/Finfish)

**Total IgE** with individual IgE allergens for:

Cod Scallop Prawn/Shrimp Squid Salmon Tuna

TAT: 2 days

11A

**3** 

# Allergy Profile 12 (Milk & Milk Proteins)

Total IgE with individual IgE allergens for:

Alpha-lactalbumin —
milk proteins
Beta-lactoglobulin —
milk proteins

Goat's milk Mare's milk Sheep's milk Whey (cow and ewe)

Casein – milk proteins Cow's milk

TAT: 2 days

12A

₿

## **Allergy Profile 13** (Stone fruit/Rosaceae family)

**Total IgE** with individual IgE allergens for:

Almond Pear Plum Apple Apricot Raspberry Strawberry Cherry Peach

TAT: 2 days

13A



## **ALEX<sup>2</sup> Allergy Test** (Venous / Self-collect)

300 allergen panel, from single sample. supplemented by Total IgE, which includes pollens, mites, cat and dog, fur, insect venoms, moulds, veasts, food and latex.

TAT: 3-4 days

ALEX

(Serum) / (B) (TDL Tiny)

## **ISAC Panel (Venous/Self-collect)**

Simultaneous measurement in a single sample of specific antibodies to more than one hundred allergen components from more than 48 preselected allergen sources.

TAT: 3 days

ISAC

(TDL Tiny)

### Allergic Rhinitis/Asthma Profile

Total IgE with individual IgE allergens for:

Asperaillius fumigatus Cat dander Dog dander Cladosporium herbarum Common silver birch Mugwort Timothy grass London plane Dust mite -Peanut Dermatophagoides Egg white pteronyssinus Cow's milk Alternaria alternata

TAT: 2 days

ALRN



## **Atopic Dermatitis/Eczema** Profile (14 allergens)

TOTAL IGE with individual IgE allergens for:

Cod fish Apple Cow's milk Dust mite -Egg white dermatophagoides Sovabean pteronyssinus Peanut Cat dander Hazelnut Dog dander Shrimp Timothy grass Wheat Common silver birch

TAT: 2 days

ALEC



## **Gluten Sensitivity Profile**

CHANGE Tissue Transglutaminase

Gluten Single IgE Allergen IaA. Deamidated Gliadin HLA DQ2/DQ8 IaG Antibodies Total IgA

TAT: 10 days

**GLUT** 





## **Individual allergens**

Allergens, when requested individually are priced as single tests, sample 1 x 1 (up to 5 allergens).

Protein allergens are manufactured by Thermofisher (Phadia) and are IgE specific.

**GRASS POLLENS** 

Bahia grass g17

Barley g201

Bermuda grass g2

Brome grass g11

Canary grass g71

Cocksfoot g3

Common reed g7

Cultivated oat a14

Cultivated rye q12

Cultivated wheat q15

Johnson grass g10

Maize, Corn q202

Meadow fescue g4

Meadow foxtail q16

Meadow grass, Kentucky blue g8

Redtop, Bentgrass q9

Rye-grass q5

Sweet vernal grass q1

Timothy grass q6

Velvet grass g13

Wild rye grass q70

**WEED POLLENS** 

Alfalfa w45

Camomile w206

Careless weed w82

Cocklebur w13

Common pigweed w14

Common ragweed w1

Dandelion w8

Dog fennel w46

False ragweed w4

Firebush (Kochia) w17

Giant ragweed w3

Goldenrod w12

Goosefoot, Lamb's quarters w10

Japanese Hop w22

Lupin w207

Marguerite, Ox-eye daisy w7

Mugwort w6

Nettle w20

Parietaria officinalis w19

Parietaria judaica w21

Plantain (English), Ribwort w9

Rape w203

Rough marshelder w16

Saltwort (prickly), Russian thistle w11

Scale, Lenscale w15

Sheep sorrel w18

Sunflower w204

Wall pellitory w19

Wall pellitory w21

Western ragweed w2

Wormwood w5

Yellow dock w23

TREE POLLENS

Acacia t19

American beech t5

Australian pine t73

Bald cypress t37

Bayberry t56

Box-elder t1

Cedar t212

Cedar elm t45

Chestnut t206

Common silver birch t3

Cottonwood t14

Cypress t222

Date t214

Elder t205

Flm t8

Eucalyptus, Gum-tree t18

European ash t25

Grey alder t2

Hackberry t44

Hazel t4

Horn beam t209

Horse chestnut t203

Italian/Mediterranean/Funeral

cypress t23

Japanese cedar t17

Linden t208

Maple leaf sycamore.

London plane t11

Melaleuca, Cajeput-tree t21

Mesquite t20

Mountain juniper t6

Mulberry t70

0ak t7

Oil Palm t223

Olive t9

Pecan, Hickory t22

Peppertree t217

Pine t213

Privet t210

Queen palm t72

Red cedar t57

neu ceuai tor

Red mulberry t71 Scotch broom t55

Spruce t201

Sweet gum t211

Walnut t10

White ash t15

White hickory t41

White pine t16

Willow t12

Virginia live oak t218

· ·

MICROORGANISMS

Acremonium kiliense m202

Alternaria alternata m6

Aspergillus flavus m228

Aspergillus fumigatus m3

A " COT

Aspergillus niger m207

Aspergillus terreus m36 Aureobasidium pullulans m12

Botrytis cinerea m7

Candida albicans m5

Chaetomium globosum m208

Cladosporium herbarum m2

Curvularia lunata m16

Epicoccum purpurascens m14

Setomelanomma rostrata

(Helminthosporium halodes) m8

Malassezia spp. m227

Mucor racemosus m4

Penicillium chrysogenum (P. notatum) m1 Penicillium glabrum m209 Phoma betae m13 Rhizopus nigricans m11 Staphylococcal enterotoxin A m80 Staphylococcal enterotoxin B m81 Staphylococcal enterotoxin C m223 Staphylococcal enterotoxin TSST m226 Stemphylium herbarum (S. botryosum) m<sub>10</sub>

Tilletia tritici m201 Trichoderma viride m15 Trichophyton mentagrophytes var. interdigitale m211 Trichophyton rubrum m205 Ulocladium chartarum m204

### **EPIDERMALS AND ANIMAL PROTEINS**

Budgerigar droppings e77 Budgerigar feathers e78 Camel dander u328 Canary bird droppings e200 Canary bird feathers e201 Cat dander e1 Chicken droppings e218

Chicken feathers e85 Chicken, serum proteins e219

Chinchilla epithelium e208 Cow dander e4

Dog dander e5 Duck feathers e86

Ferret epithelium e217 Finch feathers e214

Gerbil epithelium e209

Goat epithelium e80 Goose feathers e70

Guinea pig epithelium e6

Hamster epithelium e84

Horse dander e3

Mink epithelium e203 Mouse epithelium e71

Mouse epithelium, serum proteins

and urine proteins e88 Mouse serum proteins e76

Mouse urine proteins e72

Parrot feathers e213

Pigeon feathers e215 Rabbit epithelium e82 Rabbit, serum proteins e206

Rabbit, urine proteins e211

Rat epithelium e73

Rat epithelium, serum proteins

and urine proteins e87

Rat serum proteins e75

Rat urine proteins e74

Sheep epithelium e81

Swine epithelium e83

Turkey feathers e89

#### **MITES**

Acarus siro (Storage mite) d70 Blomia tropicalis (House dust mite) d201

Dermatophagoides farinae (House dust mite) d2

Dermatophagoides microceras (House dust mite) d3

Dermatophagoides pteronyssinus

(House dust mite) d1 Euroglyphus maynei

(House dust mite) d74

Glycyphagus domesticus (Storage mite) d73

Lepidoalyphus destructor

(Storage mite) d71

Tyrophagus putrescentiae (Storage mite) d72

#### ALLERGEN COMPONENTS

See page 139 for Component Testing and Component Allergen Profiles

#### HOUSE DUST

Greer Labs., Inc. h1 Hollister-Stier Labs. h2

#### INSECTS

Berlin beetle i76 Blood worm i73 Cockroach, American i206 Cockroach, German i6 Fire ant i70

Grain weevil i202

Green nimitti i72

Horse fly i204

Mediterranean flour moth i203 Mosquito i71

Moth i8

#### VENOMS

Bumblebee i205

Common wasp (Yellow jacket i3

European Paper Wasp i77

European hornet i75

Honey bee i1

Paper wasp i4

White-faced hornet i2

Yellow hornet i5

### DRUGS

Amoxicillovl c6 Ampicilloyl c5

Cefaclor c7

Chlorhexidine c8

Gelatin bovine c74

Insulin human c73

PenicillovI G c1

Penicilloyl V c2

Pholcodine c261

Morphine c260

Suxamethonium (succinylcholine)

c202

### OCCUPATIONAL

Bougainvillea k214

Cotton seed k83

Ethylene oxide k78

Figus k81

Formaldehyde/Formalin k80

Hexahydrophtalic anhydrid k209

Isocyanate HDI (Hexamethylene

diisocyanate) k77

Isocyanate MDI (Diphenylmethane

diisocvanate) k76

Isocyanate TDI (Toluene diisocyanate) k75

Ispaghula k72

Latex k82

Methyltetrahydrophtalic anhydrid k211

Phthalic anhydride k79

Sunflower seed k84

Trimellitic anhydride, TMA k86

**PARASITES** 

Anisakis p4

Ascaris p1

Echinococcus p2

MISCELLANEOUS

Cotton, crude fibers of

Mealworm o211

MUXE3 CCD. Bromelain o214

Seminal fluid o70

Streptavidin o212

FOODS - FRUITS & VEGETABLES

Apple f49

Apricot f237

Asparagus f261

Aubergine, eggplant f262

Avocado f96

Bamboo shoot f51

Banana f92

Beetroot f319

Blackberry f211

Blueberry f288

Broccoli f260

Brussel sprouts f217

Cabbage f216

Carrot f31

Cauliflower f291

Celery f85

Cherry f242

Cucumber f244

Date f289

Fennel, fresh f276

Fia f328 Garlic f47

Grape f259

Grapefruit f209

Kiwi f84

Lemon f208

Lettuce f215

Lime f306

Mandarin (tangerine, clementine,

satsumas) f302

Mango f91

Melon f87

Olive (black, fresh) f342

Onion f48

Orange f33

Papaya f293

Passion fruit f294

Peach f95

Pear f94

Persimon (kaki fruit, sharon) f301

Pineapple f210

Plum f255

Potato f35

Pumpkin f225

Raspberry f343

Spinach f214

Strawberry f44

Sweet potato f54

Tomato f25

Watermelon f329

FOODS - SEED. LEGUMES & NUTS

Almond f20

Barlev f6

Brazil nut f18

Buckwheat f11

Cashew nut f202

Chick pea f309

Coconut f36

Common millet f55

Fenuareek f305

Foxtail millet f56

Gluten f79

Green bean f315

Hazel nut f17

Lentil f235

Lima bean f182

Linseed f333

Lupin seed f335

Macadamia nut f345

Maize. Corn f8

Oat f7

Pea f12

Peanut f13

Pecan nut f201

Pine nut, pignoles f253

Pistachio f203

Poppy seed f224 Pumpkin seed f226

Quinoa f347

Rape seed f316

Red kidney bean f287

Rice f9

Rve f5

Sesame seed f10

Sovbean f14

Spelt wheat f124

Sugar-beet seed f227

Sweet chestnut f299

Walnut f256

Wheat f4

White bean f15

FOODS - SPICES

Anise f271

Rasil f269

Bay leaf f278

Black pepper f280

Caraway f265

Chilipepper f279

Clove f268

Coriander f317

Dill f277

Ginger f270

Green pepper (unripe seed) f263

Lovage f275

Mace f266

Marioram f274

Mint f332

Mustard f89

Oregano f283

Paprika. Sweet pepper f218

Parslev f86

Tarragon f272

Thyme f273

Vanilla f234

FOODS - FISH, SHELLFISH & MOLLUSCS

Abalone f346

Anchovy f313

Blue mussel f37

Cat fish f369

Chub mackerel f50 Clam f207

Crab f23

Cravfish f320

Fish (cod) f3

Gulf flounder f147

Haddock f42

Hake f307

Halibut f303 Herring f205

Jack mackerel, Scad f60

Langust (spiny lobster) f304

Lobster f80

Mackerel f206

Mearim f311

Octopus f59

Oyster f290

Pacific squid f58

Plaice f254

Pollock f413

Red snapper f381

Salmon f41

Sardine (Pilchard) f308

Sardine, Japanese Pilchard f61

Scallop f338

Shrimp f24

Sole f337

Squid f258

Swordfish f312

Tilapia f414

Trout f204

Tuna f40

Walleve pike f415

Whitefish (Inconnu) f384

### FOODS - EGG & FOWL

Chicken f83

Egg f245

Eaa white f1

Egg volk f75

Turkey meat f284

### FOODS - MEAT

Beef f27

Mutton f88

Pork f26

Rabbit f213

#### FOODS - MILK

Casein f78

Cheese, cheddar type f81

Cheese, mold type f82

Cow's whey f236

Goat milk f300 Mare's milk f286

Milk f2

Milk, boiled f231

Sheep milk f325

Sheep whey f326

#### FOODS - ADDITIVES

Carob (E410) f296

Guar, guar gum (E412) f246

Gum arabic (E414) f297

Cochineal extract (Carmine red) (E120)

f340

### **FOODS - MISCELLANEOUS**

Cacao f93

Coffee f221

Malt f90

Mushroom (champignon) f212

Tea f222

Yeast f45

## **Vitamins**

| TEST   | CODE | SAMPLE REQS                       | TAT             |
|--|------|-----------------------------------|-----------------|
| 1,25 Vitamin D   | D3   | <b>B</b> *                        | 5-8 days        |
| *Serum sample stable for 3 days ambient.   |      |                                   |                 |
| Beta Carotene  | CARO | В                                 | 5 days          |
| Biotin CHANGE  | BIOS | <b>B</b> 7                        | 5 days          |
| Carotenes  | CARO | <b>B</b> 13                       | 5 days          |
| Vitamin A (Retinol)  | VITA | В                                 | 5 days          |
| Vitamin B (Functional)   | FUNC | A A or 🕕                          | 5 days          |
| Vitamin B Profile  | VBP  | <b>AAB</b>                        | 5 days          |
| Vitamin B1 (Thiamine)  | VIT1 | A                                 | 5 days          |
| Vitamin B2 (Riboflavin)  | VIB2 | A                                 | 5 days          |
| Vitamin B3 (Nicotinamide)  | VIB3 | <b>B</b>                          | 5 days          |
| Vitamin B5 (Pantothenic Acid)  | VB5S | <b>B</b>                          | 5 days          |
| Vitamin B6 (Pyridoxine)  | VITB | A                                 | 5 days          |
| Vitamin B7 (Biotin) CHANGE   | BIOS | <b>3</b> 7                        | 5 days          |
| Vitamin B9 (Folic acid) – Red cell   | RBCF | A                                 | 2 days          |
| Vitamin B9 (Folic acid) – Serum  | FOLA | B                                 | 1 day           |
| Vitamin B12 (Active) (Venous/Self-collect)   | B12  | 3 / (TDL Tiny)                    | 1 day           |
| Vitamin B12 (Active)/Red Cell Folate   | B12F | <b>A</b> B                        | 2 days          |
| Vitamin C (Active) *Serum should be separated and frozen within 3 hours of venepuncture.   | VITC | (spun and frozen within 3 hours)* | 5 days          |
| Vitamin D (1, 25 Dihydroxy) *Serum sample stable for 3 days ambient.   | D3   | <b>3</b> *                        | 5-8 days        |
| Vitamin D (25-OH) (Venous/Self-collect)  | VITD | B/B (TDL Tiny)                    | 4 hours / 1 day |
| Vitamin E (Alpha Tocopherol)   | VITE | B                                 | 5 days          |
| Vitamin K (Nutritional)  * Sample should be light protected after collection, spun/separated and frozen within 24 hours of collection. | VKN  | Serum (SST or 😉) *                | 5 days          |
| Vitamin Profile 1  | VITS | <b>A B B</b> <sup>7</sup>         | 5 days          |
| Vitamin Profile 2  | VIT2 | <b>A A B B</b> 7,13               | 5 days          |

## **Nutrition and lifestyle**

This provides valuable diagnostic information, which can be assimilated with other diagnostic markers in the assessment of nutritional status, and compares favourably to semi-quantitative functional assays.

| TEST   | CODE | SAMPLE REQS                 | TAT       |
|--|------|-----------------------------|-----------|
| Caeruloplasmin   | CERU | B                           | 1 day     |
| Copper (Serum)   | COPP | B or (§                     | 5 days    |
| Essential Fatty Acid Profile (Red Cell)                            | EFAR | <b>A</b> 4                  | 10 days   |
| Folate (Red Cell)  | RBCF | A                           | 2 days    |
| Magnesium (Whole blood)  | RCMG | A or (1)                    | 4 days    |
| Mineral Screen   | MINE | <b>B (3</b>                 | 5 days    |
| Mineral Screen (Whole blood)                                       | RMIN | 00                          | 5 days    |
| Mineral Screen and Industrial Heavy<br>Metal Screen (Trace Metals) | TRAC | <b>4 8 9 9</b>              | 7-10 days |
| Omega 3/Omega 6 (Venous/Self-collect)                              | OMG3 | A 4 / A (TDL Tiny)          | 5 days    |
| Selenium (Serum) (Venous/Self-collect)                             | SELE | B / B (TDL Tiny)            | 4 days    |
| Sports/Performance Profile   | SPOR | <b>AAA</b> BBBBG <b>6</b> 4 | 5 days    |
| Xylose Tolerance Test  | XTT  | <b>J</b> <sup>1</sup>       | 7 days    |
| Zinc (Serum/Plasma) CHANGE   | ZINC | ß                           | 2 days    |
| Zinc (Urine)   | URZN | CU                          | 5 days    |
| Zinc (Whole Blood)   | RBCZ | A or (1)                    | 5 days    |

Patients taking supplements may be advised to stop medication prior to testing.

### **Mineral Screen**

Calcium Magnesium

Zinc

Iron (TIBC included)

Copper Chromium

Manganese

### TAT: 5 days

MINE



### **Mineral Screen** (Whole blood)

Whole Blood Potassium

Whole Blood Magnesium

Whole Blood Calcium

Whole Blood Manganese

Whole Blood Zinc Whole Blood Copper

Whole Blood Selenium

Whole Blood Chromium

### TAT: 5 days

RMIN



## Mineral Screen and **Industrial Heavy Metal Screen (Trace Metals)**

Aluminium

Manganese

Iron (TIBC included)

Calcium

7inc

Magnesium

Copper

Cadmium

Mercury

Lead

Chromium

### **TAT: 7-10 days**

TRAC





### **Sports/Performance Profile**

FBC/ESR

Biochemistry Profile

HDL/LDL

Ferritin

C-Reactive Protein

Omega 3/Omega 6

Mineral Screen

Vitamin B9 (Red Cell Folate) Vitamin B12 (Active)

### TAT: 5 days

SP0R









### Vitamin B Profile

Vitamin B1

Vitamin B2

Vitamin B3

Vitamin B6

Vitamin B9 (Red cell)

Vitamin B12 (Active)

### TAT: 5 days

**VBP** 



### Vitamin Profile 1

Vitamin A

Beta Carotene

Vitamin B1

Vitamin B2

Vitamin B6

Vitamin D (25-OH)

Vitamin F

### TAT: 5 days

VITS



### Vitamin Profile 2

Vitamin A

Beta Carotene

Vitamin R1

Vitamin B2

Vitamin B3

Vitamin B6

Vitamin B9 (Red Cell Folate)

Vitamin B12 (Active)

Vitamin D (25-0H)

Vitamin E

### TAT: 5 days

VIT2









# Essential Red Cell Fatty Acids Omega-3/Omega-6

Omega-3 is the name given to a family of polyunsaturated fatty acids, which the body needs but cannot manufacture itself. Omega-3 fats are used as the building blocks for fat derived hormones such as prostaglandins and leukotrienes.

The hormones with an Omega-3 base tend to reduce inflammation, while those that have an Omega-6 base increase inflammation. In the cell membrane the competition between these two essential fats has a direct bearing on the type of local hormone produced and the level of inflammation in the cell.

The Omega-6 to Omega-3 ratio in the cell membranes is key to the development of inflammatory disorders such as rheumatoid arthritis and heart disease. Diets low in oily fish and high in grains will promote inflammation and affect good health.

The ratio of Omega-6 to Omega-3 in the West is around 15 to 1, fifteen times more Omega-6 on the cell membrane promoting inflammation. Having twice as much Omega-6 is considered by most experts to be the optimal amount but a ratio of 2:1 is not easy to produce by diet alone. Many people are aware of the health benefits of Omega-3 but the supplementation to achieve optimal health is erratic. Being able to test for Essential Red Cell Fatty Acids (Omega-6/Omega-3 ratio) identifies a person's current status and is sufficiently specific to allow an accurate supplementation recommendation to be made.

Results show the Omega Ratio with a clear recommendation for the required level of Omega Supplementation (if any) to achieve optimal levels.

| TEST                                  | CODE | SAMPLE REQS        | TAT    |
|---------------------------------------|------|--------------------|--------|
| Omega 3/Omega 6 (Venous/Self-collect) | OMG3 | A 4 / A (TDL Tiny) | 5 days |



The TDL Self-Collect range of testing has been gathering increased and important attention for healthcare services. Self-collection is being adopted across different target areas of healthcare: sexual health screening, wellness testing, genetic conditions, lifestyle review, pre-operative work ups, etc. Self-collection sampling allows patients to collect samples at home, and together with Royal Mail Tracked postal returns, facilitates safe and effective delivery of samples throughout the UK to the laboratory.

As part of the ongoing development of the TDL self-collection service, the sample collection kits ensure that TDL is aligned to regulatory requirement around ISO:13485 kit manufacture and UKCA marking across the UK. This requirement for UKCA marked kits also addresses the need for clinically approved stability and comparative performance. The interest being generated for this service ensures best attention, continued development, with regular review of the repertoire, and where possible more tests will be added to the available Self-Collection list.

The TDL Self-Collect capillary blood and sample kits include a helpful range of diagnostic and screening tests. These sample collection kits are not home test kits that provide an immediate result for the patient. Samples collected at home are all returned to the laboratory for testing, using Royal Mail Tracked 24 postal services. Results are returned directly to the healthcare organisation, doctor or healthcare

professional — not to the patient. Self-Collect kits need to be UKCA marked (or dual marked with UKCA/CE) to represent the product claims that kits are being used for the collection of samples in a non-clinic setting.

The Self-Collect kit itself allows for combinations of sample types (urine, stool, swabs) — and the range of UKCA marked kits are listed on page 155. Instructions for sample collection are enclosed in each collection kit. The best results are obtained by patients who closely follow the instructions that are provided, and by collecting enough blood drops to sufficiently fill the microtainer tube(s) in their kit. A request form or specially provided tube label must be returned with the collected sample. It is exciting that the scope of this service, together with its performance and quality standards, will be revised, developed, and updated on a regular basis.

For more details relating to this service, please email **UKCAkits@tdlpathology.com** 



Find out more information about the TDL Self-Collect kits:

www.tdlpathology.com/ self-collect-kits/

### Quality is key

- Components: verified for the specific intended use of the kit and linked to the accredited tests performed in the laboratory.
- Instructions: monitored for ease of use, version controlled, with regular feedback for ongoing improvement.
- Quality: Management of technical files, regulatory submissions and manufactured to the required ISO:13485 medical device manufacturing standards.
- Supply: Assembled within the UK. Both individual kit fulfilment services and larger size kit orders are available.
- **Security**: Test kits are security sealed.
- Accompanying information: Request forms cannot be inserted into the sealed kits.
   An accompanying envelope (TDL will provide) or other clearly visible method must be sent with each kit to clearly display the request form.
- Laboratory testing: Verified diagnostic tests performed in an ISO:15189 accredited clinical laboratory

We recommend that all healthcare organisations and healthcare professionals using our TDL Tiny<sup>™</sup> and TDL Self-Collect kits are up to date with latest diagnostic testing guidelines and relevant updates, including but not limited to those published by:

- UKHSA Standards for Microbiology Investigations (SMI)
- British Association of Sexual Health and HIV Guidelines (BASHH)
- Royal College of Obstetrics and Gynaecology Guidelines (RCOG)
- NICE Evidence-based recommendations on faecal immunochemical tests (DG30)
- British Society of Haematology Evidence Based Guidance (BSH)
- Association of Clinical Biochemistry (ACB)

## **TDL's range of kits**

KT426

KT428

KT429

| Respi    | ratory virus PCR  |  |
|----------|---|--|
| KIT CODE | KIT TYPE  | SAMPLE TYPE  |
| KT293    | Respiratory Virus Swab Collection Kit (2mL)                             | Oropharyngeal and Nasal swab                                   |
|          |   |  |
| Capilla  | ary blood   |  |
| KIT CODE | KIT TYPE  | SAMPLE TYPE  |
| KT353    | Capillary Blood Collection Kit (SST)                                    | Capillary Blood (SST)  |
| KT354    | Capillary Blood Collection Kit (EDTA)                                   | Capillary Blood (EDTA)   |
| KT384    | Capillary Blood Collection Kit (SST x2)                                 | Capillary Blood (SST x2)                                       |
| KT355    | Capillary Blood Collection Kit (SST and EDTA)                           | Capillary Blood (SST and EDTA)                                 |
| KT423    | Capillary Blood Collection Kit (SST x2 and EDTA)                        | Capillary Blood (SST x2 and EDTA)                              |
| KT445    | Capillary Blood Collection Kit (Plain and SST)                          | Capillary Blood (Plain and SST)                                |
|          |   |  |
| Sexua    | l health  |  |
| KIT CODE | KIT TYPE  | SAMPLE TYPE  |
| KT356    | Sexual Health Collection Kit (Urine)                                    | Aptima Urine   |
| KT357    | Sexual Health Collection Kit (Vaginal)                                  | Aptima multisite swab  |
| KT358    | Sexual Health Collection Kit (Blood and Vaginal)                        | Capillary Blood and<br>Aptima multisite swab                   |
| KT359    | Sexual Health Collection Kit (Throat and Rectal)                        | Aptima multisite swab x 2                                      |
| KT360    | Sexual Health Collection Kit (Blood and Urine)                          | Capillary Blood and Aptima Urine                               |
| KT361    | Sexual Health Collection Kit<br>(Blood, Urine, Throat and Rectal – MSM) | Capillary Blood, Aptima Urine<br>and Aptima multisite swab x 2 |
| KT424    | Sexual Health Collection Kit<br>(Blood, Vaginal, Throat and Rectal)     | Capillary Blood and Aptima<br>multisite swab x3                |
| KT404    | Sexual Health Collection Kit (Oral lesion)                              | Oral swab  |
| KT405    | Sexual Health Collection Kit (Genital lesion)                           | Genital swab   |
| KT421    | Sexual Health Collection Kit  | Aptima Urine and   |
|          | (Urine, Throat and Rectal – MSM)  | multisite swab x 2   |
| KT425    | Sexual Health Collection Kit (Throat)                                   | Aptima multisite swab  |
|          |   |  |

**Sexual Health Collection Kit (Rectal)** 

(Blood, Urine, Vaginal, Throat and Rectal)

**Sexual Health Collection Kit** 

Sexual Health Collection Kit (Vaginal, Throat and Rectal)

Aptima multisite swab

Aptima multisite swab x3

Capillary Blood, Aptima Urine

and Aptima multisite swab x3

| Microb   | ial/Viral screening  |  |
|----------|--|--|
| KIT CODE | KIT TYPE   | SAMPLE TYPE                                      |
| KT364    | HPV Swab Collection Kit  | Qvintip swab                                     |
| KT365    | MRSA Collection Kit (Nose and Groin)                             | Purple liquid Amies swab x2                      |
| KT422    | MRSA Collection Kit (Nose, Groin and Axilla)                     | Purple liquid Amies swab x3                      |
| KT366    | GBS Collection Kit (Vaginal and Rectal)                          | Blue gel Amies swab x 2                          |
| KT441    | Vaginitis Collection Kit<br>(Vaginal – Culture and PCR)          | Aptima multisite swab and<br>Blue gel Amies swab |
| KT385    | Urinalysis Collection Kit<br>(Chemistry and Microscopy)          | Urine (Universal)                                |
| KT386    | Urinalysis Collection Kit<br>(Chemistry, Microscopy and Culture) | Urine (Universal and Boric)                      |

| Gastrointestinal |   |   |  |  |  |  |
|------------------|---|---|--|--|--|--|
| KIT CODE         | KIT TYPE                                  | SAMPLE TYPE   |  |  |  |  |
| KT362            | QFIT Collection Kit                       | QFIT sample collection device                               |  |  |  |  |
| KT363            | Faecal Collection Kit                     | Stool/faecal container                                      |  |  |  |  |
| KT430            | Faecal Collection Kit (QFIT and Stool x2) | QFIT sample collection device and stool/faecal container x2 |  |  |  |  |

Please post self-collected samples on the same day they are taken, avoid posting over weekends and bank holidays.

| TEST  | CODE | SAMPLE REQS                    | TAT      | KIT CODE          |
|---|------|--------------------------------|----------|-------------------|
| 7 STI Profile by PCR<br>(7 tests from 1 Sample)   | DL12 | Aptima urine or multisite swab | 2 days   | KT356<br>or KT357 |
| ALEX² Allergy Test 300 allergen panel, from single sample, supplemented by Total IgE, which includes pollens, mites, cat and dog, fur, insect venoms, moulds, yeasts, food and latex. | ALEX | (TDL Tiny)                     | 3-4 days | KT353             |
| Amenorrhoea Profile (LH, FSH, PROL, TEST, TOES, SHBG, FAI) CHANGE   | TAME | (TDL Tiny) (TDL Tiny)          | 1 day    | KT445             |
| Amylase   | AMY  | (TDL Tiny)                     | 1 day    | KT353             |
| Antimullerian Hormone (AMH)   | АМН  | (TDL Tiny)                     | 1 day    | KT353             |
| C Reactive Protein  | CRP  | (TDL Tiny)                     | 1 day    | KT353             |
| C Reactive Protein (High Sensitivity)   | HCRP | (TDL Tiny)                     | 1 day    | KT353             |
| CA 125  | C125 | (TDL Tiny)                     | 1 day    | KT353             |

| TEST   | CODE | SAMPLE REQS                    | TAT      | KIT CODE          |
|--|------|--------------------------------|----------|-------------------|
| <b>Calcium</b> Sample integrity may be compromised on received samples older than 2 days.      | CA   | (TDL Tiny)                     | 1 day    | KT353             |
| Calcium + Vitamin D Sample integrity may be compromised on received samples older than 2 days. | CALD | (TDL Tiny)                     | 1 day    | KT353             |
| Calprotectin   | CALP | QFIT sample collection device  | 5 days   | KT362<br>or KT430 |
| Calprotectin/QFIT Profile (Combined)   | QCAL | QFIT sample collection device  | 5 days   | KT362<br>or KT430 |
| Carbohydrate Deficient Transferrin (CDT)   | CDT  | B (TDL Tiny)⁴                  | 3 days   | KT353             |
| Chlamydia/Gonorrhoea – Rectal  | RSCG | Aptima multisite swab          | 2 days   | KT426             |
| Chlamydia/Gonorrhoea – Throat  | TSCG | Aptima multisite swab          | 2 days   | KT425             |
| Chlamydia/Gonorrhoea – Urine   | CCG  | Aptima urine                   | 2 days   | KT356             |
| Chlamydia/Gonorrhoea – Vaginal   | SCG  | Aptima multisite swab          | 2 days   | KT357             |
| Cortisol   | CORT | (TDL Tiny)                     | 1 day    | KT353             |
| COVID-19 (SARS-CoV-2) RNA by PCR Contact Laboratory.   | NCOV | Throat and nose swab           | 1 day    | KT293             |
| COVID-19 (SARS-CoV-2) Roche<br>Elecsys Anti-SARS-CoV-2 S (SPIKE)                               | SCOV | (TDL Tiny)                     | 1 day    | KT353             |
| Creatinine (including eGFR)  | CREA | (TDL Tiny)                     | 1 day    | KT353             |
| DHEA Sulphate  | DHEA | (TDL Tiny)                     | 1 day    | KT353             |
| DL12 7 STI Profile by PCR<br>(7 PCR tests from 1 Sample)                                       | DL12 | Aptima urine or multisite swab | 2 days   | KT356<br>or KT357 |
| <b>Elastase</b> *5 day stability time ambient.   | ELAS | Stool/faecal<br>container*     | 5 days   | KT363<br>or KT430 |
| Endomysial Antibodies (IgA)  | AEAB | (TDL Tiny)                     | 2 days   | KT353             |
| Female Hormone Profile (LH, FSH, PROL, TOES)   | TFIP | (TDL Tiny) (TDL Tiny)          | 1 day    | KT445             |
| Ferritin   | FERR | B (TDL Tiny)                   | 1 day    | KT353             |
| Free T3  | FT3  | B (TDL Tiny)                   | 1 day    | KT353             |
| Free T4  | FT4  | B (TDL Tiny)                   | 1 day    | KT353             |
| FSH  | FSH  | B (TDL Tiny)                   | 1 day    | KT353             |
| Gastrointestinal Pathogen PCR  | EORD | Stool/faecal container         | 2 days   | KT363<br>or KT430 |
| Gliadin Antibodies (IgG) (deamidated)  | AGAB | (TDL Tiny)                     | 2 days   | KT353             |
| Group B Strep – Vaginal and Rectal   | GBSX | Blue gel Amies<br>swab x2      | 3-5 days | KT366             |

| TEST  | CODE | SAMPLE REQS                    | TAT       | KIT CODE          |
|---|------|--------------------------------|-----------|-------------------|
| H. pylori Antigen – Stool   | HBAG | Stool/faecal container         | 3 days    | KT363<br>or KT430 |
| HbA1c   | GHB  | (TDL Tiny)                     | 1 day     | KT354             |
| Hepatitis B Immunity (IgG)  | THBI | (TDL Tiny)                     | 1 day     | KT353             |
| Hepatitis B Surface Antigen   | THBA | (TDL Tiny)                     | 1 day     | KT353             |
| Hepatitis C Antibodies  | THCV | (TDL Tiny)                     | 1 day     | KT353             |
| Hepatitis C Antigen (Early detection)   | TCAG | (TDL Tiny)                     | 1 day     | KT353             |
| Herpes Simplex (HSV) 1 & 2<br>– Genital lesion  | HERS | Aptima multisite swab          | 5 days    | KT405             |
| Herpes Simplex (HSV) 1 & 2 – Oral lesion  | HERS | Aptima multisite swab          | 5 days    | KT404             |
| HIV 1 & 2 Abs/p24Ag   | THIV | (TDL Tiny)                     | 1 day     | KT353             |
| HPV (Individually typed high risk DNA subtypes)   | HPVZ | Qvintip vaginal swab           | 3 days    | KT364             |
| HPV (mRNA all high risk subtypes)   | HPVY | Qvintip vaginal swab           | 3 days    | KT364             |
| Iron (TIBC included)  | FE   | (TDL Tiny)                     | 1 day     | KT353             |
| Iron Status Profile   | ISP  | B (TDL Tiny)                   | 1 day     | KT353             |
| ISAC Panel 112 allergen panel from single sample which includes components from 48 preselected allergen sources | ISAC | (TDL Tiny)                     | 3 days    | KT353             |
| Lipase  | LIPA | (TDL Tiny)                     | 1 day     | KT353             |
| Lipid Profile   | LIPP | (TDL Tiny)                     | 1 day     | KT353             |
| Lipoprotein (a)   | LP0A | (TDL Tiny)                     | 1 day     | KT353             |
| Liver Function Tests (Excluding AST/ALT)  | TLFT | (TDL Tiny)                     | 1 day     | KT353             |
| Luteinising Hormone (LH)  | LH   | (TDL Tiny)                     | 1 day     | KT353             |
| Lymphogranuloma Venerium (LGV) - Rectal *   | LGVP | Aptima multisite swab          | 1-2 weeks | KT426             |
| * This test can be configured to be automatically reflexed as required.   |      |                                |           |                   |
| Menopausal Profile<br>(FSH, LH, TOES, TSH, FT4)   | TMEN | (TDL Tiny) (TDL Tiny)          | 1 day     | KT445             |
| Monkeypox Virus – Lesion  | MPXV | Aptima multisite swab          | 2 days    | KT405             |
| MRSA Culture – Nose/Groin   | MRW2 | Purple liquid<br>Amies swab x2 | 2 days    | KT365             |
| MRSA Culture – Nose/Groin/Axilla  | MRW3 | Purple liquid<br>Amies swab x3 | 2 days    | KT422             |
| MRSA PCR - Nose/Groin   | MRS2 | Purple liquid<br>Amies swab x2 | 1 day     | KT365             |
| MRSA PCR – Nose/Groin/Axilla  | MRS3 | Purple liquid<br>Amies swab x3 | 1 day     | KT422             |

| TEST   | CODE | SAMPLE REQS   | TAT       | KIT CODE          |
|--|------|---|-----------|-------------------|
| Mycoplasma genitalium<br>Detection – Urine or Vaginal  | MGEN | Aptima urine or multisite swab                              | 2 days    | KT356<br>or KT357 |
| Mycoplasma genitalium Resistance – Urine or Vaginal *  * This test can be configured to be automatically reflexed as required. | MGR  | Aptima urine or multisite swab                              | 1-2 weeks | KT356<br>or KT357 |
| Oestradiol Requests for a single self-collect Oestradiol [TOES] requires 1 x (3) (TDL Tiny) only.                              | T0ES | (TDL Tiny)  | 1 day     | KT445             |
| Omega 3/Omega 6  | OMG3 | (TDL Tiny)  | 5 days    | KT354             |
| PEth (Phosphatidylethanol)   | PETH | (TDL Tiny) <sup>38</sup>                                    | 5-7 days  | KT354             |
| PLAC Test (Lp-PLA2)  | PLA2 | (TDL Tiny)  | 2 days    | KT353             |
| Progesterone   | PROG | (TDL Tiny)  | 1 day     | KT353             |
| Prolactin  | PR0L | (TDL Tiny)  | 1 day     | KT353             |
| Prostate Specific Antigen (Total)  | PSPA | (TDL Tiny)  | 1 day     | KT353             |
| QFIT/Calprotectin Profile (Combined)   | QCAL | QFIT sample collection device                               | 5 days    | KT362<br>or KT430 |
| Quantitative Faecal<br>Immunochemical Test (QFIT)  | QFIT | QFIT sample collection device                               | 1 day     | KT362<br>or KT430 |
| Respiratory PCR Panel<br>(COVID-19, Flu A/B and RSV)   | FLU4 | Throat and nose swab  | 1 day     | KT293             |
| Selenium (Serum)   | SELE | (TDL Tiny)  | 4 days    | KT353             |
| Sex Hormone Binding Globulin   | SHBG | (TDL Tiny)  | 1 day     | KT353             |
| STI Profile by PCR<br>(7 tests from 1 Sample)  | DL12 | Aptima urine or multisite swab                              | 2 days    | KT356<br>or KT357 |
| STI Profile: MSM1<br>(Blood + Urine/Throat/Rectal Swabs)   | MSM1 | (TDL Tiny) /<br>Aptima Urine / Aptima<br>multisite swab x 2 | 2 days    | KT361             |
| STI Profile: MSM2<br>(Blood + Urine/Throat/Rectal Swabs)   | MSM2 | (TDL Tiny) /<br>Aptima urine / Aptima<br>multisite swab x 2 | 3 days    | KT361             |
| Syphilis IgG/IgM   | TSYP | (TDL Tiny)  | 1 day     | KT353             |
| Testosterone   | TEST | (TDL Tiny)  | 1 day     | KT353             |
| Testosterone (Free)  | FTES | (TDL Tiny)  | 3 days    | KT353             |
| Thyroid Abs (Thyroglobulin +<br>Thyroid Peroxidase Abs)  | THAB | B (TDL Tiny)  | 2 days    | KT353             |
| Thyroid Profile 1 (FT4/TSH)  | TF   | (TDL Tiny)  | 1 day     | KT353             |
| Thyroid Profile 3 (FT3/FT4/TSH)  | TF3  | (TDL Tiny)  | 1 day     | KT353             |
| Tissue Transglutaminase IgA (Coeliac)  | TAA  | (TDL Tiny)  | 2 days    | KT353             |
|  |      |   |           |                   |

| TEST   | CODE | SAMPLE REQS   | TAT      | KIT CODE          |
|--|------|---|----------|-------------------|
| Trichomonas Vaginalis (TV)<br>– Urine or Vaginal             | TVPC | Aptima urine or multisite swab                      | 2 days   | KT356<br>or KT357 |
| Triple Swab Female STI Profile (Vaginal/Throat/Rectal Swabs) | 3SWA | Aptima multisite swab x 3 (label by site)           | 2 days   | KT428             |
| TSH  | TSH  | (TDL Tiny)  | 1 day    | KT353             |
| Urea   | UREA | (TDL Tiny)  | 1 day    | KT353             |
| Urea/Creatinine/eGFR   | TCU  | (TDL Tiny)  | 1 day    | KT353             |
| Urine Chemistry and Microscopy                               | UMIC | Urine (Universal).<br>Mid stream.                   | 1-2 days | KT385             |
| Urine Chemistry, Microscopy and Culture                      | UCEM | Urine (Universal & Boric). Mid stream.              | 1-2 days | KT386             |
| Vaginitis/BV Profile using<br>Culture & PCR Swab             | STD8 | Aptima multisite<br>swab and Blue<br>gel Amies swab | 3-5 days | KT441             |
| Vitamin B12 (Active)   | B12  | (TDL Tiny)  | 1 day    | KT353             |
| Vitamin D (25-OH)  | VITD | (TDL Tiny)  | 1 day    | KT353             |

## **Screening for Drugs of Abuse/Alcohol**

| CODE | SAMPLE REQS  | TAT   |
|------|--|---|
| AP   | ABBG   | 5-7 days  |
| ALCP | A A B B G RU   | 5-7 days  |
| AMPB | BB   | 5 days  |
| CANN | RU   | 1 day   |
| UCOC | RU   | 1 day   |
| DOAP | В  | 5 days  |
| DOA  | RU   | 2 days (5 days with<br>LC-MS/MS confirmation)   |
| DOA3 | RU   | 2 days (5 days with<br>LC-MS/MS confirmation)   |
| DOAL | RU/CoC Collection<br>Containers 1,2                                    | 2 days (5 days with<br>LC-MS/MS confirmation)   |
| DOAN | RU <sup>2</sup>  | 2 days (5 days with<br>LC-MS/MS confirmation)   |
| KETA | RU   | 7-10 days   |
| LSD  | RU   | 5 days  |
| U0PI | RU   | 2 days  |
| PETH | (TDL Tiny) <sup>38</sup>   | 5-7 days  |
| ETG  | RU   | 1 week  |
|      | AP ALCP AMPB CANN UCOC DOAP  DOA  DOAS  DOAL  DOAN  KETA LSD UOPI PETH | AP A G G G RU  ALCP A G G G RU  AMPB G G G RU  CANN RU  UCOC RU  DOAP G G G RU  DOAA RU  DOAA RU  DOAA RU  Containers 1.2  KETA RU  LSD RU  UOPI RU  PETH A 38 / A (TDL Tiny)38 |

### **Alcohol Profile**

LFT Alcohol Level PEth CDT MCV

TAT: 5-7 days

AP



### **Alcohol Profile 2**

LFT
Alcohol Level
PEth
CDT
MCV
Urine Ethyl Gluconaride (EtG)

TAT: 5-7 days

**ALCP** 

A A B B G RU

## Drugs of Abuse from Blood without Chain of Custody

Amphetamines
Barbiturates
Tricyclic Antidepressants
Benzodiazepine
Cannabinoids
Opiates
Cocaine

TAT: 5 days

**DOAP** 



### **Screening for Drugs of Abuse/Alcohol**

## Drugs of Abuse Profile – Random Urine Sample/ No Chain of Custody

Amphetamines Barbiturates

Benzodiazepine

Cannabinoids

Cocaine

Codeine – opiate

Dihydrocodeine - opiate

MDMA

Methadone

Morphine - opiate

## TAT: 2 days (5 days with LC-MS/MS confirmation)

DOA

RU

## Drugs of Abuse Profile – Random Urine Sample/No Chain of Custody Plus Alcohol

Alcohol Amphetamines

Barbiturates

Benzodiazepine Cannabinoids

Cocaine

Codeine - opiate

Dihydrocodeine - opiate

MDMA

Methadone

Morphine - opiate

## TAT: 2 days (5 days with LC-MS/MS confirmation)

DOA3

RU

# Drugs of Abuse Profile – With Chain of Custody\*

Alcohol

Amphetamines

Barbiturates

Benzodiazepine

Cannabinoids

Cocaine

Codeine - opiate

Dihydrocodeine – opiate

Ketamine

LSD

MDMA

Methadone Methagualone

Morphine – opiate

Phencyclidine

Propoxyphene

\*Appointment required at Patient Reception and Photo ID to be shown

## TAT: 2 days (5 days with LC-MS/MS confirmation)

**DOAL** 

**RU/CoC Collection Containers 1,2** 

## Drugs of Abuse Profile – Without Chain of Custody

Alcohol

Amphetamines

Barbiturates

Benzodiazepine Cannabinoids

Cocaine

Codeine – opiate

Dihydrocodeine – opiate

Ketamine LSD

MDMA

Methadone

Methagualone

Morphine – opiate

Phencyclidine Propoxyphene

TAT: 2 days (5 days with LC-MS/MS confirmation)

DOAN

RII 2

## **Occupational Health**

## **Trace metals in blood**

| TEST                         | CODE | SAMPLE REQS | TAT       |
|------------------------------|------|-------------|-----------|
| Aluminium (Blood)            | ALUM | <b>(</b>    | 7 days    |
| Arsenic (Blood)              | ARS  | A or (1)    | 5 days    |
| Cadmium (Blood)              | CADM | A or (1)    | 5 days    |
| Chromium (Blood)             | CHR0 | A           | 5 days    |
| Copper (Serum)               | COPP | B or K      | 5 days    |
| Lead (Blood)                 | LEAD | A           | 5 days    |
| Lead Profile (Hb, ZPP, Lead) | LEAZ | A 13        | 3-5 days  |
| Magnesium (Serum)            | MG   | В           | 4 hours   |
| Manganese (Serum)            | MANG | В           | 5 days    |
| Mercury (Blood)              | MERC | A or (1)    | 5 days    |
| Nickel (Serum)               | NICK | В           | 5 days    |
| Silver (Blood)               | SILV | В           | 5 days    |
| Trace Metal (Blood) Profile  | TRAC | ABBB        | 7-10 days |
| Zinc (Serum/Plasma) CHANGE   | ZINC | <b>(</b>    | 2 days    |

## **Trace metals in urine**

| TEST              | CODE | SAMPLE REQS     | TAT       |  |
|-------------------|------|-----------------|-----------|--|
| Aluminium (Urine) | ALUU | RU              | 1-2 weeks |  |
| Arsenic (Urine)   | ARSE | <b>RU</b> 30    | 5 days    |  |
| Cadmium (Urine)   | URCD | <b>RU</b> 30    | 5 days    |  |
| Chromium (Urine)  | URCR | <b>RU</b> 30    | 4 weeks   |  |
| Cobalt (Urine)    | COBA | <b>RU</b> 30    | 5 days    |  |
| Copper (Urine)    | URCU | CU              | 5 days    |  |
| Lead (Urine)      | URPB | RU              | 5 days    |  |
| Magnesium (Urine) | URMG | PU              | 1 day     |  |
| Mercury (Urine)   | URHG | RU <sup>1</sup> | 5 days    |  |
| Nickel (Urine)    | NICU | RU              | 4 weeks   |  |
| Silver (Urine)    | USIL | RU              | 5 days    |  |
| Zinc (Urine)      | URZN | CU              | 5 days    |  |
|                   |      |                 |           |  |

### **Occupational Health**

## **Tests for specific exposure**

| TEST                          | CODE | SAMPLE REQS           | TAT      |
|-------------------------------|------|-----------------------|----------|
| 2-Butanone GC                 | BUTA | RU                    | 7 days   |
| 2-Furoic Acid                 | 2FA  | RU                    | 10 days  |
| Acetone – Blood               | ACTB | A or (1)              | 2 weeks  |
| Acetone – Urine               | ACTU | RU                    | 5 days   |
| Alcohol Profile               | AP   | <b>ABBG</b>           | 5-7 days |
| Alcohol Profile 2             | ALCP | A A B B G RU          | 5-7 days |
| Benzene                       | BENZ | <b>J</b> 1,6          | 3 days   |
| Beta 2 Microglobulin (Serum)  | B2MG | B                     | 2 days   |
| Beta 2 Microglobulin (Urine)  | UB2M | RU                    | 3 days   |
| Bromide                       | BROM | В                     | 3 days   |
| Cholinesterase (Serum/Pseudo) | CHPS | B                     | 4 hours  |
| Doxepin Level (Sinequan)      | DOXE | A                     | 10 days  |
| MBOCA in Urine                | MBOC | RU                    | 10 days  |
| Molybdenum (Serum)            | MOLY | B                     | 5 days   |
| Thallium (Blood)              | THAL | <b>A</b> / <b>(1)</b> | 1 week   |
| Thallium (Urine)              | URTH | RU                    | 1 week   |
| Toluene (Blood)               | TOL  | J                     | 10 days  |
| Toluene (Urine)               | UT0L | RU                    | 10 days  |
| Trichloracetic Acid (Urine)   | UTCA | RU                    | 5 days   |
| Xanthine – Blood              | XANB | A                     | 2 weeks  |
| Xylene – Urine                | UXYL | RU 30                 | 2 weeks  |
| Zinc Protoporphyrin           | ZNPR | A                     | 5 days   |
|                               |      |                       |          |

### **Alcohol Profile**

LFT Alcohol Level PEth CDT MCV

TAT: 5-7 days

AP



### **Alcohol Profile 2**

LFT Alcohol Level PEth CDT MCV Urine Ethyl Gluconaride (EtG)

TAT: 5-7 days

**ALCP** 



# Trace Metal (Blood) Profile

Aluminium Manganese Iron (TIBC included) Calcium Zinc Magnesium Copper Cadmium Mercury Lead Chromium

**TAT: 7-10 days** 

TRAC



The cervical cytology laboratory provides a rapid service for liquid based cervical samples. All Diagnostic (Non-Gynaecological) Cytology samples are referred to a UKAS accredited laboratory for reporting.

Human papilloma virus (HPV), Chlamydia and Gonorrhoea testing is carried out routinely from ThinPrep vials and can be requested at the time the cervical sample is taken.

### **Laboratory hours**

The laboratory department is open 9.00am to 6.00pm. Out-of-hours results are available on 020 7307 7373.

### **Urgent samples**

It is helpful if requests for urgent samples can be discussed with the Senior Management Team. Please telephone **020 7307 7387**.

### Use of service/Information required

Request forms must include 3 identifiers (this can be patient's full name = 1, date of birth, hospital number or reference number). Samples will not be processed without a request form. TDL Request Forms do not include the information required for NHS requests for cervical cytology and should not be used for NHS requests.

Appropriate clinical information providing previous treatment/histological diagnosis is essential to ensure correct management recommendations can be given in the patient report. Tick boxes are provided to assist you.

The specimen container must be clearly labelled with patient details. Forms and samples which are mismatched will result in the sample being returned to the sender for correction and will delay the report turn around time.

### Clinical advice

The Consultant Cytopathologists and the Consultant Biomedical Scientist work together to provide clinical and technical advice, including recommendations for follow-up, HPV testing and management of complex cases. TDL will provide recommendation for patient management, but not undertake to provide a direct referral. No result will be entered onto the NHS CSP database and will therefore not be part of an individual's NHS screening record. Failsafe and management of the patient and their follow up, including referral for colposcopy where indicated, would need to be arranged by their referring clinician. To contact the department directly, please **020 7307 7387**.



#### RECORD...

...the patient's 3 identifiers to include date of birth on the vial, and the patient information and medical history on the cytology requisition form. TDL Request Forms do not include the information required for NHS requests and should not be used for NHS requests.



### OBTAIN...

...an adequate sample from the cervix using a Cervex Brush (broom-like device). Insert the central bristles of the brush into the endocervical canal deep enough to allow the shorter bristles to fully contact the ectocervix. Push gently and rotate the brush in a clockwise direction five times.



#### RINSE...

...the Cervex Brush immediately into the PreservCyt Solution vial by pushing it into the bottom of the vial 10 times, forcing the bristles apart. As a final step, swirl the brush vigorously to further release material. Visually inspect the Cervex Brush to ensure that no material remains attached. Discard the brush.

Do not leave the head of the Cervex Brush in the vial. Check the vial is in date before use.



### TIGHTEN...

...the cap so that the black torque line on the cap passes the black torque line on the vial. Do not over-tighten.



### PLACE...

...the vial and request form in a specimen bag for transportation to TDL.

## ThinPrep® PAP Test Cervex Brush Protocol

### Prepare all equipment before starting the procedure

- Note expiry date on sample collection vial. Do not use expired vials.
- Ensure the entire plastic seal is removed from the lid of the vial and discarded.
- Complete patient details on both the request form and the vial.
   Specimens may be returned or discarded if details are missing from the vial.
- Remove the lid from the vial before taking the sample.
- Use of lubricant is not recommended.

### **DO**

- If excessive mucus is present, this should be gently removed before sampling.
- Use either the Cervex Brush (broom-like device) on its own or a Plastic spatula and endocervical brush combination.
- The Cervex Brush should be rotated 5 times in a clockwise direction. The Plastic spatula should be rotated through 360 degrees and the endocervical brush rotated through one quarter to one half turn.
- Immediately rinse the collected material into the vial.
- Replace the lid and tighten so that the black torque line on the cap passes the black torque line on the vial to avoid leakage.
- Keep the unlabelled portion of the sample vial free of labels so that the contents can be seen.
- If barcoded labels are used these must be applied horizontally around the vial.
- Samples should be sent to the laboratory without delay.

### **DON'T**

- DO NOT leave the head of the Cervex Brush in the vial.
- DO NOT routinely clean the cervix or take a cervical swab before taking a cervical sample.
- An endocervical brush should never be used in isolation.
- DO NOT under any circumstances use a wooden spatula.
- DO NOT leave the collection device sitting in the vial whilst dealing with the patient.
- DO NOT over-tighten the lid on the vial.
- DO NOT place multiple labels on the outside of the vial.
- DO NOT apply barcoded labels vertically on the vial.
- DO NOT use expired vials.
- DO NOT delay the sending of vials to the laboratory. The sample needs to be processed within 3 weeks of collection.
- DO NOT use excessive lubricant
   please avoid if possible.

## **Gynaecological Samples**

The Cytology department processes cervical samples directly referred from all sectors of practice — Health screening, Occupational health, GP's, Consultants, Colposcopy units, Clinics, Hospitals and other Laboratories.

Liquid Based Cytology (LBC) is processed using the Hologic ThinPrep system. The Doctors Laboratory uses the Hologic Imaging system as an enhanced Quality Control.

Information for sample takers is available by contacting the department. Important: the head of the cervical broom must NOT be left in the vial.

The use of lubricant interferes with LBC sampling and may result in an inadequate sample. Use of lubricant is NOT recommended as it can affect the processing quality of the sample. Supplies of thin prep vials are available from TDL.

# STI Screening from Hologic Thin Prep Vial

Tests are priced individually. Please request tests individually. Requests for additional test can be made by contacting the laboratory by telephone on **020 7307 7373** or by email to **addons@tdlpathology.com**.

## **Infection by PCR (single tests)**

| TEST                             | CODE | SAMPLE REQS | TAT    |
|----------------------------------|------|-------------|--------|
| Chlamydia                        | TPCR | TPV         | 2 days |
| Chlamydia/Gonorrhoea             | TCG  | TPV         | 2 days |
| Chlamydia/Gonorrhoea/Trichomonas | TCGT | TPV         | 2 days |
| Gardnerella vaginalis            | GVPC | TPV         | 2 days |
| Gonorrhoea                       | TGON | TPV         | 2 days |
| Herpes Simplex I/II              | HERD | TPV         | 5 days |
| Mycoplasma genitalium            | MGEN | TPV         | 2 days |
| Mycoplasma genitalium/Ureaplasma | MUPC | TPV         | 2 days |
| Trichomonas vaginalis            | TVPC | TPV         | 2 days |
| Ureaplasma urealyticum           | UGEN | TPV         | 2 days |

## Multiple tests from a single sample

| TEST   | CODE | SAMPLE REQS | TAT    |
|--|------|-------------|--------|
| 7 STI Profile by PCR (7 tests from 1 Sample)           | PP12 | TPV         | 2 days |
| Chlamydia trachomatis, Neisseria gonorrhoea,           |      |             |        |
| Mycoplasma genitalium, Ureaplasma species, Trichomonas |      |             |        |
| vaginalis, Gardnerella vaginalis, Herpes Simplex I/II  |      |             |        |

## **Human papillomavirus (HPV)**

Human papillomavirus (HPV) is a common virus transmitted through sexual contact. High Risk subtypes of HPV (HR-HPV) are linked to the development of abnormal cells and can cause cervical cancer. HPV is a necessary cause of invasive cervical cancer. Evidence shows HPV testing is a more effective way to identify women at risk of cervical cancer than by screening microscopically for abnormal cells from a PAP test.

HR-HPV testing has been used as the primary cervical screening test in the UK since 2019 to identify women with low grade cytology abnormalities and as a follow up test of cure in women who have received treatment. In 2017 the UK NHSCSP recommended that testing for HPV should replace cytology as the first (primary test) in cervical screening. Primary HR-HPV testing has higher sensitivity for high grade CIN than primary cytology. HR-HPV testing also has a lower false negative rate than cytology. Primary HR-HPV testing was fully implemented in the UK during 2020. Sample-taking remains unchanged: HR-HPV testing is carried out from Thin Prep samples. Cytology will be undertaken as a triage if HPV is DETECTED.

## What does this change mean?

It means that HPV testing is the **FIRST LINE TEST**. It will be carried out as a single test, with a single result reported as Detected/Not Detected.

- If HR-HPV is NEGATIVE (Not Detected) this means no further testing is needed for your patient: she returns to Routine Recall
- If HR-HPV is POSITIVE (Detected) this means that CYTOLOGY will be processed from the same Thin Prep Vial. A further specimen is not required.

- If the result from the sample is HR-HPV NOT DETECTED the patient Recall will be determined by the screening history and will either be a repeat HR-HPV test in 12 months' time or, if HR-HPV remains persistent, a referral to colposcopy will be recommended.
- If the CYTOLOGY result from the sample is ABNORMAL the recommendation is to refer this patient for colposcopy or manage at the clinician's discretion.

https://www.gov.uk/government/publications/ cervical-screening-programme-and-colposcopymanagement/2-providing-a-quality-colposcopy-clinic

All TDL requests for HPV are processed as follows:

- If HPV is requested as a single test and the result is Negative/Not Detected, cervical cytology (PAPT) would only be processed if specifically requested. Should HPV and PAPT be undertaken, there would be a charge for both the HPV and the PAPT.
- If the HPV result is HR-HPV Detected, cervical cytology (PAPT) will be processed, even if the PAPT has not been requested. The PAPT will not be charged.

# **Understanding the significance of HPV testing**

The benefit of a negative HPV result is its's negative predictive value. A negative HPV result indicates that a patient is a very low risk of developing cervical disease. However neither HPV testing not negative cervical cytology are able to reduce the risk to zero. The negative predictive value of both DNA and mRNA testing is the same. DNA tests detect the presence of viral oncogenic expression.

Requests for Cervical Cytology as a single test are no longer processed without testing for HPV. In these circumstances, the HPV test will be charged in addition to the Cervical Cytology.

Requests for HPV as the PRIMARY TEST will reflex to Cervical Cytology if HR-HPV is Detected/Positive at no additional charge.

### **Requests for HPV Primary Screening as a single test**

| TEST                                | CODE | SAMPLE REQS | TAT    |
|-------------------------------------|------|-------------|--------|
| HPV (HR mRNA types 16, 18 + others) | HPVH | TPV         | 3 days |

If HR-HPV is DETECTED/POSITIVE, cervical cytology (PAPT) will be processed **without charge**. The PAPT will be processed from the same vial.

### Requests for HP20 as a single test

| TEST  | CODE | SAMPLE REQS  | TAT    |
|---|------|--------------|--------|
| HPV (Individually typed low & high risk DNA subtypes) | HP20 | TPV/PCR Swab | 3 days |

HPV low and high risk DNA subtypes will be reported individually (9 low and 19 high risk). If High Risk DNA subtypes are positive then Cervical Cytology (PAPT) using the same vial will be processed **without charge**.

### Requests for HPVT as a single test

| TEST                        | CODE | SAMPLE REQS | TAT    |
|-----------------------------|------|-------------|--------|
| HPV (DNA and reflexed mRNA) | HPVT | TPV         | 5 days |

If one or more of DNA types 16, 18, 31, 33, 45 are DETECTED/POSITIVE, reflex testing for expression of E6/E7 oncoproteins will be undertaken and Cervical Cytology (PAPT) will be processed **without charge**. The PAPT will be processed from the same vial.

## **Requests for Cervical Cytology (PAPT)**

| TEST                     | CODE        | SAMPLE REQS | TAT                      |
|--------------------------|-------------|-------------|--------------------------|
| Cervical Cytology        | PAPT        | TPV         | 6 days (combined report) |
| Cervical Cytology + HPVH | PAPT + HPVH | TPV         | 6 days (combined report) |

If PAPT is requested as a single test, HR-HPV will be undertaken additionally, and a combined report will be issued. **PAPT and HPVH will be charged as two separate tests**.

## Requests for Cervical Cytology (PAPT) with selected HPV (HPVH or HP20 or HPVT)

| TEST                     | CODE        | SAMPLE REQS  | TAT                      |
|--------------------------|-------------|--------------|--------------------------|
| Cervical Cytology + HPVH | PAPT + HPVH | TPV          | 6 days (combined report) |
| Cervical Cytology + HP20 | PAPT + HP20 | TPV/PCR Swab | 6 days (combined report) |
| Cervical Cytology + HPVT | PAPT + HPVT | TPV          | 6 days (combined report) |

Where HPV result is reported with Cervical Cytology, a recommendation for patient management will be given, based on the combined findings.

## **TDL Self-Collection HPV Test**

Human Papillomavirus (HPV) is the primary cause of nearly all cervical cancer. In most cases, the HPV virus is harmless and causes no symptoms. Most women who acquire HPV are able to clear the infection through their own immune systems. Persistent presence of high-risk types of HPV can cause cervical lesions which over time may develop into cancer if untreated. Testing for HPV determines the presence, or absence, of HPV and will determine whether the HPV type present is high risk for CIN and cervical cancer.

The Self-Collection HPV Test provides women with the option to self-collect a vaginal specimen that is then sent to the laboratory for testing. There is well documented high level of concordance between the HPV DNA results from self-collected and clinician-collected specimens.

The Self-Collection HPV Test is validated, using a CE marked sample collection device for vaginal cell collection. This sample is then sent to the laboratory for processing for 19 high risk HPV DNA subtypes. A negative result means that these high-risk subtypes HPV were not detected and the patient is at extremely low risk of developing high-grade cervical disease/CIN2+ before their next routine visit.

A positive HPV result might indicate an increased risk of developing CIN/cervical cancer, and the report from the laboratory will provide a clear recommendation for follow-up/colposcopy.

The value of HPV DNA testing in cervical cancer screening and disease detection has been proven over and over again. Self-collection of specimens for HPV testing is not intended to replace existing patient management pathways but allows for:

- Those who wish to test following a change of sexual partner
- Option for identifying individual high risk DNA subtypes
- Personal preference to self-collect vaginal samples
- An acceptable option for women who avoid having regular cervical smears
- Self-collection for HPV increases acceptability and coverage rate of cervical cancer prevention

Results will always be sent to the requesting clinician, clinic or healthcare organisation.

### **HPVY**

Self-Collected HPV DNA incorporating a collective of high risk subtypes.

#### HPV7

Self-Collected HPV DNA with **individual** reporting of all High Risk subtypes (16, 18, 31, 33, 45, 35, 39, 51, 52, 56, 58, 59, 66, 68, 26, 53, 69, 73, 82).

For more information, or to order Self-Collection HPV Test Packs, please contact Annette Wilkinson on **020 7307 7373** or **annette.wilkinson@tdlpathology.com** 

| TEST  | CODE | SAMPLE REQS          | TAT    |   |
|---|------|----------------------|--------|---|
| HPV (Individually typed high risk<br>DNA subtypes) (Self-collect) | HPVZ | Qvintip vaginal swab | 3 days | _ |
| HPV (mRNA all high risk subtypes)<br>(Self-collect)               | HPVY | Qvintip vaginal swab | 3 days | _ |

## **Non-Gynae Cytology**

## **Non-Gynaecological Cytology**

## **Cerebrospinal fluid (CSF)**

Ideally CSF should be submitted fresh or as an air dried cytospin slide, unstained and in a plastic transport slide box. A minimum of 3mls should be submitted either in fresh form or spun on multiple slides for cytopathologists' review and opinion. Please contact TDL Cytology for advice if required on 020 7307 7323 /7373.

### Fluids

All available material should be submitted in a sterile container without fixative as quickly as possible. If any delay is anticipated, the material should be submitted in cytolyt fixative.

#### **Urines**

To prevent cell degeneration it is advisable to collect urine samples in a sample pot containing preservative (available from TDL Supplies). Use of preservative will ensure the cellular material is preserved up to 48 hours.

### Ideally 10 mls (excluding preservative)

from a freshly fully voided urine (when the bladder is emptied) mid-morning sample should be submitted for cytological assessment. If microbiology or chemistry investigations are also required, **please submit separate urine samples** and mark the vials accordingly. A mid-stream urine sample is NOT recommended for cytological assessment is it could lead to a low cellular yield. If a delay of greater than 24 hours in reaching the laboratory is anticipated samples should be refrigerated at 4°C.

### **Sputum**

Sputum should be collected on at least three occasions if underlying lung carcinoma is suspected. A single sputum is sufficient for microbiological assessment. Sputum should be sent to the laboratory immediately following production, or stored in a universal container containing cytolyt cell fixative if there is a likely delay. Please note that this is only acceptable if sputum is only for Cytology. Microbiology cannot be performed on fixed material. Early morning sputum is ideal, but contamination with food, toothpaste and tobacco should be avoided.

| TEST   | CODE | SAMPLE REQS                 | TAT    |
|--|------|-----------------------------|--------|
| Fluid Cytology   | CATF | Fluid <sup>4</sup>          | 3 days |
| Urine Cytology (Urine cytology containers available from TDL Supplies) | URCY | Urine (30mls) <sup>21</sup> | 2 days |

TDL's Histopathology service supports a full range of pathology sub-specialities.

To prevent tissue degeneration, it is advisable to collect histopathology samples in sample pot(s) containing preservative, usually formalin, to at least ten times the volume of the tissue sample (available from TDL Supplies). Use of preservative will ensure that the tissue architecture and microscopic appearances of specimens are preserved.

Patient demographics, together with clinical and sample details need to be provided with the specimens. Testicular investigations for reproductive investigations are best submitted fixed in Bouins solution. Requests for products of conception require the patient's signed consent/instruction regarding sensitive disposal when the histopathology is complete. Please contact **020 7307 7380** or **020 7307 7373** for information or any query relating to histopathology.

All specimens are initially stained with H&E. However special stains and immunohistochemistry (IHC) may be recommended if additional information is needed to provide a more detailed analysis. The choice of stain depends on the findings on initial assessment, the clinical context and the preference of the pathologist within their specialist expertise. IHC may be added when routine or regular histological testing is not sufficient to form a diagnosis. There are additional charges for special stains and immunohistochemistry.

| CATEGORY | CODE      | TISSUE SAMPLE                                  |
|----------|-----------|--|
| Breast   | HIS1      | Breast Capsule                                 |
| Breast   | HIS4      | Breast Reduction (Bilateral)                   |
| Breast   | HIS3      | Breast Reduction (Unilateral)                  |
| Breast   | HIS2      | Breast Tissue                                  |
| Breast   | HIS2      | Cavity Shavings                                |
| Breast   | HIS1      | Core Biopsy (1 Specimen)                       |
| Breast   | HIS2      | Core Biopsy (2 Specimens)                      |
| Breast   | HIS3      | Core Biopsy (3 Specimens)                      |
| Breast   | HIS4      | Core Biopsy (4 Specimens)                      |
| Breast   | HIS3      | Lumpectomy                                     |
| Breast   | HIS5      | Mastecomy (simple) / Wide Local Excision (WLE) |
| Breast   | HIS5+HIS4 | Mastectomy + Axillary Clearance                |
| Breast   | HIS4      | Microdochectomy                                |
| Breast   | HIS2      | Nipple   |
| Breast   | HIS5      | Sentinal Nodes                                 |
| Cardiac  | HIS3      | Aorta  |
| Cardiac  | HIS2      | Cardiac Biopsy                                 |
| Cardiac  | HIS3      | Cardiac Tumour Excision                        |
| -        |           |  |

| CATEGORY         | CODE      | TISSUE SAMPLE                 |
|------------------|-----------|-------------------------------|
| Cardiac          | HIS2      | Heart Valves                  |
| Cardiac          | HIS2      | Mediastinal Tissue            |
| Cardiac          | HIS2      | Pericardium                   |
| Cardiac          | HIS2      | Temporal Artery Biopsy        |
| Endocrine        | HIS5      | Adrenal                       |
| Endocrine        | HIS4      | Parathyroid                   |
| Endocrine        | HIS4      | Thyroid (Lobe)                |
| Endocrine        | HIS5      | Thyroid (Total)               |
| ENT – Biopsy     | HIS2      | Bronchial Biopsy              |
| ENT – Biopsy     | HIS1      | Cholesteatoma                 |
| ENT – Biopsy     | HIS1      | Dental Cyst                   |
| ENT – Biopsy     | HIS1      | Ear Canal Biopsy              |
| ENT – Biopsy     | HIS1      | Ear Polyp                     |
| ENT – Biopsy     | HIS1      | Epiglottis                    |
| ENT – Biopsy     | HIS1      | Gingivial Tissue              |
| ENT – Biopsy     | HIS1      | Laryngeal Biopsy              |
| ENT – Biopsy     | HIS2      | Laryngeal Nodule (Bilateral)  |
| ENT – Biopsy     | HIS1      | Laryngeal Nodule (Unilateral) |
| ENT – Biopsy     | HIS2      | Mandible Biopsy               |
| ENT – Biopsy     | HIS2      | Maxillary Mucosa              |
| ENT – Biopsy     | HIS2      | Mucocele                      |
| ENT – Biopsy     | HIS1      | Nasal Biopsy                  |
| ENT – Biopsy     | HIS1      | Nasal Polyps                  |
| ENT – Biopsy     | HIS1      | Oral Biopsy                   |
| ENT – Biopsy     | HIS1      | Palatal Biopsy                |
| ENT – Biopsy     | HIS1      | Pharyngeal Biopsy             |
| ENT – Biopsy     | HIS2      | Pleural Biopsy                |
| ENT – Biopsy     | HIS1      | Thyroid Biopsy                |
| ENT – Biopsy     | HIS1      | Tongue Biopsy                 |
| ENT – Biopsy     | HIS1      | Tonsil (1 Specimen)           |
| ENT – Biopsy     | HIS2      | Tonsil Biopsy                 |
| ENT – Biopsy     | HIS2      | Tonsils (2 Specimens)         |
| ENT – Biopsy     | HIS2      | Uvelectomy                    |
| ENT – Biopsy     | HIS1      | Vocal Chords                  |
| ENT – Resections | HIS5+HIS2 | Glossectomy                   |
|                  |           |                               |

| CATEGORY               | CODE      | TISSUE SAMPLE                       |
|------------------------|-----------|-------------------------------------|
| ENT – Resections       | HIS5      | Laryngectomy                        |
| ENT – Resections       | HIS5+HIS2 | Maxillectomy                        |
| ENT – Resections       | HIS5+HIS2 | Neck Dissection                     |
| ENT – Resections       | HIS5+HIS5 | Neck Dissection (Bilateral)         |
| ENT – Resections       | HIS4      | Parotidectomy                       |
| ENT – Resections       | HIS4      | Partial Thyroidectomy               |
| ENT – Resections       | HIS5+HIS5 | Pharyngectomy                       |
| ENT – Resections       | HIS5+HIS2 | Rhinectomy                          |
| ENT – Resections       | HIS3      | Submandibular Gland – Excision      |
| ENT – Resections       | HIS2      | Thyroglossal Cyst                   |
| GI Endoscopic – Biopsy | HIS1      | Bile Duct Biopsy                    |
| GI Endoscopic – Biopsy | HIS1      | Colonic Polyp                       |
| GI Endoscopic – Biopsy | HIS1      | Endoscopic Biopsy (1 specimen)      |
| GI Endoscopic – Biopsy | 2H1       | Endoscopic Biopsy (2 specimens)     |
| GI Endoscopic – Biopsy | 3H1       | Endoscopic Biopsy (3 specimens)     |
| GI Endoscopic – Biopsy | 4H1       | Endoscopic Biopsy (4 specimens)     |
| GI Endoscopic – Biopsy | 5H1       | Endoscopic Biopsy (5 specimens)     |
| GI Endoscopic – Biopsy | 6H1       | Endoscopic Biopsy (6 specimens)     |
| GI Endoscopic – Biopsy | 7H1       | Endoscopic Biopsy (7 specimens)     |
| GI Endoscopic – Biopsy | 8H1       | Endoscopic Biopsy (8 specimens)     |
| GI Endoscopic – Biopsy | 9H1       | Endoscopic Biopsy (9 specimens)     |
| GI Endoscopic – Biopsy | 10H1      | Endoscopic Biopsy (10-15 specimens) |
| GI Endoscopic – Biopsy | HIS5      | Liver Biopsy – Medical              |
| GI Endoscopic – Biopsy | HIS3      | Liver Biopsy – Tumour               |
| GI Endoscopic – Biopsy | HIS3      | Omental Biopsy                      |
| GI Endoscopic – Biopsy | HIS1      | Pancreatic Biopsy                   |
| GI Endoscopic – Biopsy | HIS1      | Perianal Biopsy                     |
| GI-Resection – Small   | HIS2      | Anal Fistula                        |
| GI-Resection – Small   | HIS2      | Appendix                            |
| GI-Resection – Small   | HIS3      | Endo Mucosal Resection (EMR/ESD)    |
| GI-Resection – Small   | HIS2      | Gallbladder                         |
| GI-Resection – Small   | HIS2      | Haemorrhoidectomy                   |
| GI-Resection – Small   | HIS2      | Hernia Sac                          |
| GI-Resection – Small   | HIS3      | Meckel's Diverticulum               |
| GI-Resection – Small   | HIS2      | Mesentery                           |
|                        |           |                                     |

| CATEGORY             | CODE      | TISSUE SAMPLE                                |
|----------------------|-----------|--|
| GI-Resection – Small | HIS2      | Perianal Biopsy/Warts                        |
| GI-Resection – Small | HIS2      | Pilonidal Sinus                              |
| GI-Resection – Small | HIS2      | Polypectomy                                  |
| GI-Resection – Small | HIS2      | Umbilical Lesion                             |
| GI Resection – Large | HIS5      | Biliary Resection                            |
| GI Resection – Large | HIS5+HIS2 | Colon  |
| GI Resection – Large | HIS5      | Distal Pancreatectomy                        |
| GI Resection – Large | HIS5+HIS2 | Gastrectomy                                  |
| GI Resection – Large | HIS5      | Gastric Wedge Resection                      |
| GI Resection – Large | HIS5      | lleoanal Pouch Resection                     |
| GI Resection – Large | HIS4      | lleostomy                                    |
| GI Resection – Large | HIS3      | lleum  |
| GI Resection – Large | HIS5+HIS2 | Large Bowel Resection - Benign/Malignant     |
| GI Resection – Large | HIS4      | Liver Wedge Resection                        |
| GI Resection – Large | HIS5+HIS2 | Oesophagectomy                               |
| GI Resection – Large | HIS5      | Partial Hepatectomy                          |
| GI Resection – Large | HIS5      | Small Bowel Resection - Benign/Malignant     |
| GI Resection – Large | HIS5+HIS5 | Whipple's Procedure/Pancreatectoduodenectomy |
| Gynaecology          | HIS2      | Cervical Biopsy                              |
| Gynaecology          | HIS1      | Cervical Polyp                               |
| Gynaecology          | HIS4      | Cervix                                       |
| Gynaecology          | HIS1      | Curettings – Endocervical                    |
| Gynaecology          | HIS1      | Curettings – Endometial                      |
| Gynaecology          | HIS2      | Endometrial Biopsy                           |
| Gynaecology          | HIS1      | Endometrial Pipelle                          |
| Gynaecology          | HIS1      | Endometrial Polyp                            |
| Gynaecology          | HIS2      | Fallopian Tube                               |
| Gynaecology          | HIS3      | Fibroids                                     |
| Gynaecology          | HIS2      | Fimbrial Cyst                                |
| Gynaecology          | HIS4      | LLETZ and/or Cone Biopsy                     |
| Gynaecology          | HIS2      | Mastoid                                      |
| Gynaecology          | HIS2      | Ovarian Biopsy                               |
| Gynaecology          | HIS2      | Ovarian Cyst                                 |
| Gynaecology          | HIS1      | Ovarian Pipelle                              |
| Gynaecology          | HIS5      | Ovaries (Bilateral)                          |
|                      |           |  |

| 0.4750.007        |           | TIONIE CAMPIE                     |
|-------------------|-----------|-----------------------------------|
| CATEGORY          | CODE      | TISSUE SAMPLE                     |
| Gynaecology       | HIS3      | Ovary (Unilateral)                |
| Gynaecology       | HIS4      | Ovary and Tube (Unilateral)       |
| Gynaecology       | HIS5      | Ovary and Tube (Bilateral)        |
| Gynaecology       | HIS2      | Pelvic Mass                       |
| Gynaecology       | HIS1      | Peritoneal Biopsy                 |
| Gynaecology       | HIS5      | Placenta                          |
| Gynaecology       | HIS2      | Pouch of Douglas                  |
| Gynaecology       | HIS1      | Products of Conception            |
| Gynaecology       | HIS2      | Uterine Polyp                     |
| Gynaecology       | HIS4      | Uterus                            |
| Gynaecology       | HIS5      | Uterus and Cervix                 |
| Gynaecology       | HIS5      | Uterus, Tubes and Ovaries         |
| Gynaecology       | HIS1      | Vulval Biopsy                     |
| Haemato-Oncology  | HIS5      | Bone Marrow                       |
| Haemato-Oncology  | HIS2      | Lymph Node                        |
| Haemato-Oncology  | HIS3      | Lymph Node (Lymphoma)             |
| Haemato-Oncology  | HIS3      | Lymph Node (Metastatic Disease)   |
| Haemato-Oncology  | HIS5      | Spleen                            |
| Haemato-Oncology  | HIS5      | Thymus                            |
| Lung – Biopsy     | HIS3      | Lung Biopsy                       |
| Lung – Resections | HIS3      | Lung Lesion Small Wedge Resection |
| Lung – Resections | HIS5+HIS5 | Lung Resection                    |
| Lung – Resections | HIS5      | Lung Tumour Resection +/- Nodes   |
| Neurosurgery      | HIS3      | Brain Biopsy                      |
| Neurosurgery      | HIS3      | Brain Resection                   |
| Neurosurgery      | HIS5+HIS5 | Muscle Biopsy                     |
| Neurosurgery      | HIS3      | Pituitary Gland – Resection       |
| Neurosurgery      | HIS3      | Spinal Tumour Biopsy              |
| Neurosurgery      | HIS3      | Spinal Tumour Resection           |
| Neurosurgery      | HIS4      | Vertebrea                         |
| Opthalmic         | HIS1      | Conjunctival Biopsy               |
| Opthalmic         | HIS1      | Cornea                            |
| Opthalmic         | HIS4      | Globe / Removal of Eye            |
| Opthalmic         | HIS2      | Lacrimal Gland Biopsy/Excision    |
| Opthalmic         | HIS1      | Orbit Contents of Eye             |
|                   |           |                                   |

| CATEGORY             | CODE | TISSUE SAMPLE                             |
|----------------------|------|---|
| Orthopaedic          | HIS1 | Bone Biopsy                               |
| Orthopaedic          | HIS2 | Bone Currettings                          |
| Orthopaedic          | HIS2 | Bursa                                     |
| Orthopaedic          | HIS2 | Duputrenes Contracture                    |
| Orthopaedic          | HIS3 | Femoral Head Resection                    |
| Orthopaedic          | HIS1 | Ganglion Cyst                             |
| Orthopaedic          | HIS3 | Joint Resurfacing/Redo Prosthesis Capsule |
| Orthopaedic          | HIS1 | Neuroma                                   |
| Orthopaedic          | HIS2 | Synovial Biopsy                           |
| Orthopaedic          | HIS3 | Tendon                                    |
| Skin and Soft Tissue | HIS2 | Abscess                                   |
| Skin and Soft Tissue | HIS3 | Alopecia Biopsies                         |
| Skin and Soft Tissue | HIS1 | Cyst Excision                             |
| Skin and Soft Tissue | HIS1 | Fossa                                     |
| Skin and Soft Tissue | HIS1 | Granuloma                                 |
| Skin and Soft Tissue | HIS3 | Lipoma                                    |
| Skin and Soft Tissue | HIS2 | Skin Excision BCC/SCC                     |
| Skin and Soft Tissue | HIS1 | Nail                                      |
| Skin and Soft Tissue | HIS1 | Pilonidal Sinus                           |
| Skin and Soft Tissue | HIS5 | Sentinel Nodes in Skin Cancer (Melanoma)  |
| Skin and Soft Tissue | 1SK  | Skin Biopsy (1 specimen)                  |
| Skin and Soft Tissue | 2SK  | Skin Biopsy (2 specimens)                 |
| Skin and Soft Tissue | 3SK  | Skin Biopsy (3 specimens)                 |
| Skin and Soft Tissue | 4SK  | Skin Biopsy (4 specimens)                 |
| Skin and Soft Tissue | 5SK  | Skin Biopsy (5 specimens)                 |
| Skin and Soft Tissue | 6SK  | Skin Biopsy (6 specimens)                 |
| Skin and Soft Tissue | 7SK  | Skin Biopsy (7 specimens)                 |
| Skin and Soft Tissue | 8SK  | Skin Biopsy (8 specimens)                 |
| Skin and Soft Tissue | 9SK  | Skin Biopsy (9 specimens)                 |
| Skin and Soft Tissue | 10SK | Skin Biopsy (10 specimens)                |
| Skin and Soft Tissue | 11SK | Skin Biopsy (11-15 specimens)             |
| Skin and Soft Tissue | HIS3 | Soft Tissue Tumour Biopsy                 |
| Skin and Soft Tissue | HIS3 | Soft Tissue Tumour Resection              |
| Urology – Biopsy     | HIS1 | Bladder Biopsy                            |
| Urology – Biopsy     | HIS1 | Core Biopsy (Urology)                     |
|                      |      |   |

### Histopathology

| CATEGORY            | CODE         | TISSUE SAMPLE                         |
|---------------------|--------------|---------------------------------------|
| Urology – Biopsy    | HIS2         | Hydrocele                             |
| Urology – Biopsy    | HIS2         | Penile Biopsy                         |
| Urology – Biopsy    | HIS1         | Prostate Biopsy                       |
| Urology – Biopsy    | 2H1          | Prostate Biopsies x 2                 |
| Urology – Biopsy    | 3H1          | Prostate Biopsies x 3                 |
| Urology – Biopsy    | 4H1          | Prostate Biopsies x 4                 |
| Urology – Biopsy    | 5H1          | Prostate Biopsies x 5                 |
| Urology – Biopsy    | 6H1          | Prostate Biopsies x 6                 |
| Urology – Biopsy    | 7H1          | Prostate Biopsies x 7                 |
| Urology – Biopsy    | 8H1          | Prostate Biopsies x 8                 |
| Urology – Biopsy    | 9H1          | Prostate Biopsies x 9                 |
| Urology – Biopsy    | 10H1         | Prostate Biopsies x 10-12             |
| Urology – Biopsy    | HIS5         | Testicular Biopsy (Bilateral)         |
| Urology – Biopsy    | HIS4         | Testicular Biopsy (Unilateral)        |
| Urology – Biopsy    | HIS1         | Urethral Biopsy                       |
| Urology – Biopsy    | HIS2         | Vasectomy                             |
| Urology – Resection | HIS5+HIS5    | Cystoprostatectomy                    |
| Urology – Resection | HIS3         | Epididymis                            |
| Urology – Resection | HIS1         | Foreskin/Circumcision                 |
| Urology – Resection | HIS5         | Nephrectomy/Kidney                    |
| Urology – Resection | HIS5+HIS5    | Prostatectomy                         |
| Urology – Resection | HIS5+HIS5    | Radical Cystectomy                    |
| Urology – Resection | HIS3         | Testis                                |
| Urology – Resection | HIS3 - HIS5+ | TURBT (dependent on number of blocks) |
| Urology – Resection | HIS3 - HIS5  | TURP (dependent on number of blocks)  |
| <u> </u>            |              | <u> </u>                              |

| TEST  | CODE | SAMPLE REQS                          | TAT      | PAGE      |
|---|------|--------------------------------------|----------|-----------|
| 1,25 Vitamin D                                | D3   | <b>B</b>                             | 5-8 days | 149       |
| 2-Butanone GC                                 | BUTA | RU                                   | 7 days   | 164       |
| 2-Furoic Acid                                 | 2FA  | RU                                   | 10 days  | 164       |
| 5 HIAA  | RU5H | PU (collect on acid) <sup>1</sup>    | 5 days   | 29        |
| 5' Nucleotidase                               | 5NT  | В                                    | 5 days   | 29        |
| 6-Thioguanine Nucleotides                     | TGN  | AA                                   | 2 weeks  | 29        |
| 7 STI Profile by PCR                          | DL12 | Aptima urine or multisite swab       | 2 days   | 69, 73,   |
| (7 tests from 1 Sample) (Self-collect)        |      |                                      |          | 156       |
| 7 STI Profile by PCR                          | DL12 | FCRU / PCR Swab / TPV or             | 2 days   | 69, 73    |
| (7 tests from 1 Sample)                       |      | Aptima urine / multsite swab         |          |           |
| 7 STI Profile by PCR                          | PP12 | TPV                                  | 2 days   | 168       |
| (7 tests from 1 Sample) (Thin Prep)           |      |                                      |          |           |
| 11 Deoxycorticosterone                        | DEOX | <u>B</u>                             | 10 days  | 55        |
| 11 Deoxycortisol                              | 11DC | (Frozen)                             | 10 days  | 55        |
| 16S rRNA Bacterial Gene                       | 16S  | J                                    | 1 week   | 45        |
| 17 Hydroxyprogesterone                        | 170H | В                                    | 5 days   | 55        |
| 18S rRNA Fungal Gene                          | 18S  | J                                    | 1 week   | 45        |
| 21 Hydroxylase Ab's                           | 21HA | (Frozen)                             | 10 days  | 29        |
| Acetone – Blood                               | ACTB | A or (1)                             | 2 weeks  | 164       |
| Acetone – Urine                               | ACTU | RU                                   | 5 days   | 164       |
| Acetylcholine Receptor Autoantibodies         | ACRA | <b>B</b> 4                           | 5 days   | 29        |
| Acid Phosphatase – Total                      | APT  | 3                                    | 5 days   | 29        |
| ACTH (Adrenocorticotropic Hormone)            | ACTH | (Plasma, spun and                    | 1 day    | 55        |
|   |      | frozen within 2 hours) <sup>41</sup> |          |           |
| Activated Protein C Resistance                | APCR | C (Frozen) <sup>4,18</sup>           | 3 days   | 41        |
| Acute Viral Hepatitis Screen                  | AHSC | В                                    | 4 hours  | 79, 85    |
| ADAMTS-13 Antibody                            | A13A | C (Frozen) <sup>9,18</sup>           | 1 month  | 41        |
| Adenosine Deaminase                           | AD   | A / B / Fluid                        | 3 weeks  | 29        |
| Adenovirus by PCR                             | ADV  | (A) / PCR / VS / SC                  | 7 days   | 98        |
| Adiponectin                                   | ADIP | <b>3</b>                             | 2 weeks  | 29        |
| Adrenal Cortex Antibodies                     | ACTX | 3                                    | 2 days   | 79        |
| Albumin                                       | ALB  | <b>B</b>                             | 4 hours  | 29        |
| Alcohol (Medical) [Do not use alcohol         | ALC0 | <b>G</b> 1                           | 4 hours  | 29        |
| swab prior to sample taking]                  |      |                                      |          |           |
| Alcohol (Urine)                               | UALC | RU                                   | 4 hours  | 29        |
| Alcohol Profile                               | AP   | <b>ABB</b> C                         | 5-7 days | 161, 164  |
| Alcohol Profile 2                             | ALCP | A A B B G RU                         | 5-7 days | 161, 164  |
| Aldolase                                      | ALD0 | 3                                    | 5 days   | 29        |
| Aldosterone                                   | ALDN | A or B                               | 5 days   | 55        |
| Aldosterone (Urine)                           | UALD | PU                                   | 5 days   | 55        |
| ALEX <sup>2</sup> Allergy Test (Self-collect) | ALEX | (TDL Tiny)                           | 3-4 days | 139, 144, |
|   |      |                                      |          | 156       |

| TEST   | CODE | SAMPLE REQS              | TAT       | PAGE           |
|--|------|--------------------------|-----------|----------------|
| ALEX <sup>2</sup> Allergy Test (Venous)          | ALEX | (Serum)                  | 3-4 days  | 139, 144       |
| Alkaline Phosphatase                             | ALP  | В                        | 4 hours   | 29             |
| Alkaline Phosphatase Isoenzymes                  | APIE | B                        | 5 days    | 29             |
| Allergic Rhinitis/Asthma Profile                 | ALRN | В                        | 2 days    | 139, 144       |
| Allergy – Individual Allergens                   | ALLE | B                        | 2 days    | 139            |
| Allergy – 5 x Single Individual Allergens        | 5AL  | B                        | 2 days    | 139            |
| Allergy – 10 x Single Individual Allergens       | 10AL | В                        | 2 days    | 139            |
| Allergy Profile 1 (Food & Inhalants)             | 1A   | BB                       | 2 days    | 139, 142       |
| Allergy Profile 2 (UK Aero Allergen)             | 2A   | В                        | 2 days    | 139, 142       |
| Allergy Profile 3 (Food)                         | 3A   | B                        | 2 days    | 139, 142       |
| Allergy Profile 4 (Nuts & Seeds)                 | 4A   | B                        | 2 days    | 139, 142       |
| Allergy Profile 5 (Children's Panel)             | 5A   | B                        | 2 days    | 139, 142       |
| Allergy Profile 6 (Shellfish)                    | 6A   | В                        | 2 days    | 139, 143       |
| Allergy Profile 7 (Finfish)                      | 7A   | B                        | 2 days    | 139, 143       |
| Allergy Profile 8 (Cereal – singles)             | 8A   | B                        | 2 days    | 139, 143       |
| Allergy Profile 9 (Antibiotics)                  | 9A   | В                        | 2 days    | 139, 143       |
| Allergy Profile 10 (Insects)                     | 10A  | В                        | 2 days    | 139, 143       |
| Allergy Profile 11 (Combined Shellfish/Finfish)  | 11A  | B                        | 2 days    | 139, 143       |
| Allergy Profile 12 (Milk & Milk Proteins)        | 12A  | B                        | 2 days    | 139, 143       |
| Allergy Profile 13 (Stone fruit/Rosaceae family) | 13A  | B                        | 2 days    | 139, 144       |
| Alpha Gal Components (related to red meat)       | ZZ37 | B                        | 2 days    | 140            |
| Alpha-1-Antitrypsin (Serum)                      | A1AT | В                        | 1 day     | 29             |
| Alpha-1-Antitrypsin (Stool)                      | A1AF | RF                       | 10 days   | 29             |
| Alpha-1-Antitrypsin Genotype – PI*M, PI*S, PI*Z  | GENE | <b>A</b> 9               | 5 weeks   | 29             |
| Alpha-1-Glycoprotein                             | OROS | (Frozen)                 | 5 days    | 29             |
| Alpha-1-Microglobulin                            | A1MG | RU 1,22                  | 10 days   | 29             |
| Alpha-2-Macroglobulins                           | A2MG | В                        | 5 days    | 29             |
| Alpha-Fetoprotein                                | AFP  | B                        | 4 hours   | 29, 55,        |
|  |      |                          |           | 102            |
| ALT (Alanine Aminotransferase) (SGPT)            | ALT  | 8                        | 4 hours   | 29             |
| Alternaria Components                            | ZZ1  | 8                        | 2 days    | 140            |
| Aluminium (Blood)                                | ALUM | 0                        | 7 days    | 29, 163        |
| Aluminium (Urine)                                | ALUU | RU CONTRACTOR TO A       | 1-2 weeks | 163            |
| Amenorrhoea Profile (Self-collect) CHANGE        | TAME | (TDL Tiny) (3 (TDL Tiny) | 1 day     | 55, 60,<br>156 |
| Amenorrhoea Profile (Venous) CHANGE              | AMEN | <b>B</b>                 | 4 hours   | 55, 60         |
| Amikacin Level (State dose)                      | AMIK | <b>B</b> 4               | 4 hours   | 135            |
| Amino Acid (EDTA Plasma)                         | AMIN | (Frozen EDTA Plasma)     | 7 days    | 29             |
| Amino Acid Quantitative (Urine)                  | UAAQ | RU (Frozen)              | 7 days    | 29             |
| Aminolevulinic Acid (Urine)                      | RUAL | 100mls <b>PU</b>         | 5 days    | 29             |
| Amitriptyline                                    | AMTR | <b>A</b> 4               | 5 days    | 136            |
|  |      |                          |           |                |

| TEST   | CODE | SAMPLE REQS                             | TAT       | PAGE    |
|--|------|---|-----------|---------|
| AML/ALL Molecular MRD - NPM1, PML-RARA,                    | GENE | Bone Marrow / 🛕                         | 5 days    | 112     |
| CBFB-MYH11, RUNX1-RUNX1T1, ETV6-RUNX1                      |      |   |           |         |
| Ammonia  | AMM0 | (Frozen) <sup>15</sup>                  | 4 hours   | 29      |
| Amniocentesis – rapid BOBs aneuploidy                      | ABK  | AF <sup>9</sup>                         | 5-15 days | 112     |
| diagnosis for all chromosomes                              |      |   |           |         |
| (5 days) + culture (10-15 days)                            | 1000 | A=0                                     | 0.45.1    |         |
| Amniocentesis – rapid PCR diagnosis                        | APCC | AF <sup>9</sup>                         | 2-15 days | 112     |
| for common aneuploidies (2 days)<br>+ culture (10-15 days) |      |   |           |         |
| Amoebic (E. histolytica) Antibodies                        | AFAT | 3                                       | 1 week    | 89      |
| Amoebic (E. histolytica) PCR                               | AMAG | RF                                      | 2 days    | 89      |
| Amphetamines – Blood                                       | AMPB | 88                                      | 5 days    | 161     |
| Amylase (Self-collect)                                     | AMY  | ③ (TDL Tiny)                            | 1 day     | 29, 156 |
| Amylase (Urine)  | UAMY | CU                                      | 4 hours   | 29      |
| Amylase (Venous)   | AMY  | <b>B</b>                                | 4 hours   | 29      |
| Amylase Isoenzymes   | AMYI | B                                       | 5 days    | 29      |
| Amyloidosis (Amyloid A Protein)                            | SAA  | <u>B</u>                                | 5 days    | 29      |
| Anaemia Profile  | ANAE | AAB                                     | 2 days    | 40, 43  |
| Anafranil (Clomipramine)                                   | CHLO | A                                       | 7 days    | 136     |
| ANCA (Anti-Neutrophil Cytoplasmic Abs)                     | ANCA | B                                       | 2 days    | 79      |
| Andropause Profile   | ANDP | 88                                      | 8 hours   | 55, 60  |
| Androstanediol Glucuronide                                 | ANDG | B                                       | 3 weeks   | 29      |
| Androstenedione  | ANDR | (Frozen)                                | 5 days    | 55      |
| Angiotensin II   | ANG2 | (Frozen plasma)                         | 2 weeks   | 30      |
| Angiotensin Converting Enzyme                              | ACE  | В                                       | 4 hours   | 30      |
| Angiotensin Converting Enzyme – CSF                        | ACEF | CSF (Frozen)                            | 2 weeks   | 30      |
| Antenatal Profile  | ANTE | <b>A A</b> <sup>33</sup> <b>B B B G</b> | 3 days    | 40, 43  |
| Anti-Actin Antibodies                                      | AAA  | B                                       | 5 days    | 79      |
| Anti-Basal Ganglia Antibodies                              | ABGA | В                                       | 3 weeks   | 79      |
| Anti-CCP Antibodies  | CCP  | В                                       | 2 days    | 79      |
| Anti-Liver Cytosol Antibodies                              | ALCA | В                                       | 5 days    | 79      |
| Anti-MOG [Myelin Oligodendrocyte                           | AMOG | В                                       | 3 weeks   | 79      |
| Glycoprotein] Antibodies                                   |      |   |           |         |
| Anti-MUSK Antibodies                                       | MUSK | В                                       | 2 weeks   | 79      |
| Anti-Nuclear Antibodies (titre & pattern)                  | ANAB | В                                       | 2 days    | 79      |
| Anti-Phosphatidylserine Antibodies                         | PHTS | В                                       | 5 days    | 79      |
| Anti-Phospholipase A2 Receptor                             | AA2R | В                                       | 6 weeks   | 79      |
| Anti-Ri Antibodies   | RIAB | В                                       | 3 days    | 79      |
| Anti-SLA (Soluble Liver Antigen) Abs                       | LSA  | В                                       | 10 days   | 79      |
| Anti-Staphylolysin Titre (SGOT)                            | ASTT | В                                       | 3 days    | 79      |
| Anti-Streptolysin Titre/ASOT                               | ASLT | В                                       | 2 days    | 79      |
| Anti-Sulfatide Antibodies                                  | ASA  | В                                       | 5 weeks   | 79      |

| TEST  | CODE | SAMPLE REQS                  | TAT      | PAGE     |
|---|------|------------------------------|----------|----------|
| Anti-Xa Apixaban Monitoring                     | APIX | € (Frozen)*18                | 3 days   | 41       |
| Anti-Xa Edoxaban Monitoring                     | EDOX | C (Frozen)*18                | 3 days   | 41       |
| Anti-Xa Fondapariux Monitoring                  | FOND | C Frozen)*18                 | 3 days   | 41       |
| Anti-Xa LMWH Monitoring                         | LMWX | C (Frozen)*18                | 3 days   | 41       |
| Anti-Xa Rivaroxaban Monitoring                  | RIVA | C (Frozen)*18                | 3 days   | 41       |
| Antidiuretic Hormone                            | ADH  | (Plasma Frozen) <sup>4</sup> | 10 days  | 55       |
| Antimony (Urine)                                | ANTI | RU 30                        | 10 days  | 30       |
| Antimullerian Hormone (AMH) (Self-collect)      | AMH  | (TDL Tiny)                   | 1 day    | 30, 55,  |
|   |      |                              |          | 156      |
| Antimullerian Hormone (AMH) (Venous)            | AMH  | В                            | 4 hours  | 30, 55   |
| Antithrombin III                                | A111 | (Frozen) <sup>4,9,18</sup>   | 3 days   | 41       |
| AP50 Alternative Hemolytic Complement           | AP50 | (Frozen)                     | 2 weeks  | 30       |
| Apolipoprotein A1                               | AP0A | В                            | 3 days   | 30       |
| Apolipoprotein B                                | AP0B | B                            | 3 days   | 30       |
| Apolipoprotein C                                | AP0C | B                            | 3 months | 30       |
| Apolipoprotein E (12 hours fasting)             | AP0E | (fasting)                    | 5 days   | 30       |
| Apolipoprotein E genotype – E2/E3/E4            | APEG | <b>A</b> 9                   | 2 weeks  | 113      |
| Apple Components                                | ZZ36 | В                            | 2 days   | 140      |
| APTT/KCCT                                       | KCCT | <b>()</b> 18                 | 4 hours  | 40       |
| Aquaporin 4 Antibodies (Neuromyelitis Optica)   | AQUA | B                            | 2 weeks  | 79       |
| Arbovirus Antibodies/Abs                        | ARB0 | B 9,14                       | 3 weeks  | 98       |
| Arsenic (Blood)                                 | ARS  | A or (1)                     | 5 days   | 30, 163  |
| Arsenic (Urine)                                 | ARSE | RU 30                        | 5 days   | 30, 163  |
| Arylsulphatase A                                | ARYL | <b>(1)</b> 5,6               | 8 weeks  | 30       |
| Ascariasis Serology                             | ASC  | В                            | 5 days   | 79       |
| Ashkenazi Jewish Carrier Screen                 | GENE | <b>A</b> 9                   | 4 weeks  | 113      |
| Aspartate Transaminase (AST) (SGOT)             | AST  | В                            | 4 hours  | 30       |
| Aspergillus Components                          | ZZ2  | B                            | 2 days   | 140      |
| Aspergillus Precipitins                         | ASPP | В                            | 5 days   | 45       |
| Atopic Dermatitis/Eczema Profile (14 allergens) | ALEC | B                            | 2 days   | 139, 144 |
| Atypical Antibody Screen                        | AASC | A 22,33                      | 2 days   | 40       |
| (handwritten tube label)                        |      |                              |          |          |
| Atypical Pneumonia Screen                       | APS  | В                            | 2 days   | 98, 100  |
| Autoantibody Profile I                          | AUT0 | В                            | 2 days   | 79, 85   |
| Autoantibody Profile II                         | END0 | В                            | 2 days   | 79, 85   |
| Avian Precipitins (11 Species)                  | AVIA | В                            | 5 days   | 79       |
| Babesia PCR                                     | PCRB | A                            | 7 days   | 79       |
| Bancroftia/Oncerciasis/Filarial Antibodies      | TFIF | B 14                         | 2 weeks  | 89       |
| BCR/ABL Quantitative                            | BCRQ | <b>A A</b> <sup>9</sup>      | 10 days  | 113      |
| – fusion gene sizes p190 + p210                 |      |                              |          |          |
| Becker/Duchenne Muscular Dystrophy              | DMD1 | <b>A</b> 9                   | 10 days  | 113      |
| - deletions/duplications                        |      |                              |          |          |

| TEST  | CODE | SAMPLE REQS   | TAT      | PAGE     |
|---|------|---|----------|----------|
| Behcet's Disease – HLA Tissue Typing B*51   | B51  | <b>A</b> 9  | 10 days  | 114      |
| Bence-Jones Protein                         | RBJP | RU or CU  | 5 days   | 30       |
| Benzene                                     | BENZ | <b>J</b> 1,6  | 3 days   | 164      |
| Beta 2 Glycoprotein 1 Abs                   | B2GP | 3   | 5 days   | 79       |
| Beta 2 Microglobulin (Serum)                | B2MG | <b>B</b>  | 2 days   | 30, 164  |
| Beta 2 Microglobulin (Urine)                | UB2M | RU  | 3 days   | 30, 164  |
| Beta Carotene                               | CAR0 | <b>B</b>  | 5 days   | 149      |
| Beta D Glucan                               | XBDG | <b>B</b>  | 3 days   | 45       |
| Beta-Glucuronidase (Sly Disease)            | BGLU | <b>(1)</b> (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)          | 8 weeks  | 30       |
| Bicarbonate                                 | HCO3 | <b>B</b>  | 4 hours  | 30       |
| Bile Acids – Serum                          | BILE | <b>B</b>  | 4 hours  | 30       |
| Bilharzia (Schistosome) Antibody Screen     | BILH | <b>B</b> 14   | 10 days  | 89       |
| Bilharzia (Urine)                           | USCH | Mid-morning terminal urine following exercise <sup>14</sup> | 1-2 days | 89       |
| Bilirubin (Direct)                          | DBIL | <b>B</b>  | 4 hours  | 30       |
| Bilirubin (Total)                           | BILI | <b>B</b>  | 4 hours  | 30       |
| Bilirubin (Urine)                           | UBIL | RU  | 1 day    | 30       |
| Biotin CHANGE                               | BIOS | <b>B</b> 7  | 5 days   | 149      |
| Biotinidase                                 | BIOT | (Frozen plasma) 4   | 3 weeks  | 30       |
| Birch Components                            | ZZ3  | <b>B</b>  | 2 days   | 140      |
| Bismuth                                     | BISM | <b>B</b>  | 5 days   | 30       |
| BK Polyoma Virus by PCR                     | BKPV | (A)/RU  | 5 days   | 98       |
| Bleeding and Platelet Gene Panel            | R90U | <b>A A</b> <sup>9</sup>                                     | 12 weeks | 114      |
| Bleeding Disorder of Unknown Cause          | R90U | AA  | 12 weeks | 114      |
| Blood Culture#                              | BCUL | 2 x <b>BC</b> <sup>4</sup>                                  | 6 days + | 45       |
| Blood Film Examination                      | FILM | A   | 1 day    | 40       |
| Blood Group †                               | AB0  | A 22,33   | 2 days   | 40       |
| Blood PCR for Chromosome 13, 18, 21         | BPCR | A   | 5 days   | 114      |
| and sex chromosomes                         |      |   |          |          |
| BNP (NT-pro BNP)                            | BNP  | <b>B</b>  | 4 hours  | 30, 55   |
| Bone Alkaline Phosphatase                   | BALP | (Frozen)  | 2 weeks  | 30       |
| Bone Marrow (Aspirate)                      | BMAS | <b>J</b> <sup>1</sup>                                       | 14 days  | 43       |
| Bone Marrow (Trephine Biopsy)               | BMI  | <b>J</b> <sup>1</sup>                                       | 3 days   | 43       |
| Bone Screen                                 | BONE | ₿ CU  | 4 hours  | 30, 38   |
| Bone Screen (Bloods only)                   | BON2 | <u> </u>  | 4 hours  | 30, 38   |
| Borrelia Antibodies (Lyme Disease) IgG, IgM | BORR | B 9,14  | 2 days   | 79, 89   |
| Borrelia Antibodies (Lyme Disease) IgM      | BORM | <u> </u>  | 2 days   | 79, 89   |
| Borrelia Confirmation (Immunoblot)          | BORC | B 9,14  | 10 days  | 79, 89   |
| Brazil Components                           | ZZ4  | <u>B</u>  | 2 days   | 140      |
| Breast Cancer – BRCA1 + BRCA2 genes only    | GENE | <b>A</b>  | 4 weeks  | 114      |
| Breast Cancer NGS Panel                     | GENE | <b>A A</b> 9,11   | 4 weeks  | 102, 114 |
| Bromide                                     | BROM | <b>B</b>  | 3 days   | 164      |

| TEST   | CODE | SAMPLE REQS                     | TAT              | PAGE     |
|--|------|---------------------------------|------------------|----------|
| Brucella Serology                                    | BRUC | <b>B</b> 9                      | 2-3 weeks        | 79       |
| BUN (Blood Urea Nitrogen)                            | BUN  | 3                               | 4 hours          | 30       |
| C-KIT D816V variant – Mastocytosis                   | GENE | Bone Marrow / 🙆                 | 4 weeks          | 114      |
| C Peptide  | CPEP | 3                               | 3 days           | 55       |
| C Reactive Protein (Self-collect)                    | CRP  | (TDL Tiny)                      | 1 day            | 30, 156  |
| C Reactive Protein (Venous)                          | CRP  | 3                               | 4 hours          | 30       |
| C Reactive Protein (High Sensitivity) (Self-collect) | HCRP | (TDL Tiny)                      | 1 day            | 30, 156  |
| C Reactive Protein (High Sensitivity) (Venous)       | HCRP | 3                               | 4 hours          | 30       |
| C1 Esterase Inhibitor                                | C1EI | 3                               | 5 days           | 79       |
| C1 Esterase: Function & Total                        | FC1E | (Plasma Frozen) <sup>4,18</sup> | 10 days          | 30       |
| C1q Binding Immune Complex                           | IMCP | <b>3</b>                        | 5 days           | 31       |
| C3 Complement  | C3   | <b>3</b>                        | 4 hours          | 79       |
| C3/C4 Complement                                     | COMP | 3                               | 4 hours          | 79       |
| C4 Complement  | C4   | <b>3</b>                        | 4 hours          | 79       |
| CA 15-3  | C153 | <b>3</b>                        | 4 hours          | 102      |
| CA 19-9  | C199 | <b>B</b>                        | 4 hours          | 102      |
| CA 50  | CA50 | <b>3</b>                        | 5 days           | 102      |
| CA 72-4  | C724 | <b>3</b>                        | 5 days           | 102      |
| CA 125 (Self-collect)                                | C125 | (TDL Tiny)                      | 1 day            | 102, 156 |
| CA 125 (Venous)                                      | C125 | <b>3</b>                        | 4 hours          | 102      |
| Cadmium (Blood)                                      | CADM | A or (1)                        | 5 days           | 31, 163  |
| Cadmium (Urine)                                      | URCD | RU <sup>30</sup>                | 5 days           | 31, 163  |
| Caeruloplasmin                                       | CERU | <b>B</b>                        | 1 day            | 31, 150  |
| Calcitonin   | CAT0 | (Frozen) <sup>4</sup>           | 1 day            | 55       |
| Calcium (24 hour Urine)                              | UCA  | PU or acid urine                | 4 hours          | 31       |
| Calcium (Self-collect)                               | CA   | (TDL Tiny)                      | 1 day            | 31, 157  |
| Calcium (Venous)                                     | CA   | <b>B</b>                        | 4 hours          | 31       |
| Calcium + Vitamin D (Self-collect)                   | CALD | (TDL Tiny)                      | 1 day            | 31, 157  |
| Calcium + Vitamin D (Venous)                         | CALD | <b>B</b>                        | 1 day            | 31       |
| Calcium/Creatinine Ratio                             | CACR | RU 😉                            | 4 hours          | 31       |
| Calprotectin   | CALP | QFIT sample collection device   | 5 days           | 79, 157  |
| Calprotectin/QFIT Profile (Combined)                 | QCAL | QFIT sample collection device   | 5 days           | 45, 48,  |
|  |      |                                 |                  | 80, 85,  |
| Compulabortor laiuni Antihadiaa                      | CJAB | •                               | F dovo           | 157      |
| Campylobacter Jejuni Antibodies                      |      | CTM /OC                         | 5 days           | 45       |
| Candida (Culture)                                    | CANC | STM/CS                          | 2-4 days         | 45       |
| Cannobinoida (Urina) Sarcan                          | CANA | B                               | 5 days           | 45       |
| Cannabinoids (Urine) Screen                          | CARB | RU                              | 1 day<br>4 hours | 161      |
| Carbamazepine (Tegretol)                             | MDR  |                                 |                  | 136      |
| Carbapenemase producing organism screen              | CDG  | STM (rectal)                    | 4-5 days ‡       | 45<br>31 |
| Carbohydrate Deficient Glycoprotein                  | UDG  | В                               | 2 weeks          | 31       |

| TEST   | CODE           | SAMPLE REQS                       | TAT                      | PAGE      |
|--|----------------|-----------------------------------|--------------------------|-----------|
| Carbohydrate Deficient Transferrin<br>(CDT) (Self-collect) | CDT            | (TDL Tiny) <sup>4</sup>           | 3 days                   | 31, 157   |
| Carbohydrate Deficient Transferrin (CDT)<br>(Venous)       | CDT            | <b>B</b> <sup>4</sup>             | 3 days                   | 31        |
| Carboxyhaemoglobin   | CBHB           | A                                 | 1 week                   | 40        |
| Carcino Embryonic Antigen                                  | CEA            | В                                 | 4 hours                  | 102       |
| Cardiolipin Antibodies (IgG+IgM)                           | ACAB           | <b>B</b>                          | 2 days                   | 80        |
| Cardiovascular Risk Profile 1                              | PP10           | <b>BB</b>                         | 3 days                   | 31, 38    |
| Cardiovascular Risk Profile 2                              | PP11           | <b>B B B C</b> 34                 | 3 days                   | 31, 38    |
| Carotenes  | CAR0           | B 13                              | 5 days                   | 149       |
| Carrier Screen (Ashkenazi Jewish)                          | GENE           | <b>A</b> 9                        | 4 weeks                  | 114, 131  |
| Carrier Screen (Ashkenazi Jewish)                          | GENE           | <b>A</b> 9                        | 4 weeks                  | 115, 131  |
| – Partnered Report   |                |                                   |                          |           |
| Carrier Screen (Pan-Ethnic)                                | GENE           | <b>A</b> 9                        | 4 weeks                  | 115, 131  |
| Carrier Screen (Pan-Ethnic) – Partnered Report             | GENE           | <b>A</b> 9                        | 4 weeks                  | 115, 131  |
| Cashew Components  | ZZ35           | <b>B</b>                          | 2 days                   | 140       |
| Cat Components   | ZZ5            | В                                 | 2 days                   | 140       |
| Cat Scratch Fever (Bartonella IgG)                         | CAT            | <b>3</b>                          | 5 days                   | 98        |
| Catecholamines (Plasma)                                    | CATE           | A (Plasma Frozen) <sup>4</sup>    | 5 days                   | 55        |
| Catecholamines (Urine)                                     | UCAT           | PU (collect on acid) <sup>1</sup> | 5 days                   | 55        |
| CCP Antibodies (RF)  | CCP            | В                                 | 2 days                   | 80        |
| CD3/CD4/CD8  | LYSS           | <b>A</b> 10                       | 1 day                    | 43, 97-98 |
| CD16   | CD16           | <b>A</b> 4                        | 1 day                    | 43        |
| CD19 B Cells   | CD19           | <b>A</b> 4                        | 1 day                    | 43        |
| CD20   | CD20           | <b>A</b> 10                       | 2 days                   | 43        |
| CD25   | CD25           | <b>A</b> 10                       | 2 days                   | 43        |
| CD56   | CD56           | <b>A</b> <sup>4</sup>             | 1 day                    | 43        |
| CD57   | CD57           | A                                 | 1 day                    | 43        |
| Celery Components  | ZZ6            | B                                 | 2 days                   | 140       |
| Centromere Autoantibodies                                  | CENT           | B                                 | 2 weeks                  | 80        |
| Cervical Cytology (PAPT)                                   | PAPT           | TPV                               | 6 days (combined report) | 170       |
| Cervical Cytology + HP20                                   | PAPT +<br>HP20 | TPV / PCR SWab                    | 6 days (combined report) | 170       |
| Cervical Cytology + HPVH                                   | PAPT +<br>HPVH | TPV                               | 6 days (combined report) | 170       |
| Cervical Cytology + HPVT                                   | PAPT +<br>HPVT | TPV                               | 6 days (combined report) | 170       |
| CH50 (Classical pathway)                                   | CH50           | (Frozen) <sup>4</sup>             | 4 days                   | 80        |
| Chagas Disease Serology                                    | CHGA           | B 9,14                            | 10 days                  | 80        |
| (S.American Trypanosomiasis) T. Cruzi                      |                |                                   |                          |           |
| Chest Pain Profile   | CPP            | В                                 | STAT                     | 31, 38    |
| Chikungunya Virus Abs                                      | CHIK           | B 9,14                            | 10 days                  | 98        |
| Chlamydia – PCR swab                                       | SPCR           | PCR                               | 2 days                   | 69        |

| TEST   | CODE | SAMPLE REQS             | TAT        | PAGE    |
|--|------|-------------------------|------------|---------|
| Chlamydia – Thin Prep  | TPCR | TPV                     | 2 days     | 69, 168 |
| Chlamydia – Urine  | CPCR | FCRU                    | 2 days     | 69      |
| Chlamydia Species Specific (MIF) Ab Screen                               | CHAB | B                       | 2 days     | 80, 85  |
| Chlamydia/Gonorrhoea – Vaginal (PCR)                                     | SCG  | PCR                     | 2 days     | 69      |
| Chlamydia/Gonorrhoea – Vaginal (Self-collect)                            | SCG  | Aptima multisite swab   | 2 days     | 69, 157 |
| Chlamydia/Gonorrhoea – Rectal (PCR)                                      | RSCG | PCR                     | 2 days     | 69      |
| Chlamydia/Gonorrhoea – Rectal (Self-collect)                             | RSCG | Aptima multisite swab   | 2 days     | 69, 157 |
| Chlamydia/Gonorrhoea – Thin Prep   | TCG  | TPV                     | 2 days     | 69, 168 |
| Chlamydia/Gonorrhoea – Throat (Self-collect)                             | TSCG | Aptima multisite swab   | 2 days     | 69, 157 |
| Chlamydia/Gonorrhoea – Throat (PCR)                                      | TSCG | PCR                     | 2 days     | 69      |
| Chlamydia/Gonorrhoea – Urine (Self-collect)                              | CCG  | Aptima urine            | 2 days     | 69, 157 |
| Chlamydia/Gonorrhoea – Urine (FCRU)                                      | CCG  | FCRU                    | 2 days     | 69      |
| Chlamydia/Gonorrhoea/Trichomonas – PCR Swab                              | SCGT | PCR                     | 2 days     | 69      |
| Chlamydia/Gonorrhoea/Trichomonas – Thin Prep                             | TCGT | TPV                     | 2 days     | 69, 168 |
| Chlamydia/Gonorrhoea/Trichomonas – Urine                                 | CCGT | FCRU                    | 2 days     | 69      |
| Chloride   | CL   | B                       | 4 hours    | 31      |
| Cholesterol  | CH0  | B                       | 4 hours    | 31      |
| Cholesterol (Familial Hypercholesterolaemia)                             | GENE | <b>A A</b> <sup>9</sup> | 7 weeks    | 31      |
| Cholinesterase (Serum/Pseudo)  | CHPS | B                       | 4 hours    | 31, 164 |
| Chromium (Blood)   | CHRO | A                       | 5 days     | 31, 163 |
| Chromium (Urine)   | URCR | RU 30                   | 4 weeks    | 31, 163 |
| Chromogranin A   | CGA  | B                       | 5 days     | 31      |
| Chromogranin A & B   | MTAB | (Plasma Frozen)         | 3 weeks    | 31      |
| Chromosome Analysis (Amniocentesis) – culture only                       | ACUL | AF <sup>9</sup>         | 10-15 days | 115     |
| Chromosome Analysis (Amniocentesis)                                      | ABK  | AF 9                    | 5-15 days  | 115     |
| - rapid BOBs aneuploidy diagnosis for all                                | ADIC | 711                     | o to dayo  | 110     |
| chromosomes (5 days) + culture (10-15 days)                              |      |                         |            |         |
| Chromosome Analysis (Amniocentesis)                                      | APCC | AF 9                    | 2-15 days  | 115     |
| – rapid PCR diagnosis for common   |      |                         |            |         |
| aneuploidies (2 days) + culture (10-15 days)                             |      |                         |            |         |
| Chromosome Analysis (Blood)  | KARY | <b>(1)</b> 9            | 2-3 weeks  | 115     |
| Chromosome Analysis (Chorionic Villus)                                   | CBK  | CVS 9                   | 5-15 days  | 115     |
| - rapid BOBs aneuploidy diagnosis for all                                |      |                         |            |         |
| chromosomes (5 days) + culture (10-15 days)                              | OVDO | 010 10                  | 0.45 days  |         |
| Chromosome Analysis (Chorionic Villus)  – rapid PCR diagnosis for common | CVPC | CVS 1,9                 | 2-15 days  | 115     |
| aneuploidies (2 days) + culture (10-15 days)                             |      |                         |            |         |
| Chromosome Analysis (Chorionic Villus)                                   | CVSC | CVS 1,9                 | 10-15 days | 115     |
| – culture only   | 3400 | 010                     | 10 10 4430 | 110     |
| Chromosome Analysis (Products of Conception)                             | PROC | Placental Sample 1,9    | 20-25 days | 115     |
| ,  |      |                         |            |         |

| TEST   | CODE | SAMPLE REQS          | TAT        | PAGE    |
|--|------|----------------------|------------|---------|
| Chromosome Analysis (Products of Conception)       | PBK  | Placental Sample 1,9 | 10-25 days | 116     |
| - BOBs rapid aneuploidy diagnosis for all          |      |                      |            |         |
| chromosomes (10 days) + culture (25 days)          |      |                      |            |         |
| Chromosome Analysis (Solid Tissue)                 | PROC | Fetal tissue 1,9     | 4-5 weeks  | 116     |
| Chronic Fatigue Syndrome Profile                   | VIP1 | A + B 10             | 5 days     | 80, 85  |
| Citrate (Blood)                                    | CITR | В                    | 5 days     | 31      |
| Citrate (Urine)                                    | UCIT | CU (Frozen)          | 5 days     | 31      |
| CK (MB Fraction)                                   | CKMB | В                    | 4 hours    | 31      |
| CK Isoenzymes                                      | CKIE | <u> </u>             | 5 days     | 31      |
| Clobazam   | CLOB | A                    | 5 days     | 136     |
| Clomipramine (Anafranil)                           | CHLO | A                    | 7 days     | 136     |
| Clonazepam   | CLON | A                    | 7 days     | 136     |
| Clostridium Difficile Toxin by PCR                 | CLOS | RF*                  | 2 days     | 45      |
| Coagulation Profile 1                              | CLPF | <b>©</b> 18          | 4 hours    | 40, 43  |
| Coagulation Profile 2                              | CLOT | <b>A</b> C 18        | 4 hours    | 40, 43  |
| Cobalt (Blood)                                     | COB  | A                    | 5 days     | 31      |
| Cobalt (Urine)                                     | COBA | RU 30                | 5 days     | 31, 163 |
| Cocaine (Urine) Screen                             | UCOC | RU                   | 1 day      | 161     |
| Coeliac Disease – HLA DQ2/DQ8 Genotype             | Q2Q8 | <b>A</b> 9           | 10 days    | 80      |
| Coeliac/Gluten Genetic Profile 2 CHANGE            | GSA2 | AB                   | 10 days    | 80, 85  |
| Coeliac/Gluten Sensitivity Profile CHANGE          | GSA  | В                    | 2 days     | 80, 85  |
| Coenzyme Q10                                       | CQ10 | В                    | 2 weeks    | 31      |
| Cold Agglutinin                                    | CAGG | $\mathbf{J}^1$       | 5 days     | 31      |
| Collagen (Type I, II, IV) Antibodies               | COAB | В                    | 10 days    | 31      |
| Collagen Type 1 Cross-Linked                       | NTX  | 2nd EMU              | 2 weeks    | 32      |
| N-Telopeptide – NTX                                |      |                      |            |         |
| Colloid Antigen-2 Antibodies                       | CA2A | В                    | 2 weeks    | 80      |
| Colorectal Cancer NGS Panel                        | GENE | <b>A A</b> 9,11      | 4 weeks    | 116     |
| Comparative Genomic Hybridisation (Array CGH)      | CGH  | CVS / AF / (A) (1) 9 | 10 days    | 116     |
| Complement C1q                                     | C1Q  | В                    | 5 days     | 32      |
| Complement C2                                      | C2   | В                    | 10 days    | 32      |
| Complement C5                                      | C5A  | B                    | 2 weeks    | 32      |
| Complement C6                                      | C6   | (Frozen)*            | 5 weeks    | 32      |
| Complement C7                                      | C7   | (Frozen)*            | 5 weeks    | 32      |
| Complement C8                                      | C8   | (Frozen)*            | 5 weeks    | 32      |
| Complement C9                                      | C9   | (Frozen)*            | 5 weeks    | 32      |
| Complement Factor H                                | FACH | B                    | 3 weeks    | 32      |
| Complex PSA (Prostate Specific Ag)                 | CPSA | В                    | 3 days     | 102     |
| Congenital Absence of Vas Deferens – karyotype     | GRP  | <b>A</b> (1) 9       | 10-15 days | 116     |
| + cystic fibrosis screen + polyT(5T) + Y deletions |      |                      |            |         |
| Coombs (Direct Antiglobulin Test)                  | COOM | A                    | 2 days     | 42      |

| TEST  | CODE  | SAMPLE REQS                 | TAT          | PAGE     |
|---|-------|-----------------------------|--------------|----------|
| Copper (Serum)                                  | COPP  | 3 or <b>(</b>               | 5 days       | 32, 150, |
|   |       |                             |              | 163      |
| Copper (Urine)                                  | URCU  | CU                          | 5 days       | 32, 163  |
| Cortisol (Self-collect)                         | CORT  | (TDL Tiny)                  | 1 day        | 55, 157  |
| Cortisol (Urine)                                | UCOR  | CU                          | 5 days       | 55       |
| Cortisol (Venous)                               | CORT  | <b>B</b>                    | 4 hours      | 55       |
| Cortisol Binding Globulin                       | CBG   | (Frozen)                    | 1 month      | 32       |
| Cotinine (Serum)                                | COT   | <b>B</b>                    | 4 days       | 80       |
| Cotinine (Urine)                                | COTT  | RU                          | 2 days       | 32       |
| COVID-19 (SARS-CoV-2) Rapid RNA Sequencing      | COSQ  | RNA or PCR swab 43          | 48-72 hours  | 98       |
| COVID-19 (SARS-CoV-2) (PCR)                     | NCOV  | PCR Swab (nasal/pharyngeal) | 1 day        | 98       |
| COVID-19 (SARS-CoV-2) RNA by PCR (Self-collect) | NCOV  | Throat and nose swab        | 1 day        | 98, 157  |
| COVID-19 (SARS-CoV-2) Roche Elecsys             | SCOV  | (TDL Tiny)                  | 1 day        | 80, 157  |
| Anti-SARS-CoV-2 S (SPIKE) (Self-collect)        |       |                             |              |          |
| COVID-19 (SARS-CoV-2) Roche Elecsys             | SCOV  | SST/Serum (3) (Venous)      | 1 day        | 80       |
| Anti-SARS-CoV-2 S (SPIKE) (Venous)              |       |                             |              |          |
| Cow's Milk Components                           | ZZ7   | <b>B</b>                    | 2 days       | 140      |
| Creatine Kinase (CK, CPK)                       | CKNA  | 3                           | 4 hours      | 32       |
| Creatinine (including eGFR) (Self-collect)      | CREA  | (TDL Tiny)                  | 1 day        | 32, 157  |
| Creatinine (including eGFR) (Venous)            | CREA  | <b>B</b>                    | 4 hours      | 32       |
| Creatinine (Urine)                              | UCR   | CU                          | 4 hours      | 32       |
| Creatinine Clearance                            | CRCL  | 3 CU                        | 4 hours      | 32       |
| Cri du Chat Syndrome                            | PBOB, | CVS / AF / 🛕 🚹 9            | 5-15 days    | 116      |
| – BOBs (5 days) + karyotype (15 days)           | KARY  |                             |              |          |
| Cri du Chat Syndrome – BOBs only                | PB0B  | CVS / AF / (A) 9            | 5 days       | 116      |
| Crosslaps (Serum DPD)                           | SDPD  | (Freeze within 24 hours)    | 4 days       | 32       |
| Cryoglobulins                                   | CRY0  | <b>J</b> 6                  | 10 days      | 32       |
| Cryptococcal Antigen                            | CRYC  | Serum or CSF                | 1 day        | 45       |
| Cryptosporidium                                 | CRP0  | RF                          | 2 days       | 45       |
| Cryptosporidium Detection by PCR                | CRPA  | RF                          | 2 days       | 89       |
| CSF for Microscopy and Culture                  | CSF   | CSF                         | 1-3 days     | 45       |
| CSF Screen by PCR                               | VPCR  | CSF                         | 2 days       | 98, 100  |
| CT/GC/Trichomonas/Mgen – PCR Swab               | SGTM  | PCR Swab                    | 2 days       | 69, 73   |
| CT/GC/Trichomonas/Mgen – Thin Prep              | TGTM  | TPV                         | 2 days       | 69       |
| CT/GC/Trichomonas/Mgen – Urine                  | CGTM  | FCRU                        | 2 days       | 69, 73   |
| Culture (Any site)                              | CULT  |                             | up to 5 days | 45       |
| CVS PCR for common aneuploidies                 | CVPC  | CVS 1,9                     | 2-15 days    | 116      |
| (2 days) + culture (10-15 days)                 |       |                             |              |          |
| CVSBOBs – rapid BOBs aneuploidy diagnosis for   | CBK   | CVS 9                       | 5-15 days    | 116      |
| all chromosomes (5 days) + culture (10-15 days) | _     |                             |              |          |
| CVSBOBs only – rapid aneuploidy                 | CB0B  | CVS 9                       | 5 days       | 116      |
| diagnosis for all chromosomes +                 |       |                             |              |          |
| common microdeletion syndromes                  |       |                             |              |          |

| TEST                                       | CODE | SAMPLE REQS                    | TAT       | PAGE    |
|--|------|--------------------------------|-----------|---------|
| Cyclosporin                                | CYCL | A                              | 1 day     | 32      |
| Cyfra 21-1                                 | CY21 | <b>B</b>                       | 4 days    | 102     |
| Cystatin C                                 | CYCC | <b>B</b>                       | 5 days    | 32      |
| Cystic Fibrosis (139 common variants)      | CFS  | <b>A</b> 9                     | 5-7 days  | 116     |
| – reflex to Poly T when required           |      |                                |           |         |
| Cystine – Quantitative (Beta-CTX)          | QCYS | PU                             | 5 days    | 32      |
| Cytomegalovirus (CMV-DNA) Amnio            | CMVD | AF                             | 5 days    | 98      |
| Cytomegalovirus (IgG/IgM) Antibodies       | CMV  | <b>B</b>                       | 4 hours   | 98      |
| Cytomegalovirus (PCR) Semen                | SCVM | Semen                          | 7 days    | 98      |
| Cytomegalovirus (PCR) Urine                | CMVU | RU                             | 5 days    | 98      |
| Cytomegalovirus Avidity                    | CMAV | <b>B</b>                       | 10 days   | 98      |
| Cytomegalovirus DNA (PCR)                  | CMVP | A                              | 5 days    | 98      |
| Cytomegalovirus Resistance                 | CMVR | (2 x 6mls)                     | 21 days   | 98      |
| D-Dimers (Fibrinogen Degradation Products) | DDIT | <b>C</b> 4                     | 4 hours   | 40      |
| Dengue Fever PCR                           | DPCR | A or (B) 9,14                  | 2 weeks   | 98      |
| Dengue Virus Serology                      | DENG | B 9,14                         | 5 days    | 89      |
| Deoxypyridinoline (DPD) – Serum            | SDPD | (Freeze within 24 hours)       | 4 days    | 32      |
| Deoxypyridinoline (DPD) – Urine            | DPD  | EMU                            | 4 days    | 32      |
| DHEA                                       | DHEX | <b>B</b>                       | 7-10 days | 55      |
| DHEA – Urine (Dehydroepiandrosterone)      | UDHE | CU                             | 3 weeks   | 55      |
| DHEA Sulphate (Self-collect)               | DHEA | (TDL Tiny)                     | 1 day     | 55, 157 |
| DHEA Sulphate (Venous)                     | DHEA | 3                              | 4 hours   | 55      |
| Diabetes – Obesity NGS Panel               | GENE | A                              | 6 weeks   | 116     |
| Diabetic Profile 1                         | DIAB | <b>A</b> G                     | 8 hours   | 32, 38  |
| Diabetic Profile 2                         | DIA2 | <b>A G</b> RU                  | 2 days    | 32, 38  |
| Diamine Oxidase Activity                   | DIAM | <b>B</b>                       | 2 weeks   | 32      |
| Diazepam (Valium)                          | DIAZ | A                              | 7 days    | 136     |
| DiGeorge Syndrome (22q11 & 10p14 deletion) | DGB, | CVS / AF / (A) (1) 9           | 5-15 days | 116     |
| - BOBs (5 days) + karyotype (15 days)      | KARY |                                |           |         |
| DiGeorge Syndrome (22q11 & 10p14)          | DGB  | CVS / AF / 🙆 9                 | 5 days    | 117     |
| - BOBs only                                |      |                                |           |         |
| Digoxin                                    | DIGO | 8                              | 4 hours   | 136     |
| Dihydrotestosterone                        | DHT  | 88                             | 7 days    | 55      |
| Diphtheria Antibodies                      | DIPH | <u> </u>                       | 5 days    | 80      |
| DL1-DL12 Screening Profiles                |      |                                |           | 26-27   |
| DL12 7 STI Profile by PCR                  | DL12 | Aptima urine or multisite swab | 2 days    | 157     |
| (7 PCR tests from 1 Sample) (Self-collect) | DNAA | 0                              | 0.4       |         |
| DNA (Double Stranded) Antibodies IgG       | DNAA | 8                              | 2 days    | 80      |
| DNA (Single Stranded) Antibodies           | DNAS | <b>B</b>                       | 5 days    | 80      |
| DNA Extraction & Storage                   | XDNA | <b>A</b> 9                     | 20 days   | 117     |
| - 3 years (longer upon request)            | DNAF | <b>A</b> 9,11                  | 10 days   | 117     |
| DNA Identity Profile – 15 STR markers      | DNAF | <b>₩</b>                       | 10 days   | 117     |

| TEST   | CODE   | SAMPLE REQS                         | TAT   | PAGE    |
|--|--------|-------------------------------------|---|---------|
| Dog Components                                     | ZZ8    | <b>B</b>                            | 2 days  | 140     |
| Down Syndrome Risk Bloods only                     | HCGF/  | B                                   | 4 hours                                       | 55      |
| (Risk to be calculated by clinician)               | PAPA   |                                     |   |         |
| Down Syndrome Risk Profile                         | DRP    | DRP form <sup>7,8</sup>             | 5 days  | 55      |
| (2nd trimester) Quad                               |        |                                     |   |         |
| Down Syndrome Risk Profile with                    | DRP    | B DRP form +                        | 5 days  | 55      |
| risk calculation first trimester                   |        | image of scan <sup>7,8</sup>        |   |         |
| Doxepin Level (Sinequan)                           | DOXE   | A                                   | 10 days                                       | 164     |
| Drugs of Abuse from Blood                          | DOAP   | <b>B</b>                            | 5 days  | 161     |
| without Chain of Custody                           |        |                                     |   |         |
| Drugs of Abuse Profile – Random Urine              | DOA    | RU                                  | 2 days (5 days with                           | 161-162 |
| Sample/No Chain of Custody                         |        |                                     | LC-MS/MS confirmation)                        |         |
| Drugs of Abuse Profile – Random Urine              | DOA3   | RU                                  | 2 days (5 days with                           | 161-162 |
| Sample/No Chain of Custody Plus Alcohol            | DOM    | DII/0 - 0 0 - II 1                  | LC-MS/MS confirmation)                        | 101 100 |
| Drugs of Abuse Profile –<br>With Chain of Custody* | D0AL   | RU/CoC Collection<br>Containers 1,2 | 2 days (5 days with<br>LC-MS/MS confirmation) | 161-162 |
| Drugs of Abuse Profile –                           | DOAN   | RU 2                                |   | 161-162 |
| Without Chain of Custody                           | DUAN   | nu -                                | 2 days (5 days with<br>LC-MS/MS confirmation) | 101-102 |
| Duchenne Muscular Dystrophy –                      | DMD1   | <b>A</b> 9                          | 10 days                                       | 117     |
| deletions/duplications only                        | וטואוט |                                     | 10 uays                                       | 111     |
| DVT/Pre-travel Screen                              | DVT1   | <b>AAB</b> <sup>9</sup>             | 5 days  | 40, 44, |
| 21//10 11/10/05/05/                                | 5111   |                                     | o dayo  | 89-90,  |
|  |        |                                     |   | 117     |
| Echinococcus (Hydatid) Antibodies                  | EFAT   | B 9,14                              | 5 days  | 80, 89  |
| Egg Components                                     | ZZ9    | B                                   | 2 days  | 140     |
| Ehrlichiosis Antibodies                            | EHRL   | B 9,14                              | 10 days                                       | 80      |
| Elastase (RF)                                      | ELAS   | RF*                                 | 5 days  | 32      |
| Elastase (Self-collect)                            | ELAS   | Stool/faecal container*             | 5 days  | 32, 157 |
| Electrolytes                                       | ELEC   | B                                   | 4 hours                                       | 32      |
| Electrolytes (Urine)                               | UELE   | CU                                  | 4 hours                                       | 33      |
| ELF/Enhanced Liver Fibrosis                        | ELF    | B                                   | 5 days  | 33      |
| Endometrial Biopsy Immune Profiling                | 23RF   | J (Contact Referrals)               | 2 weeks                                       | 59      |
| Endomysial Antibodies (IgA) (Self-collect)         | AEAB   | (TDL Tiny)                          | 2 days  | 80, 157 |
| Endomysial Antibodies (IgA) (Venous)               | AEAB   | B                                   | 2 days  | 80      |
| Enteric Organism Rapid Detection                   | EORD   | RF                                  | 2 days  | 89-90   |
| Eosin-5 Maleimide Dye binding test for             | EMA    | A                                   | 2 days  | 42      |
| Hereditary spherocytosis (EMA)                     |        |                                     | •   |         |
| Eosinophil Cationic Protein                        | ECP    | <b>B</b>                            | 7 days  | 33      |
| Epanutin (Phenytoin)                               | PHEN   | В                                   | 4 hours                                       | 136     |
| Epstein-Barr Virus Antibodies IgG/IgM              | EBVA   | (A) or (B)                          | 2 days  | 98      |
| Epstein-Barr Virus PCR                             | EBVQ   | A                                   | 5 days  | 98      |
| Erectile Dysfunction Profile                       | IMP0   | ABBG                                | 3 days  | 55, 60  |
| Erythropoietin                                     | ERY    | B                                   | 4 days  | 42, 136 |
| ·-   |        |                                     |   |         |

| TEST                                       | CODE | SAMPLE REQS               | TAT     | PAGE    |
|--|------|---------------------------|---------|---------|
| ESR  | ESR  | A                         | 4 hours | 40      |
| Essential Fatty Acid Profile (Red Cell)    | EFAR | <b>A</b> 4                | 10 days | 150     |
| Ethosuximide                               | ETH0 | A                         | 7 days  | 136     |
| Extractable Nuclear Antibodies             | ENA  | <b>B</b>                  | 2 days  | 80      |
| (nRNP, Sm, Ro, La, Jo1, ScI70) CENP-B      |      |                           |         |         |
| Factor II Assay                            | FAC2 | (Frozen) <sup>9,18</sup>  | 5 days  | 41      |
| Factor II Prothrombin – G20210A Variant    | FX2  | <b>A</b> 9                | 5 days  | 117     |
| Factor V Assay                             | FAC5 | (Frozen) <sup>9,18</sup>  | 5 days  | 41      |
| Factor V Leiden – G1691A Variant           | FX5  | <b>A</b> 9                | 5 days  | 117     |
| Factor VII Assay                           | FAC7 | (Frozen) <sup>9,18</sup>  | 5 days  | 41      |
| Factor VIII Assay                          | FAC8 | (Frozen) <sup>9,18</sup>  | 5 days  | 41      |
| Factor VIII Inhibiting Antibody            | F8IA | <b>C C</b> <sup>18</sup>  | 2 weeks | 41      |
| Factor IX Assay                            | F1X  | (Frozen) <sup>9,18</sup>  | 5 days  | 41      |
| Factor IX Inhibiting Antibody              | F9IA | <b>© ©</b> 18             | 2 weeks | 41      |
| Factor X Assay                             | FX   | (Frozen) 9,18             | 5 days  | 41      |
| Factor XI Assay                            | FX1  | (Frozen) 9,18             | 5 days  | 41      |
| Factor XII Assay                           | FX11 | (Frozen) 9,18             | 5 days  | 41      |
| Factor XIII Assay                          | FA13 | (Frozen) 9,18             | 5 days  | 41      |
| Faecal Fat (1 Day Collection)              | TFFA | LF <sup>6</sup>           | 5 days  | 33      |
| Faecal Fat (3 day)                         | FFAT | LF <sup>6</sup>           | 5 days  | 33      |
| Faecal Lactoferrin                         | FLAC | RF                        | 5 days  | 33      |
| Faecal Sugar Chromatography                | FCR0 | RF (Frozen)               | 3 weeks | 33      |
| Familial Hypercholesterolaemia NGS panel   | GENE | AA <sup>9</sup>           | 6 weeks | 118     |
| Farmers Lung Precipitins                   | FARM | <b>B</b>                  | 5 days  | 80      |
| Fasciola Hepatica Antibodies (Liver Fluke) | FASC | <b>B</b>                  | 2 weeks | 80      |
| FAST Chlamydia – PCR Swab                  | FSCT | PCR Swab                  | 4 hours | 75      |
| FAST Chlamydia – Urine                     | FCT  | FCRU                      | 4 hours | 75      |
| FAST CT/GC – PCR Swab                      | FSCG | PCR Swab                  | 4 hours | 75      |
| FAST CT/GC – Rectal PCR Swab               | FRCG | PCR Swab                  | 4 hours | 75      |
| FAST CT/GC – Throat PCR Swab               | FTCG | PCR Swab                  | 4 hours | 75      |
| FAST CT/GC – Urine                         | FCG  | FCRU                      | 4 hours | 75      |
| FAST Gonorrhoea – PCR Swab                 | FSGN | PCR Swab                  | 4 hours | 75      |
| FAST Gonorrhoea – Urine                    | FGN  | FCRU                      | 4 hours | 75      |
| FAST Screen SHORT with Swab                | FSSS | B PCR Swab                | 4 hours | 75      |
| FAST Screen SHORT with Urine               | FSSC | (3) FCRU                  | 4 hours | 75      |
| FAST Screen with Swab                      | FSWS | B PCR Swab                | 4 hours | 75      |
| FAST Screen with Urine                     | FUSC | 13 FCRU                   | 4 hours | 75      |
| Fasting Insulin Resistance Index (FIRI)    | FIRI | <b>B G</b>                | 4 hours | 55      |
| Female Hormone Profile (Self-collect)      | TFIP | (TDL Tiny) (B) (TDL Tiny) | 1 day   | 56, 157 |
| Female Hormone Profile (Venous)            | FIP  | В                         | 4 hours | 56, 61  |
| Ferritin (Self-collect)                    | FERR | (TDL Tiny)                | 1 day   | 33, 157 |
| Ferritin (Venous)                          | FERR | <b>B</b>                  | 4 hours | 33      |

| TEST  | CODE  | SAMPLE REQS              | TAT         | PAGE    |
|---|-------|--------------------------|-------------|---------|
| Fibrinogen  | FIB   | C 4,18                   | 4 hours     | 40      |
| Fibrotest (Liver Fibrosis)                          | FIBT  | B                        | 2 weeks     | 33      |
| Filaria (Lymphatic and Non-Lymphatic)<br>Antibodies | FIFA  | <b>B</b> 9,14            | 10 days     | 89      |
| First Trimester Antenatal Screen                    | HCGF/ | <b>B</b>                 | 4 hours     | 56, 61  |
| (Risk to be calculated by requesting clinician)     | PAPA  | U                        | 4 110018    | 30, 01  |
| Fish Components                                     | ZZ10  | ß                        | 2 days      | 140     |
| FK506 (Tacrolimus/Prograf)                          | FK5   | <b>A</b> 4               | 1-2 days    | 136     |
| Flecainide (Tambocor)                               | FLEC  | A                        | 5 days      | 136     |
| Fluid Culture                                       | FLUD  | SC                       | 2-7 days    | 45      |
| Fluid Cytology                                      | CATE  | Fluid <sup>4</sup>       | 3 days      | 172     |
| Fluid for Crystals + Culture                        | FLU2  | SC                       | 1 day       | 45      |
| Fluoride (Urine)                                    | UFL   | RU                       | 5 days      | 33      |
| Fluoxetine (Prozac)                                 | PROZ  | <b>A</b> <sup>4</sup>    | 5 days      | 136     |
| Folate (Red Cell)                                   | RBCF  | A                        | 2 days      | 33, 150 |
| Folate (Serum)                                      | FOLA  | B                        | 1 day       | 33      |
| Fragile X Syndrome screen –                         | GENE  | AAA <sup>9</sup>         | 5 weeks     | 118     |
| FMR1 repeat analysis PCR                            | ULITE |                          | o wood      | 110     |
| Free Fatty Acids                                    | FFA   | (Frozen) 1               | 10 days     | 33      |
| Free T3 (Self-collect)                              | FT3   | (TDL Tiny)               | 1 day       | 56, 157 |
| Free T3 (Venous)                                    | FT3   | B                        | 4 hours     | 56      |
| Free T4 (Self-collect)                              | FT4   | (TDL Tiny)               | 1 day       | 56, 157 |
| Free T4 (Venous)                                    | FT4   | B                        | 4 hours     | 56      |
| Fructosamine  | FRUC  | B                        | 1 day       | 33      |
| FSH (Self-collect)                                  | FSH   | (TDL Tiny)               | 1 day       | 56, 157 |
| FSH (Venous)  | FSH   | B                        | 4 hours     | 56      |
| Full Blood Count                                    | FBC   | A                        | 4 hours     | 40      |
| Fungal ID + Sens                                    | FUID  | Fungal sample / STM      | 14 days     | 45      |
| Fungal investigations                               | FUN   | All specimens other than | From 3 days | 45      |
| (non-superficial extended culture)                  |       | Skin, Hair and Nails     |             |         |
| Fungal investigations                               | DERM  | Skin, Hair, Nails        | 3-7 days    | 45      |
| (superficial/dermatophyte PCR test)                 |       |                          |             |         |
| FXIII A Subunit                                     | F13S  | (Frozen) <sup>9,18</sup> | 14 days     | 41      |
| G6PD  | G6PD  | A                        | 4 days      | 42      |
| Gabapentin  | GABA  | <b>B</b> 4               | 5 days      | 136     |
| Galactomanan (Aspergillus Antigen)                  | SGAL  | В                        | 2 weeks     | 45      |
| Galactose-1-Phosphate Uridyltransferase             | GAL1  | <b>(1)</b> 5,6           | 2 weeks     | 33      |
| Galactosidase – Alpha*                              | GALA  | J*                       | 6 weeks     | 33      |
| Gall Stone Analysis                                 | RSTA  | STONE                    | 10 days     | 33      |
| Gamma GT  | GGT   | В                        | 4 hours     | 33      |
| Ganglionic Acetylcholine Receptor Antibodies        | GACA  | В                        | 1 month     | 80      |
| Ganglioside GM1, GD1B, GQ1B Abs                     | GANG  | <b>B</b>                 | 5 days      | 80      |

| TEST  | CODE  | SAMPLE REQS                  | TAT        | PAGE               |
|---|-------|------------------------------|------------|--------------------|
| Gardnerella vaginalis (Thin Prep)                 | GVPC  | TPV                          | 2 days     | 168                |
| Gardnerella vaginalis by PCR                      | GVPC  | FCRU / PCR / TPV             | 2 days     | 69                 |
| Gastric Parietal Autoantibodies                   | GASP  | B                            | 2 days     | 80                 |
| Gastrin   | GAST  | (Plasma)                     | 5 days     | 33                 |
| Gastrointestinal Pathogen PCR (Self-collect)      | EORD  | Stool/faecal container       | 2 days     | 89, 157            |
| Genetics: TDL Genetics                            |       |                              |            | 105-134            |
| Genetic Reproductive Profile (Male)               | GRP   | <b>A ()</b> 9                | 10-15 days | 118                |
| Gentamicin Assay                                  | GENT  | <b>B</b> 4                   | 4 hours    | 135                |
| Giardia Serology                                  | GIAR  | B                            | 5 days     | 80                 |
| Gliadin Antibodies (IgG)                          | AGAB  | (TDL Tiny)                   | 2 days     | 80, 157            |
| (deamidated) (Self-collect)                       |       |                              |            |                    |
| Gliadin Antibodies (IgG) (deamidated) (Venous)    | AGAB  | В                            | 2 days     | 80                 |
| Globulin  | GLOB  | В                            | 4 hours    | 33                 |
| Glomerular Basement Membrane Abs                  | AGBM  | В                            | 2 days     | 80                 |
| Glucagon  | GLUG  | (Plasma)                     | 10 days    | 33                 |
| Glucose   | RBG   | G                            | 4 hours    | 33                 |
| Glucose Challenge Test/Mini-GTT                   | RBGM  | G                            | 1 day      | 135                |
| Glucose Tolerance Test (Extended Plus)            | GTTX  | 7 x 📵 , 7 x <b>RU</b>        | 1 day      | 135                |
| Glucose Tolerance Test (Extended)                 | GTTE  | 5 x 📵 , 5 x <b>RU</b>        | 1 day      | 135                |
| Glucose Tolerance Test (Short)                    | GTTS  | 2 x 🕒 , 2 x RU               | 1 day      | 135                |
| Glucose Tolerance Test/OGTT                       | GTT   | 3 x 🕒 , 3 x RU               | 1 day      | 135                |
| Glucose Tolerance with Growth Hormone             | GTT + | 3 x 🔒 35,                    | 1 day      | 135                |
|   | GHDF  | 3 x <b>G</b> , 3 x <b>RU</b> |            |                    |
| Glucose Tolerance with Insulin                    | GTTI  | 3 x 📵 , 3 x 📵 ,              | 1 day      | 135                |
|   |       | 3 x RU                       |            |                    |
| Glutamic Acid Decarboxylase Antibodies            | GAD   | В                            | 5 days     | 81                 |
| (GAD 65)  | 004   | •                            | 0.4        |                    |
| Gluten Sensitivity Evaluation CHANGE              | GSA   | 000                          | 2 days     | 81                 |
| Gluten Sensitivity Profile CHANGE                 | GLUT  | <b>ABB</b>                   | 10 days    | 81, 86<br>139, 144 |
| Gluten/Coeliac Genetic Profile 2 CHANGE           | GSA2  | AB                           | 10 days    | 81                 |
| Glycan Determinants                               | ZZ27  | <b>B</b>                     | 2 days     | 140                |
| Gonorrhoea  | TGON  | TPV                          | 2 days     | 168                |
| Gonorrhoea – Culture                              | GONN  | CS <sup>‡‡‡</sup>            | 2-3 days   | 45, 69             |
| Gonorrhoea – PCR swab                             | SGON  | PCR                          | 2 days     | 69                 |
| Gonorrhoea – Thin Prep                            | TGON  | TPV                          | 2 days     | 69                 |
| Gonorrhoea – Urine                                | CGON  | FCRU                         | 2 days     | 69                 |
| Granulocyte Immunology                            | GRIM  | A (or 10ml) B                | 2 weeks    | 81                 |
| Group B Strep – Vaginal and Rectal (Self-collect) | GBSX  | Blue gel Amies swab x2       | 3-5 days   | 46, 157            |
| Group B Strep – Vaginal and Rectal (STM)          | GBSX  | 2 x STM                      | 3-5 days   | 46, 137            |
| Growth Hormone (Fasting)                          | GH    | (E) 7,35                     | 4 hours    | 56                 |
| aromai normone (rasung)                           | uii   | <u> </u>                     | TIIUUIU    |                    |

| TEST                                      | CODE | SAMPLE REQS               | TAT     | PAGE     |
|---|------|---------------------------|---------|----------|
| Gut Hormone Profile                       | GUTP | (Frozen within            | 3 weeks | 56       |
|   |      | 15 minutes) <sup>41</sup> |         |          |
| H. pylori Antibodies (IgG)                | НВРА | В                         | 2 days  | 81       |
| H. pylori Antigen – Breath                | HBQT | J                         | 5 days  | 81       |
| H. pylori Antigen – Stool (Self-collect)  | HBAG | Stool/faecal container    | 3 days  | 46, 158  |
| H. pylori Antigen – Stool (RF)            | HBAG | RF                        | 3 days  | 46       |
| H. pylori Culture                         | HPCU | J                         | 3 weeks | 46       |
| Haematology Profile                       | PP3  | A                         | 4 hours | 40, 44   |
| Haemochromatosis                          | HMD  | <b>A</b> 9                | 3 days  | 33       |
| - HFE common variants C282Y + H63D        |      |                           |         |          |
| Haemoglobin                               | НВ   | A                         | 4 hours | 40       |
| Haemoglobin Electrophoresis               | HBEL | A                         | 4 days  | 42       |
| Haemophilus B Influenzae Antibodies       | HINF | B                         | 5 days  | 81       |
| Haemophilus ducreyi by PCR                | DUCR | PCR                       | 7 days  | 69       |
| Haemosiderin (Urine)                      | HSID | EMU                       | 2 weeks | 33       |
| Hantavirus Serology                       | HANV | <b>B</b> 9                | 10 days | 98       |
| Haptoglobin                               | HAPT | В                         | 5 days  | 33       |
| Hazelnut Components                       | ZZ11 | B                         | 2 days  | 140      |
| HbA1c (Self-collect)                      | GHB  | (TDL Tiny)                | 1 day   | 33, 158  |
| HbA1c (Venous)                            | GHB  | A                         | 6 hours | 33       |
| HCG (Oncology)                            | HCGQ | B                         | 4 hours | 102      |
| HCG (Quantitative)                        | QHCG | В                         | 4 hours | 56       |
| HDL Cholesterol                           | HDL  | B                         | 4 hours | 33       |
| HE4 + ROMA (Earlier Detection             | HE4  | B                         | 1 day   | 102, 104 |
| of Ovarian Tumour)                        |      |                           |         |          |
| Hepatitis (Acute) Screen                  | AHSC | В                         | 4 hours | 91, 100  |
| Hepatitis A (IgM)                         | HAVM | В                         | 4 hours | 91       |
| Hepatitis A Immunity (IgG/IgM)            | HAIM | В                         | 4 hours | 91       |
| Hepatitis A Profile                       | HEPA | B                         | 4 hours | 69, 91   |
| Hepatitis A RNA by PCR                    | HAVR | (A) or (B)                | 3 weeks | 91       |
| Hepatitis A, B & C Profile                | ABC  | В                         | 4 hours | 91, 100  |
| Hepatitis B 'e' Antigen and Antibody      | HEPE | B                         | 4 hours | 91       |
| Hepatitis B (PCR) Genotype                | BGEN | A                         | 7 days  | 91       |
| Hepatitis B Core Antibody – IgM           | HBCM | B                         | 4 hours | 91       |
| Hepatitis B Core Antibody – Total         | HBC  | B                         | 4 hours | 91       |
| Hepatitis B DNA (Viral load)              | DNAB | A                         | 5 days  | 91       |
| Hepatitis B Immunity                      | HBIM | B                         | 4 hours | 91       |
| Hepatitis B Immunity (IgG) (Self-collect) | THBI | (TDL Tiny)                | 1 day   | 91, 158  |
| Hepatitis B Immunity (IgG) (Venous)       | THBI | B                         | 1 day   | 91       |
| Hepatitis B Profile                       | HEPB | B                         | 4 hours | 92, 100  |
| Hepatitis B Resistant Mutation            | HBRM | A or B                    | 7 days  | 92       |
| -   |      |                           |         |          |

| TEST  | CODE | SAMPLE REQS           | TAT     | PAGE               |
|---|------|-----------------------|---------|--------------------|
| Hepatitis B Surface Antigen (Self-collect)          | THBA | (TDL Tiny)            | 1 day   | 69, 92,            |
|   |      |                       |         | 158                |
| Hepatitis B Surface Antigen (Venous)                | AUAG | B                     | 4 hours | 69, 92             |
| Hepatitis C Abs Confirmation (RIBA)                 | RIBA | В                     | 5 days  | 92                 |
| Hepatitis C Antibodies (Self-collect)               | THCV | (TDL Tiny)            | 1 day   | 69, 92,            |
|   |      |                       |         | 158                |
| Hepatitis C Antibodies (Venous)                     | HEPC | В                     | 4 hours | 69, 92             |
| Hepatitis C Antigen (Early detection) (Self-collect |      | (TDL Tiny)            | 1 day   | 92, 158            |
| Hepatitis C Antigen (Early detection) (Venous)      | HCAG | 8                     | 4 hours | 92                 |
| Hepatitis C Genotype                                | CGEN | A                     | 5 days  | 92                 |
| Hepatitis C Quantification (Viral Load)             | QPCR | (A) or (B)            | 5 days  | 92                 |
| Hepatitis Delta Antibody                            | HEPD | B                     | 5 days  | 92                 |
| Hepatitis Delta Antigen                             | HDAG | В                     | 5 days  | 92                 |
| Hepatitis Delta RNA                                 | DRNA | (Frozen plasma)       | 5 days  | 92                 |
| Hepatitis E (PCR)                                   | EHEP | A                     | 2 weeks | 92                 |
| Hepatitis E IgG/IgM                                 | HBE  | B                     | 5 days  | 92                 |
| Hepatitis G (PCR)                                   | HEPG | (Frozen plasma)       | 2 weeks | 92                 |
| Herpes Simplex (HSV) 1 & 2 – Genital lesion         | HERS | Aptima multisite swab | 5 days  | 70, 98,            |
|   |      |                       |         | 158                |
| Herpes Simplex (HSV) 1 & 2 – Oral lesion            | HERS | Aptima multisite swab | 5 days  | 70, 98,            |
|   |      |                       |         | 158                |
| Herpes Simplex (HSV) 1 & 2 (PCR)                    | HERS | PCR                   | 5 days  | 70, 98             |
| Herpes Simplex I/II (Thin Prep)                     | HERD | TPV                   | 5 days  | 168                |
| Herpes Simplex I/II Antibody Profile (IgG)          | HERP | 8                     | 2 days  | 98                 |
| Herpes Simplex I/II by PCR (Urine)                  | HERD | FCRU                  | 5 days  | 70, 98             |
| Herpes Simplex I/II IgM                             | HERM | 8                     | 2 days  | 98                 |
| HFE gene (Haemochromatosis)                         | HMD  | <b>A</b> 9            | 3 days  | 42                 |
| - common variants C282Y + H63D                      | LUDD | •                     | 41      | 50.01              |
| Hirsutism Profile                                   | HIRP | <u>B</u>              | 4 hours | 56, 61             |
| Histamine (Blood)                                   | HITT | (Frozen plasma)       | 5 days  | 81                 |
| Histamine (Urine)                                   | HITU | RU                    | 5 days  | 81                 |
| Histamine Releasing Urticaria Test                  | CURT | <u>B</u>              | 3 weeks | 81, 139            |
| Histone Antibodies                                  | HISA | В                     | 5 days  | 81                 |
| Histopathology                                      |      |                       |         | 173-179            |
| Histoplasmosis                                      | HISP | <u>B</u>              | 10 days | 81                 |
| HIV 1 & 2 Abs/p24Ag (Self-collect)                  | THIV | (TDL Tiny)            | 1 day   | 70, 97,            |
|   | HBHA | •                     | 41      | 158                |
| HIV 1 & 2/p24Ag (Venous)                            | HDU0 | 8                     | 4 hours | 70                 |
| HIV Confirmation of Positive Screens                | HIVC | В                     | 1 day   | 97                 |
| (Using 3 methodologies)                             | LUIV | (Magutainar anly)     | 4 houro | 70.74              |
| HIV Rapid RNA HIV-1 QUALITATIVE                     | LHIV | (Vacutainer only)     | 4 hours | 70, 74,<br>97, 100 |
|   |      |                       |         | 31, 100            |

| TEST  | CODE | SAMPLE REQS             | TAT                | PAGE    |
|---|------|-------------------------|--------------------|---------|
| HIV Rapid RNA HIV-1 QUANTITATIVE  | RHIV | (Vacutainer only)       | 4 hours            | 70, 74, |
|   |      |                         |                    | 97, 101 |
| HIV Screening: HIV1 & 2 Abs/p24 Ag (4th Gen)                              | HDU0 | B                       | 4 hours            | 97      |
| HIV Therapeutic Drug Monitoring   | TDM  | J                       | 21 days            | 97      |
| HIV-1 Genotypic Resistance (Integrase)                                    | INTE | (2 x 6ml whole blood)   | 21 days            | 97      |
| HIV-1 Genotypic Resistance (RT & Protease)                                | HIVD | (2 x 6ml whole blood)   | 21 days            | 97      |
| HIV-1 Proviral DNA  | HIVP | A Whole blood           | 7 days             | 97      |
| HIV-1 RNA Viral Load by PCR   | HIV1 | (2 x 6ml whole blood)   | 3 days             | 97      |
| HIV-1 Tropism   | TRPM | (2 x 6ml whole blood)   | 28 days            | 97      |
| HIV-2 RNA by PCR  | HIV2 | A                       | 21 days            | 97      |
| HIV/HBV/HCV Screen by PCR/NAAT  | STDX | (A) 10mls or 2 x 4mls   | 3 days             | 70, 73, |
| (10 days post exposure)   |      | (Vacutainer only)       |                    | 97-98,  |
|   |      | 0.0                     |                    | 100     |
| HIV/HBV/HCV (Early detection by   | STXX | (B) A 10mls or 2 x 4mls | 3 days             | 70, 73  |
| PCR/NAAT) with Syphilis   | 1405 | 00                      | Ouradia            |         |
| HLA A, B, C   | 14RF | <b>A A</b> 9            | 2 weeks            | 59      |
| HLA B*57:01   | HL57 | <b>A</b> 9              | 10 days            | 97      |
| HLA B27   | HLAB |                         | 3 days             | 81      |
| HLA DQ Alpha Antigens   | 10RF | 00                      | 2 weeks            | 59      |
| HLA DQ Beta Antigens  | 11RF | 00                      | 2 weeks            | 59      |
| HLA DR Antigens   | 9RF  | 00                      | 2 weeks            | 59      |
| HLA-C   | 26RF | <b>AA</b>               | 2 weeks            | 59      |
| HLA Tissue Typing A   | HLA  | <b>A</b> 9              | 10 days            | 119     |
| HLA Tissue Typing A+B   | HLBA | <b>A</b> 9              | 10 days            | 119     |
| HLA Tissue Typing A+B+C (Class I)   | HABC | <b>A</b> 9              | 10 days            | 119     |
| HLA Tissue Typing A/B/DRB1/3/4/5  | HLAF | <b>A</b> 9              | 10 days            | 119     |
| HLA Tissue Typing A/B/DRB1/3/4/5/DQB1                                     | HLF  | <b>A</b> 9              | 10 days            | 119     |
| HLA Tissue Typing A/B/C/  | HLFC | <b>A</b> 9              | 10 days            | 120     |
| DRB1/3/4/5/DQB1 (Class I & II)  | HLB  | <b>A</b> 9              | 10 dayo            | 120     |
| HLA Tissue Typing B   | HLAB | <b>A</b> 9              | 10 days            | 120     |
| HLA Tissue Typing B*27 only HLA Tissue Typing B*51 (Behcet's Disease)     | B51  | <b>A</b> 9              | 3 days<br>10 days  | 120     |
|   | HL57 | <b>A</b> 9              | 10 days            | 120     |
| HLA Tissue Typing B*57:01 high resolution HLA Tissue Typing C             | HLC  | <b>A</b> 9              | 10 days            | 120     |
| HLA Tissue Typing Coeliac Disease – DQ2/DQ8                               | Q2Q8 | <b>A</b> 9              | 10 days            | 120     |
|   | DRB1 | <b>A</b> 9              | <u> </u>           | 120     |
| HLA Tissue Typing DRB1/3/4/5 HLA Tissue Typing DRB1/3/4/5/DQB1 (Class II) | HLDQ | <b>A</b> 9              | 10 days<br>10 days | 120     |
|   | GENE | <b>A</b> 9              | 3 weeks            | 120     |
| HLA Tissue Typing Narcolepsy – DQB1*06:02                                 | HOMO | B 17 or (A) (Plasma)    |                    | 33      |
| Homocysteine (Quantitative)   | HCYS | CU (Plasma)             | 1 day<br>2 weeks   | 33      |
| Homocysteine (Urine)  | HVA  | PU                      |                    |         |
| Homovanillic Acid (HVA)   |      | (3)                     | 5 days             | 33      |
| Horse Components  | ZZ38 | U                       | 2 days             | 140     |

| TEST   | CODE | SAMPLE REQS              | TAT      | PAGE     |
|--|------|--------------------------|----------|----------|
| House Dust Mite Components                             | ZZ12 | В                        | 2 days   | 140      |
| HPV (DNA and reflexed mRNA)                            | HPVT | TPV                      | 5 days   | 70, 170  |
| HPV (HR mRNA types 16, 18 + others)                    | HPVH | TPV                      | 3 days   | 70, 170  |
| HPV (Individually typed low &                          | HP20 | TPV / PCR swab           | 3 days   | 70, 170  |
| high risk DNA subtypes)                                |      |                          |          |          |
| HPV (Individually typed high risk                      | HPVZ | Qvintip vaginal swab     | 3 days   | 70, 158, |
| DNA subtypes) (Self-collect)                           |      |                          |          | 171      |
| HPV (mRNA all high risk subtypes) (Self-collect)       | HPVY | Qvintip vaginal swab     | 3 days   | 70, 158, |
| HDT Drofile 4  | UDT  | <b>B</b>                 | A have   | 171      |
| HRT Profile 1  | HRT  |                          | 4 hours  | 56, 61   |
| HRT Profile 2  | HRT2 | <b>B G</b>               | 4 hours  | 56, 61   |
| HTLV 1 & 2 Abs. (Human T Lymphotropic Virus Type I-II) | HTLV | 3                        | 8 hours  | 97       |
| HTLV by PCR  | HTLP | A Whole blood            | 21 days  | 97       |
| Hughes Syndrome  | LUPA | B C C 4,18               | 2 days   | 41       |
| Human Herpes Virus – 6 by PCR                          | HHV6 | <b>A</b>                 | 5 days   | 98       |
| Human Herpes Virus – 8 (IgG)                           | HHV8 | 8                        | 10 days  | 98       |
| Human Herpes Virus – 8 by PCR                          | HV8D | A                        | 5 days   | 99       |
| Human Parvovirus B19 – DNA                             | PCRP | <u> </u>                 | 2 weeks  | 99       |
| HVS  | HVS  | STM/CS****               | 2-4 days | 46       |
| Hyaluronic Acid  | AHT  | <b>B</b>                 | 1 week   | 33       |
| Hydroxybutyrate Dehydrogenase                          | HBD  | (Frozen)                 | 1 week   | 33       |
| Hydroxyprolene   | UHYD | CU                       | 2 weeks  | 33       |
| Identity Profile (DNA) – 15 STR markers                | DNAF | <b>A</b> 9,11            | 10 days  | 120      |
| IgE (Total)  | IGE  | B                        | 1 day    | 81       |
| IGF-1 (Somatomedin)                                    | SOMA | (Frozen) <sup>4</sup>    | 1 day    | 56       |
| IGF-BP3  | IGF3 | (Frozen) <sup>4</sup>    | 5 days   | 56       |
| IgG Subclasses   | IGSC | <b>B</b>                 | 5 days   | 34       |
| Imipramine   | IMIP | <b>A</b> 4               | 4 days   | 136      |
| Immune Function Evaluation (Total)                     | TIE  | A + B 5,10               | 7 days   | 40       |
| Immune-Complexes                                       | IMCP | B                        | 5 days   | 81       |
| Immunoglobulin A                                       | IGA  | B                        | 4 hours  | 34       |
| Immunoglobulin D                                       | IGD  | B                        | 5 days   | 34       |
| Immunoglobulin E – Total                               | IGE  | В                        | 1 day    | 34       |
| Immunoglobulin G                                       | IGG  | B                        | 4 hours  | 34       |
| Immunoglobulin M                                       | IGM  | В                        | 4 hours  | 34       |
| Immunoglobulins (IgG, IgM, IgA)                        | IMM  | В                        | 4 hours  | 34, 81   |
| Impotence Profile                                      | IMP0 | ABBG                     | 3 days   | 56, 61   |
| Individual Semen Parameters                            | SPOD | Semen 1                  | 1 day    | 64       |
| Inhibin A  | INIA | <b>B</b>                 | 1 month  | 56       |
| Inhibin B  | INIB | (Day 3 of cycle, frozen) | 5 days   | 56       |
| INR  | PTIM | <b>(</b> ) 18            | 4 hours  | 40       |
|  |      |                          |          |          |

| TEST                                | CODE         | SAMPLE REQS                   | TAT        | PAGE      |
|-------------------------------------|--------------|-------------------------------|------------|-----------|
| Insect/Worm/Ova/Cysts               | FLEA         | Send Specimen <sup>9,14</sup> | 5 days     | 89        |
| Insulin                             | INSU         | B                             | 4 hours    | 56        |
| Insulin Antibodies                  | INAB         | B                             | 5 days     | 81        |
| Insulin-Like Growth Factor 2        | IGF2         | <b>B</b> 6                    | 1 month    | 34        |
| Interleukin 1 Beta                  | ILB          | (Frozen) <sup>4,7</sup>       | 1-2 weeks  | 81        |
| Interleukin 2                       | IL2          | (Frozen) <sup>4,7</sup>       | 1-2 weeks  | 81        |
| Interleukin 4                       | IL4A         | (Frozen) <sup>4,7</sup>       | 1-2 weeks  | 81        |
| Interleukin 6                       | IL6          | (Frozen) <sup>4,7</sup>       | 1-2 weeks  | 81        |
| Interleukin 8                       | IL8          | (Frozen) <sup>4,7</sup>       | 1-2 weeks  | 81        |
| Interleukin 10                      | IL10         | (Frozen) <sup>4,7</sup>       | 1-2 weeks  | 81        |
| Interleukin 28b Genotype            | IL28         | A                             | 2 weeks    | 81        |
| Intrinsic Factor Antibodies         | IFAB         | B                             | 2 days     | 81        |
| lodide – Urine                      | UIOD         | RU                            | 1 week     | 34        |
| lodine – Serum                      | IODI         | B                             | 1 week     | 34        |
| Ionised Calcium                     | ICPA         | B                             | 5 days     | 34        |
| Iron (TIBC included) (Self-collect) | FE           | (TDL Tiny)                    | 1 day      | 34, 158   |
| Iron (TIBC included) (Venous)       | FE           | B                             | 4 hours    | 34        |
| Iron Overload Profile               | IOP          | <b>△ B</b> <sup>9</sup>       | 3 days     | 34, 38    |
| Iron Status Profile (Self-collect)  | ISP          | (TDL Tiny)                    | 1 day      | 34, 38,   |
|                                     |              |                               |            | 158       |
| Iron Status Profile (Venous)        | ISP          | B                             | 4 hours    | 34, 38    |
| ISAC Panel (Self-collect)           | ISAC         | (TDL Tiny)                    | 3 days     | 139, 144, |
|                                     |              |                               |            | 158       |
| ISAC Panel (Venous)                 | ISAC         | В                             | 3 days     | 139, 144  |
| Islet Cell Antibodies               | ICAB         | B                             | 3 days     | 81        |
| IUCD for Culture                    | IUCD         | Send Device                   | 11-12 days | 46        |
| JC Polyoma Virus by PCR             | JCPV         | A/B/CSF                       | 5 days     | 99        |
| Ketamine Screen                     | KETA         | RU                            | 7-10 days  | 161       |
| KIR (Killer-like Immunoglobulin-    | 17RF         | AAA                           | 2-3 weeks  | 59        |
| like Receptors) Genotyping          | 7700         | •                             | 0 de       | 440       |
| Kiwi Components                     | ZZ32         | <b>B</b>                      | 2 days     | 140       |
| Lactate (Plasma)                    | LACT         | <b>G</b> 16                   | 1 day      | 34        |
| Lactate Dehydrogenase (LDH)         | LDH          | <u>B</u>                      | 4 hours    | 34        |
| Lactate Pyruvate Ratio              | LPR          | J <sup>1</sup>                | 4-6 weeks  | 34        |
| Lactose Intolerance Gene            | LACG         | <b>A</b>                      | 2 weeks    | 121       |
| Lactose Tolerance Test              | LTT          | By appointment only           | 1 day      | 34, 135   |
| Lamotrigine                         | LAM0         | B 4                           | 5 days     | 136       |
| Langer-Giedion Syndrome –           | PBOB,        | CVS / AF / (A) (1) 9          | 5-15 days  | 121       |
| BOBs (5 days) + karyotype (15 days) | KARY<br>PB0B | CVS / AF / (A) 9              | E dovo     | 121       |
| Langer-Giedion Syndrome – BOBs only |              |                               | 5 days     |           |
| Latex Components  LDL7 Subfractions | ZZ13         | <b>3</b>                      | 2 days     | 140<br>34 |
| EDE! SUBILACIONS                    | LDL7         | U                             | 10 days    | 34        |

| TEST   | CODE | SAMPLE REQS  | TAT      | PAGE    |
|--|------|--|----------|---------|
| Lead (Blood)                                 | LEAD | A  | 5 days   | 34, 163 |
| Lead (Urine)                                 | URPB | RU   | 5 days   | 34, 163 |
| Lead Profile (Hb, ZPP, Lead)                 | LEAZ | A 13   | 3-5 days | 163     |
| Legionella Antibodies                        | LEG0 | <b>B</b>   | 2 days   | 81      |
| Legionella Urine Antigen                     | LEGA | RU   | 1 day    | 46, 81  |
| Leishmania Antibodies                        | LEIS | B  | 5 days   | 89      |
| Leptin                                       | LEPT | (height and weight required) 19                    | 5 days   | 34      |
| Leptospirosis (Weil's Disease) Abs (IgM)     | LEP  | В  | 5 days   | 81      |
| Leucocyte Antibody Detection Panel FEMALE    | 8RF  | B  | 1 week   | 59      |
| Leucocyte Antibody Detection Panel MALE      | 7RF  | <b>(1)</b> (1) (1) (1) (1) (1) (1) (1) (1) (1) (1) | 1 week   | 59      |
| Leukaemia Immunophenotyping                  | LYPT | A 4,5  | 5 days   | 43      |
| Leukotriene E4                               | LTE4 | CU (Frozen)  | 3 weeks  | 81      |
| Levetiracetam (Keppra)                       | LEVE | <b>B</b> 4   | 3 days   | 136     |
| Lipase (Self-collect)                        | LIPA | (TDL Tiny)   | 1 day    | 34, 158 |
| Lipase (Venous)                              | LIPA | B  | 4 hours  | 34      |
| Lipid Profile (Self-collect)                 | LIPP | (TDL Tiny)   | 1 day    | 34, 39, |
|  |      |  |          | 158     |
| Lipid Profile (Venous)                       | LIPP | <u>B</u>   | 4 hours  | 34, 39  |
| Lipid Transfer Proteins                      | ZZ23 | 3  | 2 days   | 140     |
| Lipocalins                                   | ZZ28 | <u>B</u>   | 2 days   | 140     |
| Lipoprotein (a) (Self-collect)               | LP0A | (TDL Tiny)   | 1 day    | 34, 158 |
| Lipoprotein (a) (Venous)                     | LP0A | <u>B</u>   | 4 hours  | 34      |
| Lipoprotein Electrophoresis                  | LEL  | <u>B</u>   | 5 days   | 34      |
| Lithium (take 12 hours after dose)           | LITH | <u>B</u>   | 4 hours  | 34, 136 |
| Liver Fibrosis (Enhanced Liver Fibrosis ELF) | ELF  | <u> </u>   | 5 days   | 34      |
| Liver Fibrosis Fibrotest                     | FIBT | <u> </u>   | 2 weeks  | 34      |
| Liver Function Tests (Excluding AST/ALT)     | TLFT | (TDL Tiny)   | 1 day    | 34, 39, |
| (Self-collect)                               |      |  |          | 158     |
| Liver Function Tests (Venous)                | LFT  | 8  | 4 hours  | 34, 39  |
| Liver Immunoblot                             | LIVI | 8  | 3 days   | 81      |
| Liver Kidney Microsomal Antibodies           | LKM  | 3  | 2 days   | 81      |
| Lorazepam                                    | LORA | <b>A</b> 4   | 10 days  | 136     |
| Lp-PLA2 (PLAC) Test                          | PLA2 | <u>B</u>   | 2 days   | 34      |
| LSD  | LSD  | RU   | 5 days   | 161     |
| Lupus Anticoagulant and Anticardiolipin Abs  | LUPA | B 6 4,9,18   | 2 days   | 41, 81  |
| Lupus Anticoagulant only                     | LUPC | <b>6 6</b> 9,18                                    | 2 days   | 41      |
| Luteinising Hormone (LH) (Self-collect)      | LH   | (TDL Tiny)   | 1 day    | 56, 158 |
| Luteinising Hormone (LH) (Venous)            | LH   | <u> </u>   | 4 hours  | 56      |
| Lyme Disease (Borrelia Abs) IgG, IgM         | BORR | B 9,14   | 2 days   | 82      |
| Lyme Disease (Borrelia Abs) IgM              | BORM | 3  | 2 days   | 82      |

| TEST  | CODE | SAMPLE REQS                                    | TAT        | PAGE    |
|---|------|--|------------|---------|
| Lymphocyte Subsets (CD3/CD4/CD8)                          | LYSS | <b>A</b> 10                                    | 1 day      | 40      |
| Lymphogranuloma Venerium (LGV) (PCR)                      | LGVP | PCR <sup>42</sup>                              | 1-2 weeks  | 70      |
| Lymphogranuloma Venerium (LGV)<br>– Rectal (Self-collect) | LGVP | Aptima multisite swab                          | 1-2 weeks  | 70, 158 |
| Lysosomal Enzyme Screen                                   | LE   | <b>(1)</b> (1) (1)                             | 2 months   | 34      |
| Lysozyme  | LYS0 | В  | 5 days     | 34      |
| Macrolide Resistance Test (Mgen)                          | MGR  | FCRU / PCR                                     | 1-2 weeks  | 70      |
| Macroprolactin  | PRLD | B  | 4 days     | 56      |
| Magnesium (Serum)   | MG   | В  | 4 hours    | 35, 163 |
| Magnesium (Urine)   | URMG | PU   | 1 day      | 35, 163 |
| Magnesium (Whole blood)                                   | RCMG | A or (1)                                       | 4 days     | 150     |
| Malarial Antibodies (Pl. falciparum)                      | MALA | B 9,14   | 5 days     | 89      |
| Malarial Antibodies (species specific)                    | MALS | B 9,14   | 10 days    | 89      |
| Malarial Parasites  | MALP | A 4,9,14                                       | STAT       | 40      |
| Malarial Parasites (visa, non-urgent)                     | MP48 | A  | 2 days     | 40      |
| Male Genetic Reproductive Profile                         | GRP  | <b>A (1)</b> 9                                 | 10-15 days | 121     |
| Male Hormone Profile                                      | MIPR | B  | 4 hours    | 56, 61  |
| Manganese (Serum)   | MANG | В  | 5 days     | 35, 163 |
| MBOCA in Urine  | MBOC | RU   | 10 days    | 164     |
| Mean Cell Volume (MCV)                                    | MCV  | A  | 4 hours    | 40      |
| Measles Antibodies (IgG) Immunity                         | MEAS | В  | 1 day      | 91, 99  |
| Measles Antibodies (IgM)                                  | MEAM | <b>B</b> 9                                     | 2 days     | 91, 99  |
| Measles PCR   | MEAP | Buccal swab                                    | 48 hours   | 99      |
| Measles, Mumps, Rubella (MMR)                             | MMR  | В  | 1 day      | 91      |
| Melatonin (Serum)   | MEL  | (Frozen)                                       | 5 days     | 56      |
| Melatonin (Urine)   | UMEL | CU <sup>13</sup>                               | 2 weeks    | 56      |
| Meningococcal Serology (only serogroup C)                 | MENI | В  | 6 weeks    | 82      |
| Menopausal Profile (Self-collect)                         | TMEN | (TDL Tiny) (3) (TDL Tiny)                      | 1 day      | 56, 61, |
|   |      |  |            | 158     |
| Menopause Profile (Venous)                                | MENO | 8  | 4 hours    | 56, 61  |
| Mercury (Blood)   | MERC | (A) or (B)                                     | 5 days     | 35, 163 |
| Mercury (Urine)   | URHG | RU 1   | 5 days     | 35, 163 |
| MERS Coronavirus Test                                     | MERS | J  | 1 day      | 99      |
| Metabolic Syndrome Profile                                | METS | <b>ABBB</b>                                    | 9 days     | 56, 61  |
| Metanephrines (Plasma)                                    | PMET | (Frozen plasma, must be frozen within 2 hours) | 7 days     | 56      |
| Metanephrines (Urine)                                     | UMEX | <b>PU</b> (collect on acid) <sup>1</sup>       | 5 days     | 56      |
| Methaqualone  | METQ | RU   | 5 days     | 35      |
| Methotrexate  | METX | <b>B</b>                                       | 2 days     | 136     |
| Methylmalonic Acid – Serum                                | MMAS | <b>B</b>                                       | 5 days     | 35      |
| Methylmalonic Acid – Urine                                | MMA  | CU   | 2 weeks    | 35      |
| Metronidazole Level                                       | METR | <b>3</b> 4                                     | 7 days     | 135     |

| TEST  | CODE  | SAMPLE REQS                    | TAT       | PAGE    |
|---|-------|--------------------------------|-----------|---------|
| Microdeletion (common) Syndromes                | PB0B  | CVS / AF / (A) 9               | 5 days    | 122     |
| - BOBs only                                     |       |                                |           |         |
| Microfilaria Blood Film                         | MICF  | A                              | STAT      | 40      |
| Miller-Dieker Syndrome                          | PBOB, | CVS / AF / (A) (1) 9           | 5-15 days | 122     |
| - BOBs (5 days) + karyotype (15 days)           | KARY  |                                |           |         |
| Miller-Dieker Syndrome – BOBs only              | PB0B  | CVS / AF / (A) 9               | 5 days    | 122     |
| Mineral Screen                                  | MINE  | BØ                             | 5 days    | 150-151 |
| Mineral Screen (Whole blood)                    | RMIN  | 00                             | 5 days    | 150-151 |
| Mineral Screen and Industrial Heavy             | TRAC  | <b>A B H G</b>                 | 7-10 days | 150-151 |
| Metal Screen (Trace Metals)                     |       |                                |           |         |
| Miscarriage/Thrombotic Risk Profile             | PROP  | <b>AABOO</b> <sup>18</sup>     | 5 days    | 41, 44  |
| Mitochondrial Antibodies                        | AMIT  | В                              | 3 days    | 82      |
| Mitochondrial Antibodies M2                     | MAM2  | В                              | 2 days    | 82      |
| Molybdenum (Serum)                              | MOLY  | B                              | 5 days    | 164     |
| Monkeypox Virus – Lesion (Self-collect)         | MPXV  | Aptima multisite swab          | 2 days    | 70, 158 |
| MRSA (Rapid PCR) one swab per site              | MRSA  | Blue Micro Swab                | 4 hours   | 46      |
| MRSA (Rapid PCR) one swab per site x 2          | MRS2  | Blue Micro Swab x 2            | 4 hours   | 46      |
| MRSA Culture – Nose/Groin                       | MRW2  | Purple liquid Amies swab x2    | 2 days    | 158     |
| MRSA Culture - Nose/Groin (Self-collect)        | MRW2  | Purple liquid Amies swab x2    | 2 days    | 46      |
| MRSA Culture – Nose/Groin/Axilla                | MRW3  | Purple liquid Amies swab x3    | 2 days    | 158     |
| MRSA Culture - Nose/Groin/Axilla (Self-collect) | MRW3  | Purple liquid Amies swab x3    | 2 days    | 46      |
| MRSA Culture one swab per site                  | MRSW  | Blue Micro Swab                | 2 days    | 46      |
| MRSA Culture one swab per site x 2              | MRW2  | Blue Micro Swab x 2            | 2 days    | 46      |
| MRSA PCR - Nose/Groin                           | MRS2  | Purple liquid Amies swab x2    | 1 day     | 158     |
| MRSA PCR - Nose/Groin (Self-collect)            | MRS2  | Purple liquid Amies swab x2    | 1 day     | 46      |
| MRSA PCR - Nose/Groin/Axilla                    | MRS3  | Purple liquid Amies swab x3    | 1 day     | 158     |
| MRSA PCR - Nose/Groin/Axilla (Self-collect)     | MRS3  | Purple liquid Amies swab x3    | 1 day     | 46      |
| Mucopolysaccharides                             | MPS   | RU (Frozen)                    | 3 weeks   | 35      |
| Mumps Antibodies (IgG)                          | MUMP  | В                              | 1 day     | 91      |
| Mumps Antibodies (IgM)                          | MUMM  | B                              | 1 day     | 91, 99  |
| Myasthenia Gravis Evaluation                    | MGE   | B                              | 5 days    | 82      |
| Mycology/Skin Scrapings by PCR                  | DERM  | Submit Sample                  | 3-7 days  | 46      |
| Mycophenolic Acid (Cellcept)                    | MYCP  | A                              | 5 days    | 136     |
| Mycoplasma genitalium (Thin Prep)               | MGEN  | TPV                            | 2 days    | 168     |
| Mycoplasma genitalium by PCR                    | MGEN  | FCRU / PCR / TPV               | 2 days    | 70      |
| Mycoplasma genitalium Detection                 | MGEN  | Aptima urine or multisite swab | 2 days    | 70, 159 |
| - Urine or Vaginal (Self-collect)               |       |                                |           |         |
| Mycoplasma genitalium Resistance                | MGR   | Aptima urine or multisite swab | 1-2 weeks | 70, 159 |
| - Urine or Vaginal (Self-collect)               | MUDC  | TDV                            | 0.4       | 100     |
| Mycoplasma genitalium/Ureaplasma (Thin Prep)    | MUPC  | TPV                            | 2 days    | 168     |
| Mycoplasma genitalium/Ureaplasma by PCR         | MUPC  | FCRU / PCR / TPV               | 2 days    | 70      |
| Mycoplasma species – DNA                        | MPCR  | A                              | 5 days    | 99      |

| TEST  | CODE   | SAMPLE REQS                   | TAT                 | PAGE     |
|---|--------|-------------------------------|---------------------|----------|
| Myelin Associated Glycoprotein Antibodies   | MAG    | B                             | 5 days              | 82       |
| Myelin Basic Protein Antibodies   | MBPA   | B                             | 2 weeks             | 82       |
| Myeloma Screen  | MYEL   | <b>(∆ (B) (G)</b> RU          | 5 days              | 35, 39   |
| Myeloperoxidase Antibodies  | MP0    | B                             | 2 days              | 82       |
| Myocardial Antibodies   | MY0    | B                             | 1 week              | 82       |
| Myoglobin (Serum)   | SMY0   | B                             | 4 hours             | 35       |
| Myoglobin (Urine)   | UMY0   | RU                            | 5-10 days           | 35       |
| Myositis Panel  | MYOS   | B                             | 3 days              | 82       |
| Mysoline (Primidone)  | PRIM   | <b>B</b> 4                    | 3 days              | 136      |
| Nail Clippings  | DERM   | Nail clippings                | 3-7 days            | 46       |
| Natural Killer Profile 2  | NKP2   | <b>A</b> 10                   | 2 days              | 40, 44   |
| Needle Stick Injury Profile   | NSI    | BB                            | 4 hours             | 99, 101  |
| Neurological Viral Screen   | NVIR   | BB                            | 2 days              | 99, 101  |
| Neuronal Antibody (Hu, Ri, Yo, Cv2, Ma2)  | NEUR   | B                             | 10 days             | 82       |
| Neurone Specific Enolase  | NSE    | B                             | 5 days              | 102      |
| Newborn Screening Panel   | GUTH   | <b>J</b> 1                    | 2 weeks             | 35       |
| Nickel (Serum)  | NICK   | B                             | 5 days              | 35, 163  |
| Nickel (Urine)  | NICU   | RU                            | 4 weeks             | 35, 163  |
| NK (CD69) and NK Cytotoxicity   | 69C    | <b>000</b> *                  | Send Mon-Thurs only | 60       |
| NK (CD69) Cell Assay  | CD69   | <b>(</b> )*                   | Send Mon-Thurs only | 60       |
| NK Assay Follow-Up Panel  | 5RF    | 000                           | 1 week              | 59       |
| NK Assay Panel + Intralipids  | 16RF   | 000                           | 1 week              | 59       |
| NK Assay/Cytotoxicity Panel   | 4RF    | 000                           | 1 week              | 59       |
| NK Cytotoxicity Assay   | HSNK   | <b>000</b> *                  | Send Mon-Thurs only | 60       |
| NK Cytotoxicity with suppression with steroid,<br>IVIg and intralipin, and NK (CD69) cell assay | 69CI   | 000*                          | Send Mon-Thurs only | 60       |
| NK Cytotoxicity with suppression, steroid, IVIg & Intralipin                                    | NKCY   | 000*                          | Send Mon-Thurs only | 60       |
| NMDA Receptor Antibodies  | NMDA   | B                             | 3 weeks             | 82       |
| Non-Invasive Prenatal Testing (NIPT)  – common aneuploidy screening                             | NIPT   | J / Special tube <sup>1</sup> | 2-4 days            | 123, 132 |
| from maternal blood NEW   |        |                               |                     |          |
| Nucleic Acid Antigen Antibodies   | DNA    | B                             | 2 days              | 82       |
| Oestradiol (Self-collect)   | TOES   | (TDL Tiny)                    | 1 day               | 56, 159  |
| Oestradiol (Venous)   | OEST   | B                             | 4 hours             | 56       |
| Oestriol (Estriol)  | E3     | 88                            | 4 days              | 56       |
| Oestrone  | <br>E1 | 88                            | 4 days              | 57       |
| Olanzapine  | OLAN   | <b>A</b> <sup>4</sup>         | 5 days              | 137      |
| Oligoclonal Bands   | CSF0   | CSF + (3)                     | 5 days              | 82       |
| Oligosaccharides  | UOLI   | RU                            | 6 weeks             | 35       |
| Olive Components  | ZZ14   | В                             | 2 days              | 140      |
|   |        |                               |                     | 110      |

| TEST                                      | CODE  | SAMPLE REQS                       | TAT        | PAGE      |
|---|-------|-----------------------------------|------------|-----------|
| Omega 3/Omega 6 (Self-collect)            | OMG3  | (TDL Tiny)                        | 5 days     | 150, 152, |
|   |       |                                   |            | 159       |
| Omega 3/Omega 6 (Venous)                  | OMG3  | <b>A</b> 4                        | 5 days     | 150, 152  |
| Opiate Screen (Urine)                     | UOPI  | RU                                | 2 days     | 161       |
| Orosomucoid (A1AG – Alpha 1 Glycoprotein) | OROS  | (Frozen)                          | 5 days     | 35        |
| Osmolality (Serum)                        | 0SM0  | В                                 | 1 day      | 35        |
| Osmolality (Urine)                        | ROSM  | RU                                | 1 day      | 35        |
| Osteocalcin                               | 0ST   | ⊕ (Frozen) <sup>4</sup>           | 4 days     | 57, 102   |
| Osteoporosis Screen                       | 0PS   | BB                                | 4 days     | 35, 39    |
| Ovarian Autoantibodies                    | OVAB  | В                                 | 2 days     | 82        |
| Oxalate (Plasma)                          | POXA  | (Frozen)                          | 7 days     | 35        |
| Oxalate (Urine)                           | UOXA  | PU                                | 5 days     | 35        |
| Oxidative Stress in Semen (ROS + MIOXSYS) | SROS  | Semen 1                           | 1 day      | 64        |
| P2Y12 Receptor Platelet Function          | P2Y   | J** 1                             | 1 day      | 41        |
| Analysis (Clopidogrel Resistance)         |       |                                   |            |           |
| PAI-1 4G/5G Polymorphism                  | PAIP  | A                                 | 2 weeks    | 40, 59    |
| Pancreatic Peptide                        | PP    | J                                 | 4 weeks    | 35        |
| Paracetamol                               | PARA  | В                                 | 4 hours    | 137       |
| Paragomius Serology                       | PRGM  | В                                 | 2 weeks    | 82        |
| Parathyroid Antibodies                    | PTHA  | В                                 | 1 week     | 82        |
| Parathyroid Hormone (Whole)               | PTHI  | <b>A</b> 4                        | 1 day      | 57        |
| Parathyroid Related Peptide               | PTRP  | 2ml 🛕 Plasma frozen               | 2 weeks    | 35        |
|   |       | (Freeze immediately) <sup>1</sup> |            |           |
| Parvalbumins                              | ZZ29  | В                                 | 2 days     | 140       |
| Parvovirus Antibodies (IgM)               | PARV  | В                                 | 2 days     | 99        |
| Parvovirus IgG Antibodies                 | PARG  | <b>B</b>                          | 2 days     | 99        |
| Parvovirus IgG/IgM Abs                    | PARP  | В                                 | 2 days     | 99        |
| Paternity Testing (postnatal and          | PATT  | (A) / AF / CVS 1,12 Contact       | 5 days     | 124       |
| prenatal) – sample required from each     |       | Genetics lab                      |            |           |
| person being tested (3 people)            |       | •                                 |            |           |
| Paul Bunnell (Monospot)                   | PAUL  | (A) or (B)                        | 8 hours    | 40        |
| Peach Components                          | ZZ15  | 8                                 | 2 days     | 140       |
| Peanut Components                         | ZZ16  | <u>B</u>                          | 2 days     | 140       |
| Pemphigus/Pemphigoid Autoantibodies       | SKAB  | <u>B</u>                          | 2 days     | 82        |
| Pertussis (Whooping Cough) Antibodies     | PERS  | <u>B</u>                          | 5 days     | 82, 91    |
| PEth (Phosphatidylethanol) (Self-collect) | PETH  | (TDL Tiny) <sup>38</sup>          | 5-7 days   | 35, 159,  |
|   |       | <b>0</b> 00                       |            | 161       |
| PEth (Phosphatidylethanol) (Venous)       | PETH  | A 38                              | 5-7 days   | 35, 161   |
| Phelan-McDermid Syndrome –                | KARY, | CVS / AF / (1) 9                  | 12-17 days | 124       |
| karyotype + FISH                          | FISH  | DII                               | E doug     |           |
| Phencyclidine (PCP)                       | DUST  | RU                                | 5 days     | 35        |
| Phenobarbitone                            | PHB   | <b>3</b>                          | 4 hours    | 137       |

| TEST   | CODE | SAMPLE REQS                     | TAT      | PAGE     |
|--|------|---------------------------------|----------|----------|
| Phenytoin (Epanutin)                                     | PHEN | <b>B</b>                        | 4 hours  | 137      |
| Phosphate  | PH0S | <b>B</b>                        | 4 hours  | 35       |
| Phosphate (24 hour Urine)                                | UPH  | PU                              | 4 hours  | 35       |
| Pituitary Antibodies                                     | PITU | <b>B</b> 4                      | 1 month  | 82       |
| Pituitary Function Profile CHANGE                        | PITF | <b>BB</b> <sup>7</sup>          | 1 day    | 57, 62   |
| PLAC Test (Lp-PLA2) (Self-collect)                       | PLA2 | (TDL Tiny)                      | 2 days   | 35, 159  |
| PLAC Test (Lp-PLA2) (Venous)                             | PLA2 | <b>B</b>                        | 2 days   | 35       |
| Plasminogen  | PLAS | <b>(</b> Frozen plasma)⁴        | 5 days   | 35       |
| Plasminogen Activator Inhibitor – 1                      | PAI1 | (Frozen plasma)                 | 2 weeks  | 35       |
| Platelet Aggregation Studies                             | PLAG | <b>J</b> ** <sup>1</sup>        | 3 days   | 42       |
| Platelet Function Test Screen – PFA-100/200              | PFAT | <b>J</b> ** <sup>1</sup>        | 1 day    | 42       |
| Pleural Fluid for Culture                                | FLUP | SC                              | 7 days   | 46       |
| Pneumococcal Antibodies – Serotype Specific              | PASS | <b>B</b>                        | 5 weeks  | 82       |
| Pneumococcal Antibody Screen                             | PNEU | <b>B</b>                        | 5 days   | 82, 91   |
| Pneumococcal Antigen                                     | PNAG | RU                              | 1 day    | 46       |
| Pneumocystis Jiroveci (PCP) Examination                  | PCYS | BAL <sup>‡‡</sup>               | 2-3 days | 46       |
| Pneumonia (Atypical) Screen                              | APS  | <b>B</b>                        | 2 days   | 99       |
| Polcalcins   | ZZ25 | 3                               | 2 days   | 141      |
| Polycystic Ovary Syndrome Profile                        | PCOP | <b>ABBB G</b> <sup>7</sup>      | 5 days   | 57, 62   |
| Polycystic Ovary Syndrome SHORT                          | PCOS | <b>3 G</b>                      | 4 hours  | 57, 62   |
| Porphyrin (Blood)  | PORP | <b>A</b> 3                      | 15 days  | 35       |
| Porphyrin (Stool)  | FP0R | RF <sup>3</sup>                 | 3 weeks  | 35       |
| Porphyrin (Urine)  | RPOR | RU <sup>3</sup>                 | 3 weeks  | 35       |
| Porphyrin Full Screen                                    | PORS | ARU, RF <sup>3</sup>            | 3 weeks  | 36, 39   |
| (Total: Urine, Stool, Blood)                             |      |                                 |          |          |
| Post-Travel Screen 1 (Prior to 6 weeks)                  | PTS  | <b>A B G</b> 14                 | 10 days  | 89, 90   |
| Post-Travel Screen 2 (Prior to 6 weeks)                  | PTS2 | <b>AABBB</b> (3 14              | 10 days  | 89, 90   |
| Postnatal array CGH                                      | CGH  | <b>A (1)</b> 9                  | 10 days  | 124, 130 |
| Potassium  | K    | <u> </u>                        | 4 hours  | 36       |
| PR-10 Proteins   | ZZ22 | <u> </u>                        | 2 days   | 141      |
| Prader-Willi Syndrome (Primary Screen) – methylation PCR | PWAM | <b>A</b> 9                      | 10 days  | 124      |
| Prealbumin   | PALB | <b>B</b>                        | 3 days   | 139      |
| Pregnancy (Serum) [Quantitative]                         | QHCG | 3                               | 4 hours  | 36, 57   |
| Pregnancy Test (Urine)                                   | PREG | RU                              | 4 hours  | 36       |
| Pregnenolone   | PREN | <b>B</b>                        | 15 days  | 57       |
| Prenatal array CGH                                       | CGH  | Amniotic fluid, CVS or POC $^9$ | 10 days  | 124, 130 |
| Pre-Travel Screen (DVT)                                  | DVT1 | <b>A B</b> <sup>9</sup>         | 5 days   | 40, 44,  |
|  |      |                                 |          | 89, 124  |
| Primidone (Mysoline)                                     | PRIM | <b>B</b> 4                      | 3 days   | 137      |
| Procalcitonin  | PCAL | (Frozen) <sup>4,7</sup>         | 1 day    | 36       |
| Procollagen 1 Peptide N-Terminal (NTX)                   | P1NP | В                               | 5 days   | 36       |

| TEST  | CODE         | SAMPLE REQS                   | TAT               | PAGE      |
|---|--------------|-------------------------------|-------------------|-----------|
| Procollagen 3 Peptide                                       | PRCO         | <b>B</b>                      | 5 days            | 36        |
| Products of Conception – rapid BOBs                         | PBK          | Placental Sample 1,9          | 10-25 days        | 125       |
| aneuploidy diagnosis for all chromosomes                    |              |                               |                   |           |
| (10 days) + culture (25 days)                               |              |                               |                   |           |
| Products of Conception (BOBs + Culture)                     | PBK          | Placental Sample 1,9          | 10-25 days        | 125       |
| Products of Conception BOBs only – rapid                    | KB0B         | Placental Sample or           | 10 days           | 125       |
| aneuploidy diagnosis for all chromosomes                    | 7704         | Solid Tissue 1,9              | 0.4               | 444       |
| Profilins   | ZZ24         | (TDI Time)                    | 2 days            | 141       |
| Progesterone (Self-collect)                                 | PROG         | (TDL Tiny)                    | 1 day             | 57, 159   |
| Progesterone (Venous)                                       | PROG         | (Franco places)               | 4 hours           | 57        |
| Proinsulin  | PROI         | (Frozen plasma) <sup>4</sup>  | 5 days            | 57        |
| Prolactin (Macro)   | PRLD         | (FDI Time)                    | 4 days            | 57        |
| Prolactin (Self-collect)                                    | PROL<br>PROL | (TDL Tiny)                    | 1 day             | 57, 159   |
| Prolactin (Venous)  | PRO          | <b>B</b> 4                    | 4 hours           | 57        |
| Propanalol  | DPRO         | RU                            | 7 days            | 137<br>36 |
| Propoxyphene Prostate Profile (Total & Free PSA)            | PR2          | B                             | 5 days<br>4 hours | 102, 104  |
| Prostate Specific Antigen (Total) (Self-collect)            | PSPA         | B (TDL Tiny)                  |                   | 102, 104  |
| Prostate Specific Antigen (Total) (Venous)                  | PSPA         | (TUL TIIIY)                   | 1 day<br>4 hours  | 102, 139  |
| Prostatic Acid Phosphatase                                  | PACP         | (Frozen)                      |                   | 36        |
| Protein (Urine)   | UPRT         | CU                            | 3 days<br>4 hours | 36        |
| Protein (Grine)  Protein 14.3.3 (Creutzfeldt–Jakob Disease) | CJD          | J                             | 5 weeks           | 36        |
| Protein C   | PRC          | © (Frozen) 4,9,18             | 3 days            | 42        |
| Protein Electrophoresis incl. immunoglobulin                | PRTE         | (11026H) ***                  | 5 days            | 36        |
| Protein S Activity  | PS1          | © (Frozen) <sup>4,9,18</sup>  | 5 days            | 42        |
| Protein S Free Ag   | FPRS         | (Frozen) 4,9,18               | 3 days            | 42        |
| Protein Total (Blood)                                       | PROT         | (11026H) ***                  | 4 hours           | 36        |
| Protein/Creatinine Ratio (Urine)                            | UCPR         | RU                            | 4 hours           | 36        |
| Proteinase 3 Ab   | PR3          | 6                             | 2 days            | 82        |
| Prothrombin Time  | PTIM         | (e) 18                        | 4 hours           | 40        |
| Prothrombin Time + Dose                                     | PT+D         | <b>©</b> 18                   | 4 hours           | 40        |
| Purkinje Cell Antibody (Hu and Yo)                          | PURK         | B                             | 10 days           | 82        |
| Pyruvate Kinase (M2-PK)                                     | M2ST         | RF <sup>4</sup>               | 5 days            | 102       |
| Pyruvate Kinase (M2-PK)                                     | M2PK         | (Frozen plasma) <sup>7</sup>  | 5 days            | 102       |
| Q Fever (C Burnetti) Antibodies                             | QFEV         | B 9                           | 10 days           | 82        |
| QF-PCR rapid common aneuploidy screen                       | APC          | <b>AF</b> / (A) 9             | 2 days            | 125       |
| QFIT/Calprotectin Profile (Combined)                        | QCAL         | QFIT sample collection device | <u> </u>          | 46, 82,   |
|   |              |                               | · .               | 159       |
| Quantitative Faecal Immunochemical Test (QFIT)              | QFIT         | QFIT sample collection device | 1 day             | 46, 159   |
| Rabies Antibody   | RABI         | <b>B</b>                      | 20 days           | 91        |
| Rapid Strep (incl. m/c/s)                                   | RAPS         | STM**                         | 1-3 days**        | 46        |
|   |              |                               |                   |           |

| TEST  | CODE | SAMPLE REQS                   | TAT        | PAGE    |
|---|------|-------------------------------|------------|---------|
| Rapid Xpert HIV-1 RNA Qualitative           | LHIV | (Vacutainer only)             | 4 hours    | 70      |
| – Early Detection from 10 days              |      |                               |            |         |
| Rapid Xpert HIV-1 RNS Viral Load – Rapid    | RHIV | (Vacutainer only)             | 4 hours    | 70      |
| Testing for HIV-Positive Patient Prognosis  |      |                               |            |         |
| and Response To Antiretroviral Therapy      |      |                               |            |         |
| Recurrent Miscarriage Profile (female)      | RMP  | <b>A A B 9</b> ,18            | 10-15 days | 125     |
| Renal Calculi Screen (Metabolic)            | RSPR | J <sup>6</sup>                | 5 days     | 36      |
| Renal Stone Analysis                        | RSTA | STONE                         | 10 days    | 36      |
| Renin                                       | RENI | (Frozen plasma) <sup>36</sup> | 5 days     | 57      |
| Reproductive Immunophenotype Panel          | 3RF  | 000                           | 1 week     | 59      |
| Respiratory PCR Panel                       | FLU4 | Throat and nose swab          | 1 day      | 99-100, |
| (COVID-19, Flu A/B and RSV) (Self-collect)  |      |                               |            | 159     |
| Respiratory PCR Panel                       | FLU4 | PCR nasopharyngeal            | 1 day      | 99-100  |
| (COVID-19, Flu A/B and RSV) (PCR)           |      |                               |            |         |
| Reticulocyte Count                          | RETC | A                             | 4 hours    | 40      |
| Retinol Binding Protein                     | RBP  | В                             | 3 days     | 36      |
| Retrograde Ejaculation                      | RTR0 | Contact lab                   | 2 days     | 64      |
| Reverse T3                                  | RT3  | B 7,37                        | 15 days    | 57      |
| Rheumatoid Factor (Latex Test)              | RF   | <b>B</b>                      | 1 day      | 82      |
| Rheumatology Profile 1 (Screen)             | RH   | AB                            | 2 days     | 82, 86  |
| Rheumatology Profile 2 (Connective tissue)  | RH2  | AABB                          | 3 days     | 82, 86  |
| Rheumatology Profile 3 (Rheumatoid/Basic)   | RH3  | AB                            | 2 days     | 82, 86  |
| Rheumatology Profile 4 (Systemic Lupus)     | RH4  | ABB                           | 2 days     | 82, 86  |
| Rheumatology Profile 5 (Mono Arthritis)     | RH5  | AABB                          | 3 days     | 82, 86  |
| Rheumatology Profile 6 (Rheumatoid Plus)    | RH6  | B                             | 2 days     | 82, 87  |
| Rheumatology Profile 7 (Sjogren's Syndrome) | RH7  | В                             | 10 days    | 83, 87  |
| Rickettsial Species Antibody Profile        | RICK | B                             | 7 days     | 83, 89  |
| Risperidone                                 | RISP | <b>A</b> 4                    | 7 days     | 137     |
| RNA Polymerase Antibodies                   | RNAP | B                             | 3 days     | 83      |
| Rotavirus in Stool by PCR                   | ROTA | RF                            | 1 day      | 99      |
| RPR (Syphilis)                              | RPR  | B                             | 2 days     | 70, 83  |
| Rubella Antibody (IgG)                      | RUBE | B                             | 4 hours    | 91, 99  |
| Rubella Antibody (IgM)                      | RUBM | В                             | 4 hours    | 91, 99  |
| Rubella Avidity                             | RUAV | В                             | 1 week     | 99      |
| Rubella PCR                                 | RUBP | (A) / Amniotic Fluid          | 5 days     | 91      |
| S100 Malignant Melanoma                     | S100 | В                             | 4 days     | 102     |
| Saccharomyces Cerevisiae Antibodies         | ASCA | В                             | 2 weeks    | 83      |
| Salicylates                                 | SALI | B                             | 4 hours    | 36      |
| Salivary Duct Antibodies                    | SAB  | B                             | 12 days    | 83      |
| Schistosoma (Urine)                         | USCH | Mid-morning terminal urine    | 1-2 days   | 47      |
|   |      | following exercise 14         |            |         |
| -   |      |                               |            |         |

| TEST   | CODE | SAMPLE REQS                       | TAT           | PAGE            |
|--|------|-----------------------------------|---------------|-----------------|
| Schistosome (Bilharzia) Antibodies             | BILH | <b>B</b> 14                       | 10 days       | 89              |
| Scleroderma Immunoblot                         | SCLI | <b>B</b>                          | 3 days        | 83              |
| Screening Profile 1 – Biochemistry             | PP1  | <b>B G</b>                        | 4 hours       | 26              |
| Screening Profile 2 – Haematology/Biochemistry | PP2  | <b>AB</b> G                       | 4 hours       | 26              |
| Screening Profile 3 – Haematology              | PP3  | A                                 | 4 hours       | 26              |
| Screening Profile 4 – Haematology/             | PP4  | ABG                               | 4 hours       | 26              |
| Biochemistry (Short)                           |      |                                   |               |                 |
| Screening Profile 5 – Haematology/             | PP5  | <b>A B G</b>                      | 4 hours       | 26              |
| Biochemistry (Postal)                          |      |                                   |               |                 |
| Screening Profile 6 – Well Person              | PP6  | 000                               | 4 hours       | 26              |
| Screening Profile 7 – Well Man                 | PP7  | 000                               | 4 hours       | 27              |
| Screening Profile 8 – Well Person              | PP8  | 000                               | 2 days        | 27              |
| Screening Profile 9F – Senior Female           | PP9F | ABBGRU <sup>4</sup>               | 2 days        | 27              |
| Screening Profile 9M – Senior Male             | PP9M | ABBGRU <sup>4</sup>               | 2 days        | 27              |
| Screening Profile 10 – Cardiovascular Risk 1   | PP10 | 88                                | 3 days        | 27              |
| Screening Profile 11 – Cardiovascular Risk 2   | PP11 | <b>BBB 6</b> 34                   | 3 days        | 27              |
| Screening Profile 12 – Sexual Health Screen    | PP12 | FCRU / PCR / TPV                  | 2 days        | 27              |
| Seed Storage Proteins                          | ZZ26 | В                                 | 2 days        | 141             |
| Selenium (Serum) (Self-collect)                | SELE | B (TDL Tiny)                      | 4 days        | 36, 150,<br>159 |
| Selenium (Serum) (Venous)                      | SELE | B                                 | 4 days        | 36, 150         |
| Self-collection samples                        |      |                                   |               | 153-160         |
| Sellotape Test                                 | SELL | Send Sample***                    | 1 day         | 47              |
| Semen Analysis, Comprehensive                  | SPER | Semen 1                           | 2 days*       | 64              |
| Semen Analysis, Post-Vasectomy                 | PVAS | Semen 1                           | 2 days        | 64              |
| Semen Analysis, Vasectomy Reversal             | SPER | Semen 1                           | 2 days*       | 64              |
| Semen Culture                                  | SPCU | Semen                             | 2-4 days      | 47, 64          |
| Semen Fructose                                 | SPCF | Semen                             | 2 days        | 64              |
| Semen Leucocytes                               | PMNS | Semen                             | 2 days        | 64              |
| Semen Zinc                                     | SPCZ | Semen                             | up to 10 days | 64              |
| Serotonin                                      | SERT | (Frozen whole blood) <sup>1</sup> | 10 days       | 57              |
| Serotonin (Urine)                              | USER | PU 50mls (Frozen) <sup>1</sup>    | 5 days        | 57              |
| Serum Albumins                                 | ZZ30 | B                                 | 2 days        | 141             |
| Serum Free Light Chains                        | SLC  | В                                 | 5 days        | 36              |
| Sesame Components                              | ZZ39 | В                                 | 2 days        | 141             |
| Sex Hormone Binding Globulin (Self-collect)    | SHBG | (TDL Tiny)                        | 1 day         | 57, 159         |
| Sex Hormone Binding Globulin (Venous)          | SHBG | <b>B</b>                          | 4 hours       | 57              |
| Shrimp Components                              | ZZ17 | <b>B</b>                          | 2 days        | 141             |
| Silver (Blood)                                 | SILV | <b>B</b>                          | 5 days        | 36, 163         |
| Silver (Urine)                                 | USIL | RU                                | 5 days        | 36, 163         |
| Sinequan (Doxepin)                             | DOXE | A                                 | 10 days       | 137             |
| Sirolimus                                      | SIR0 | A                                 | 3 days        | 137             |
|  |      |                                   |               |                 |

| TEST   | CODE          | SAMPLE REQS   | TAT           | PAGE    |
|--|---------------|---|---------------|---------|
| Sjogren's Syndrome   | RH7           | <b>B</b>  | 10 days       | 83      |
| Skin (Pemphigus/Pemphigoid) Autoantibodies                           | SKAB          | <b>B</b>  | 2 days        | 83      |
| Skin Antibodies by Immunofluorescence                                | STSK          | <b>B</b>  | 1 month       | 83      |
| Skin Scrapings/Mycology by PCR                                       | DERM          | Send Sample   | 3-7 days      | 47      |
| Sleeping Sickness Serology<br>(African Trypanosomiasis)              | TRYP          | <b>B</b> 9  | 10 days       | 83      |
| Smith-Magenis Syndrome<br>– BOBs (5 days) + karyotype (15 days)      | PBOB,<br>KARY | CVS / AF / (A) (B) 9  | 5-15 days     | 126     |
| Smith-Magenis Syndrome – BoBs only                                   | PB0B          | CVS / AF / (A) 9  | 5 days        | 126     |
| Smooth Muscle Antibodies   | ASM0          | <b>B</b>  | 2 days        | 83      |
| Sodium   | NA            | <b>B</b>  | 4 hours       | 36      |
| Somatomedin (IGF-1)  | SOMA          | ⊕ (Frozen) <sup>4</sup>   | 1 day         | 57      |
| Soybean Components   | ZZ18          | <b>B</b>  | 2 days        | 141     |
| Specific Gravity (Urine)   | USG           | RU  | 24 hours      | 47      |
| Sperm Aneuploidy   | SPPL          | Semen 1   | 4 weeks       | 64      |
| Sperm Antibodies (Serum)   | ASAB          | <b>B</b>  | 5 days        | 64, 83  |
| Sperm Antibodies/MAR Test (Semen)†                                   | ASPA          | Semen   | 1 day         | 64      |
| Sperm Comet®   | CMET          | Semen 1   | 1-2 weeks     | 64      |
| Sperm Count (Post-Vasectomy)   | PVAS          | Semen 1   | 2 days        | 64      |
| Sperm DNA Fragmentation (SCSA)                                       | SEXT          | Semen 1   | 1-2 weeks     | 64      |
| Sperm Morphology (Kruger strict criteria)                            | MRPH          | Semen 1   | 2 days        | 64      |
| Sports/Performance Profile   | SPOR          | <b>A A A B B B B G G G</b>  | 5 days        | 150-151 |
| Sputum for Routine Culture   | SPU1          | SC  | 2-4 days      | 47      |
| Sputum for TB Culture (AFB)  | SPU2          | SC  | up to 8 weeks | 47      |
| Squamous Cell Carcinoma  | SCC           | <b>B</b>  | 4 days        | 102     |
| STD1 M/F STD Quad (Urine and Serology)                               | STD1          | □ FCRU  | 2 days        | 71-72   |
| STD2 M/F STI Profile Plus (Urine and Serology)                       | STD2          | FCRU (If culture<br>swabs are needed please<br>request separately)  | 4 days        | 71-72   |
| STD3 Female STD Quad (PCR Swab and Serology)                         | STD3          | □ PCR   | 2 days        | 71-72   |
| STD4 Female STI Profile Plus<br>(PCR Swab and Serology)              | STD4          | © PCR (If culture swabs<br>are needed please<br>request separately) | 4 days        | 71-72   |
| STD5 Serology only   | STD5          | <b>B</b>  | 4 hours       | 71-72   |
| STD6 Serology only without HIV                                       | STD6          | <b>B</b>  | 4 hours       | 71-72   |
| STD8 Vaginitis/BV Profile using<br>Culture & PCR Swab                | STD8          | PCR and STM   | 3 days        | 71-72   |
| STD9 Symptomatic lesion sample using PCR Swab from lesion & PCR Swab | STD9          | 2 x PCR Swab  | 7 days        | 71, 73  |
| Steroid Cell Antibody  | SCA           | <b>B</b>  | 2 days        | 83      |
| STI Profile by PCR<br>(7 tests from 1 Sample) (Self-collect)         | DL12          | Aptima urine or multisite swab                                      | 2 days        | 71, 159 |

| TEST  | CODE   | SAMPLE REQS                                  | TAT                 | PAGE     |
|---|--------|--|---------------------|----------|
| STI Profile: MSM1 (Blood + Urine/   | MSM1   | (TDL Tiny) / Aptima Urine                    | 2 days              | 71, 74,  |
| Throat/Rectal Swabs) (Self-collect)   |        | / Aptima multisite swab x 2                  |                     | 159      |
| STI Profile: MSM1 (Venous)  | MSM1   | 3 / FCRU / PCR Swab                          | 2 days              | 71, 74   |
|   |        | Throat / PCR Swab Rectal                     |                     |          |
| STI Profile: MSM2 (Blood + Urine/   | MSM2   | (TDL Tiny) / Aptima urine                    | 3 days              | 71, 74,  |
| Throat/Rectal Swabs) (Self-collect)   | 140140 | / Aptima multisite swab x 2                  | 0.1                 | 159      |
| STI Profile: MSM2 (Venous)  | MSM2   | 3 / FCRU / PCR Swab Throat / PCR Swab Rectal | 3 days              | 71, 74   |
| Stool for OCP and Culture   | PENT   | RF   | 2.2 daya            | 47       |
| Stool for OVA Cysts & Parasites by PCR  | MOCP   | RF   | 2-3 days<br>2 days  | 47       |
|   | STRS   | RF <sup>7</sup>                              |                     | 47       |
| Stool Reducing Substances Streptomycin Levels   | STRM   | (i)  | 5 days              | 137      |
| Striated/Skeletal Muscle Antibody   | STRA   | B  | 5 days<br>2 days    | 83       |
| Strongyloides Antibodies  | STGA   | <u> </u>                                     | 10 days             | 83       |
|   | SULP   | <b>3</b> 4                                   |                     | 137      |
| Sulpiride Superavida Diamutasa Inhihitar  |        | <b>A</b> / <b>(1)</b>                        | 4 days              |          |
| Superoxide Dismutase Inhibitor  | SODI   |  | 5 days              | 36<br>60 |
| Suppression with steroid, IVIg and intralipin, NK (CD69) cell assay, TH1/TH2 cytokines CHAN |        | <b>0000</b> *                                | Send Mon-Thurs only | 00       |
| Swab (Cervical)   | CERS   | STM / CS                                     | 2-4 days            | 47       |
| Swab (Ear)  | EARS   | STM  | 2-4 days (Culture)  | 47       |
| (-11.7)   |        |  | 8-9 days (Fungal)   |          |
|   |        |  | – same swab         |          |
| Swab (Eye)  | EYES   | STM  | 2-4 days            | 47       |
| Swab (Nasal)  | NASS   | STM  | 2-4 days            | 47       |
| Swab (Oral)   | ORSW   | STM/CS                                       | 2-4 days            | 47       |
| Swab (Penile)   | PENS   | STM/CS                                       | 2-4 days            | 47       |
| Swab (Rectal)   | RECG   | STM/CS                                       | 2-4 days            | 47       |
| Swab (Skin)   | SKIS   | STM  | 2-4 days            | 47       |
| Swab (Throat)   | THRS   | STM  | 2-4 days            | 47       |
| Swab (Urethral)   | URES   | STM/CS                                       | 2-4 days            | 47       |
| Swab (Vaginal)  | VAGS   | STM/CS                                       | 2-4 days            | 47       |
| Swab (Vulval)   | VULV   | STM/CS                                       | 2-4 days            | 47       |
| Swab (Wound)  | WOUS   | STM  | 2-4 days            | 47       |
| Synacthen Stimulation Test  | SYNA   | By appointment only                          | 1 day               | 135      |
| Synovial Fluid (for microscopy and culture)   | FLU2   | SC†††  | 14 days             | 47       |
| Syphilis by PCR (chancre)   | SYPS   | PCR  | 5 days              | 71       |
| Syphilis IgG/IgM (Self-collect)   | TSYP   | (TDL Tiny)                                   | 1 day               | 71, 83,  |
|   |        |  |                     | 159      |
| Syphilis IgG/IgM (Venous)   | SERJ   | <u> </u>                                     | 4 hours             | 71, 83   |
| T Regulatory Cells  | 25RF   | 0  | 3 days              | 59       |
| <u>T3</u>   | T3     | <b>3</b>                                     | 4 hours             | 57       |
| T3 (Reverse)  | RT3    | B 7,37                                       | 15 days             | 57       |
| Tacrolimus/Prograf (FK506)  | FK5    | <b>A</b> 4                                   | 1-2 days            | 137      |
|   |        |  |                     |          |

| TEST   | CODE | SAMPLE REQS                             | TAT                 | PAGE           |
|--|------|---|---------------------|----------------|
| Taipan Snake Venom Time  | TTVT | <b>6 6</b> 9,18                         | 1 week              | 42             |
| TB (Pleural Fluid)   | TBCU | SC                                      | up to 8 weeks       | 47             |
| TB Culture   | SPU2 | SC                                      | up to 8 weeks       | 47             |
| TB Culture (Urine)   | TBUR | 3 x EMU                                 | up to 8 weeks       | 47             |
| TB Quantiferon®-TB Gold*   | TBQ4 | Special tubes or (1)                    | 3 days              | 83             |
| TB Slopes – Confirmation and Sensitivity                               | TBSL | TB slope (LJ medium-green) <sup>6</sup> | up to 8 weeks       | 48             |
| Tegretol (Carbamazepine)   | CARB | <b>B</b>                                | 4 hours             | 137            |
| Teicoplanin Assay  | TEIC | <b>B</b>                                | 5 days              | 135            |
| Temazepam  | TEMA | <b>B</b> 4                              | 4 days              | 137            |
| Testicular Tumour Profile (LDH, AFP, HCQG)                             | TTP  | <b>B</b>                                | 4 hours             | 102, 104       |
| Testosterone (Self-collect)  | TEST | (TDL Tiny)                              | 1 day               | 57, 159        |
| Testosterone (Venous)  | TEST | <b>B</b>                                | 4 hours             | 57             |
| Testosterone (Free) (Self-collect)                                     | FTES | (TDL Tiny)                              | 3 days              | 57, 159        |
| Testosterone (Free) (Venous)   | FTES | <b>B</b>                                | 3 days              | 57             |
| Tetanus Antibody   | TETA | <b>B</b>                                | 5 days              | 83, 91         |
| TH1/TH2 Cytokine Profile   | 1TH2 | 000*                                    | Send Mon-Thurs only | 60             |
| TH1/TH2 Cytokine Ratio   | 6RF  | <b>000</b> <sup>5</sup>                 | 1 week              | 59             |
| TH1/TH2 Intracellular Cytokine Ratios with IVIG                        | 21RF | <b>000</b> <sup>5</sup>                 | 1 week              | 59             |
| TH1/TH2 Intracellular Cytokine   | 20RF | <b>000</b> 5                            | 1 week              | 59             |
| Ratios with IVIG, Prednisolone   |      |   |                     |                |
| TH1/TH2 Intracellular Cytokine   | 22RF | <b>000</b> <sup>5</sup>                 | 1 week              | 59             |
| Ratios with Prednisolone   |      |   |                     |                |
| Thalassaemia Screen  | HBEL | <b>A</b>                                | 4 days              | 42             |
| Thallium (Blood)   | THAL | <b>A</b> / <b>()</b>                    | 1 week              | 164            |
| Thallium (Urine)   | URTH | RU                                      | 1 week              | 164            |
| Theophylline   | THE0 | 3                                       | 4 hours             | 137            |
| Thiopurine Methyl Transferase  | TPMT | <b>A</b> 5                              | 5 days              | 36             |
| Thrombin Time  | THR0 | <b>(</b> ) 18                           | 4 hours             | 41             |
| Thrombotic Risk Profile  | PROP | <b>AABOO</b> 18                         | 5 days              | 42, 44,        |
|  | =    | •                                       |                     | 127            |
| Thyroglobulin Abs  | TGAB | 8                                       | 1 day               | 57             |
| Thyroglobulin Assay  | TGA  | B (TD) Ti )                             | 1 day               | 57             |
| Thyroid Abs (Thyroglobulin + Thyroid<br>Peroxidase Abs) (Self-collect) | THAB | (TDL Tiny)                              | 2 days              | 57, 83,<br>159 |
| Thyroid Abs (Thyroglobulin + Thyroid                                   | THAB | <b>B</b>                                | 1 day               | 57, 83         |
| Peroxidase Abs) (Venous)   | INAD | 0                                       | i uay               | 37, 03         |
| Thyroid Peroxidase Antibodies/Anti TPO                                 | TPEX | B                                       | 1 day               | 57, 83         |
| Thyroid Profile 1 (FT4/TSH) (Self-collect)                             | TF   | ③ (TDL Tiny)                            | 1 day               | 57, 62,        |
| ,  |      | (IDE IIII)                              | . uuj               | 159            |
| Thyroid Profile 1 (FT4/TSH) (Venous)                                   | TF   | <b>B</b>                                | 4 hours             | 57, 62         |
| Thyroid Profile 2  | TF2  | <u> </u>                                | 2 days              | 57, 62         |
| · · · · · · · · · · · · · · · · · · ·                                  |      |   |                     | , 02           |

| TEST   | CODE | SAMPLE REQS                    | TAT           | PAGE    |
|--|------|--------------------------------|---------------|---------|
| Thyroid Profile 3 (FT3/FT4/TSH) (Self-collect)                   | TF3  | (TDL Tiny)                     | 1 day         | 57, 62, |
|  |      |                                |               | 159     |
| Thyroid Profile 3 (FT3/FT4/TSH) (Venous)                         | TF3  | <u> </u>                       | 4 hours       | 57, 62  |
| Thyroxine (T4)   | T4   | <u> </u>                       | 4 hours       | 57      |
| Thyroxine Binding Globulin                                       | TBG  | (Frozen)                       | 10 days       | 58      |
| Timothy Grass Components   | ZZ19 | <u> </u>                       | 2 days        | 141     |
| Tissue for culture   | TISS | Tissue sample                  | up to 14 days | 48      |
| Tissue Polypeptide Antigen                                       | TPA  | <b>B</b>                       | 1 week        | 36      |
| Tissue Transglutaminase IgA                                      | TAA  | (TDL Tiny)                     | 2 days        | 83, 159 |
| (Coeliac) (Self-collect)   | T    | •                              | 0.1           |         |
| Tissue Transglutaminase IgA (Coeliac) (Venous)                   | TAA  | 8                              | 2 days        | 83      |
| Tissue Transglutaminase IgG                                      | TAAG | 8                              | 5 days        | 83      |
| Tobramycin Assay (Provide Clinical Details)                      | TOBR | <b>B</b>                       | 3 days        | 135     |
| Toluene (Blood)  | TOL  | J                              | 10 days       | 164     |
| Toluene (Urine)  | UTOL | RU                             | 10 days       | 164     |
| Topiramate (Topamax)   | TOPI | B 4                            | 4 days        | 137     |
| Torch Screen   | TORC | 8                              | 2 days        | 99, 101 |
| Total Acid Phosphatase   | APT  | 8                              | 5 days        | 36      |
| Total Bile Acid/Bile Salts                                       | BILS | 8                              | 1 week        | 36      |
| Total IgE  | IGE  | <u>B</u>                       | 1 day         | 36, 139 |
| Total Immune Function Evaluation                                 | TIE  | A + B 5,10                     | 7 days        | 83      |
| Total Immunoglobulin E   | IGE  | <b>3</b>                       | 1 day         | 83      |
| Toxocara Antibodies (IgG)  | TFAT | <b>B</b> 9                     | 5 days        | 83      |
| Toxoplasma Antibodies (IgG+IgM)                                  | TFAM | <b>B</b> 9                     | 4 hours       | 83, 89  |
| Toxoplasma Antibody Full Evaluation (IgM, Dye Test, IgG Avidity) | TDYE | B 9                            | 10 days       | 83      |
| Toxoplasma by PCR  | TXAG | A                              | 5 days        | 84      |
| TPPA   | TPPA | <b>B</b>                       | 2 days        | 71, 84  |
| Trace Metal (Blood) Profile                                      | TRAC | <b>ABO</b>                     | 7-10 days     | 163     |
| Transferrin  | TRAN | <b>B</b>                       | 1 day         | 36      |
| Transferrin Electrophoresis                                      | TREL | <b>B</b>                       | 2 weeks       | 36      |
| Trichinella Serology   | TRIC | 3                              | 5 days        | 84      |
| Trichloracetic Acid (Urine)                                      | UTCA | RU                             | 5 days        | 164     |
| Trichomonas vaginalis  | TVPC | FCRU / PCR / TPV               | 2 days        | 71      |
| Trichomonas vaginalis (Thin Prep)                                | TVPC | TPV                            | 2 days        | 168     |
| Trichomonas vaginalis (TV)  – Urine or Vaginal (Self-collect)    | TVPC | Aptima urine or multisite swab | 2 days        | 71, 160 |
| Triglycerides  | TRI  | <b>B</b>                       | 4 hours       | 36      |
| Trimethylaminuria (Fish Odour Syndrome)                          | FOS  | J                              | 6 weeks       | 36      |
| Trimipramine   | TRIM | A                              | 5 days        | 137     |
| Triple Swab Female STI Profile                                   | 3SWA | PCR swab x 3 (label by site)   | 2 days        | 71      |
| (Vaginal/Throat/Rectal Swabs) (PCR)                              |      |                                |               |         |
|  |      |                                |               |         |

| TEST  | CODE | SAMPLE REQS                                      | TAT          | PAGE    |
|---|------|--|--------------|---------|
| Triple Swab Female STI Profile                                  | 3SWA | Aptima multisite swab                            | 2 days       | 71, 160 |
| (Vaginal/Throat/Rectal Swabs) (Self-collect)                    |      | x 3 (label by site)                              |              |         |
| Tropical Screen (from 6 weeks post-travel)                      | TROP | <b>B B</b> 9,14                                  | 10 days      | 89-90   |
| Tropomyosins  | ZZ31 | <b>B</b>   | 2 days       | 141     |
| Troponin T (High sensitive)                                     | TR0T | <b>B</b>   | 4 hours      | 36      |
| Trypanosome (Chagas) Antibodies                                 | CHGA | <b>B</b> 9,14                                    | 10 days      | 84      |
| Tryptase  | STRY | B  | 2 days       | 37, 139 |
| TSH (Self-collect)  | TSH  | (TDL Tiny)                                       | 1 day        | 58, 160 |
| TSH (Venous)  | TSH  | B  | 4 hours      | 58      |
| TSH-Receptor Antibodies   | TSI  | В  | 4 days       | 58, 84  |
| Tularaemia Antibodies   | TULA | <b>B</b> 14                                      | 5 days       | 84      |
| Tumour Necrosis Factor – Alpha                                  | TNF  | (Frozen) 4                                       | 2 weeks      | 37      |
| Urate (Uric acid)   | UA   | <b>B</b>   | 4 hours      | 37      |
| Urea (Self-collect)   | UREA | (TDL Tiny)                                       | 1 day        | 37, 160 |
| Urea (Urine)  | UURE | CU   | 4 hours      | 37      |
| Urea (Venous)   | UREA | B  | 4 hours      | 37      |
| Urea and Electrolytes   | U/E  | B  | 4 hours      | 37, 39  |
| Urea Electrolytes (Urine)                                       | UELE | CU   | 4 hours      | 37      |
| Urea/Creatinine/eGFR (Self-collect)                             | TCU  | (TDL Tiny)                                       | 1 day        | 37, 160 |
| Ureaplasma urealyticum (Thin Prep)                              | UGEN | TPV  | 2 days       | 168     |
| Ureaplasma urealyticum by PCR                                   | UGEN | FCRU / PCR / TPV                                 | 2 days       | 71      |
| Uric Acid (Serum)   | UA   | <b>B</b>   | 4 hours      | 37      |
| Uric Acid (Urine)   | UURI | CU   | 4 hours      | 37      |
| Urinary Bladder Cancer Antigen                                  | UBC  | RU (Freeze within 48 hours)**                    | 5 days       | 37, 102 |
| Urinary Methyl Histamine  | UHIT | RU (Frozen)                                      | 2 weeks      | 84      |
| Urine (Microscopy Only)   | UMIC | RU   | 1 day        | 48      |
| Urine Chemistry and Microscopy (Self-collect)                   | UMIC | Urine (Universal). Mid stream.                   | 1-2 days     | 48, 160 |
| Urine Chemistry, Microscopy                                     | UCEM | Urine (Universal &                               | 1-2 days     | 48, 160 |
| and Culture (Self-collect)                                      |      | Boric). Mid stream.                              |              |         |
| Urine Cytology (Urine cytology containers                       | URCY | Urine (30mls) 21                                 | 2 days       | 172     |
| available from TDL Supplies)                                    |      |  |              |         |
| Urine EtG (Ethyl glucuronide)                                   | ETG  | RU   | 1 week       | 161     |
| Urine for Extended Culture                                      | UCXD | MSU  | up to 7 days | 48      |
| Urine for Microscopy and Culture                                | UCEM | MSU ††††   | 1-2 days     | 48      |
| Urine Microalbumin/Creatinine Ratio                             | UMA  | RU   | 4 hours      | 37      |
| Urine Organic Acids   | UORG | RU (Frozen)                                      | 3 weeks      | 37      |
| Urine Steroid Screen (Steroid Hormones)                         | USTE | CU <sup>9</sup>                                  | 2 weeks      | 37      |
| Urine Sugar Chromatography                                      | UCR0 | RU (Frozen)                                      | 3 weeks      | 37      |
| Urticaria Test (Histamine Releasing)                            | CURT | В  | 3 weeks      | 84      |
| Vaginitis/BV Profile (Culture & PCR)                            | STD8 | PCR and STM                                      | 3 days       | 71      |
| Vaginitis/BV Profile using Culture<br>& PCR Swab (Self-collect) | STD8 | Aptima multisite swab and<br>Blue gel Amies swab | 3-5 days     | 71, 160 |

# **Alphabetical test index**

| TEST                                 | CODE | SAMPLE REQS                       | TAT       | PAGE     |
|--------------------------------------|------|-----------------------------------|-----------|----------|
| Valium (Diazepam)                    | DIAZ | A                                 | 7 days    | 137      |
| Valproic Acid (Epilim)               | VALP | B                                 | 4 hours   | 137      |
| Vancomycin Hydrochloride             | VANC | B                                 | 4 hours   | 135      |
| Varicella zoster – DNA               | VZPC | A                                 | 5 days    | 99       |
| Varicella zoster Antibodies (IgG)    | VZOS | B                                 | 1 day     | 91, 99   |
| Varicella zoster Antibodies (IgM)    | VZOM | B                                 | 1 day     | 91, 99   |
| Vascular Endothelial Growth Factor   | VEGF | B                                 | 14 days   | 84       |
| Venom Components                     | ZZ33 | B                                 | 2 days    | 141      |
| Very Long Chain Fatty Acids          | VLCF | (Frozen) 9                        | 4-6 weeks | 37       |
| Vigabatrin (Sabril)                  | VIGA | A                                 | 10 days   | 137      |
| Viral Antibody Screen                | VIRA | BB                                | 2 days    | 99, 101  |
| Viral Eye by PCR                     | VPE  | PCR                               | 3 days    | 99, 101  |
| Viral Respiratory RNA Screen by PCR  | VPR  | PCR or as specified               | 2 days    | 99, 101  |
|                                      |      | on the form                       |           |          |
| Viral Skin/Mucosa by PCR             | VPSK | PCR                               | 2 days    | 99, 101  |
| Viscosity (Plasma)                   | VISC | A 4*                              | 3 days    | 42       |
| Vitamin A (Retinol)                  | VITA | В                                 | 5 days    | 149      |
| Vitamin B (Functional)               | FUNC | A A or H                          | 5 days    | 149      |
| Vitamin B Profile                    | VBP  | AAB                               | 5 days    | 149, 151 |
| Vitamin B1 (Thiamine)                | VIT1 | A                                 | 5 days    | 149      |
| Vitamin B2 (Riboflavin)              | VIB2 | A                                 | 5 days    | 149      |
| Vitamin B3 (Nicotinamide)            | VIB3 | B                                 | 5 days    | 149      |
| Vitamin B5 (Pantothenic Acid)        | VB5S | B                                 | 5 days    | 149      |
| Vitamin B6 (Pyridoxine)              | VITB | A                                 | 5 days    | 149      |
| Vitamin B7 (Biotin) CHANGE           | BIOS | <b>B</b> 7                        | 5 days    | 149      |
| Vitamin B9 (Folic acid) – Red cell   | RBCF | A                                 | 2 days    | 149      |
| Vitamin B9 (Folic acid) – Serum      | FOLA | B                                 | 1 day     | 149      |
| Vitamin B12 (Active) (Self-collect)  | B12  | (TDL Tiny)                        | 1 day     | 37, 149, |
|                                      |      |                                   |           | 160      |
| Vitamin B12 (Active) (Venous)        | B12  | B                                 | 1 day     | 37, 149  |
| Vitamin B12 (Active)/Red Cell Folate | B12F | <b>A</b> B                        | 2 days    | 37, 149  |
| Vitamin B12 (Total)                  | TB12 | B                                 | 1 day     | 37       |
| Vitamin C (Active)                   | VITC | (spun and frozen within 3 hours)* | 5 days    | 149      |
| Vitamin D (1, 25 Dihydroxy)          | D3   | <b>B</b>                          | 5-8 days  | 149      |
| Vitamin D (25-OH) (Self-collect)     | VITD | (TDL Tiny)                        | 1 day     | 37, 149, |
|                                      |      |                                   |           | 160      |
| Vitamin D (25-OH) (Venous)           | VITD | В                                 | 4 hours   | 37, 149  |
| Vitamin E (Alpha Tocopherol)         | VITE | B                                 | 5 days    | 149      |
| Vitamin K (Nutritional)              | VKN  | Serum (SST or 📵) *                | 5 days    | 149      |
| Vitamin K (With PIVKA II)            | VITK | B 13                              | 10 days   | 41       |
| Vitamin Profile 1                    | VITS | <b>A B B</b> <sup>7</sup>         | 5 days    | 149, 151 |
|                                      |      |                                   |           |          |

# **Alphabetical test index**

| TEST   | CODE   | SAMPLE REQS         | TAT           | PAGE     |
|--|--------|---------------------|---------------|----------|
| Vitamin Profile 2  | VIT2   | <b>A A B B</b> 7,13 | 5 days        | 149, 151 |
| VLDL Cholesterol   | VLDL   | B 13                | 1 week        | 37       |
| VMA  | UVMA   | PU 1                | 5 days        | 37       |
| Voltage Gated Calcium Channel Antibodies                                 | CCAB   | B                   | 3 weeks       | 84       |
| Voltage Gated Potassium Channel Antibodies                               | VPCA   | B                   | 3 weeks       | 84       |
| Von Willebrand Profile   | FVWF   | <b>Q Q Q</b> 4,9,12 | 5 days        | 42, 44   |
| Von Willebrands Multimers  | VWM    | <b>CC C</b> 18      | 3 months      | 42       |
| Wall Pellitory Components  | ZZ20   | B                   | 2 days        | 141      |
| Walnut Components  | ZZ34   | B                   | 2 days        | 141      |
| West Nile Virus Abs  | WNV    | B                   | 2 weeks       | 99       |
| Wheat Components   | ZZ21   | B                   | 2 days        | 141      |
| Whooping Cough (Pertussis) Antibodies                                    | PERS   | B                   | 5 days        | 84       |
| Whooping Cough (Pertussis) by PCR  | PERP   | Prenasal (posterior | 5 days        | 84       |
|  |        | nasopharynx) swab   |               |          |
| Wolf-Hirschhorn Syndrome   | PBOB,  | CVS / AF / 🛕 🚯 9    | 5-15 days     | 127      |
| - BOBs (5 days) + karyotype (15 days)                                    | KARY   |                     |               |          |
| Wolf-Hirschhorn Syndrome – BOBs only                                     | PB0B   | CVS / AF / 🙆 9      | 5 days        | 127      |
| Xanthine – Blood   | XANB   | A                   | 2 weeks       | 164      |
| Xylene – Urine   | UXYL   | RU <sup>30</sup>    | 2 weeks       | 164      |
| Xylose Tolerance Test  | XTT    | J <sup>1</sup>      | 7 days        | 150      |
| Y chromosome microdeletions  | YDEL   | <b>A</b> 9          | 5 days        | 127      |
| - AZFa + AZFb + AZFc + SRY   |        |                     |               |          |
| Yellow Fever Antibodies  | YELL   | B 9,14              | 10 days       | 84       |
| Yersinia Antibodies  | YERS   | B                   | 4 days        | 84       |
| Zika Abs IgM and IgG   | ZKAB   | B                   | Up to 14 days | 84, 89,  |
| – Antibody detection from 15 days  |        |                     |               | 99       |
| Zika RNA by PCR in Semen   | ZIKS   | Semen               | Up to 14 days | 84, 89,  |
|  |        |                     |               | 99       |
| Zika RT PCR – Window of detection from                                   | ZIKU   | RU                  | Up to 14 days | 84, 89   |
| 1-14 days from onset of symptoms  Zika RT PCR – Window of detection from | 711/ A |                     | Un to 14 days | 04.00    |
| 1-7 days from onset of symptoms  | ZIKA   | 3                   | Up to 14 days | 84, 89   |
| Zinc (Serum/Plasma) CHANGE   | ZINC   | K                   | 2 days        | 150, 163 |
| Zinc (Urine)   | URZN   | CU                  | 5 days        | 150, 163 |
| Zinc (Whole Blood)   | RBCZ   | A or (1)            | 5 days        | 150      |
| Zinc Protoporphyrin  | ZNPR   | A                   | 5 days        | 164      |
| Zygosity testing – comparative DNA profile                               | DNAC   | (From each twin     | 5 days        | 127      |
|  |        | and both parents)9  |               |          |
|  |        |                     |               |          |

# **TDL Referral laboratories**

For certain specialist tests TDL has developed a selected network of TDL Group and Reference Laboratories. These Group or specialist laboratories can be identified by a code assigned to reports. The quality of these laboratories is recognised by UKAS, or similar accrediting bodies for the laboratories outside the UK.

# **TDL Referral laboratories**

Addenbrooke's Hospital – BGU and Immunology [899]

Alder Hey Children's NHS Foundation Trust — Biochemistry Department [880]

Analytical Services International Ltd, St George's University of London – Forensic Toxicology Service [994]

Animal and Plant Health Agency – Veterinary labs [911]

Bio Predictive [Original report]

Bioscientia (Germany) [868]

Birmingham Children's Hospital NHS Foundation Trust – Clinical Chemistry [970]

Birmingham University Hospital NHS Foundation Trust [836]

Brucella Reference Unit – Liverpool Clinical Laboratories, Royal Liverpool and Broadgreen Hospital [947]

Cambridge Clinical Laboratory [867]

Cambridge Life Sciences [997]

Cambridge Nutritional Science Ltd [Original report]

Cardiff and Vale University Health Board — The Analytical Toxicology Department [998]

Douglass Hanly Moir Pathology (Australia) [Original report]

Epsom and St Helier University Hospital NHS Trust – Biochemistry Department [968]

Epsom and St Helier University Hospital NHS Trust – Immunology Department [968]

Epsom and St Helier University Hospital NHS Trust – Microbiology Department [951]

Eurofins - Biomnis (France) [950]

Great Ormond Street Hospital –
Department of Chemical Pathology [964]

Great Ormond Street Hospital – Enzyme Unit, Chemical Pathology [964]

Great Ormond Street Hospital – Immunology Department [924]

Great Ormond Street Hospital – Neurometabolic Unit [964]

Guildford RSCH Trace Element Laboratory, SAS Trace Element Centre [955]

HCA Healthcare UK – HCA Laboratories [982]

HFL Sport Science (LGC Group) [861]

Igenomix UK [Original Report]

Imperial College Healthcare NHS Trust – Charing Cross Hospital, Chemical Pathology Department [912]

Imperial College Healthcare NHS Trust – Charing Cross Hospital, Infection and Immunity Department [962]

Imperial College Healthcare NHS Trust — Charing Cross Hospital, Medical Oncology [912]

Imperial College Healthcare NHS Trust – Hammersmith Hospital, Molecular Endocrinology [931]

Imperial College Healthcare NHS Trust, St Mary's Hospital – Virology Department [912]

Institute of Aquaculture – University of Stirling [1000]

Institute of Neurology – Neurogenetics Unit [975]

King's College Hospital – HMDC Laboratory for Molecular Haemato-Oncology [943]

Labor Augsburg MVZ GmbH (Germany) [900]

Latis Scientific [927]

London School of Hygiene & Tropical Medicine

– Diagnostic Parasitology Lab [933]

Matrix Diagnostics [896]

Mayo Clinic Laboratories (Netherlands [894]

Meningococcal reference unit (Men RU)

Manchester – Manchester Royal Infirmary [949]

Micropathology Ltd [920]

National Blood Service - Colindale,

Red Cell Immuno Haematology Department [910]

# **TDL Referral laboratories**

NHS Blood and Transplant – Birmingham [856]

NHS Blood and Transplant – H & I Laboratory [855]

NHS Blood and Transplant – Tooting [854]

Norfolk and Norwich University Hospital NHS Foundation Trust – SAS Metabolic Bone Laboratory [993]

Oxford Immunotec [841]

Oxford University Hospital NHS Foundation Trust — Churchill Hospital [983]

UKHSA – Bacteriology Reference Department (BRD), Colindale [910]

UKHSA – Virus Reference Department (VRD) – Colindale [910]

UKHSA Mycology Reference Laboratory – UKHSA South West Laboratory, Southmead Hospital, Bristol [903]

UKHSA National Mycobacterium Reference Service National Infection Service, Colindale [974]

UKHSA Rare and imported pathogens laboratory – Porton Down [981]

Queens University Hospital, Belfast – Institute of Clinical Science [853]

Reflab (Denmark) [988]

Reproductive Immunology Centre [839]

Rosalind Franklin University (USA) - [Original report]

Royal Berkshire Hospital NHS Foundation Trust – Clinical Biochemistry [847]

Royal Devon and Exeter NHS Foundation Trust [838]

Royal Surrey County Hospital – SAS Peptide Hormone Section [959]

Sandwell and West Birmingham NHS Trust – City Hospital Birmingham, Clinical Biochemistry Department [970]

SCSA Diagnostics (USA) [Original report]

Sheffield Children's NHS Trust – Clinical Chemistry [847]

Sheffield Teaching Hospital NSH Foundation Trust – Protein Reference Laboratory Unit and Immunology Department [966] Southmead Hospital -

Antimicrobial Reference Laboratory, Bristol [915]

St George's University Hospital NHS Foundation Trust – Cell Marker Department [846]

SYNLAB Laboratory Service – Abergavenny [941]

The Epilepsy Society (Chalfont Centre) [837]

The Leeds Teaching Hospital NHS Trust – Endocrinology Laboratory (including SAS Steroid Centre), Department of Specialist Laboratory Medicine, St James University Hospital) [992]

The Leeds Teaching Hospitals NHS Trust – Mycology Reference Centre [973]

The Newcastle upon Tyne Hospitals — Royal Victoria Infirmary [878]

The Royal Marsden Hospital — Department of Haematology / Oncology [989]

The Royal Marsden Hospital – Department of Pathology [990]

Toxoplasma Reference Unit, Public Health Wales Microbiology ABM, Singleton Hospital – Swansea [969]

Trace Laboratories Ltd [955]

UCL Great Ormond Street Institute of Child Health [935]

UCL Queen Square Institute of Neurology – Department of Neuroimmunology [975]

University Hospital Birmingham NHS Foundation Trust – Heartlands Hospital [843]

University Hospital of Wales –

Cardiff Medical Immunology Department [842]

Synnovis – Guy's Hospital.

Biochemistry Genetics Laboratory [930]

Synnovis - King's College Hospital,

Clinical Biochemistry [914]

Synnovis – St Thomas' Hospital Haemophilia Centre [956]

Synnovis – St Thomas' Hospital Immunohistology [961]

Synnovis - St Thomas' Hospital Purine

Research Laboratory [925]

# **TDL Referral laboratories**

# **Group laboratories**

Royal Free London NHS Foundation Trust – Haemostasis [984]

University College London Hospitals NHS Foundation Trust (UCLH) – Cytology [Original report]

University College London Hospitals NHS Foundation Trust (UCLH) – Hospital for Tropical disease [933]

University College London Hospitals NHS Foundation Trust (UCLH) – Molecular Virology [999]

University College London Hospitals NHS Foundation Trust (UCLH) – Special Chemistry [953]

# **TDL Genetics Referral laboratories**

All Wales Medical Genetics Service

Anthony Nolan, Histocompatability and Immunogenetics

Asper Biotech

Bioscientia GmBH

Bristol Genetics Laboratory (North Bristol NHS Trust)

CentoGene

DiaGenom GmbH

Douglass Hanly Moir Pathology

East Scotland Regional Genetics Service (NHS Tayside)

Exeter Clinical Laboratory - Department

of Molecular Genetics

**Fulgent Diagnostics** 

Institute of Neurology, Queen's Square

International Blood Group Reference Laboratory

London South East Genetics Service

Medical Genetics Laboratory — Central Manchester University Hospitals NHS Foundation Trust

Medical Neurogenetics Laboratory LLC

Micropathology Ltd

Molecular Genetics Laboratory –Liverpool's Women NHS Foundation Trust

Molecular Vision Laboratory

Newcastle Mitochondrial NGC Diagnostic Service

North East Thames Regional Genetic Service

North West London Pathology

North West Thames Regional Genetic Service

Northern Genetics Service

Oxford Genetics Laboratory - Oxford

University Hospitals

Prevention Genetics

Progenika Biopharma Grifols

Protein Reference Unit & Immunology

Department - Sheffield Protein Unit

Purine Research Laboratory - St Thomas' Hospital

Royal Marsden - Haemato-Oncology Unit

Sheffield Diagnostic Genetics Service

 ${\sf SIHMDS-Cytogenetics\ Laboratory},$ 

Great Ormond Street Hospital

South East Scotland Genetics Service (NHS Lothian)

South West Thames Regional Genetics Service

SYNLAB Budapest Diag Center

The Leeds Genetics Laboratory Viapath Analytics LLP

Wessex Region Genetics Service

West Midlands Regional Genetics Laboratory

West of Scotland Genetic Service (NHS Greater Glasgow and Clyde)

The definitions which apply to these Terms and Conditions are set out in clause 19

### 1 THE SERVICES

- 1.1 These Terms and Conditions will apply to any services or consumables that The Doctors Laboratory Limited or TDL Genetics Limited provides to the Client, unless those services are the subject of a separate written agreement signed by TDL and the Client. These Terms and Conditions apply to the exclusion of any other terms presented by the Client or implied by custom or course of dealing.
- 1.2 By submitting a Pathology Request, a request for any other services described in the Laboratory Guide or in any other proposal provided by TDL, or an order for any Consumables described in the Laboratory Guide (in each case an 'Order'), the Client offers to purchase those Tests, other services or Consumables on these Terms and Conditions from TDL. TDL may accept or reject any Order.
- 1.3 A contract between TDL and the Client for the provision of Services and / or Consumables, incorporating these Terms and Conditions and the Order (an 'Agreement') takes effect when TDL confirms acceptance of the Client's Order in writing, logs the relevant Pathology Request in its laboratory information management system, or begins performing the Services (whichever occurs first). Any request for add-on Tests (as described in the Laboratory Guide) constitutes a request for further Services under that Agreement, which TDL may accept or decline. In the event of a conflict between the Order and these Terms and Conditions, the Terms and Conditions will take priority.
- 1.4 TDL will provide the Services under the Agreement:
- 1.4.1 in accordance with Good Industry Practice;
- 1.4.2 in accordance with the UKAS medical laboratory accreditation standard (ISO 15189); and
- 1.4.3 using suitably skilled and experienced staff.
- 1.5 TDL will use reasonable efforts to achieve the Test turnaround times quoted in the Laboratory Guide, but does not warrant that it will achieve those times in the case of any particular Sample.
- 1.6 The Laboratory Guide sets out Sample rejection criteria. If the Sample meets those criteria, or if TDL considers that the Sample is otherwise unsuitable for Testing or TDL is unable to conduct the Testing then TDL may decline to carry out the Testing under the Agreement and will be entitled to dispose of the Sample.
- 1.7 As part of its Services TDL will, on request, arrange for collection of Samples from locations within the M25 motorway. Such collection service is included within the price of the Test unless otherwise specified by TDL. Collection of Samples from locations outside

- the M25 is by special arrangement, and may incur an additional charge. Where collection by TDL has not been requested and agreed, the Client will be responsible, at its own cost, for the transport of Samples to TDL. Where TDL arranges collection of Samples it will use reasonable efforts to achieve the timescales it quotes for collection, but does not warrant that it will achieve those timescales in the case of any particular collection.
- 1.8 TDL may destroy or dispose of a Sample after completing the Testing or on termination of the Agreement, unless otherwise agreed in writing with the Client.
- 1.9 In providing the Services, TDL shall comply with all Applicable Law relating to anti-bribery and anticorruption, including the Bribery Act 2010. TDL shall not, and shall ensure that its staff do not, engage in any activity which would constitute an offence under the Bribery Act 2010.
- 1.10 TDL is committed to trading ethically, with zero tolerance for modern slavery (including forced labour or human trafficking of any kind), human rights violations, and child labour. In performing its obligations under the Agreement, TDL will comply with all Applicable Law and applicable internal policies relating to anti-slavery and human trafficking.
- 1.11 TDL's laboratories are operated by members of the TDL Group. TDL uses those laboratories to undertake the Tests, except where TDL refers the Tests to suitably accredited laboratories operated outside the TDL Group. The UKAS accreditation numbers for the TDL Group laboratories in the UK are as follows: 8059 (HSL Analytics LLP) Genetics and Molecular Sciences, 8169 (HSL Analytics LLP) Blood Sciences, 8860 (HSL Analytics LLP) Infection Sciences, 8812 (The Doctors Laboratory Limited) Haematology, Blood Transfusion, Biochemistry, Microbiology, Molecular Biology, 10199 (The Doctors Laboratory Limited) Andrology, 8511 (HSL Analytics LLP) Cytology, 9706 (The Doctors Laboratory Limited) Urine Cytology.

### 2 SUPPLY OF CONSUMABLES

- 2.1 TDL shall supply Consumables to the Client in accordance with the terms of the Agreement.
- 2.2 The Consumables shall: (i) be of satisfactory quality (within the meaning of the Sale of Goods Act 1979) and fit for any purpose held out by TDL; and (ii) comply with all Applicable Law.
- 2.3 TDL shall not be liable for Consumables' failure to comply with clause 2.2 if: (i) the Client makes any further use of those Consumables after notifying TDL of such failure; (ii) the defect arises because the Client failed to follow TDL's instructions for the storage, use or maintenance of the Consumables or (if there are none) good practice regarding the same; (iii) the Client alters or repairs those Consumables without TDL's

- prior written consent; (iv) the defect arises as a result of fair wear and tear, deliberate damage, negligence, or abnormal storage or working conditions; or (v) the Consumables differ from their description as a result of changes made to ensure they comply with Applicable Law.
- 2.4 In the event the Consumables do not comply with clause 2.2, TDL shall provide replacement Consumables without undue delay. This shall be the Client's only remedy for such non-compliance. The terms of this clause 2 shall apply to any such replacement Consumables provided by TDL.
- 2.5 TDL shall ensure that the Consumables are properly packed and secured in a manner to enable them to reach their destination in good condition, and in a manner which complies with Applicable Law.
- 2.6 If the Client or the Client's carrier will collect the Consumables from TDL's premises, delivery shall be completed when TDL places the Consumables at the Client's disposal at TDL's premises. In all other cases, delivery shall be completed on the loading of the Consumables at the premises where they are loaded onto transport for carriage.
- 2.7 TDL may deliver Consumables by instalments, which may be invoiced and paid for separately. Time for delivery of Consumables is not of the essence of the Agreement and delays in the delivery of Consumables shall not entitle the Client to refuse to take delivery. TDL shall have no liability for any failure or delay in delivering Consumables to the extent that any failure or delay is caused by the Client's failure to comply with its obligations under the Agreement.
- 2.8 Title and risk in the Consumables shall pass to the Client on delivery, except that any biofreeze bottles provided by TDL shall remain the property of TDL at all times, regardless of any use by the Client of the biofreeze bottles.
- 2.9 The Client must not resell the Consumables or provide them to any third party without TDL's prior written consent.
- 2.10 The Client shall ensure that: (i) any Consumables provided by TDL are only used by healthcare professionals who are appropriately qualified and trained in the proper use of such Consumables; and (ii) the healthcare professionals use the Consumables in accordance with any instructions relating to the use of the Consumables provided by TDL and in any event with the degree of skill and care reasonably to be expected of a healthcare professional experienced in the use of such Consumables.

### 3 PRICE AND PAYMENT TERMS

- 3.1 The price payable by the Client for the Services and / or the Consumables will be the most recent price confirmed by TDL to the Client in writing or by telephone prior to the Client submitting its Order. If TDL has not confirmed the price for the Services and / or Consumables, the price will be that indicated in the Laboratory Guide.
- 3.2 As at the date of these Terms and Conditions many of TDL's services are VAT exempt. All of TDL's prices are stated exclusive of VAT and where VAT is chargeable on the Services and/or Consumables the Client will pay it at the applicable rate.
- 3.3 Invoices are normally issued on a monthly basis, but TDL reserves the right to issue them more frequently. The Client will pay TDL's invoices under the Agreement within 30 days of the date of the invoice, without any deduction or set off. At TDL's option, interest may be charged on late payments at the statutory rate prescribed from time to time by regulations under the Late Payments of Commercial Debts (Interest) Act 1998. Invoices paid from outside the UK must be paid by either direct bank transfer or by cheque drawn on a UK branch. All payments will be made in pounds sterling.
- 3.4 If the Client disputes any invoice: (i) the Client shall notify TDL in writing as soon as practicably possible and in any event not later than 90 days after the date of the invoice, specifying the reasons for disputing the invoice; (ii) the Client shall pay to TDL all amounts not disputed by the Client as set out in clause 3.3 above; and (iii) the parties shall attempt to resolve the dispute promptly and in accordance with clause 18.1 below.
- 3.5 If the Client does not dispute an invoice in accordance with clause 3.4 above then the amount stated on the invoice shall be deemed payable by the Client and the Client shall not be entitled to dispute the amount invoiced.
- 3.6 Without affecting any of its other rights, TDL may suspend or cease provision of the Services and / or Consumables if the Client fails to pay an invoice due to TDL, or if the total of the sums payable by the Client to TDL under any agreements between the Client and TDL meets or exceeds any credit limit that TDL communicates to the Client from time to time.

## 4 CONFIDENTIALITY

- 4.1 TDL agrees that it will hold and maintain the confidence of:
- 4.1.1 all information of a confidential nature which is received by TDL from the Client or its patients in connection with the Services; and

- 4.1.2 all Test results, invoices and other information of a confidential nature issued by TDL to the Client or its patients in connection with the Services, and, save with the Client's consent or as otherwise permitted under the Agreement, will not disclose such information other than to its professional staff, independent consultants and/ or persons to whom it has delegated the performance of the Services and who require the information for such purpose. Where TDL has been provided with the details of a patient's private medical insurance in connection with the Services, TDL will be entitled to assume (and the Client so warrants) that both the Client and the patient consent to the disclosure of information relating to that patient to the insurer concerned.
- 4.2 The restrictions in clause 4.1 will not apply to information which: (i) was in TDL's possession prior to disclosure by the Client; or (ii) is now or hereafter comes into the public domain other than by default of TDL; or (iii) was lawfully received by TDL from a third party acting in good faith having a right of further disclosure; or (iv) is required by law to be disclosed by TDL; or (v) which is required by a regulatory or accreditation body to be disclosed to it for the purpose of regulating or accrediting the TDL Group.

### 5 CLIENT RESPONSIBILITIES

- 5.1 Except where TDL obtains the Sample directly from the patient during a home visit or at TDL's patient reception facility, the Client will ensure that the Sample is obtained from the patient, packaged, and labelled in accordance with Applicable Law good clinical practice and, if applicable, TDL's written instructions.
- 5.2 Except where TDL agrees to arrange transport of the Sample to TDL's laboratory, the Client will ensure that the Sample is transported to TDL's laboratory in accordance with Applicable Law and good clinical practice. Where TDL agrees to arrange transport of the Sample the Client will ensure that the Samples are ready for collection by TDL or its carrier at the agreed times.
- 5.3 The Client will ensure that all necessary consents and permissions are obtained and all necessary information provided to the patient, which is required under Applicable Law or good clinical practice in order to permit the performance of the Testing, and any other Services, and the use of the Protected Data as contemplated in the Agreement.
- 5.4 The Client will provide TDL with any information reasonably necessary for performing the Services and / or supplying Consumables, including by ensuring that the Pathology Request contains sufficient information regarding the Sample, the relevant patient, and the persons to whom the Test results are to be reported, and will ensure that any information the Client provides to TDL in connection with the Services and / or Consumables is accurate and complete.

### 6 LIABILITY

- 6.1 Nothing in the Agreement will limit or exclude liability for death or personal injury caused by negligence or any other liability that cannot be limited or excluded under Applicable Law.
- 6.2 In these Terms and Conditions 'liability' means any liability whether in contract, tort (including negligence), misrepresentation, breach of statutory duty or otherwise, which arises in connection with the Services, the Consumables or under or in connection with any Agreement.
- 6.3 The liability of TDL and the Client will each be limited to £2,000,000 in total. This limit applies per Agreement and in aggregate for all Agreements made in a calendar year.
- 6.4 Neither TDL nor the Client will have any liability for:
- 6.4.1 loss of profit or revenue;
- 6.4.2 loss of anticipated savings:
- 6.4.3 loss of reputation or goodwill; or
- 6.4.4 indirect, special or consequential loss.
- 6.5 TDL will have no liability for any delay or failure in performance of the Services or provision of the Consumables arising from the Client's delay or failure in performing its obligations under clause 5 (Client Responsibilities).
- 6.6 All of the warranties which TDL gives in relation to the Services and / or the Consumables are expressly set out in these Terms and Conditions. All other warranties, whether implied or express, are excluded from the Agreement where it is lawful to exclude them.
- 6.7 In this clause 6, references to TDL include the members of TDL's Group, and for the purpose of the limit in clause 6.3 the liabilities of TDL and the TDL Group Members will be counted in aggregate. The members of TDL's Group may enforce this clause 6.

# 7 FORCE MAJEURE

If the performance of any obligation under the Agreement (except for an obligation to pay) is prevented, restricted or interfered with by reason of circumstances beyond the reasonable control of that party obliged to perform it (a 'Force Majeure Event'), the party so affected will be excused from any resulting failure or delay in performance, and the time for performance will be extended by an amount of time equal to the duration of the Force Majeure Event. The party so affected will use reasonable endeavours to mitigate the effect of the Force Majeure Event on its performance of its obligations. If the Force Majeure Event delays or prevents performance of a party's obligations for more than three months, either party may terminate the Agreement on written notice to the other.

### 8 DATA PROCESSOR AND DATA CONTROLLER

- 8.1 When TDL processes Protected Data on behalf of the Client in providing the Services the parties agree that the Client will be the controller and TDL will be the processor. The Annex to these Terms and Conditions sets out when TDL processes Protected Data on behalf of the Client. Clause 17 describes the circumstances where TDL will use Protected Data on its own behalf as controller.
- 8.2 When TDL processes Protected Data as processor, clauses 9 to 16 will apply in relation to the Protected Data. Where TDL processes Protected Data as controller, clause 17 will apply instead.
- 8.3 The Client will comply with the Data Protection Laws in relation to the Protected Data, and ensure that all instructions given by it to TDL in respect of Protected Data will at all times be in accordance with Data Protection Laws.

### 9 DATA PROCESSING INSTRUCTIONS

- 9.1 When TDL processes Protected Data as processor, TDL will comply with the obligations of processors under the Data Protection Laws.
- 9.2 Unless required to do otherwise by Applicable Law, TDL will (and will take steps to ensure each person acting under its authority will) process the Protected Data only in accordance with the Client's documented instructions as set out in the Order, pursuant to these Terms & Conditions, and in the Annex (the 'Processing Instructions').
- 9.3 If Applicable Law requires TDL to process Protected Data other than in accordance with the Processing Instructions, TDL will notify the Client of any such requirement before processing the Protected Data (unless Applicable Law prohibits TDL from doing so).
- 9.4 TDL will promptly inform the Client if TDL becomes aware of a Processing Instruction that, in TDL's opinion, infringes Data Protection Laws. TDL will have no liability for any processing in accordance with those Processing Instructions after giving the notice. TDL's obligations under this clause 9.4 do not limit the Client's obligations under clause 8.3.

### 10 DATA SECURITY MEASURES

In relation to the processing of the Protected Data, TDL will implement and maintain, at its cost and expense, appropriate technical and organisational measures to ensure for the Protected Data a level of security appropriate to the risks presented by the processing, taking into account the state of the art, the cost of implementation and the nature, scope, context and purpose of the processing of the Protected Data, as well as the risk of varying likelihood and severity of the rights and freedoms of natural persons.

### 11 USING STAFF AND OTHER PROCESSORS

- 11.1 TDL will not engage any processor to process the Protected Data on the Client's behalf (a 'Sub-Processor') without the Client's authorisation of that specific Sub-Processor. The Client will not unreasonably withhold, condition or delay such consent. By accepting these Terms and Conditions the Client authorises the appointment of the Authorised Sub-Processors.
- 11.2 TDL will ensure that each Sub-Processor is appointed under a written contract containing materially the same obligations as clauses 9 to 16 (inclusive).
- 11.3 TDL will ensure that all persons authorised to process Protected Data are subject to a binding obligation to keep the Protected Data confidential (except where disclosure is required in accordance with Applicable Law, in which case TDL will, where practicable and not prohibited by Applicable Law, notify the Client of any such requirement before such disclosure).

# 12 ASSISTANCE WITH THE CLIENT'S COMPLIANCE AND DATA SUBJECT RIGHTS

- 12.1 Taking into account the nature of the processing, TDL will implement and maintain reasonable measures to assist the Client to respond to the Data Subject Requests relating to the Protected Data that TDL processes on the Client's behalf. TDL will refer such Data Subject Requests it receives to the Client promptly, and in any event within five Business Days of receipt of the request.
- 12.2 TDL will provide such assistance as the Client reasonably requires (taking into account the nature of processing and the information available to TDL) to the Client in ensuring compliance with the Client's obligations under Data Protection Laws with respect to: (i) security of processing, (ii) data protection impact assessments, (iii) prior consultation with the relevant regulator regarding high risk processing, and (iv) notifications to the regulator and / or communications to data subjects by the Client in response to any Personal Data Breach. The Client will pay TDL's charges for providing the assistance in this clause 12, such charges to be calculated on a time and materials basis at TDL's applicable daily or hourly rates in force from time to time.

### 13 INTERNATIONAL DATA TRANSFERS

13.1 The Client agrees that TDL may transfer Protected Data to countries outside the United Kingdom for the purpose of providing the Services, provided all transfers by TDL of Protected Data to such recipients are in accordance with such safeguards or other mechanism(s) for transfers of personal data as may be permitted under the Data Protection Laws from time to time. The Client agrees that TDL may implement such safeguards by entering into standard data protection clauses authorised under the Data Protection Laws, subject to clause 13.2

- 13.2 Where the Client requires TDL to transfer Protected Data for the purpose of providing the Services to a country outside the United Kingdom which is not subject to an adequacy regulation under the Data Protection Laws (a **Third Country**) then:
- 13.2.1 the Client will enter into (or where relevant use reasonable endeavours to procure that the applicable third party recipient of the Protected Data enters into) standard data protection clauses with TDL authorised under the Data Protection Laws for the international transfer of personal data that provide sufficient safeguards for the relevant transfer, on terms acceptable to TDL (acting reasonably); and
- 13.2.2 where the data protection clauses referred to in clause 13.2.1 are not entered into, the Client will procure that prior to the transfer the relevant data subjects provide valid consent to the transfer or the purposes of the Data Protection Laws, and the Client will provide evidence of such consents to TDL on request.

### 14 RECORDS. INFORMATION AND AUDIT

- 14.1 TDL will maintain, in accordance with the Data Protection Laws binding on TDL, written records of all categories of processing activities carried out on behalf of the Client.
- 14.2 TDL will, in accordance with the Data Protection Laws, make available to the Client such information as is reasonably necessary to demonstrate TDL's compliance with its obligations as a processor under these Terms and Conditions and the Data Protection Laws and allow for and contribute to audits, including inspections, by the Client (or another auditor mandated by the Client) to the extent reasonably necessary for that purpose, subject to the Client:
- 14.2.1 giving TDL reasonable prior notice and in any event not less than 30 days' notice of such information request, audit and/or inspection required by the Client;
- 14.2.2 ensuring that all information obtained or generated by the Client or its auditor(s) in connection with such information requests, inspections and audits is kept strictly confidential (save for disclosure to the relevant regulator or as otherwise required by Applicable Law); and
- 14.2.3 ensuring that such audit or inspection is undertaken during normal business hours, with minimal disruption to TDL's business, any Sub-Processor's business and the business of other customers of TDL.

### 15 BREACH NOTIFICATION

TDL will, without undue delay, notify the Client of a personal data breach involving the Protected Data, and provide the Client with details of the personal data breach.

# 16 DELETION OR RETURN OF PROTECTED DATA AND COPIES

TDL will, at the Client's written request, either delete or return all of the Protected Data to the Client in such form as the Client reasonably requests within a reasonable time after the end of the provision of the relevant Services related to processing, and delete existing copies (unless storage of any data is required by Applicable Law, in which case TDL will inform the Client of any such requirement). Where TDL will process that Protected Data as controller under clause 17, TDL may retain the Protected Data.

# 17 PROTECTED DATA THAT TDL PROCESSES AS A CONTROLLER

- 17.1 TDL may process Protected Data as controller in the circumstances and for the purposes set out in TDL's Privacy Notice. In particular TDL may:
- 17.1.1 retain and submit the Protected Data to a Health Authority in the United Kingdom for the purposes of a Public Health Programme operated by that Health Authority, or to a regulator for the purpose of complying with regulatory obligations; and
- 17.1.2 retain and process Protected Data in its laboratory records in order to meet the requirements of the UKAS medical laboratory accreditation standard (ISO 15189) and implement the guidelines of the Royal College of Pathologists for the retention and storage of pathological records and specimens.
- 17.3 When TDL processes Protected Data to provide Non-Invasive Prenatal Tests, TDL does so as a controller.
- 17.4 When TDL processes personal data on its own behalf as controller, it will do so in accordance with the obligations of data controllers under the Data Protection Laws and with the applicable terms of the Agreement.

### 18 GENERAL

- 18.1 Disputes
- 18.1.1 If any dispute arises relating to the Agreement or any breach or alleged breach of the Agreement, the parties will make a good faith effort to resolve such dispute without recourse to legal proceedings. If, notwithstanding such good faith efforts, the dispute is not resolved either party may submit the dispute to the jurisdiction of the English Courts.
- 18.1.2 Except to the extent clearly prevented by the area of dispute, the parties will continue to perform their respective obligations in respect to any existing Agreements while such dispute is being resolved.

### 18.2 Variation

- 18.2.1 TDL may amend these Terms and Conditions by updating the Laboratory Guide and providing the Client with a copy of the update or publishing it on TDL's website. Such amendments will only apply to an Order submitted after the date of the update, and the Client will be deemed to accept those amendments by submitting an Order after that date.
- 18.2.2 Except as set out in clause 18.2.1, any amendments to the Agreement will not be effective unless in writing and signed by an authorised signatory on behalf of each of the parties. The terms of the Agreement may be varied by agreement of the parties but without the consent of any third party whether or not the rights of such third party are affected by such variation. The Client will not unreasonably withhold, delay or condition its agreement to any variation to the Agreement requested by TDL in order to ensure the Services and TDL (and each Sub-Processor) can comply with any change in Applicable Laws.

### 18.3 Rights and waiver

All rights granted to either of the parties will be cumulative and not exhaustive of any rights and remedies provided by law. The failure of either party to enforce (or delay in enforcing) at any time for any period any one or more of the terms of the Agreement will not be a waiver of such term or of the right of such party at any time subsequently to enforce all the terms of the Agreement.

### 18.4 Severability

If any provision of the Agreement is or becomes invalid, illegal or unenforceable in any respect under any law, the validity, legality and enforceability of the remaining provisions will not be in any way affected.

# 18.5 Sub-contracting and Assignment

TDL may assign or sub-contract the performance of the Agreement (in whole or in part) or any one or more of the Tests to be performed hereunder to any member of the TDL Group or any suitably accredited laboratories including those listed in the Laboratory Guide. The Client may not assign the Agreement or any of its rights or obligations hereunder without the prior approval of TDL.

### 18.6 Relationship of the parties

It is acknowledged and agreed that TDL and the Client are independent contractors and nothing in the Agreement will create or be construed as creating a partnership or a relationship of agent and principal between the parties. The Client acknowledges and agrees that, in requesting Services from TDL, it is not acting as agent for any patient or patients to which the Services relate.

### 18.7 Notices

All notices given under the Agreement will be in writing and will be delivered by hand or sent by prepaid first class post or by prepaid first class recorded delivery or by email transmission. All notices will be delivered at or sent, in the case of TDL, to: post The Halo Building. 1 Mabledon Place, London WC1H 9AX, email notices@tdlpathology.com and, in the case of the Client to the address and/or email address set out in the Order (or such other address as that party will notify in writing to the other for this purpose). A notice sent by post will be deemed to be served at 9.00 am on the second Business Day following the date of posting: a notice sent by email transmission will (provided the sender receives no error message indicating that delivery has been unsuccessful) be deemed to have been served at the time it is transmitted, if transmitted within business hours (9.00 am to 6.00 pm on a Business Day) or, if transmitted outside business hours, as soon thereafter as such business hours commence. This clause does not apply to the service of any proceedings or any documents in any legal action or, where applicable, any arbitration or other method of dispute resolution.

### 18.8 Entire agreement

The Agreement is the entire agreement between the Client and TDL and supersedes and extinguishes all prior and contemporaneous agreements, promises, assurances, discussions, representations and understandings between them, whether written or oral, relating to its subject matter. Each party acknowledges that it has not entered into the Agreement in reliance on, and will have no remedies in respect of, any statement, representation, assurance or warranty (whether made innocently or negligently) that is not expressly set out in the Agreement except in the case of fraudulent misrepresentation.

### 18.9 Third parties

The Agreement is not intended to create any rights for, nor be enforceable by, any third party except as set out in clause 6, and where the Client and The Doctors Laboratory Limited agree that these Terms and Conditions will apply to any Orders, that agreement is also for the benefit of and enforceable by TDL Genetics Limited.

### 18.10 Governing law

The Agreement and any dispute arising out of or in connection with it (including non-contractual disputes and claims) or its subject matter or formation will be governed by and construed in accordance with English law and each of the parties submits to the exclusive jurisdiction of the English Courts.

### 19 INTERPRETATION

19.1 In these Terms and Conditions and the Annex:

'Agreement' has the meaning given in clause 1.3;

'Annex' means the annex to the Terms and Conditions:

'Applicable Law' means the laws, regulations and judgments binding on the relevant party, as amended from time to time:

'Authorised Sub-Processors' means:

 a) Health Service Laboratories LLP and any other member of the TDL Group which provides the applicable Test or Service:

 b) accredited specialist centres for onward referral of esoteric assays as identified in the TDL Laboratory Guide;

c) persons who provide information technology services that TDL uses in the course of providing the Services; and

d) any Sub-Processor referred to in the Annex;

'Business Day' means a day other than a Saturday, Sunday, or public holiday in England;

'Client' means the person or organisation requesting Services and / or Consumables from TDL and for whom TDL has agreed to provide the Services and / or Consumables:

'controller', 'data subject', 'data protection impact assessment', 'personal data', 'personal data breach', 'process' and 'processor' have the meanings given to those terms in the Data Protection Laws;

'Consumables' means any goods to be provided by TDL in order for the Client to benefit from the Services;

'Data Protection Laws' means the UK GDPR, the Data Protection Act 2018, and any other Applicable Law having effect in the United Kingdom concerning privacy or the use of personal data;

'Data Subject Request' means a request made by a data subject to exercise any rights of data subjects under Data Protection Laws;

'Good Industry Practice' means the standard of skill and care reasonably to be expected from a professional provider of the Services;

'Group' in respect of any undertaking, means such undertaking and its group undertakings ('undertaking' and 'group undertaking' having the meanings given in the Companies Act 2006);

'Health Authority' means (i) a department of the UK government or of a devolved administration, (ii) an executive agency of such department, or (iii) a body exercising statutory functions in relation to public health in the UK or any part of the UK;

'Laboratory Guide' means TDL's Laboratory Guide current at the time the Client submits the Order, as supplied to the Client or, if not so supplied, available on request from TDL, including any updates or supplements issued by TDL;

'Order' has the meaning given in clause 1.2;

'Pathology Request' means a request for Testing submitted by the Client in a format TDL accepts from time to time and by any of the methods TDL accepts from time to time, whether in hard copy or via one of TDL's electronic portals;

'Privacy Notice' means TDL's detailed Privacy Notice available at tdlpathology.com;

'Processing Instructions' has the meaning given to that term in paragraph 8.2;

'Protected Data' means personal data provided to TDL by the Client or a third party on the instructions of the Client, or collected or generated by TDL in the course of providing the Services or Consumables:

'Public Health Programme' means a programme administered by a Health Authority to monitor or analyse health data for the purpose of public health or for statistical, scientific or research purposes in the public interest:

'Sample' means a pathology sample provided by the Client to TDL for Testing;

'Services' means the services to be provided under the Agreement;

'Sub-Processor' has the meaning given in clause 11.1:

'TDL' means (i) The Doctors Laboratory Limited or, (ii) TDL Genetics Limited in the case of services offered under the TDL Genetics name:

'TDL Group' means TDL Genetics Limited and The Doctors Laboratory Limited and its Group and Health Service Laboratories LLP and its Group;

'Test' means a laboratory test to be carried out by TDL on a Sample, and 'Testing' means the process of conducting that Test and reporting the results;

'UKAS' means the United Kingdom Accreditation Service, or any successor to it;

'UK GDPR' has the same meaning as it does in section 3(10) of the Data Protection Act 2018, read with section 205(4) of that Act.

19.2 References to the singular include the plural and vice versa.

19.3 Clause headings and paragraph headings are for ease of reference only and are not part of these Terms and Conditions for the purpose of construction.

19.4 References to paragraphs are to paragraphs of the Annex.

- 19.5 Words following the terms 'including', 'include', 'in particular', 'for example' or any similar expression shall be construed as illustrative and shall not limit the sense of the words, preceding those terms.
- 19.6 The Annex is incorporated into these Terms and Conditions.

### ANNEX

### Subject matter and nature of processing

- 1.1 TDL processes Protected Data as processor on behalf of the Client:
- 1.1.1 in the case of Testing, when TDL receives a Pathology Request and Sample and processes the corresponding Protected Data to carry out the Test and report the Test results in accordance with the Processing Instructions:
- 1.1.2 when TDL carries out the Client's 'fee to patient' instructions, as described below; and
- 1.1.3 in the case of any other Services or the provision of Consumables, when TDL is required to process Protected Data on the Client's behalf to fulfil the Client's instructions
- 1.2 The subject matter and nature of TDL's processing of the Protected Data are:
- 1.2.1 Samples and Test results for the purpose of providing clinical pathology Services;
- 1.2.2 information about clinicians who order Tests, for the purposes of reporting the Test results to the Client;
- 1.2.3 information about a patient's health insurance for the purposes of administering payment for the Services; and
- 1.2.4 billing information for a patient where the Client has asked TDL to direct TDL's invoice to the patient.

## 2 Duration of processing

The duration of the processing is the time necessary to carry out the Services or provide the Consumables.

### 3 Types of personal data

- 3.1 The Protected Data may comprise the following types of personal data:
- 3.1.1 name
- 3.1.2 gender
- 3.1.3 date of birth
- 314 address
- 3.1.5 identity numbers assigned by TDL or the Client
- 3.1.6 types of Tests conducted
- 3.1.7 results of Tests
- 3.1.8 health insurance policy details

- 3.1.9 billing information
- 3.1.10 the types of data referred to in the TDL Laboratory Guide

### 4 Categories of data subjects

The Protected Data concerns patients in respect of whom TDL conducts Tests, and clinicians who request Tests.

## 5 Reporting Test results

- 5.1 TDL will report Test results using the method selected by the Client from the range of options offered by TDL or, if no method is selected by the Client, using a method selected by TDL from that range of options.
- 5.2 TDL will report the Test results using the contact details supplied to TDL in the relevant section of the Pathology Request. The Client will be responsible for ensuring that those contact details are correct.
- 5.3 Where TDL supplies Test results electronically it will ensure that the results are supplied in the format selected by the Client (from the range of options offered by TDL) and are supplied to the address indicated when the Client selects electronic results reporting. The Client will be responsible for ensuring that the selected format is compatible with the Client's information systems and for making the results available to the users of those systems.

# 6 Fee to patient

Where the Client selects the 'fee to patient' option in a Pathology Request form, the Client instructs TDL to seek payment from the patient of the fees owed by the Client in respect of that test. The Client confirms that the patient has agreed with the Client to pay those fees to TDL for the Client. The Client instructs TDL to recover the fees by invoicing the patient using the personal data provided by the Client. The Client instructs TDL on the Client's behalf to appoint debt collectors to recover the fees from the patient if the patient does not pay the invoice by the date payment falls due. The Client authorises TDL to appoint those debt collectors as Sub-Processors in accordance with clauses 9 to 16.

# **Request forms**

Visit the TDL website to download:

- Maternal Screening Request Form: For Down, Edwards and Patau Syndromes screening
- Leukaemic Studies Request Form (Cytogenetics/Molecular genetics)
- Genetic Request Form
- TDL Supplies Re-order Form
- TDL Request Form



SCAN ME

Download TDL Request Forms from:

www.tdlpathology.com/ tests/request-forms/

| Lavender<br>Gold  | Anticoagulant                       | Capacity         |   |
|---|-------------------------------------|------------------|---|
| Gold  | EDTA                                | 4ml/10ml*        |   |
|   | SST/Gel                             | 5ml              |   |
| Light blue  | Citrate                             | 4.5ml            |   |
| Red   | None                                | 6ml              |   |
| Grey  | Fluoride oxalate                    | 2ml, 4ml         |   |
| Green   | Lithium heparin                     | 6ml              |   |
| Dark blue   | Trace metal                         | 7ml              |   |
| * 10ml EDTA tubes are used  | for specific PCR assays             |                  |   |
| Blood culture bottle: co  | ontact laboratory                   |                  |   |
| Contact laboratory for advice on sample taking  |                                     |                  |   |
| Test by appointment   |                                     |                  |   |
| Random faeces   |                                     |                  |   |
| Faecal collection   |                                     |                  |   |
| Random urine  |                                     |                  |   |
| Mid stream urine  |                                     |                  |   |
| First catch random urine (for DL12/Chlamydia, etc.)   |                                     |                  |   |
| 30ml aliquot from a 24  | hour urine collection – state total | volume           |   |
| 30ml aliquot from a 24 hour urine collection with 10ml of 0.1N hydrochloric acid added – state total volume |                                     |                  |   |
| Early morning urine (1st sample of the day)   |                                     |                  |   |
| 60ml container (sterile)  |                                     |                  |   |
| Cytyc thin prep vial  |                                     |                  | i |
| Orange/Blue swab for  | culture – swab in transport mediun  | n/Blue microswab |   |
| Black charcoal swab   |                                     |                  |   |
| Green viral swab  |                                     |                  |   |
| PCR swab for Chlamydia/PCR infection screening  |                                     |                  |   |
| Tap/bottled water mouth wash – 20mls  |                                     |                  |   |
| Ammotic fluid (5mls PCR – 10mls Karyotype)  |                                     |                  |   |
| Chorionic villus (medium provided by laboratory)  |                                     |                  |   |

The Doctors Laboratory The Halo Building 1 Mabledon Place London WC1H 9AX

T +44 (0)20 7307 7373 E tdl@tdlpathology.com www.tdlpathology.com